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Abstract 
Infiltration of inflammatory cells into the tissue during the inflammatory 
response is beneficial to the host. Chemokines and their receptors are 
instrumental in this process by influencing the migration and behaviour of 
leukocytes in the tissue. However, prolonged inflammation is associated with 
many diseases. 
In recent years, a family of atypical receptors have emerged which do not seem 
to signal. One of these receptors, D6, is able to internalise and degrade 12 pro-
inflammatory CC chemokines and has a role in the resolution of the 
inflammatory response. Here, using a murine transgenic approach, the potential 
therapeutic role of D6 in suppressing cutaneous inflammation in vivo has been 
investigated, using a well-characterised model of skin inflammation. In addition, 
expression of D6 in a range of inflammatory disorders has also been 
characterised. 
Transgenic mice were generated (K14D6), using an epidermis-specific transgene, 
in which expression of the D6 transgene was driven by the human keratin 14 
promoter in epidermal keratinocytes. K14D6 mice were validated and we have 
shown that D6 is expressed in K14D6 but not in wild-type epidermal 
keratinocytes. The K14D6 transgene was shown to be functional as only K14D6 
keratinocytes were able to bind CCL2 and progressively deplete extracellular 
CCL3. K14D6 mice can dampen down cutaneous inflammation in response to a 
topical application of TPA. In addition, K14D6 mice displayed reduced 
infiltration of epidermal T cells and mast cells compared to wild-type mice.  
Using a microarray approach, we examined the transcriptional consequences of 
non-ligated D6 and after ligand binding in primary murine keratinocytes from 
K14D6 and wild-type mice. Although limited conclusions could be made from the 
microarray data, our results suggest the possibility that non-ligated D6 in murine 
keratinocytes may have a negative impact on the transcription of some genes, 
such as chemokines.  
In a previous study, D6 null mice displayed a human psoriasis-like pathology after 
chemical induced skin inflammation, suggesting a possible involvement of D6-
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dysfunction as a contributing factor in the pathogenesis of psoriasis. We have 
investigated the possible correlation between D6 expression levels and 
cutaneous disease development. Analysis of skin biopsies revealed that D6 mRNA 
levels were 8-fold higher in uninvolved psoriatic skin compared to matching 
psoriatic lesional skin, atopic dermatitis and control skin. In PBMCs, there was no 
significant difference in D6 mRNA expression in psoriasis patients compared to 
control. A preliminary study examining surface D6 expression on leukocytes from 
control and rheumatoid arthritis patients revealed enhanced D6 expression on B 
cells and myeloid DCs.  
In this study, we have shown for the first time that increased expression of D6 in 
vivo can limit cutaneous inflammation, therefore providing a rationale for 
exploring the therapeutic potential of D6 in human inflammatory diseases. In 
addition, we provide evidence that D6 expression is dysregulated in 
inflammatory disorders further suggesting an involvement of this receptor in the 
pathogenesis of these diseases. 
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1 Introduction 
1.1 Haemopoiesis 
Within the body, there are many different types of blood cells with various 
functions. Haemopoiesis is the expansion and development of these blood cells 
from haemopoietic stem cells (HSCs). The principle site of haemopoiesis varies 
depending on the developmental stage of the mammal. In the fetus, 
haemopoiesis initially takes place in the yolk sac then the 
aortic/gonad/mesonephrous (AGM) region, and finally the liver (Cumano and 
Godin, 2007). After birth, the major location for haemopoiesis is within 
specialised niches in the bone marrow (Adams and Scadden, 2006). 
Haemopoietic stem cells are defined by two main properties, self-renewal and 
multipotency (Bonnet, 2002). By having the capacity to renew, HSCs have the 
ability to proliferate and maintain their population. Multi-potency refers to the 
potential of a single HSC to generate differentiated progenitor (also known as 
precursor) cells that can become various types of blood cell (Cumano and Godin, 
2007).  
Haemopoietic stem cells divide and give rise to two common progenitor cells, 
myeloid and lymphoid progenitors, which are specifically committed to generate 
myeloid and lymphoid cells respectively. Under normal circumstances, these 
progenitors do not generate cells belonging to the other pathway (Kondo et al., 
1997). A common myeloid progenitor cell (CMP) has the ability to differentiate 
into a granulocyte monocyte precursor (GMP), a megakaryocyte erythroid 
precursor (MEP) or an immature precursor that is positive for a cell surface 
protein known as cluster of differentiation (CD) 34. MEP can differentiate into a 
megakaryocyte, which gives rise to platelets, or erythroblasts from which 
erythrocytes are derived. A GMP can differentiate and give rise to granulocytes 
(eosinophils, neutrophils and basophils), mast cells or monocytes (see 1.2.1.3). 
Macrophages, osteoclasts and myeloid dendritic cells (mDCs) are cell types, 
which are differentiated from monocytes (Palucka et al., 1998, Schneider et al., 
1986). Two subsets of dendritic cells (DCs), Langerhans cells and interstitial 
dendritic cells (see 1.2.1.3) are derived from the CD34+ DC precursor, but 
Langerhans cells can also be derived from monocytes (Ginhoux et al., 2006). A 
third type of DC, plasmacytoid dendritic cells (pDCs; see 1.2.1.3) are derived 
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from common lymphoid progenitor cells that also give rise to either a T cell 
precursor or a B cell precursor. T lymphocytes (see 1.2.1.4) and natural killer 
cells are derived from T cell precursors whereas B lymphocytes (see.1.2.1.4) are 
derived from B cell precursors. The theory that haemopoiesis has two common 
progenitors cells feeding into distinct pathways is the classical model, however 
there is evidence that lineage pathways are sufficiently flexible to allow myelo-
lymphoid progenitors and myelo-erythroid progenitors to exist (Arinobu et al., 
2007). A summary of the classical model of development of the different blood 
lineages is shown in Figure 1.1.   
 
 
 
Figure 1.1 The development of cell subsets during haemopoiesis. 
Haemopoietic stem cells (HSCs) can differentiate into common myeloid progenitor (CMP) or 
common lymphoid progenitor (CLP) which give rise to a variety of distinct cells. (GMP) 
granulocyte monocyte precursor, (MEP) myeloid erythrocyte precursor, (CD34+ im pre DC) 
cluster of differentiation 34+ immature dendritic cell precursor, (pDC) plasmacytoid DC, 
(mDC) myeloid DC, (NK cell) natural killer cell, (Th lymphocyte) T helper lymphocyte, (Tc 
lymphocyte) cytotoxic T lymphocyte. 
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1.2 The immune system 
The immune system is composed of an organised network of specialised cells, 
molecules, tissues and organs that play a role in protecting the host from tissue 
damage or potentially harmful ‘foreign’ substances that are ‘non-self’ material. 
The immune response (see 1.2.1) is the reaction of the immune system to tissue 
damage or ‘foreign’ material and consists of two components, the innate- and 
the adaptive-response.   
Viruses, bacteria, fungi, protozoa and worms are foreign substances that can 
cause infection and damage to the host, if the immune system is unable to 
detect and neutralise them. Potentially pathogenic material can invade the body 
through a variety of routes, including across the respiratory or gastrointestinal 
tracts, or through breaks in the skin. As a result, several lines of defence are in 
place within the body to prevent invasion and eliminate foreign matter. Areas of 
the body susceptible to the outside world contain ‘tools’ to augment physical 
barriers. For example, cilia and mucus, within the respiratory tract serve to trap 
and expel pathogens. Whereas chemical barriers, such as peptide antibiotics in 
the intestine (Ayabe et al., 2000), enzymes in the lungs, (Akinbi et al., 2000) 
and gastric acid within the stomach (Tennant et al., 2008) are all mechanisms 
that discourage microorganisms from surviving within the body. However, if a 
foreign substance does manage to invade or tissue damage occurs, the body 
responds using specialised cells and proteins of the immune system to eliminate 
pathogens, limit tissue damage and stimulate tissue repair. A sign of host 
response to infection or injury is acute inflammation (see 1.4) in which pain, 
heat, redness and swelling are all classical signals that the process is occurring. 
1.2.1 The immune response  
Present and functional from birth, the innate immune system is the first line of 
defence and responds immediately to pathogens or tissue damage.  However, 
the innate immune response has no immunological ‘memory’ and cannot ‘learn’ 
from previous encounters and upon repeat exposure to the same pathogen, the 
nature and strength of the innate immune response remains the same 
throughout life (Ptak and Szczepanik, 1998). In contrast, the adaptive immune 
response occurs later than the innate immune response but develops as a 
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specific response to a previously ‘seen’ molecule, known as an antigen (Ag). 
Therefore, the adaptive immune response is said to have immunological 
‘memory’. This results in a quicker and more robust response to an antigen when 
detected the second or subsequent time. 
1.2.1.1 Recognition of pathogens in innate immunity 
The innate immune system can respond to various classes of microbes by 
recognising highly conserved structures, known as Pathogen Associated Molecular 
Patterns (PAMPs). In bacteria and fungi, PAMPs tend to be components of the 
cell wall whereas the PAMP within viruses is viral nucleic acid (Medzhitov, 2007). 
The recognition of PAMPs is mediated by Pattern Recognition Receptors (PRRs), 
which are encoded within the germline, and are present either on the surface, 
within cells or may be secreted by them (Janeway and Medzhitov, 2002).  
Pathogen recognition receptors 
There are several classes of pathogen recognition receptors and the Toll-like 
receptors (TLRs) are the most well characterised class. TLRs are cell surface 
receptors that can recognise components of bacteria, fungi, viruses and 
parasites (Akira et al., 2006). Discovery of the  family began when the Toll gene, 
encoding a transmembrane receptor within Drosophila (Hashimoto et al., 1988) 
was also found to exist within humans (Medzhitov et al., 1997). Within 
mammals, at least 11 members of the Toll-like receptor family have been 
identified and the stimuli for various TLRs are known. Recognition of 
peptidoglycan and lipoteichoic acid from Gram-positive bacteria is mediated by 
TLR2 (Schwandner et al., 1999) whilst TLR1 forms a heterodimer with TLR2 to 
recognise triacylated lipopeptides (Takeuchi et al., 2002). TLR6 can also 
heterodimerize with TLR2 to recognise diacylated bacterial lipoproteins 
(Takeuchi et al., 2001). TLR3 binds to double stranded RNA (Alexopoulou et al., 
2001) while TLR4 recognises lipopolysaccharide (LPS), which is a major 
component of the outer membrane of Gram negative bacteria whereas viral 
single stranded RNA is recognised by TLR7 and TLR8 (Heil et al., 2004, Lund et 
al., 2004). TLR9 binds bacterial DNA that contains CpG regions (Hemmi et al., 
2000) and no endogenous ligand is yet known for TLR10. A ligand known for 
murine TLR11 is a molecule from a protozoan parasite (Yarovinsky et al., 2005). 
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In addition, murine TLR11 prevents infection by uropathogenic bacteria (Zhang 
et al., 2004) however the specific ligand responsible for the infection is not 
known. In addition to TLRs, there are other cell-surface PRRs, for example, the 
C-type lectin family. These receptors can bind carbohydrate structures 
associated with pathogens. One example is Dectin1, which can bind β-glucans 
and is important in antifungal immunity (Taylor et al., 2007).  
In addition to cell-surface PRRs, other PRRs are present within the cytoplasm of 
the cell and detect PAMPs intracellularly. This includes a family of NOD-like 
receptors (NLRs), so called because they contain a Nucleotide-binding 
Oligomerization Domain (NOD) at the carboxy terminus (Fritz et al., 2006). 
There are two proteins established within the NOD subfamily, known as NOD1 
and NOD2, both are known to recognise bacterial lipopolysaccharide resulting in 
the activation of various genes (Inohara et al., 2001). Other NLRs such as NLRP1 
(Nod-like receptor, pyrin domain containing 1) and NLRP3 form multimeric 
protein complexes known as inflammasomes, which lead to the activation of 
enzymes involved in the cleavage of certain cytokines (Martinon and Tschopp, 
2007). Other types of cytosolic receptors are RNA helicases, such as retinoic-
acid-inducible gene 1 and melanoma differentiation-associated gene 5 
(Yoneyama et al., 2004, Andrejeva et al., 2004), which detect and unwind 
double stranded RNA prior to mediating signalling responses important for 
antiviral immunity. 
PRRs are expressed on a variety of immune cells and can influence functions 
within the innate and the adaptive immune response. Antigen presenting cells 
(see 1.2.1.3) predominately express cell-surface PRRs, in particular TLRs  
(Gordon, 2002). Direct interaction of a cell-surface PRR and its ligand can result 
in the internalisation of the pathogen expressing the ligand (Medzhitov, 2001), in 
a process known as phagocytosis (see 1.2.1.3).  Internalisation of the pathogen is 
enhanced by the surface of the pathogen being coated in opsonins, which can be 
antibodies, also known as immunoglobulins (Ig) or proteins involved in the 
complement cascade. The first discovered complement pathway, so called the 
classical pathway, involves antibodies forming immune complexes and acting as 
opsonins. The detection of mannose binding lectin results in activation of the 
Lectin pathway (Fujita et al., 2004) whereas the alternative pathway is triggered 
by recognition of the complement protein C3b.  All three pathways converge at 
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the complement protein C3, which can be cleaved to form active proteins C3a, 
C3b, C4a and C5a.  Another complement protein, C5b, induces the formation of 
a multiple protein complex, known as the membrane attack complex, which 
forms a pore in the target cell membrane resulting in lysis of the cell and 
consequently cell death (Walport, 2001).   
1.2.1.2 Immune response to endogenous danger signals 
In addition, the immune system can detect endogenous molecules associated 
with tissue damage or stress, therefore act as ‘danger signals’ and elicit an 
immune response (Gallucci and Matzinger, 2001). Examples of endogenous 
‘danger signals’, known as Damage Associated Molecular Patterns (DAMPs), 
include heat shock proteins, high mobility group box 1 and hyaluronic acid 
(Bianchi, 2007).  Some DAMPs can activate the immune response via TLRs, such 
as TLR4 (Termeer et al., 2002) or the inflammasome (Martinon et al., 2006). 
Both result in the transcription of many genes involved in the immune response. 
1.2.1.3 Cells of the innate immune system 
Leukocytes, also known as white blood cells, are involved in the innate immune 
response. Leukocytes are derived from HSCs (see 1.1) and leukocytes of the 
innate immune system include basophils, eosinophils, neutrophils, mast cells, 
monocytes, macrophages, dendritic cells and natural killer cells. All the cells 
have different morphology and distinct functions.  
Granulocytes; neutrophils, eosinophils and basophils 
Granulocytes are white blood cells characterised by the presence of granules 
within their cytoplasm. They are classified into three types by their histological 
appearance following staining. Eosinophilic granules stain pink with acidic stains, 
basophilic granules stain blue with basic reagent and neutrophils contain neutral 
staining granules.  
Neutrophils are the most abundant leukocyte within the human body and 
normally circulate within the blood. Neutrophils are one of the first cells 
recruited in an immune response and are a hallmark of acute inflammation (see 
1.4). Stimulation of neutrophils results in the release of granules from the 
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cytoplasm (known as degranulation), which are toxic and help destroy the 
encountered pathogen. Two main types of granules are contained within the 
cytoplasm of neutrophils, azurophilic granules and specific granules. Azurophilic 
granules contain microbicidal substances such as defensins, enzymes such as 
myeloperoxidase and the proteases, elastase, proteinase-3 and cathepsin G 
(Faurschou and Borregaard, 2003). Specific granules contain enzymes including 
properdin, which induces the production of the complement molecule, C5a 
(Schwaeble and Reid, 1999). In turn, C5a is a chemotactic molecule, which  
enhances the migration of macrophages, mast cells, dendritic cells and more 
neutrophils to the site of infection or inflammation (Sozzani et al., 1995). 
Eosinophils develop and mature in the bone marrow making up to 5% of the 
leukocyte population. After maturation, eosinophils circulate in the blood ready 
to respond to chemokines (see 1.5) and migrate into inflammatory tissues or to 
the site of a parasitic helminth infection. Activation of eosinophils by interleukin 
(IL) 5, a cytokine released from Th2 cells (see 1.2.1.4), results in the release of 
contents from preformed granules containing major basic protein and eosinophil 
cationic protein (Kita et al., 1992). Upon activation, eosinophils also produce 
lipid mediators, including prostaglandins and leukotrienes (Bandeira-Melo et al., 
2002) which are both instrumental in inflammation. Additionally, eosinophils are 
widely known for their role in allergic responses, such as atopic asthma, where 
the immune system overreacts to allergens (Hogan et al., 2008).  
Basophils are the least common type of granulocyte, constituting less than 1% of 
white blood cells within a healthy individual. Basophils are found within the 
circulation and have the ability to move into tissues. Upon activation, basophils 
release preformed mediators such as histamine and heparin alongside lipid 
mediators and cytokines (Galli et al., 1991). Histamine increases vascular 
permeability, smooth muscle contraction and mucous secretion (Maintz and 
Novak, 2007) and these effects are augmented by leukotrienes and 
prostaglandins, which also mediate vasodilatation and increased permeability. 
All of these substances therefore contribute to the inflammatory process. 
Notably, basophils are major producers of a cytokine called IL-4 (Min et al., 
2004) and this has been linked to their role in chronic allergic inflammation 
(Mukai et al., 2005). Recent evidence has demonstrated that basophils can also 
act as antigen presenting cells (see antigen presenting cells below) in response 
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to protease allergens and helminth parasites (Perrigoue et al., 2009, Sokol et 
al., 2009). 
Monocytes and macrophages 
Monocytes constitute 10-15% of leukocytes in humans and enter the circulation 
from the bone marrow where they patrol the blood. From the bloodstream, 
monocytes can undergo migration into tissues where they differentiate into 
macrophages. Human monocytes express CD14 on their surface however they are 
a heterogeneous population as another subset of monocytes were discovered to 
be CD14low CD16+ (Passlick et al., 1989, Ziegler-Heitbrock, 2000). A spontaneous 
null mutation in the coding region of the colony stimulating factor 1 gene in 
Csfmop/Csfmop mice has demonstrated a key role for macrophage-colony 
stimulating factor in the development and differentiation of macrophages (Marks 
and Lane, 1976, Yoshida et al., 1990). Csfmop/Csfmop mice have excess bone 
formation resulting in osteopetrosis characterised by dense and brittle bones 
(Marks and Lane, 1976). Csfmop/Csfmop mice also have reduced number of 
osteoclasts, which are bone resorbing cells, and  macrophages within their 
tissues (Naito et al., 1991).   
The presence of infection or inflammation results in the recruitment of 
monocytes into the tissue, where they may differentiate into macrophages. In 
response to cytokines, small protein molecules that act as extracellular 
messengers (see 1.4.1), macrophages are polarised functionally.  Macrophages 
are referred to as M1 (classically activated) if they are induced by cytokines, 
interferon-γ (IFN-γ) and tumour necrosis factor (TNF) or M2 (alternatively 
activated) macrophages if induced by IL-4 or IL-10 (Gordon, 2003). 
Like neutrophils, macrophages are also known as professional phagocytes. 
Phagocytes are cells that ingest and destroy solid particles by a process called 
phagocytosis (Allen and Aderem, 1996). Phagocytes express PRRs (see 1.2.1.1) 
which are able to bind PAMPs, and fragment crystalline γ receptors (FcγR), which 
recognise the carboxy-terminal constant region of immunoglobulin isotype G 
(IgG) on opsonin-coated pathogens (Swanson and Hoppe, 2004). Upon recognition 
of PAMPs and opsonin-coated pathogens, the cell plasma membrane elongates 
and extends around the object and internalises the pathogen forming a vesicle 
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known as a phagosome. The phagosome then fuses with lysosomes, which 
contain destructive enzymes. Killing of the microbe is mediated by the 
production of reactive oxygen intermediates converted from oxygen by 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and lysosomal 
proteases (Roos et al., 2003). Chronic granulomatous disease, caused by defects 
in the NADPH oxidase enzyme within phagocytic cells, leads to increased 
susceptibility to infections illustrating the importance of phagocytosis in innate 
immunity (Rosenzweig, 2008).  
Phagocytosis is also a mechanism to remove ‘self’ cells in the body that are 
undergoing apoptosis (programmed cell death). Apoptosis alters membrane 
phospholipid symmetry resulting in exposure of phosphatidylserine, which 
targets the cell for phagocytosis (Fadok et al., 2001). This mechanism 
distinguishes healthy ‘self’ cells from non-healthy ‘self’ cells and avoids 
phagocytosis of healthy cells. Phagocytosis of apoptotic cells prevents the 
surrounding cells and tissues from being exposed to the contents of the 
apoptotic cell, and in terms of phosphatidylserine actually promotes an anti-
inflammatory response (Huynh et al., 2002). 
Mast cells 
Mast cells are long-lived cells found in various locations. Mast cell precursors are 
present in the circulation and differentiate into mature mast cells within the 
tissue in which they reside (Metcalfe et al., 1997). Mast cells are present within 
the skin, mucosal tissues and in close proximity to the blood vessels ready to 
encounter pathogens. Activation of mast cells results in the secretion of 
contents, which is similar to that of basophils. Histamine from preformed 
granules is released, as is newly synthesised lipid mediators and cytokines 
(Marshall, 2004). Mast cells can function as effector cells in both the innate and 
the adaptive immune response. These effector functions include the degradation 
of toxins (Metz et al., 2006) and the killing of pathogens (Dawicki and Marshall, 
2007). Mast cells are considered immunomodulatory due to their ability to 
influence immune cells (Galli et al., 2008). Through the release of a soluble 
mediator known as tumour necrosis factor (see 1.4.1), mast cells can recruit 
innate immune cells, such as dendritic cells (Suto et al., 2006) and cells of the 
adaptive immune response such as T lymphocytes (see 1.2.1.4). Mast cells have 
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also been described as being able to mediate a negative effect on the immune 
response by producing  IL-10 (Grimbaldeston et al., 2007) but the mechanism by 
which IL-10 produced by mast cells mediates this effect is unknown (Galli et al., 
2008). Mast cells have been implicated in allergy, inflammation and 
autoimmunity (Lee et al., 2002, Nakae et al., 2007). 
Dendritic cells 
These cells were discovered and named by Steinman and Cohn in 1973, due to 
their appearance resulting from branched projections (dendrites) from the cell 
(Steinman and Cohn, 1973). DCs are a heterogeneous population with several 
subsets, including plasmacytoid DCs (pDCs), myeloid DCs (mDCs), Langerhans 
cells (see 1.3.2) and interstitial DCs (Shortman and Liu, 2002). All DCs are 
capable of acting as antigen presenting cells (see below) but dendritic cell 
subtypes reside in different locations. The differentiation of DCs is under the 
influence of FMS-related tyrosine kinase 3-ligand (Flt3-L). Disruption of 
haemopoiesis occurs in mice that lack Flt3-L and they consequently have low 
numbers of DCs (McKenna et al., 2000).  In vivo studies have shown increased 
numbers of myeloid and plasmacytoid DCs after treatment with recombinant 
Flt3-L (Karsunky et al., 2003). In addition, DCs can be cultured from blood 
monocytes in the presence of granulocyte macrophage-colony stimulating factor 
and the cytokine IL-4 (Sallusto and Lanzavecchia, 1994). However, Langerhans 
cells are dependent on transforming growth factor-β (TGF-β) for their 
development as  mice lacking TGF-β do not have Langerhans cells in their skin 
(Borkowski et al., 1996). DCs are characterised by specific cell surface markers, 
with different subsets mediating different functions. The main functions of DCs 
is antigen presentation and they are important in the adaptive response, by 
providing signals to T lymphocytes which influence the development of T cell 
clones into distinct subsets (see 1.2.1.4). 
Antigen presenting cells; linking innate and adaptive immunity 
Antigen presenting cells (APCs), mainly dendritic cells and macrophages, are 
capable of capturing, processing and presenting pathogen-derived particles 
known as antigens, on their cell surface to T lymphocytes (see 1.2.1.4). 
Dendritic cells are the ‘professional APC’ as these cells are capable of initiating 
the adaptive response to antigen upon the first exposure. Immature dendritic 
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cells in peripheral tissues continuously sample the environment ready to detect 
pathogens or cell damage. Activation of PRRs results in phagocytosis by the DC 
which then begin to process the pathogenic molecule into peptides, which are 
presented on the cell surface, by major histocompatibility complex class II 
molecules (Blander and Medzhitov, 2006). Dendritic cells undergo maturation 
where they begin to lose the ability to capture antigen and increase their 
expression of cell surface molecules, such as CD80 and CD86 (Banchereau and 
Steinman, 1998). At the same time, DCs migrate from their site of activation 
(i.e. a Langerhans cell in the epidermis) to lymph nodes, which is under the 
control of the chemokine receptor CCR7. This is discussed in more detail in 
section 1.5.4.  Once in the lymph nodes, DCs can present the antigenic peptide 
to T lymphocytes (see 1.2.1.4) and generate an adaptive immune response 
(Jenkins et al., 2001). 
1.2.1.4 Cells of adaptive immunity 
Lymphocytes 
Lymphocytes are cells involved in the adaptive immune response and these too 
are derived from HSCs (see 1.1). Lymphocytes can be classified as T lymphocytes 
(T cells) or B lymphocytes (B cells) and the functions of both are described 
below. B lymphocytes develop in the bone marrow and T lymphocytes do too but 
undergo further selection and development in the thymus (Boehm and Bleul, 
2007). Both subsets of lymphocytes have very diverse repertoires of receptors on 
their surfaces that enable them to recognise specific motifs on any pathogenic 
material they may encounter. The diversity of these lymphocyte receptors is 
formed by somatic recombination of V(D)J gene segments during development 
(Tonegawa, 1983, Bassing et al., 2002). Lymphocytes expressing receptors with 
high affinity for ‘self’-molecules are usually deleted, whereas lymphocytes 
expressing receptors with high affinity binding to pathogen-associated molecules 
will survive (Boehm and Bleul, 2007). The antigen specific receptor present on T 
lymphocytes is known as the T cell receptor (TCR) whereas the antigen specific 
receptor on B lymphocytes is known as the B cell receptor (BCR). 
Naive lymphocytes (those not yet engaged by an antigen for their receptor) 
move continuously between the bloodstream and lymph nodes, via the 
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lymphatics, to search for antigens. The chemokine receptor, CCR7 (see 1.5.4) is 
expressed on naive T cells and is important in mediating their migration 
(Britschgi et al., 2008).    
T Lymphocytes 
Naive T cells continuously search for antigens, being ‘presented’ on the surface 
of antigen presenting cells (see 1.2.1.3). The interaction between a TCR and the 
‘presenting’ major histocompatibility complex (MHC) is restricted by the 
expression of a cell-surface molecule on naive T cells. The expression of CD4 on 
one type of naive T cells restricts their interaction to being with MHC class II 
presented antigen whereas CD8 positive (CD4 null) expressing naive T cells may 
only interact with MHC class I presented antigens, which are generally 
intracellular pathogens. The interaction between T cells and APCs is focused at a 
specialised cell-cell junction, known as the immunological synapse (Dustin, 
2002). Additionally, during T cell stimulation by APCs, the chemokine receptors 
CCR5 and CXCR4 (see 1.5.2) are recruited to the immunological synapse (Molon 
et al., 2005). Recognition of the presented antigen by the TCR with a 
simultaneous second signal, provided by the interaction of co-stimulatory 
molecules, results in the proliferation and activation of T cells. The best-
characterised co-stimulatory pathway is the B7-1/B7-2-CD28/CTLA4 pathway. 
For example, CD86 (B7-2), a co-stimulatory molecule present on mature DCs, 
binds CD28 on the surface of naive T lymphocytes (Caux et al., 1994). This 
interaction between CD28 and B7-1 or B7-2 results in promotion of T cell survival 
and the induction of cytokine release, in particular IL-2, which in turn stimulates 
clonal expansion of the engaged T cell (Carreno and Collins, 2002). Naive T cells 
then differentiate into effector T cells that perform specific functions according 
to the type of antigen that activated them. The differentiation of naive T cells is 
regulated by transcription factors and the cytokine milieu in the environment. 
Upon activation and proliferation, CD4+ naive T cells differentiate into various 
subsets of effector cells. One effector cell subset is defined as T helper cells due 
to their ability to help B cells (see below). Upon activation, T helper cells 
secrete a variety of cytokine combinations, which define T helper cells into 
three main subtypes. These are T helper cell type 1 (Th1), T helper cell type 2 
(Th2) and T helper cell type 17 (Steinman, 2007). In turn, cytokines may be 
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described by the type of cell that primarily produces them and are classified as 
Th1- or Th2-associated. IL-1, IL-6, IL-12, tumour necrosis factor (TNF) and IFN-
γ are Th1-associated cytokines whereas Th2-associated cytokines are IL-4, IL-5 
and IL-13 (Abbas et al., 1996).  
TCR activation induces low expression of a T box transcription factor, T-bet, 
which in turn induces the expression of IL-12β2R and results in the T cell being 
responsive to IL-12 (Mullen et al., 2001). T-bet is also upregulated by signal 
transducer and activator 1 (STAT1), which is induced by IFN-γ (Afkarian et al., 
2002). IL-12 binding results in the upregulation of the transcription factor STAT4 
(Thierfelder et al., 1996). Both T-bet expression and the activation of STAT4 
result in the production of IFNγ. The secretion of IFNγ by the T helper cell is very 
effective in activating macrophages in a classical manner and defines the cell as 
a Th1 cell.  
IL-4 is the predominant cytokine capable of inducing differentiation of naive T 
cells into Th2 cells by inducing the production of STAT6, which then activates 
the transcription factor GATA-3 (Kaplan et al., 1996). STAT6 activation induces 
high levels of GATA-3 (Zhu et al., 2001). As GATA-3 levels rise, this inhibits T-bet 
and, as a result, this attenuates Th1 development (Ouyang et al., 1998). 
Moreover, GATA-3 results in the production of cytokines, IL-4, IL-5 and IL-13, 
which characterise these cells as Th2 (Murphy and Reiner, 2002). These 
cytokines activate B cells and help in the defence against parasites.  
Another subset of T helper cells has been discovered that are distinct from Th1 
and Th2. These cells produce IL-17 (Harrington et al., 2005) and are accordingly 
called Th17 cells. Th17 cells produce IL-17A, IL-17F, IL-6, IL-22 and TNF-α. The 
differentiation of naive T cells into Th17 cells can be induced by IL-23 (Aggarwal 
et al., 2003) or IL-6 (see 1.4.1) along with TGF-β (Kimura et al., 2007, Mangan et 
al., 2006). The expression of IL-17 by Th17 cells in response to IL-6 and TGF-β 
requires an orphan nuclear receptor RORγt and is regulated by STAT3 (Ivanov et 
al., 2006, Yang et al., 2007). Th17 cells are shown to be present, and play a role 
in, tissue inflammation and autoimmunity (Hirota et al., 2007a, Park et al., 
2005, Pene et al., 2008).  
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Additionally, a new subset of T helper cells, known as Th9 cells, was recently 
discovered that produced high levels of IL-9 and IL-10 (Dardalhon et al., 2008, 
Veldhoen et al., 2008). These cells are similar to Th2 yet they are distinct from 
Th2 cells as they produce IL-9. However, it remains to be determined whether 
these cells are functionally different from Th2 cells. 
CD4+ naive T cells can also differentiate into a subset of cells known as 
regulatory T cells (Treg cells). These cells are able to suppress and regulate 
effector T cell responses and  play a role in maintaining peripheral tolerance and 
prevent autoimmune diseases (Sakaguchi et al., 2006). Treg cells are 
characterised by the expression of the transcription factor, forkhead box P3 
(Foxp3) which plays a role in the development of these cells (Hori et al., 2003). 
Two subsets of Foxp3+ Treg cells have been identified, one subset is the naturally 
occurring CD4+CD25+ Treg (nTreg) cells and the second subset is known as inducible 
Treg (iTreg) cells. Natural occurring Treg cells are derived in the thymus whilst 
iTregs are derived from CD4
+ naive T cells induced to express Foxp3 by TGF-β in 
the periphery (Chen et al., 2003). In vivo, Scurfy mice carry a spontaneous 
mutation of Foxp3, which results in the development of a fatal autoimmune 
disease (Brunkow et al., 2001). Foxp3 has also been identified as the defective 
gene in humans with immunodysregulation polyendocrinopathy and enteropathy, 
X-linked (IPEX) syndrome (Bennett et al., 2001). These conditions illustrate the 
importance of Treg cells. Although CD4
+ T cells can be classified into functional 
subsets, there is evidence of functional plasticity in CD4+ T cell subsets. For 
example, there is evidence that Th17 cells can convert to Th1 cells (Lee et al., 
2009) and regulatory T cells can change to memory T cells (Zhou et al., 2009).  
After the activation and proliferation of T cells, these cells migrate to sites of 
inflammation, a process regulated by many factors including adhesion 
molecules, chemokines and chemokine receptors (see 1.5.3.1). After the 
clearance of pathogen, some Ag-specific T cells will remain in the body, known 
as memory T cells. These cells reside in peripheral tissue and subsequent 
exposure to the antigen will result in a more rapid response than the initial 
exposure response  (Woodland and Kohlmeier, 2009). 
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B Lymphocytes 
Although B cells are primarily known as antibody producing cells, B cells can also 
act as antigen presenting cells (Chen and Jensen, 2008). Presentation of Ag on B 
cells and their recognition by T cells, involves co-stimulatory molecules and the 
release of cytokines. This triggers B cell proliferation and the secretion of 
antibodies (Parker, 1993). Cytokines released by the activated T helper cells 
during this process, feedback to act in an autocrine manner inducing the T cell 
to proliferate. In addition, B cells also influence T cell differentiation through 
the secretion of polarising cytokines (Harris et al., 2000).  
1.3 Cutaneous immune system 
The skin is the largest organ in the body and one of its main functions is to act as 
a physical barrier to protect the internal organs and tissues within the body. 
Originally thought as a passive barrier, the skin is highly equipped with 
immunological mechanisms to be the body’s first line of defence against 
infection and tissue injury (Elias, 2007). 
1.3.1 Structure of the skin 
The skin is composed of many epithelial layers and is divided into distinct 
compartments, which contain various cell types within it. In humans, the skin is 
composed of three main compartments, the epidermis, the dermis and the 
hypodermis whereas mice have two main compartments, the epidermis and the 
dermis. The epidermis is the outer layer of the skin, consisting of many layers of 
stratified squamous epithelial cells.  The epidermis is subdivided into five layers, 
from the deepest layer to outermost layer, stratum basale (basal cell layer), 
stratum spinosum (prickle cell layer), stratum granulosum (granular cell layer), 
stratum lucidum and finally the stratum corneum. It is of note that murine skin 
contains less cell layers of keratinocytes than human epidermis, resulting in 
murine skin having a thinner epidermis in comparison to human epidermis. The 
structure of murine skin is shown in Figure 1.2.  
The epidermis of both human and mouse skin constantly renews itself in a 
process known as tissue homeostasis. This maintenance of tissue homeostasis is 
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driven by stem cells, which replace cells that are lost through normal 
differentiation or cell death due to tissue injury (Blanpain et al., 2007). The 
major cells of the epidermis are keratinocytes, which undergo terminal 
differentiation regularly to maintain homeostasis. Keratinocytes with the 
stratum basale, known as basal keratinocytes undergo differentiation whilst 
gradually moving outwards through each layer, changing shape and the types of 
structural proteins they express. Within the basal layer, keratinocytes express 
keratin 5 and keratin 14  (K5 and K14) but as these cells differentiate and enter 
the spinosum layer, the expression of K5 and K14 is downregulated and other 
keratin proteins, K1 and K10 are expressed (Blanpain and Fuchs, 2009). Upon 
reaching the stratum corneum, the cells within this layer are known as 
corneocytes, which are derived from dead keratinocytes, which begin to shed off 
the skin surface. The stratum corneum is an important layer as this prevents the 
skin from dehydration and prevents toxic agents from entering the skin (Proksch 
et al., 2008). Other cells within the epidermis are melanocytes, which produce 
melanin responsible for the pigmentation of skin, which are located within the 
basal layer of the epidermis. Langerhans cells are specialised dendritic cells that 
reside within the epidermis and merkel cells are associated with sensory nerve 
endings.  
Underneath the epidermis connected by the basement membrane (basal lamina), 
the dermis consists of connective tissue. The dermis contains many cell types 
alongside hair follicles, sweat glands, sebaceous glands, blood vessels, lymphatic 
vessels and sensory nerves. Underlying the dermis in humans is the hypodermis 
layer, consisting of a layer of subcutaneous fat, helping to insulate the body. 
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Figure 1-2. The structure and layers within murine skin.  
The skin is one of the largest organs within the body and contains many layers within it. The 
outer layer, known as the epidermis, contains cell layers composed of keratinocytes. The 
compartment underneath the epidermis is the dermis and contains connective tissues and 
blood vessels. 
 
1.3.2 Immune response within the skin 
Bos and Kapsenberg first proposed the concept of the ‘skin immune system’ in 
1986, in which both epithelial and immune cells were associated with a role in 
the cutaneous immune response. The main cells involved are keratinocytes and 
Langerhans cells within the epidermis, whilst within the dermis, mast cells, 
dermal dendritic cells and T cells are key players (Bos and Kapsenberg, 1986, 
Kupper and Fuhlbrigge, 2004). Their main function is to alert the innate immune 
system when the skin is disturbed by trauma, ultraviolet radiation or pathogens. 
Originally, keratinocytes were considered as only being required for the 
structural component of the skin but are increasingly being considered important 
participants in the cutaneous immune response. Keratinocytes constitutively 
produce antibiotic peptides to kill microbial pathogens that enter the skin 
(Wiedow et al., 1998). Additionally, injury or infection results in the production 
of  β-defensins and cathelicidins, both antimicrobial peptides, by keratinocytes 
(Harder et al., 1997, Dorschner et al., 2001). Keratinocytes have the ability to 
recognise PAMPs (see 1.2.1.1) due to their expression of various Toll-like 
receptors (Kollisch et al., 2005). Keratinocyte TLRs binding to PAMPs results in 
the production of various immunological agents, including cytokines (see 1.4.1), 
chemokines (see 1.5) and antimicrobial peptides. TLRs confirmed to be 
expressed on the human keratinocyte cell surface include TLR1, TLR2, TLR4 and 
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TLR5 as well as endosomal TLR3 and TLR9 (Lebre et al., 2007). Keratinocytes 
express NLRs, such as NLRP3, which can recognise PAMPs or DAMPs present in 
the cytoplasm (Feldmeyer et al., 2007). Various cytokines are released from 
keratinocytes after stimulation with endotoxin and ultraviolet light, notably 
TNFα, IL-1 and IL-6 (Kock et al., 1990, Petit-Frere et al., 1998). Indeed, IL-1β 
secretion from human keratinocytes induced by ultraviolet irradiation is 
mediated by NLRP3 and activation of the inflammasome complex (Feldmeyer et 
al., 2007). These cytokines play a role in activating other resident immune cells 
and upregulate the expression of adhesion molecules on the endothelium, which 
in turn recruits more leukocytes from the vasculature into the skin (see 1.4.1). 
Additionally, keratinocytes are capable of stimulating Langerhans cells and T 
cells of the adaptive immune system. In response to a TLR9 ligand, keratinocytes 
produce cytokines which enhance the antigen presenting ability of Langerhans 
cells (Sugita et al., 2007). Another study has suggested that keratinocytes can 
induce functional responses in memory T cells by processing and presenting 
peptides to antigen-experienced T cells resulting in T cell cytokine production 
(Black et al., 2007).  
Langerhans cells are the subset of dendritic cells that reside within the 
epidermis and are characterised by the presence of Birbeck granules (rod-shaped 
organelles within their cytoplasm) and expression of Langerin in their membrane 
(Valladeau et al., 2000). Langerhans cells are derived from CD34+ 
haematopoietic progenitor cells during haemopoiesis (see 1.1). These DC 
progenitors then differentiate into either of two alternative DC subsets; one 
expresses cutaneous lymphocyte-associated antigen (CLA) and subsequently 
differentiates into a CD11c+CD1a+ cell, the alternative lacks CLA and 
differentiates into a CD11c+ CD1a-  cell (Ito et al., 1999, Strunk et al., 1997). The 
CD11c+CD1a+ population migrate to the epidermis and become Langerhans cells 
whilst the CLA- population become interstitial DCs, of which a subpopulation of 
these are dermal DCs found in the dermis of the skin. Langerhans cells express 
TLR2, TLR4 and TLR5 whereas dermal DCs express TLR3 and TLR4 and as a result 
they secrete different cytokines in response to specific stimulation (Rozis et al., 
2008). Both subsets can capture and process antigen (Nestle et al., 1998). 
Recent data suggests that dermal DCs and Langerhans cells drain to the lymph 
nodes but only dermal DCs induce proliferation of T cells (Fukunaga et al., 
2008). The migration of DCs from the skin through the afferent lymphatics to the 
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skin draining lymph nodes is mediated by the surface expression of chemokine 
receptors including CCR7 (see 1.5.3.2). In the lymph nodes, DCs will present 
antigen to T and B cells, which will then migrate to the skin and eliminate the 
trigger causing the response. 
Normal healthy skin contains twice as many T cells than there are in the blood 
and the majority are skin-homing memory T cells (Clark et al., 2006). Within the 
population of T cells, a subset known as intraepithelial lymphocytes (IELs) are 
associated with epithelial and mucosal tissues. IELs express TCRs composed of γ 
and δ chains (γδ T cells) whereas other T cells express an αβ TCR (αβ T cells) and 
these are predominately found in the blood and lymphatics (Girardi and Hayday, 
2005). In mice, a proportion of γδ IELs are localised in the skin and are termed 
dendritic epidermal T cells (DETCs). These cells are the first T cells to develop 
in mice with limited diversity and they express a canonical Vγ5Vδ1 TCR (Asarnow 
et al., 1988). Although no equivalent population has been found in human skin, 
γδ T cells with limited diversity have been discovered in the human dermis, 
which are distinct from peripheral blood γδ T cell populations (Holtmeier et al., 
2001). DETCs can be activated by stressed, damaged or transformed 
keratinocytes (Havran et al., 1991). Studies have shown that DETCs play a role in 
keratinocyte homeostasis. DETCs constitutively express insulin like growth 
factor-1 (IGF-1) but increased levels are released upon stimulation and this in 
turn promotes keratinocyte survival (Boismenu and Havran, 1994, Sharp et al., 
2005). In vivo, increased numbers of keratinocytes were found to be undergoing 
apoptosis in mice lacking DETCs (Sharp et al., 2005). Additionally, by culturing 
DETCs with skin from TCRδ−/−  mice (lack DETCs), Sharp et al., demonstrated that 
DETCs can promote keratinocyte survival by the production of IGF-1  (Sharp et 
al., 2005). A role for IGF-1 in skin homeostasis has been established by the 
overexpression of IGF-1 in vivo, which resulted in epidermal thickening (Bol et 
al., 1997) whilst mice lacking IGF-1R have a thinner, disrupted epidermis (Liu et 
al., 1993) as a consequence of decreased proliferation and accelerated rate of 
differentiation in keratinocytes (Sadagurski et al., 2006). In addition, DETCs play 
a role in maintaining epidermal integrity and barrier function in response to 
environmental challenges (Girardi et al., 2006).  Other studies have shown that 
DETCs play a role in promoting wound healing and protecting against 
inflammatory responses. Wound healing was found to be delayed in TCRδ-/- mice 
compared to wild-type controls (Jameson et al., 2002). In the same study, the 
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delay in wound closure was rescued by activated DETCs or keratinocyte growth 
factor-1 (Jameson et al., 2002), which had previously been shown to be 
produced by DETCs in vitro upon activation (Boismenu and Havran, 1994). 
Girardi et al., demonstrated a role for DETCs in regulating the inflammatory 
response by showing that DETCs can downregulate spontaneous cutaneous 
inflammation in TCRδ−/−  mice (Girardi et al., 2002). Moreover, microarray data 
showed epidermal cells from TCRδ−/−  mice have increased expression of various 
inflammatory genes, such as IL-1β and chemokines (Girardi et al., 2006). A 
mechanism for the DETC regulation of cutaneous inflammation is that DETCs 
induce protein expression of hyaluronan, which allows macrophage infiltration 
into the damaged tissue to facilitate wound repair (Jameson et al., 2005). 
1.4 Acute inflammation 
Acute inflammation is a normal physiological response triggered by infection or 
tissue damage. Resident cells within the tissue, such as epithelial cells, 
macrophages or mast cells, trigger the release of various inflammatory 
mediators, including cytokines (see 1.4.1), chemokines (see 1.5) and vasodilative 
amines upon stimulation by agents suggestive of infection or tissue damage. 
Acute inflammation is characterised by the infiltration of leukocytes controlled 
by chemokines (discussed in detail in 1.5.3.1), in which initially neutrophils, 
then 24 to 48hrs later, mononuclear cells dominate (Medzhitov, 2008). 
Additionally, increased blood flow and vascular permeability, mediated by 
histamine results in the heat, redness and swelling associated with inflammation 
(Maintz and Novak, 2007). 
1.4.1 Cytokines in inflammation 
Cytokines allow one cell to mediate effects on cells at a distance, on 
neighbouring cells, or even on itself. When the immune system is insulted, cells 
of the innate and adaptive immune system can secrete and detect cytokines, 
which are involved in many important biological processes, including 
inflammation (Vilcek and Feldmann, 2004). 
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Tumour necrosis factor 
One family of cytokines, known as the tumour necrosis factor (TNF) superfamily 
can mediate various biological responses. One member, TNFα, is mainly 
produced by activated macrophages but can also be released by other types of 
leukocytes and it plays an important role in host defence (Medzhitov and 
Janeway, 2000). TNFα is produced in a pro-form as a 26kDa transmembrane 
protein arranged as a homotrimer (Kriegler et al., 1988, Tang et al., 1996). This 
membrane form can be cleaved by TNF-α converting enzyme (TACE) to release 
soluble TNF (Black et al., 1997). TNFα can bind two membrane receptors, TNFR1 
(p55) or TNFR2 (p75), which are members of the TNF receptor superfamily 
(Locksley et al., 2001). Signalling through TNFR1 and TNFR2 can lead to the 
activation of transcription factors, NF-κB or activating protein-1 (AP-1), which 
can promote cell survival and inflammation, or caspase-induced cell death (Baud 
and Karin, 2001). The inflammatory response is mainly coordinated through NF-
κB, resulting in increased transcription of various genes, including those 
triggering the cytokine cascade by producing IL-1β, IL-6, more TNFα, chemokines 
(see 1.5) and adhesion molecules (Bonizzi and Karin, 2004). 
Tumour necrosis factor is a key mediator in inflammation and its overexpression 
can result in many chronic inflammatory diseases and autoimmune diseases 
(Kollias et al., 1999). The interest in pro-inflammatory cytokines started when 
pro-inflammatory cytokines were detected in biopsy samples from rheumatoid 
arthritis (RA) patients, which illustrated their importance in joint inflammation 
(Feldmann and Maini, 1999). Studies using animal models of arthritis indicated 
TNFα as a key mediator of the disease, as anti-TNF treatment ameliorated 
collagen-induced arthritis (Piguet et al., 1992, Williams et al., 1992) which is an 
accepted murine model of RA (see 1.4.3.3). Additionally, it was discovered that 
overexpression of human TNFα  (hTNFα) in mice resulted in a spontaneous 
arthritis (Keffer et al., 1991). Butler et al., backcrossed hTNFα  transgenic mice 
onto an arthritis susceptible DBA/1 background and the expected elevated levels 
of human TNFα  were accompanied by increased IL-1β and IL-6 levels in the 
joints of these mice (Butler et al., 1997). As a result, TNFα in particular and 
other cytokines have been targeted for therapeutic use in RA and other 
inflammatory diseases. This is discussed in more detail in 1.4.4. 
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IL-1 family 
Members of the interleukin-1 (IL-1) family are produced by macrophages, 
activated Th1 cells, epithelial and endothelial cells. The IL-1 family is composed 
of 11 members including IL-1α, IL-1β, IL-1 receptor antagonist (IL-1Ra), IL-33 and 
several new members, resulting in the proposal of a new terminology, IL-1F1 
through to IL-1F11 (Sims et al., 2001). Like TNF, IL-1α and IL-1β exist in 
precursor forms and whilst  IL-1α is active in its precursor (Kaplanski et al., 
1994) and mature form, IL-1β secretion is dependent on cleavage by IL-1β 
converting enzyme (ICE) also known as caspase 1 (Thornberry et al., 1992). 
Notably, for the secretion of IL-1β from monocytes and macrophages, 
stimulation by adenosine triphosphate (ATP) is required, which then activates 
the P2x7 receptor (Ferrari et al., 2006) and this subsequently triggers the 
formation of active caspase 1. Both IL-1α and IL-1β can bind IL-1 receptor type I 
(IL-1RI) and IL-1R type II, however only IL-1RI is able to initiate signal 
transduction (Sims et al., 1993) which requires IL-1R accessory protein in order 
to do so (Cullinan et al., 1998) whereas IL-1RII acts as a decoy receptor (Colotta 
et al., 1993). 
IL-1β induces endothelial cells to upregulate the expression of adhesion 
molecules involved in leukocyte binding and so indirectly recruits leukocytes to 
sites of inflammation (Wang et al., 1995). IL-1β , like TNF, can induce fever by 
acting on the hypothalamus and it can also induce the synthesis of acute phase 
proteins, a response impaired in IL-1β deficient mice (Zheng et al., 1995). 
Additionally, IL-1 results in the production of other cytokines such as IL-6 which 
is also involved in the inflammatory response (Dinarello, 1996). Membrane IL-1α 
has been shown to play a role in lipid-mediated inflammation as IL-1α deficient 
mice demonstrated reduced lesion size in an atherogenesis model induced by 
high cholesterol (Kamari et al., 2007). Within the interleukin-1 family, an 
endogenous antagonist exists, IL-1Ra can block the action of IL-1 by binding to 
IL-1RI, therefore preventing the activity of IL-1 (Arend, 1991). Mice deficient in 
IL-1Ra develop spontaneous diseases such as arthritis (Horai et al., 2000).  
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IL-6  
IL-6 was originally identified as a substance released by T lymphocytes which 
induced B lymphocytes to produce antibodies (Hirano et al., 1986). IL-6, is now 
known to mediate various biological functions including the activation of T and B 
cells, macrophages, osteoclasts (bone absorbing cells) and the proliferation of 
keratinocytes as well as having effects on haemopoiesis  (Kishimoto, 2005). IL-6 
exerts it effects by binding to the IL-6 receptor which then associates with 
glycoprotein 130 (gp130), a signal transducer protein (Taga et al., 1989). As well 
as a membrane bound IL-6R, a natural soluble form of IL-6R (sIL-6R) can also be 
produced by shedding from the cell surface or alternatively from spliced mRNA 
(Lust et al., 1992, Matthews et al., 2003). Soluble IL-6R along with IL-6 can 
stimulate cells that express gp130 but do not express membrane bound IL-6R 
(Mackiewicz et al., 1992) and this process is known as trans-signalling (Rose-John 
and Heinrich, 1994).  
In the context of inflammation, IL-6 plays a role in stimulating endothelial cells 
to upregulate their expression of the chemokine, CCL2 (see 1.5) and it therefore 
plays a role in recruiting leukocytes to sites of inflammation (Romano et al., 
1997). Illustrating the role of IL-6 in inflammation, IL-6 deficient mice were 
found to be resistant or to have reduced severity to experimental induced 
arthritis and collagen induced arthritis respectively (Boe et al., 1999, Sasai et 
al., 1999). In addition, Nowell et al., demonstrated that in an experimental 
induced model of arthritis, it is sIL-6R which directs the IL-6 activity and this can 
be blocked by exogenous soluble glycoprotein 130 (Nowell et al., 2003). Indeed, 
elevated levels of IL-6 and sIL-6R have been documented in both rheumatoid 
arthritis and crohns disease  (Mitsuyama et al., 2006, Robak et al., 1998). This 
has subsequently led to the therapeutic targeting of IL-6, in which one antibody, 
Tocilizumab, is currently subject to clinical trials (see 1.4.4). 
1.4.2 Resolution of inflammation 
Normally the acute inflammatory response is followed by resolution of 
inflammation and tissue repair, through the removal of leukocytes and debris at 
the inflamed site, resulting in tissue homeostasis. The mechanisms involved have 
been described in three phases; 1) leukocytes migrate to the site containing the 
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stimuli to fight and remove it 2) cell clearance occurs and 3) the site where the 
inflammatory response took place returns back to it normal state (Serhan et al., 
2007). The resolution of inflammation was thought to be a passive process but in 
recent years, new cellular and molecular mechanisms for the resolution phase of 
inflammation have been discovered. These mechanisms involve families of lipid 
mediators, known as lipoxins, resolvins and protectins. 
Lipoxins were the first to be discovered and are derived from Arachidonic Acid 
(AA) present within the cell membrane. It was discovered that during acute 
inflammation prostaglandins, especially prostaglandin E2 (PGE2), also derived 
from AA can encourage the conversion of a class of molecules known as 
leukotrienes to lipoxins, which promote resolution (Levy et al., 2001). Resolvins 
and protectins are derived from omega-3-polyunsaturated fatty acid, known as 
Eicosapentanoic Acid and Docosahexanoic acid. Resolvins are split into two 
groups; the Resolvin E series and Resolvin D series, named according to the fatty 
acid they are derived from. Resolvin E series are derived from Eicosapentanoic 
acid and the D series are generated from Docosahexanoic acid. Protectins are 
also derived from Docosahexanoic acid (Serhan et al., 2002). Lipoxins A4 and B4 
as well as Resolvin E1 mediate the first mechanisms involved in resolving 
inflammation. They are capable of preventing neutrophils from migrating across 
the vascular endothelium into the tissues (Colgan et al., 1993, Papayianni et al., 
1996, Serhan et al., 2000). Lipoxin A4 and Resolvin E1 can inhibit IL-12 
production from dendritic cells (Aliberti et al., 2002, Arita et al., 2005) 
therefore preventing activation of T cells in the area. Protectin D1 inhibits the 
production of TNFα and IFNγ from stimulated T cells and induces T cell apoptosis 
(Ariel et al., 2005). Consequently, protectin D1 limits the activation of 
leukocytes and causes T cell death. Lipoxin A4, Resolvin E1 and Protectin D1 can 
stimulate macrophages to take-up neutrophils by phagocytosis (Godson et al., 
2000, Schwab et al., 2007) therefore by removing apoptotic cells, cell clearance 
occurs. Macrophages then leave the site of inflammation via the draining lymph 
node allowing the tissue to return to normal (Bellingan et al., 1996). 
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1.4.3  Chronic inflammation 
When acute inflammation persists or complete resolution does not occur, the 
beneficial aspect of inflammation is lost and inflammation becomes chronic. This 
can last days, months or even years and can result in tissue damage. The cell 
infiltrate changes, leukocytes accumulate with increased numbers of adaptive 
immune cells. Chronic inflammation results in the development of a wide variety 
of inflammatory diseases, influenced by both genetic predisposition and 
environmental factors. 
1.4.3.1  Psoriasis 
Psoriasis is an inflammatory skin disease which is prevalent worldwide and 
affects 2-3% of the population in the UK (Smith and Barker, 2006). Psoriasis is a 
disease mediated by components of the immune system with evidence of genetic 
predisposition to the disease (Bowcock and Krueger, 2005). Clinical symptoms of 
psoriasis can appear in a variety of ways depending on location, severity and 
activity of the disease.  
Clinical spectrum of psoriasis 
Psoriasis is a recurring inflammatory disease with a wide clinical spectrum 
including five types of psoriasis, summarised in Table 1.1 (as reviewed by Naldi 
and Gambini, 2007). Psoriatic lesions are generally characterised by 
erythematous plaques covered with silvery scales surrounded by a distinct 
border, and the skin may itch or bleed more easily. The most common type of 
psoriasis is psoriasis vulgaris, also known as plaque psoriasis. Guttate psoriasis is 
common in children or young adults after streptococcal infection (Telfer et al., 
1992, Gudjonsson et al., 2003). Pustular types of psoriasis are rarer than the 
non-pustular forms however, both can progress to psoriatic erythroderma, in 
which active psoriasis involves the whole skin or near total involvement affecting 
the whole body. In some psoriasis patients, physical trauma to the skin can 
trigger psoriatic lesions, known as the Koebner phenomenon (Weiss et al., 2002). 
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Table 1-1. Clinical spectrum of psoriasis 
Five different types of psoriasis occur and the location and presentation of the psoriatic 
lesions vary in each type. 
 
Pathological changes in psoriasis 
Within psoriatic skin, pathological changes occur and the lesions contain 
common histological hallmark features. Within fully developed plaques, hallmark 
features are; epidermal hyperplasia (increased number of cells within the 
epidermal compartment), hyperkeratosis, (overgrowth of the corneous layer of 
the skin), infiltration of immune cells, angiogenesis and epidermal thickening 
caused by increased keratinocyte proliferation (Murphy et al., 2007).  
Immunopathogenesis of psoriasis 
Originally, the pathology of psoriasis was proposed to be mediated by 
keratinocytes, due to abnormalities in keratinocyte proliferation compared to 
normal skin (Weinstein et al., 1984). By the late 1970’s, T cells were assumed to 
be the main mediators driving the disease. Consistent with this, when 
cyclosporin A (a drug that inhibits T cell activation) was given to a transplant 
patient, clearance of the patients psoriasis occurred (Mueller and Herrmann, 
1979). Further studies with targeted therapy against activated T cells confirmed 
the role of T cells in the pathogenesis of psoriasis (Nicolas et al., 1991). Studies 
examining clonality of the T cell receptor have shown that infiltrating T cells in 
psoriatic plaques express a highly restricted TCR repertoire indicating oligoclonal 
expansion (Lin et al., 2001b). This suggests that a common antigen is present 
that drives the pathogenic T cell response in psoriasis (Prinz et al., 1999). One 
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such example could be an antigen derived from streptococcal infection which 
can preceed type 1 psoriasis, which is characterised by early manifestation of 
the disease, i.e., under 40 years of age (Weisenseel et al., 2002). Additionally, a 
study by Vollmer et al., has shown that the same T cell receptor pattern 
dominates in repeated flares of psoriasis (Vollmer et al., 2001). Although it has 
also been suggested that regulatory T cells are dysfunctional resulting in 
uncontrolled T cell activation (Sugiyama et al., 2005). 
Characterisation of T cells within psoriatic lesions shows that they belong to the 
Th1 subset and produce type 1 cytokines including TNFα, IFNγ and IL-2 (Austin et 
al., 1999, Schlaak et al., 1994). As a result, psoriasis has been classified as Th1-
mediated disease (Lew et al., 2004). TNFα, in particular is implicated as an 
important mediator as it is central to the presentation of spontaneous psoriasis 
in a murine model (Boyman et al., 2004). Additionally the study by Boyman et 
al., illustrated that resident populations of T cells and DCs are able to induce 
psoriasis, shown by grafting non-lesional human skin from psoriasis patients to 
immunodeficient AGR129 mice (these mice are deficient in both type 1 and type 
II IFN receptors and for the recombinase activating gene 2). 
There is also evidence of the innate immune system being dysregulated in 
psoriasis (Bos et al., 2005). IFNα  released from plasmacytoid DCs (see 1.2.1.3) is 
able to drive T cell proliferation and development of the disease (Nestle et al., 
2005). Plasmacytoid dendritic cells can be activated by environmental TLR  
agonists (see 1.2.1.1), heat shock proteins produced by damaged cells (see 
1.2.1.2) or even anti-microbial peptides produced by keratinocytes (Buchau and 
Gallo, 2007). In addition, in vivo models have implicated macrophages as having 
a pathogenic role in the disease (Stratis et al., 2006, Wang et al., 2006). 
A central role for pro-inflammatory cytokines within psoriasis was proposed over 
15 years ago (Nickoloff, 1991). Indeed the levels of IL-6 was discovered to be 
elevated in psoriatic plaques and was found to promote keratinocyte 
proliferation in vitro (Grossman et al., 1989). Therefore, the altered 
proliferation of keratinocytes was thought to be a consequence of the 
inflammatory response driven by cytokines. In vitro studies have shown exposure 
to TNFα and IL-1β induces changes to keratinocytes, which are observed in 
psoriasis (Wei et al., 1999). More recently described cytokines such as IL-15, IL-
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19 and IL-20 are present in psoriatic lesions and play a role in promoting 
keratinocyte survival and inhibiting keratinocyte apoptosis (Ruckert et al., 2000, 
Wei et al., 2005). To determine the role of single cytokines, transgenic mice 
expressing cytokines in basal keratinocytes were studied. In mice overexpressing 
IL-6, no psoriasis phenotype was seen and no effect on keratinocyte 
differentiation or proliferation occurred (Turksen et al., 1992). However, when 
IL-1α was overexpressed in a similar manner, inflammatory lesions were 
observed along with hyperkeratosis (Groves et al., 1995). Of the several new IL-1 
family members that have been described, one, IL-1F6, when overexpressed in 
the mouse skin resulted in a phenotype of hyperkeratosis, accumulation of 
inflammatory cell infiltrate and increased levels of cytokines and chemokines 
(Blumberg et al., 2007). The same study found that IL-1F5 was antagonistic of 
the effects and therefore the balance between IL-1F5 and IL-1F6 plays a role in 
regulating skin inflammation (Blumberg et al., 2007).    
Altered signal transduction and transcription pathways in epidermal 
keratinocytes have been suggested as an explanation for dysregulation of 
keratinocyte proliferation in psoriasis (McKenzie and Sabin, 2003). Indeed, mice 
with specific deletion of the I kappa B kinase 2 (IKK2), which is a protein 
involved in the process of activating NF-κB, in the epidermis developed a 
psoriasis-like pathology mediated by TNFα, implicating a role for NF-κB in the 
pathology of the disease (Pasparakis et al., 2002). A study by Zenz et al., 
targeted in the skin the deletion of specific transcription factors (junB and c-jun 
proteins) involved in activating transcription factor AP-1, which in turn is 
involved in the regulation of genes involved in keratinocyte differentiation 
(Eckert and Welter, 1996). Mice deficient of jun proteins within their 
keratinocytes demonstrated a psoriasis-like pathology (Zenz et al., 2005). 
Additionally, when JunB and jun were deleted in keratinocytes of recombinase 
activating gene 2 deficient mice or TNFR1 deficient mice, it was discovered that 
involvement of T and B cells, as well as TNFα,  were required for development of 
a psoriasis phenotype (Zenz et al., 2005). Interestingly, this study illustrated 
that changes within the epidermis can have consequences for distant sites such 
as joints, as these mice also developed arthritic like lesions (Zenz et al., 2005). 
Signal transducers and activators of transcription are involved in conveying 
extracellular signals to the nucleus. One of these, STAT3 was found to be 
activated in the lesional skin of psoriatic patients (Sano et al., 2005). Transgenic 
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mice with constitutively active STAT3 expression in the epidermis developed 
spontaneous psoriatic lesions, which were dependent on activated T cells (Sano 
et al., 2005). These studies therefore indicate that the pathogenesis of psoriasis 
is mediated by cross-talk between immune cells and keratinocytes. 
Recent emerging data has implicated IL-23 and Th17 cells (see 1.2.1.4) in the 
pathogenesis of psoriasis. IL-23 was implicated when it was shown that an 
injection of IL-23 into murine skin resulted in histopathological features similar 
to psoriasis (Chan et al., 2006). IL-23 is a heterodimeric protein composed of IL-
23p19 and a subunit of IL-12, IL-12p40 (Oppmann et al., 2000). IL-23 binds and 
signals through the IL-23 receptor complex which is composed of IL-12RB1 (IL-
12p40) and IL-23R subunits (Parham et al., 2002). In human psoriatic skin 
lesions, it was discovered that there was elevated mRNA levels of IL-23p19 and 
IL-12p40 compared to uninvolved skin (Lee et al., 2004). Additionally, it has 
been shown that polymorphisms in the genes that encode for IL-23R or IL-12p40 
can contribute to the psoriasis phenotype and depending on the polymorphism in 
these genes, they can promote susceptibility or protection from developing 
psoriasis (Capon et al., 2007, Cargill et al., 2007, Nair et al., 2008). It is of note 
that STAT3 is the main mediator involved in IL-23 signalling (Yang et al., 2007). 
IL-23 can induce Th17 cells to produce Th17 cytokines (Aggarwal et al., 2003). 
Indeed IL-17 mRNA was detected in lesional psoriatic skin but not in uninvolved 
skin (Teunissen et al., 1998) and cells producing IL-17 have been isolated from 
the dermis of psoriatic lesions (Lowes et al., 2008). These studies therefore 
implicate Th17 and IL-17 (see 1.2.1.4) in the pathogenesis of psoriasis. Other 
Th17-type cytokines have also been implicated such as IL-22.  A study by Zheng 
et al., found that the inflammatory skin reaction induced by injections of IL-23 
was dependent on IL-22 (Zheng et al., 2007). Consistent with this, human studies 
have revealed elevated levels of IL-22 mRNA and protein levels in psoriatic skin 
(Boniface et al., 2007). It is of note that IL-12, a Th1 cytokine and IL-23, both 
signal using IL-12p40 subunit and the studies by Chan et al., and Zheng et al., 
both illustrated that the injection of IL-12 is able to mediate skin inflammation 
although not to the same extent. Therefore, the studies to date suggest that the 
pathogenesis of psoriasis seems to involve interactions between keratinocytes 
and immune cells, which are mediated by Th1 and Th17 pathways. 
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1.4.3.2  Psoriatic arthritis  
Psoriatic arthritis (PsA) is an inflammatory joint disease (arthritis) that is 
associated with psoriasis. As with all types of arthritis, inflammation of the 
joints results in swelling, redness and pain. Psoriatic arthritis is recognised as 
being distinct from rheumatoid arthritis (see 1.4.3.3) by clinical features such as 
involvement of distal interphalangeal joints, asymmetrical joint distribution, 
dactylitis (inflammation of the whole digit) and inflammation at the site where 
the tendon enters the bone, known as enthesitis (Gladman et al., 2005). 
Diagnosis depends on the presentation pattern of joints affected along with a 
history of psoriasis in the patient, or the patient’s family and can also involve 
radiographic imaging in which erosion of the joint and bony proliferations are 
characteristic of PsA (Kleinert et al., 2007). 
1.4.3.3 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily causes 
swelling and destruction of joints and their surrounding tissue. RA is a disease 
where complications occur away from the joint and it is associated with 
increased mortality (Gabriel, 2008). RA affects approximately 1% of the 
population in the UK and affects more women than men in a ratio of 3:1 
(Symmons et al., 2002). RA is described as an autoimmune condition because the 
immune system begins to attack host molecules. In many cases of RA, the 
immune system may produce antibodies that are specific for immunoglobulin 
class G (IgG) or citrullinated peptides (Schellekens et al., 1998). However, these 
can be present before the onset of disease. The trigger of clinical onset of 
disease is not entirely known, although genetic predisposition and environmental 
components are high risk factors. For example, RA is associated with certain 
alleles of HLA DR4 and smoking is implicated as an environmental risk factor in 
these individuals in the development of the disease (Klareskog et al., 2006).  
The clinical features of rheumatoid arthritis are presentation with stiffness and 
inflammation in several joints in a symmetrical pattern. Pathologically, the 
lining of the synovium becomes inflamed (synovitis) and synovial hyperplasia 
occurs due to increased numbers of leukocytes, including T and B cells 
infiltrating the synovium and proliferation of fibroblast-like synoviocytes 
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(Sweeney and Firestein, 2004). The synovium begins to invade the cartilage and 
forms a mass of tissue called the pannus. As disease progresses, the pannus 
begins to cause damage to the cartilage and erosion of the bone which can lead 
to joint destruction and severe disability (Sweeney and Firestein, 2004). 
Increased understanding of the mechanisms involved has allowed therapeutics to 
be developed. The most successful of these so far is anti-TNF therapy 
(Feldmann, 2002).   
1.4.4 Treatment of inflammatory diseases 
Patients with chronic inflammatory diseases suffer a severely reduced quality of 
life. Fortunately research into understanding the pathogenesis of the diseases, 
and in particular, how the various immune mechanisms involved in the 
inflammatory response can cause damage has revealed several therapeutic 
targets for treatment. New therapies have targeted cytokines as these are 
thought to be the principle mediators involved in inflammation (see 1.4.1). 
Therapies that block TNF include Etanercept (a fusion protein), Infliximab (an 
anti-TNFα chimeric monoclonal antibody) and Adalimumab (a humanised 
monoclonal antibody against TNF). Targeting IL-1, Anakinra is an IL-1 receptor 
antagonist.  Etanercept, Infliximab and Adalimumab have all been approved for 
use in psoriasis (Tzu and Kerdel, 2008) and RA. Infliximab is also used to treat 
Crohns disease (Mouser and Hyams, 1999) whilst use of Anakinra is restricted to 
treating RA (Bresnihan et al., 1998). A new emerging therapy is Tocilizumab, an 
anti-IL-6 receptor antibody which, in clinical trials has reduced disease activity 
in rheumatoid arthritis patients (Genovese et al., 2008). Although these 
therapies do improve clinical symptoms, one problem is that some patients do 
not respond well to these treatments. However, increased understanding of how 
the inflammatory process is mediated has led to targeting small molecules 
known as chemokines for alternative treatments (Pease and Williams, 2006). 
1.5 Chemokines 
Chemokines are small peptide molecules (8-12kDa) that belong to a larger 
family, known as cytokines. This subset of cytokines have the ability to regulate 
cell migration either for homeostasis (see 1.5.3.2) or to direct leukocytes to 
sites of inflammation or infection (see 1.5.3.1) and are also known as 
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‘chemotactic cytokines’. Due to their ability to guide the directional movement 
of leukocytes, chemokines are involved in multiple biological processes including 
lymphoid organ development, lymphocyte trafficking, angiogenesis and 
inflammation (Rot and von Andrian, 2004). The functional role of chemokines is 
discussed in detail in 1.5.3.  
To date, approximately 50 chemokines have been discovered with a shared 
homology of between 20 and 80% in amino acid sequences (Borish and Steinke, 
2003). To be classified as a chemokine, the molecule must have a characteristic 
biochemical hallmark (see 1.5.1) as well as the ability to regulate chemotaxis. 
Chemokines mediate their biological effects through their own family of 
chemokine receptors (see 1.5.2), which are part of a larger family of G Protein 
Coupled Receptors (Murphy et al., 2000). Chemokine ligands are often described 
as being ‘promiscous’ because many bind to multiple different receptors. Usually 
a member of a certain chemokine family will only bind to members of the 
relevant chemokine receptor family (i.e., CCLs mostly bind CCRs).  
1.5.1 Nomenclature 
Originally, upon identification, chemokines were given names reflecting their 
assumed function. However, due to the large number of chemokines discovered, 
and to prevent molecules being given multiple names, a systematic 
nomenclature system was established (Zlotnik and Yoshie, 2000).  
The structural motif required to be classified as a chemokine, is a series of 
cysteine residues. Chemokines are named according to the precise nature of this 
cysteine sequence, followed by L (for ligand) and a number. The spacing and 
positioning of the first two N-terminal cysteine residues determines their 
chemokine classification. Following this classification, chemokines are divided 
into four subfamilies. A summary of the systematic classification is shown in 
Table 1-2. 
CC chemokine family 
Chemokines assigned to the CC family have the first two N-terminal cysteine 
residues adjacent to each other (CC). Twenty-eight members, CCL1 to CCL28, 
currently belong to the CC chemokine family making it the largest of the four 
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subgroups. The majority of the CC chemokines are regarded as being important 
in controlling the movement of cells to sites of inflammation. Examples of CC 
chemokines in this role include CCL3 and CCL5, which are involved in eosinophil, 
macrophage and mast cell recruitment to sites of inflammation (Conti and 
DiGioacchino, 2001) whereas CCL2, CCL7, CCL8 and CCL13 are all involved in 
controlling the migration of monocytes. Other CC chemokines, such as CCL19 
and CCL21 function under homeostatic conditions and are important in 
coordinating the innate and the adaptive immune responses (see 1.5.3.2). CC 
chemokines tend to bind a subgroup of chemokine receptors referred to as CC 
chemokine receptors (CCRs; see 1.5.2) 
CXC chemokine family 
The CXC subfamily, where any amino acid (X) separates the first two adjacent 
cysteine residues, is the second largest family with 16 members. CXCL8 (IL-8) is 
an important chemokine that recruits polymorphonuclear cells and is the most 
potent chemokine for neutrophils. Additionally, CXCL8 can trigger firm adhesion 
of monocytes to vascular endothelium in vitro (Gerszten et al., 1999). Mice 
however do not express CXCL8 but MIP-2 and KC are homologues of human CXC 
chemokines and both bind murine CXCR2 (Bozic et al., 1994). Another CXC 
chemokine, CXCL12, was discovered to have an important role in embryonic 
development and haemopoiesis (see 1.5.3.3). 
Additionally, CXC chemokines can be further subdivided by the presence or 
absence of a specific motif, known as the ELR motif (see 1.5.3.4). The presence 
of the motif correlates with the ability of the chemokine to stimulate blood 
vessel formation, a process known as angiogenesis (see 1.5.3.4).  
 
XC and CX3C chemokine family 
The XC subfamily contains the second and fourth conserved cysteine residues 
whilst in the CX3C subfamily, chemokines contain three amino acids between 
the first and second cysteine residue. Two members form the XC subfamily (XCL1 
and XCL2) whilst the CX3C chemokine family only has one member, CX3CL1, also 
known as fractalkine (Bazan et al., 1997, Ono et al., 2003). CX3CL1 is one of two 
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chemokines that is membrane bound, the other is CXCL16 (Matloubian et al., 
2000) whereas all the others are secreted.  
Constitutive versus inflammatory chemokines 
Additionally, chemokines and their receptors can be broadly divided into 
constitutive or inflammatory subgroups. Homeostatic (constitutive) chemokines 
are present under normal conditions and have a role in basal leukocyte 
trafficking and lymphoid organ structure. CCL19, CCL21 and CCL25 are 
considered constitutive chemokines. Mice which are homozygous for the paucity 
of lymph node T cell (plt) mutation do not express CCL19 or CCL21 and this 
consequently results in T lymphocytes and dendritic cells being unable to home 
to the secondary lymphoid organs (Gunn et al., 1999). CXCR5 is a receptor which 
only binds one ligand, CXCL13 (Legler et al., 1998). CXCR5 deficient mice have 
defects in the development of B cell follicles within the spleen (Voigt et al., 
2000).  
In contrast, inflammatory (inducible) chemokines can be produced at very high 
levels upon stimulation with inflammatory agents. The genes for human 
inflammatory chemokines are mostly found on chromosome 17 for CC 
chemokines and inflammatory CXC chemokines are typically found on 
chromosome 4 (Murphy et al., 2000). Inflammatory chemokines, such as CCL2, 
CCL3 and CCL5, are produced by many different cell types and recruit 
leukocytes to sites of infection, inflammation or tissue injury. The chemokine 
receptor, CCR2, is regarded as an inflammatory receptor, which binds a 
subgroup of chemokines, previously named monocyte chemotactic proteins 
(MCPs 1-4), now known as CCL2, CCL7, CCL8 and CCL13 (Murphy et al., 2000). 
Inflammatory chemokines and their receptors tend to be more promiscuous than 
chemokines involved in basal trafficking and homing. However, some chemokines 
cannot be strictly classified as inflammatory or constitutive as they have the 
ability to function as both (Moser et al., 2004). A summary of inflammatory and 
constitutive chemokines is shown in Table 1-2. 
1.5.2 Chemokine receptors 
Chemokine receptors are seven transmembrane spanning receptors, which are 
coupled to heterotrimeric GTP binding proteins. Chemokine receptor length 
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varies between 340 and 370 amino acid and most contain a DRYLAIV motif in the 
second intracellular loop, which is highly conserved (Murphy et al., 2000). The 
three dimensional structure of chemokine receptors is not known and current 
models are based on the three dimensional structure of another G-protein 
coupled receptor (GPCR) known as rhodopsin (Palczewski et al., 2000). 
The chemokine receptors have a systematic classification system (Murphy et al., 
2000), in which receptors are named according to the subfamily of chemokines 
they bind, followed by R (for receptor) and a number. This is summarised in 
Table 1-2. 
CC chemokine receptors 
Currently the CCR subfamily consists of 10 receptors and all bind chemokines 
within the CC subfamily. CCR1 was the first CC chemokine receptor to be 
identified and is the receptor for multiple chemokines, which include CCL3, 
CCL5, CCL7 and CCL14 (Gao et al., 1997). CCR1 is expressed on monocytes, 
basophils, eosinophils, T and B lymphocytes. In mice lacking CCR1, neutrophils 
failed to migrate in response to CCL3 (Gao et al., 1997). Additionally, using a 
model of granuloma formation induced with Schistosoma mansoni eggs, the size 
of lung granuloma formation was reduced in CCR1 deficient mice and was also 
associated with an imbalance in Th1/Th2 cytokines (Gao et al., 1997). CCR1 
knockout mice have also been shown to prolong allograft survival in corneal- and 
cardiac- transplants (Gao et al., 2000, Hamrah et al., 2007) as well as showing 
partial resistance to development of experimental autoimmune 
encephalomyelitis (Rottman et al., 2000). 
CCR2 is predominantly expressed on monocytes but is also expressed on T cells 
and dendritic cells. Based on chemokine receptor expression, monocytes can be 
subdivided into two subsets, CCR2hi CX3CR1lo which migrate to sites of 
inflammation and a CCR2lo CX3CR1hi homeostatic subset (Geissmann et al., 
2003). In a model of experimental peritoneal inflammation, mice lacking CCR2 
were unable to recruit monocytes and macrophages to the peritoneum (Kurihara 
et al., 1997). It was also discovered, when mice deficient in CCR2 were crossed 
with apolipoprotein E (ApoE) null mice, that lack of CCR2 resulted in reduction 
of atherosclerotic lesions (Boring et al., 1998). In contrast, CCR2 is thought to be 
protective in a model of Alzheimer’s disease. Mice deficient in CCR2 displayed 
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accelerated disease progression and  reduced accumulation of microglia within 
the brain  (El Khoury et al., 2007). 
CCR3 is a chemokine receptor predominately expressed on eosinophils and its 
ligand CCL11 is a potent chemo-attractant and activator of this cell type (Elsner 
et al., 1998). Basophils, mast cells and Th2 cell subsets express CCR3 to a lesser 
extent and other ligands of CCR3 are CCL5, CCL7, CCL13, and CCL26 (Murphy et 
al., 2000). Due to the expression profile of CCR3 and the association of these 
cells with allergic disease, in particular asthma, CCR3 was thought to play a key 
role in these diseases. A study by Humbles et al., showed that after allergen 
challenge, eosinophils were unable to migrate to the lungs in CCR3 deficient 
mice (Humbles et al., 2002). It was discovered that large numbers of eosinophils 
had accumulated beneath the blood vessels in the subendothelial space in  CCR3 
deficient mice (Humbles et al., 2002). Additionally, in a model of allergic skin 
inflammation, eosinophils failed to migrate to the skin in CCR3 knockout mice 
(Ma et al., 2002). Together these data suggest that CCR3 plays a key role in 
mediating eosinophil migration and subsequently allergic disease. 
CCR4 is expressed on distinct subsets of T cells, such as Th2 and skin homing T 
cells (Bonecchi et al., 1998, Campbell et al., 1999). CCL17 and CCL22 are ligands 
which bind with high affinity to CCR4 (Imai et al., 1997, Imai et al., 1998). The 
contribution that CCR4 makes towards Th2 responses in the lung requires 
clarification since in a model of airway inflammation, which was Th2 dependent, 
no disrupted effects were seen in mice lacking CCR4 (Chvatchko et al., 2000). 
CCR4 is required in the homing of T cells to the skin (see 1.5.3.2). 
CCL3, CCL4, CCL5 and CCL8 are all ligands for CCR5, which is a major co-
receptor for HIV (see 1.5.4.1). Expression of CCR5 can be found on macrophages, 
dendritic cells and certain T cell subsets. CCR5 knockout mice infected with 
Listeria monocytogenes had reduced efficiency in clearing the infection and had 
impaired macrophage function (Zhou et al., 1998). CCR5 is also involved in T cell 
stimulation within the immunological synapse (Contento et al., 2008) and is 
thought to be protective against West Nile virus (see 1.5.4.1). 
To date, only one ligand, CCL20, has been identified, which is able to bind CCR6 
(Baba et al., 1997). Various subsets of T cells, in particular Th17 cells and 
immature dendritic cells express CCR6. Using CCR6 knockout mice, CCR6 was 
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discovered to be involved in the localisation of DCs, homeostasis of lymphocytes 
and the immune response within the gut (Cook et al., 2000). CCR6 is involved in 
controlling the migration of Th17 cells to the intestine and the regulation of 
effector T cell subsets (Wang et al., 2009). CCR6 has a pathological role in 
experimental autoimmune encephalomyelitis (EAE) in which CCR6 has been 
shown to be involved in the initiation of EAE by regulating the entry of Th17 
cells into the central nervous system (Reboldi et al., 2009) and by controlling 
regulatory CD4+ T cells (Villares et al., 2009).  
Studies using CCR7 knockout mice confirmed the importance of CCR7 in 
lymphoid organ development as well as involvement in co-ordinating the innate 
and the adaptive immune response (see 1.5.3.2). CCR7 is a receptor for CCL19 
and CCL21 and is constitutively expressed on T cells and mature DCs in the 
lymphoid organs (Forster et al., 1999). CCR7 plays a key role in mediating the 
trafficking of mature dendritic cells from peripheral tissues to the lymph node 
and the role of CCR7 is discussed in more detail in 1.5.3.2.  
The role of CCR8 is not well-defined as studies involving this receptor are 
conflicting. CCR8 is the receptor for CCL1 and CCL16 and expression of CCR8 is 
predominantly on Th2 cells (Roos et al., 1997). A role for CCR8 in the functional 
Th2 response was implicated in the first study on CCR8 knockout mice. In the 
study, CCR8 knockout mice displayed a dysfunctional Th2 immune response, in 
which there was defective Th2 cytokine production and reduced eosinophil 
recruitment in an ovalbumin induced model of airway inflammation (Chensue et 
al., 2001). However, other studies have shown that absence of CCR8 did not 
affect Th2 cytokine response or eosinophilia in a murine model of allergic airway 
inflammation (Chung et al., 2003). In a model of ovalbumin induced allergic 
airway disease, CCR8 knockout mice developed pathological disease similar to 
wild-type mice and the absence of CCR8 did not affect the Th2 response in this 
model (Goya et al., 2003). Other studies have shown that CCR8 may have a 
negative impact on the immune response. In septic peritonitis, CCR8 knockout 
mice displayed an enhanced innate immune response to clear bacteria 
(Matsukawa et al., 2006). Additionally, in a model of asthma induced by fungal 
allergens, CCR8 knockout mice were able to clear the fungal material from the 
lung more rapidly than the wild-type (Buckland et al., 2007). These differences 
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may reflect the complexity of utilising distinct in vivo models to define the role 
of individual receptors. 
CCR9 binds CCL25 which is expressed in the small intestine (Zaballos et al., 
1999). Studies utilizing CCR9 deficient mice have demonstrated a role for CCR9 
in regulating T cell development within the thymus and migration of γδ T cells to 
the small intestine (Uehara et al., 2002). As a homing receptor for the gut, CCR9 
has been implicated in crohns disease (Papadakis et al., 2001) and also cancer 
(see 1.5.4.2). 
Another CC chemokine receptor to which CCL27 and CCL28, have been shown to 
bind is CCR10 (Homey et al., 2000b, Wang et al., 2000). CCR10 is expressed on a 
subset of T cells, which home in a CCL27 dependent manner to the skin (see 
1.5.3.2) and has been implicated in cutaneous diseases such as psoriasis (see 
1.5.4.3) and cancer (see 1.5.4.2). Additionally, CCR10 is involved in directing 
the migration of IgA producing plasma cells towards CCL28 expressed in mucosal 
tissue (Kunkel et al., 2003). 
CXC chemokine receptors 
To date, there are six chemokine receptors which belong to the CXC subfamily 
and are accordingly named CXCR1 through to CXCR6 (although see 1.6.3 for 
CXCR7). CXCR1 and CXCR2 are two closely related receptors with 77% homology 
and bind to CXCL8 in humans with high affinity. Both receptors are 
predominately expressed on human neutrophils (Doroshenko et al., 2002). CXCR1 
can also bind CXCL6 whereas CXCL1 to CXCL7 can all bind to CXCR2. CXCR1 
expression on human neutrophils is thought to be important for the clearance of 
urinary tract infection. Indeed, disease-associated polymorphisms in CXCR1 have 
been identified in children prone to the most severe form of urinary tract 
infection known as acute pyelonephritis (Lundstedt et al., 2007). In the same 
study, reduced expression of CXCR1 was found in the children prone to acute 
pyelonephritis (Lundstedt et al., 2007). Murine CXCR1 has been identified and 
shown to be a functional receptor but the exact role of murine CXCR1 is 
unknown (Fan et al., 2007). CXCR2 deficient mice displayed impaired neutrophil 
migration and CXCR2 is protective against Toxoplasma gondii infection (Del Rio 
et al., 2001). CXCR2 also plays a role in wound healing (see 1.5.3.4) and deletion 
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of CXCR2 slowed the progression of atherosclerosis in mice (Boisvert et al., 
2000). 
CXCR3 is highly expressed on activated lymphocytes, predominantly Th1 
lymphocytes and CXCL9, CXCL10 and CXCL11 are ligands for CXCR3. In a model 
of acute cardiac allograft rejection, CXCR3 deficient mice were resistant to the 
development of rejection (Hancock et al., 2000) and CXCR3 has also been 
implicated in atherosclerosis, glomerulonephritis and multiple sclerosis (Lazzeri 
and Romagnani, 2005).  
CXCR4 binds one ligand, CXCL12 (Nagasawa et al., 1999) and in mice, targeted 
deletion of CXCR4 is perinatally lethal showing an important role for CXCR4 in 
embryonic development and haemopoiesis (see 1.5.3.3). CXCR4, expressed on T 
lymphocytes, plays a role in the immunological synapse and is a major co-
receptor for human immunodeficiency virus (see 1.5.4.1).  
CXCR5, to date, only has one ligand which is CXCL13 (Legler et al., 1998). CXCR5 
is expressed on B lymphocytes and plays a role in B cell migration and 
organisation of secondary lymphoid organs (see 1.5.3.2). The last of the CXC 
chemokine receptors discovered to date is CXCR6. One ligand, CXCL16, is known 
to bind CXCR6 which is expressed on T lymphocytes and has been shown to have 
a minor role in the entry of human immunodeficiency virus (HIV) to T 
lymphocytes (Matloubian et al., 2000). 
CX3CR1 and XCR1 
CX3CR1 facilitates peripheral blood leukocyte migration and adhesion. In a 
model of atherosclerosis, reduced lesion size in ApoE and CX3CR1 double 
deficient mice was reported and thought to be mediated by CX3CR1 expression 
on macrophages (Combadiere et al., 2003) however impaired dendritic cell 
migration has also been reported (Liu et al., 2008). 
Neutrophils and B cells express XCR1 which supports chemotaxis towards XCL1 
(Huang et al., 2001). XCR1 has been implicated in rheumatoid arthritis as the 
receptor was found to be upregulated on mononuclear cells infiltrating the 
synovial tissue from joints of RA patients (Wang et al., 2004a). Within the RA 
synovium, XCL1 was produced by infiltrating T cells (Blaschke et al., 2003). 
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Cell specific chemokine receptors 
Each cell type expresses a certain ‘set’ of chemokine receptors, whose 
expression can be modulated over time by environmental stimuli. Additionally, 
chemokine receptors can distinguish between cell subsets, such as T cells. Naive 
T cells express CCR7 and, depending on the conditions during activation, CD4+ 
naive T cells can differentiate into various effector subsets each with their own 
pattern of receptors. Th1 cells tend to express CXCR3, CXCR6 and CCR5 whilst 
CCR4 and CCR8 are typically expressed on Th2 cells (Syrbe et al., 1999). Th17 
cells express CCR6 (Hirota et al., 2007b). Expression of CCR7 can also 
differentiate the subsets of memory T cells (Sallusto et al., 1999). Receptor 
expression can also change on cells under inflammatory conditions, for example 
on antigen presenting cells.  This allows the cells to move from the site of 
inflammation to the lymph nodes (see 1.5.3.2). In addition, patterns of 
chemokine receptors also allow cells to home to certain tissues (see 1.5.3.2).   
Cells can express various chemokine receptors and chemokines may have 
multiple target receptors (Mantovani, 1999). This means a single chemokine 
could enhance the infiltration of multiple cell types whilst other chemokines in 
the local environment affect different subsets of cells. Additionally, cells may be 
‘pulled’ in opposing directions when surrounded by multiple chemokines. Also by 
having multiple receptors on cells, if one chemokine receptor or ligand is 
defective then the biological function can be achieved by other chemokine 
receptors, therefore creating redundancy within the system. 
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 Systematic name Chemokine receptor 
CCL1 CCR8 
CCL2 CCR2 
CCL3 CCR1, CCR5 
CCL3L1 CCR5 
CCL4 CCR5 
CCL5 CCR1, CCR3, CCR5 
CCL6  
CCL7  CCR1, CCR2, CCR3 
CCL8 CCR2, CCR3, CCR5 
CCL9  
CCL10  
CCL11 CCR3 
CCL12 CCR2 
CCL13 CCR2, CCR3 
CCL14 CCR1 
CCL15 CCR1, CCR3 
CCL16 CCR1 
CCL17 CCR4 
CCL18  
CCL19 CCR7 
CCL20 CCR6 
CCL21 CCR7 
CCL22 CCR4 
CCL23 CCR1 
CCL24 CCR3 
CCL25 CCR9 
CCL26 CCR3 
CCL27 CCR10 
CCL28 CCR3, CCR10 
CXCL1 CXCR1, CXCR2 
CXCL2 CXCR2 
CXCL3 CXCR2 
CXCL4 CXCR3 
CXCL5 CXCR2 
CXCL6 CXCR1, CXCR2 
CXCL7 CXCR2 
CXCL8 CXCR1, CXCR2 
CXCL9 CXCR3 
CXCL10 CXCR3 
CXCL11 CXCR3 
CXCL12 CXCR4 
CXCL13 CXCR5 
CXCL14  
CXCL15  
CXCL16 CXCR6 
CX3CL1 CX3CR1 
XCL1 XCR1 
XCL2 XCR1  
Table 1-2. Classification of chemokines and their receptors 
Chemokines are classified according to their subfamily, CC, CXC, CX3C or C and the 
receptors are classified according to the subfamily of chemokines that they bind. 
Chemokines can also be classified as inflammatory (red), constitutive (blue) or function as 
both (yellow). The receptors for some chemokines are not known (left blank) or the 
functions for chemokines are not known (white). Table is adapted from (Moser et al., 2004, 
Zlotnik and Yoshie, 2000). 
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1.5.2.1 Chemokine receptor signalling 
Ligand binding to GPCRs catalyses the exchange of bound guanosine diphosphate 
(GDP) for guanosine triphosphate (GTP) in the α subunit of the G-protein.  
Consequently, the G-protein dissociates into active α and βγ subunits. The α 
and βγ subunits can subsequently activate downstream intracellular signalling 
pathways or directly affect functional proteins depending on the Gα subtype, 
which has four main classes Gs, Gi, Gq/11, Gα12/13 and a recently discovered 
fifth class, known as Gv (Oka et al., 2009). Chemokine receptors are 
predominantly thought to couple to Gi proteins for chemotaxis as ligand induced 
signalling was suppressed with pertussis toxin, an inhibitor of Gi proteins 
(Thelen, 2001). However, an alternative signalling pathway which is dependent 
on Gi proteins and also Gq proteins is required for dendritic cell migration in 
response to inflammatory agents (Shi et al., 2007). Additionally, CXCR4 and 
CCR5 recruited to the immunological synapse of T cells were coupled to Gq 
and/or G11 protein and lost their ability to initiate chemotaxis (Molon et al., 
2005).  An essential step for cell migration is the release of the subunits and the 
regulation of cell migration is mediated by the βγ subunit (Neptune et al., 1999). 
The βγ subunits activate the membrane-associated enzymes phospholipase Cβ2 
and phospholipase Cβ3 (Barr et al., 2000, Sankaran et al., 1998), which catalyse 
the cleavage of phosphatidylinositol-4, 5-bisphosphate leading to the formation 
of inositol-1, 4, 5-trisphosphate (IP3) and diacylglycerol (DAG). Increased levels 
of IP3 induce the release of calcium from intracellular vesicles resulting in a 
transient rise in the levels of free calcium within the cell. DAG activates protein 
kinase C. The βγ subunit also activates phosphatidylinositol 3 kinase γ (Stephens 
et al., 1994) leading to the activation of protein kinase B (Didichenko et al., 
1996), which is important in inducing changes within the cell required for 
chemotaxis (Li et al., 2000). Signalling is terminated by GTP hydrolysis, allowing 
re-association of α  with the βγ subunit. Signalling results in a variety of cellular 
responses such as chemotaxis, adhesion, respiratory burst and degranulation 
depending on the cell type, ligand and the receptor present. 
1.5.2.2 Chemokine receptor internalisation 
Upon ligand binding, chemokine receptors may internalise into the cell in two 
ways, either by clathrin mediated endocytosis or by lipid raft/caveolae-
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dependent internalisation (Venkatesan et al., 2003). Internalisation of a 
chemokine receptor can affect the response by the cell to chemokines. 
In clathrin-mediated endocytosis, ligand binding results in G-protein coupled 
receptor kinases phosphorylating residues of the carboxy terminus and 
intracellular loops on chemokine receptors, resulting in the G-protein becoming 
uncoupled from the receptor (Ferguson, 2001). Phosphorylation allows two 
adapter molecules, adaptin-2 and β-arrestin to associate with the receptor, 
recruit clathrin, and form clathrin coated pits (Laporte et al., 1999). These pits 
form from the cell membrane wrapping round the receptor and pinch off from 
the membrane. The chemokine receptor is targeted for recycling back to the 
cell surface (to be exposed to ligand) or for degradation in the late endosomal 
compartment. Studies have shown that CXCR1 requires both β-arrestins and 
dynamin for endocytosis (Barlic et al., 1999) while CXCR4 also requires β-arrestin 
but not dynamin (Cheng et al., 2000). 
There are reports that chemokine receptors can mediate receptor internalisation 
in a mechanism that does not involve clathrin; instead, they use lipid rafts or 
caveolae, which are cholesterol rich structures. Receptors enter a compartment 
known as a caveosome upon internalisation and fuse with endosomes which 
merge with the clathrin coated pathway (Sharma et al., 2003). Studies have 
shown that CCR5 uses the caveolae pathway by showing its colocalisation with a 
protein, known as caveolin 1, which is thought to be involved in stabilising the 
caveolae structure (Nguyen and Taub, 2002). However, CCR5 has also been 
shown to be dependent on clathrin mediated endocytosis (Signoret et al., 2005). 
Regulation of receptor internalisation is controlled by a family of small GTPases, 
known as Rabs, which cycle between the inactive GDP bound and active GTP 
bound states. Rab GTPases localise to specific compartments within the cell. 
Rab4, Rab5 and Rab11 are known to associate with the early endosomal 
compartment (van der Sluijs et al., 1992, Sonnichsen et al., 2000). Rab11 also 
associates with the recycling compartment (Ullrich et al., 1996). In vitro studies 
examining internalisation of CXCR2 after stimulation using overexpression of 
dominant negative mutants of Rab5 and Rab11 prevented receptor 
internalisation and recycling respectively (Fan et al., 2003). Overall, both cell 
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type and the regulation process may determine how a cell can respond to 
subsequent ligand. 
1.5.3 Functions of chemokines and their receptors 
Chemokines are described as chemotactic because they are able to elicit 
directional cell movement, known as chemotaxis. Due to the ability of 
chemokines to influence cell migration, chemokines are involved in many roles 
within the immune system. 
1.5.3.1 Leukocyte migration 
Leukocyte extravasation is the movement of leukocytes from the circulation 
through the blood vessel walls into the tissues, which is regulated by the 
endothelium. In particular, chemokines trigger the arrest of leukocytes whilst 
rolling along the endothelium (Campbell et al., 1998).  Leukocyte extravasation 
was initially characterised as a three-step cascade, involving leukocyte rolling, 
activation and arrest (Butcher, 1991) but is now viewed to have the additional 
steps of adhesion strengthening, intravascular crawling and transmigration (Ley 
et al., 2007).  
The expression of adhesion molecules on endothelial cells, which play an 
important role in the rolling and arrest of leukocytes, are upregulated by 
inflammatory stimuli. A family of adhesion molecules known as selectins are 
involved in the process of leukocyte rolling along the endothelium. Resting 
endothelial cells store P-selectin within specialised secretory vesicles and 
activation of endothelial cells by histamine or cytokines results in the expression 
of P-selectin on the cell surface (Jones et al., 1993, Ley and Reutershan, 2006). 
In response to inflammatory cytokine binding, such as TNFα or IL-1, transcription 
occurs within the endothelial cell resulting in the expression of E-selectin (Ley 
and Reutershan, 2006, Gotsch et al., 1994). The interaction of selectins with 
their ligands present on leukocytes allows leukocytes to adhere to the 
endothelium. The speed of leukocyte rolling along the endothelium was found to 
be faster in mice deficient in E-selectin compared to the speed of leukocytes 
rolling in wild-type mice and demonstrated that E-selectin was required for slow 
rolling of leukocytes (Kunkel and Ley, 1996). To support cell adhesion, P-selectin 
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and L-selectin require shear stress and ‘catch’ bonds to make the interactions 
stronger (Lawrence et al., 1997, Yago et al., 2004). A second class of molecules, 
known as integrins, present on leukocytes also participate in rolling and firm 
adhesion of leukocytes to the endothelium. Slow rolling in vivo was shown to 
require β2-integrins as well as E-selectin. A study by Dunne et al., revealed that 
slow rolling of leukocytes required lymphocyte function associated antigen-1 
(LFA-1) and macrophage antigen-1 (Dunne et al., 2002). Slow leukocyte rolling 
mediated by macrophage antigen-1 (MAC-1) was shown to bind intracellular 
adhesion molecule-1 (ICAM-1) present on the endothelium in order to do so 
(Dunne et al., 2003). Additionally recent evidence suggests E-selectin can induce 
LFA-1 on neutrophils into a structural conformation which has an intermediate 
affinity (Salas et al., 2004) for its ligand ICAM-1 on endothelial cells and allows 
for transient binding (Chesnutt et al., 2006). However, chemokines are the 
dominant activators of integrin-mediated adhesion between leukocytes and the 
endothelium.  
Inflammatory cytokines stimulate endothelial cells to express chemokines on 
their surface.  Additionally, platelets can also deposit CCL5 on the endothelium 
which then triggers the arrest of monocytes (von Hundelshausen et al., 2001). 
Most circulating leukocytes express their integrins in a low affinity state (Carman 
and Springer, 2003) and chemokines are capable of activating integrins into a 
high affinity state (Laudanna et al., 2002). Evidence from T cells suggest that 
chemokines, such as CXCL12 and CCL21, can increase the affinity of the LFA-1 
integrin (Constantin et al., 2000) by inducing ‘inside-out’ signalling  resulting in 
conformational changes  (Shamri et al., 2005). In human monocytes, increased 
affinity in very late antigen-4 (VLA-4) binding of vascular cell adhesion molecule-
1 involves conformational changes (Chan et al., 2001) and requires 
phospholipase C mediated calcium signalling to facilitate monocyte arrest 
(Hyduk et al., 2007).  Once firm adhesion of these cells occurs, transmigration 
can then take place. 
Transmigration (diapedesis) is a process where leukocytes cross the vascular 
wall, which is composed of endothelial cells connected by adhesive junctions, 
and the endothelial-cell basement membrane. Transmigration can be initiated 
by chemoattractants and shear stress signals (Cinamon et al., 2004). There is 
evidence that crawling along the endothelium is required for transmigration. 
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This has been shown for monocytes and neutrophils which are dependent on 
ICAM1 and MAC-1 present on the leukocyte (Schenkel et al., 2004, Phillipson et 
al., 2006). Diapedesis can occur in two ways, the paracellular route, which is the 
route most commonly used where the cells migrate between endothelial cells at 
their junctions, or transcellular where leukocytes go directly through a cell 
(Engelhardt and Wolburg, 2004).  
Leukocytes transmigrating by the paracellular route require an increase in 
intracellular calcium levels within endothelial cells which has been proposed to 
be activated by crosslinking signals, such as ICAM-1 or soluble proteins from 
activated leukocytes (Etienne-Manneville et al., 2000, Muller, 2003). Increased 
intracellular levels of calcium results in the activation of myosin light chain 
kinase resulting in a conformational change in myosin II regulatory light chain 
and subsequently leading to the retraction of endothelial cells that might 
facilitate leukocyte passage (Hixenbaugh et al., 1997). Myosin light chain kinase 
mediates vascular permeability and was required for neutrophil transmigration 
in the lung (Xu et al., 2008). Proteins involved in the transmigration of 
leukocytes are platelet endothelial cell adhesion molecule 1 (Muller et al., 
1993), CD99 (Schenkel et al., 2002), and a family of proteins known as junction 
adhesion molecules (JAMs), which are also members of the immunoglobulin 
superfamily (Bazzoni, 2003). Platelet endothelial cell adhesion molecule 1 
(PECAM-1), CD99 and JAMs have homophilic interactions but additionally JAMs 
can also interact with integrins to facilitate leukocyte transmigration 
(Ostermann et al., 2002). PECAM-1 can translocate from intracellular vesicles 
within endothelial cells to endothelial junctions (Mamdouh et al., 2003). 
Blocking PECAM-1 with a soluble form of PECAM-1, which acts as a competitive 
inhibitor, has been shown to reduce transmigration by 90%, in vivo (Liao et al., 
1997). To add to this, PECAM-1 deficient mice are still able to recruit leukocytes 
to sites of inflammation and additionally demonstrate there are PECAM-1 
independent mechanisms for leukocyte transmigration (Duncan et al., 1999). 
Blocking CD99 reduced diapedesis of monocytes and neutrophils whilst blocking 
both CD99 and PECAM-1 resulted in an additive effect on monocytes and 
leukocyte migration (Lou et al., 2007, Schenkel et al., 2002). Junction adhesion 
molecules are present on epithelial cells and endothelial cells localised in the 
tight junction of cells and are present on various leukocytes. The first evidence 
for a functional role for JAMs in vivo was shown in an air pouch model of skin 
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inflammation (Martin-Padura et al., 1998). By blocking JAM-A with a monoclonal 
antibody, monocytes and neutrophil transmigration was reduced (Martin-Padura 
et al., 1998). Subsequent studies have found that JAM-A can bind in a homophilic 
manner between JAM-A on leukocytes and endothelial cells (Bazzoni et al., 
2000). Additionally, JAM-A  is also able to bind leukocyte integrin LFA-1 and this 
interaction was required for diapedesis of T cells and neutrophils (Ostermann et 
al., 2002). In vitro studies have revealed JAM-A is able to relocate from 
intracellular junctions to the surface of endothelial cells in response to 
stimulation with TNFα and IFNγ (Ozaki et al., 1999). In addition to this, it has 
been shown at endothelial junctions that JAM-A co-localises with LFA-1 on 
projections of the neutrophil membrane, known as pseuopods (Shaw et al., 
2004). JAM-B is able to bind VLA-4 but in order to do so, JAM-B has to bind to 
JAM-C present on the leukocyte first (Cunningham et al., 2002). JAM-B has been 
implicated in lymphocyte transmigration across high endothelial venules (HEV) 
where it is highly expressed (Johnson-Leger et al., 2002). As well as binding to 
JAM-B, JAM-C can bind leukocyte integrin MAC1 (Santoso et al., 2002). 
Overexpression of JAM-C in endothelial cells in vivo resulted in an influx of 
monocytes and granulocytes in a lung inflammation model and a specific JAM-C 
antibody blocked the increase in recruitment of cells (Aurrand-Lions et al., 2005) 
illustrating a role for JAM-C in the transmigration process. 
The ability of leukocytes to penetrate endothelial cells by the transcellular route 
was first shown by neutrophils (Feng et al., 1998). Leukocytes travelling by the 
transcellular route also extend protrusive structures, termed podosomes, to 
break and invade the endothelial surface (Carman et al., 2007). The 
transcellular pathway is mediated by caveolin, a protein involved in endocytosis, 
and F-actin, a structural filament protein. It has been proposed that ligation of 
ICAM-1 leads to the translocation of ICAM-1 to caveolin and F-actin rich areas 
(Millan et al., 2006). Other endothelial membrane structures such as vesiculo-
vacuolar organelles (Dvorak and Feng, 2001) may also be involved in forming a 
transmembrane pore and allowing leukocytes to migrate through the cell. 
Upon migration into the surrounding tissues, leukocytes are guided by local 
sources of chemokines to move towards the area of infection or inflammation. 
Leukocytes are then activated either by cytokines released by resident cells 
within the tissue or by direct contact through recognition of pathogen.  
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1.5.3.2 Cell trafficking and surveillance 
During homeostasis, naive T lymphocytes (see 1.2.1.4) search for antigens by 
recirculating between the blood and the secondary lymphoid organs. In doing so, 
naive T cells exit the blood and enter the lymph nodes via high endothelial 
venules (von Andrian and Mempel, 2003). Two homeostatic chemokines, CCL19 
and CCL21 and the shared receptor for these chemokines, CCR7, are required for 
the migration of lymphocytes across the high endothelial venules (HEVs) into the 
lymph nodes. Naive lymphocytes, Tregs and a subpopulation of memory T cells, 
known as central memory T cells (TCM cells), all express CCR7 (Reif et al., 2002, 
Sallusto et al., 1999, Szanya et al., 2002). CCR7 expressing cells home towards 
the ligands, CCL19 and CCL21, which are displayed on HEVs. CCL21 is 
constitutively expressed by HEVs (Gunn et al., 1998) whereas CCL19 is 
transcytosed across the endothelial barrier and displayed on the lumen of HEV 
(Baekkevold et al., 2001). The importance of CCR7 and its ligands in mediating T 
cell entry into the lymph nodes was demonstrated in mice deficient in CCR7 
(Forster et al., 1999) and in mice unable to produce CCL19 and CCL21 due to a 
spontaneous plt mutation (Gunn et al., 1999). In both strains of mice, there are 
reduced numbers of naive T cells present in the lymph nodes. Once in the lymph 
node, and in the absence of antigen stimulation, T cells resensitise to 
sphingosine 1-phosphate (S1P), which binds the S1P receptor 1 expressed on T 
cells and mediates lymph node egress to the bloodstream via the efferent 
lymphatics (Schwab and Cyster, 2007). 
Antigen presenting cells (see 1.2.1.3), such as monocytes and dendritic cells 
patrol the blood and migrate to the tissues to scavenge for pathogens. During 
this process, monocytes and immature DCs express inflammatory chemokine 
receptors such as CCR1, CCR2 and CCR5 (MartIn-Fontecha et al., 2003). After 
antigen capture and maturation, macrophages and dendritic cells downregulate 
the inflammatory receptors and upregulate the expression of CCR7 (Yanagihara 
et al., 1998). CCR7 on ‘mature’ DCs mediates their exit from the tissues, such as 
the skin and intestine, into the draining and mesenteric lymph nodes 
respectively (Jang et al., 2006, MartIn-Fontecha et al., 2003).  
Once in the lymph nodes, DCs can activate naive lymphocytes to form effector T 
cells. Within the lymph node, CCR7 expressing cells are recruited to the T cell 
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area (the paracortex) which expresses CCL19 (Gunn et al., 1998) whereas 
CXCL13 is produced in the follicular compartment enriched with B cells (Schaerli 
et al., 2000). Indeed, (as mentioned above in 1.5.1) the structure of the 
follicular compartments within the spleen and lymph nodes are disrupted in 
CXCR5 deficient mice (Gunn et al., 1999). CXCR5 deficient mice displayed 
disorganisation of B cell follicles, and lymphocytes lacking CXCR5 were unable to 
migrate to B cell follicles (Forster et al., 1996). Additionally, CCR7 is also 
involved in secondary lymphoid organ development in coordination with CXCR5, 
as shown using mice double deficient in CXCR5 and CCR7 which lacked 
peripheral lymph nodes (Ohl et al., 2003). Following activation in the lymph 
node, follicular B cells upregulate CCR7 and downregulate CXCR5 which directs 
them to the T cell zone to receive help from CD4+ T helper cells (Reif et al., 
2002). Additionally, activated CD4+ T cells transiently express CXCR5 upon 
stimulation (Schaerli et al., 2000). During this process, a subset of T helper cells 
are generated, known as follicular Th cells, which express CD4 and stable 
expression of CXCR5 along with low levels of CCR7. These cells migrate towards 
the B cell area and co-localise with B cells providing help for antibody 
production (Hardtke et al., 2005). 
Upon encounter with antigen, lymphocytes upregulate their expression of 
adhesion molecules and chemokine receptors during differentiation, which 
allows them to migrate into distinct peripheral tissues, such as the skin or the 
intestine. The mechanism that drives the pattern of molecule expression is 
known as ‘imprinting’, which is mediated by DCs and the lymph node 
environment (Sigmundsdottir and Butcher, 2008). There is evidence that naive T 
lymphocytes are ‘reprogrammed’ during activation and the lymph node 
environment can influence this process. This was demonstrated in mice using 
naive transgenic T cells. Molecules important in intestinal homing were 
upregulated on the T cells when activated in the mesenteric lymph nodes yet 
when the cells were activated in the skin draining lymph nodes, molecules 
associated with trafficking to the peripheral tissues were upregulated (Campbell 
and Butcher, 2002). 
Indeed, environmental stimuli have been implicated in influencing the homing 
properties of antigen experienced memory or effector T cells, in which DCs 
process both the antigen present and the stimuli from the environment and 
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present them to T cells in the lymph node. For example, vitamin D3 which can 
be generated in the skin after exposure to sunlight, can increase the expression 
of CCR10 on proliferating T cells (Sigmundsdottir et al., 2007). Keratinocytes and 
DCs also express enzymes which are involved in vitamin D3 metabolism 
(Sigmundsdottir et al., 2007). Another example is retinoic acid, which is derived 
from the diet in the form of vitamin A. Retinoic acid has been shown in vitro to 
upregulate α4β7 integrin and  CCR9 on T cells, which are both homing receptors 
for the gut and bind mucosal vascular addressin cell adhesion molecule 1 and 
CCL25 respectively (Iwata et al., 2004). 
A subset of T lymphocytes express cutaneous lymphocyte-associated antigen 
(CLA) and are capable of homing to the skin (Sigmundsdottir and Butcher, 2008). 
CLA+ T lymphocytes are able to transmigrate through the blood vessel into the 
skin by binding E selectin (Fuhlbrigge et al., 1997). Chemokine receptors 
implicated in T cell homing to the skin are CCR4 and CCR10. Circulating CLA+ 
CD4+ T cells express CCR4 (Campbell et al., 1999) and a subset of these cells also 
express CCR10 (Hudak et al., 2002). Both have been shown to be important in 
recruiting T cells to inflamed skin (Reiss et al., 2001). Cells expressing CCR4 
migrate towards its ligand, CCL17, which is produced by keratinocytes and 
dendritic cells within the skin (Campbell et al., 1999). Epidermal keratinocytes 
constitutively and inducibly express CCL27, a ligand for CCR10 (Morales et al., 
1999).  
1.5.3.3 Haemopoiesis 
Chemokines not only play a role within the immune system but also play a role in 
development and migration of stem cells and haemopoiesis (see 1.1). CXCL12, 
also known as stromal derived factor 1, is a constitutive chemokine, which binds 
CXCR4 (Nagasawa et al., 1999). Mice deficient in either CXCR4 or CXCL12 show 
problems with heart, brain and blood cell development and ultimately the 
deletions are perinatally lethal (Nagasawa et al., 1996, Zou et al., 1998). The 
phenotype of the CXCR4 and CXCL12 deficient mice are very similar and this was 
thought to be due to the monogamous relationship between the ligand and its 
receptor. However, it is of note that another chemokine receptor, CXCR7 (see 
1.6.3) was recently shown to bind CXCL12 (Balabanian et al., 2005). Additional 
defects described in CXCR4 and CXCL12 deficient mice were problems with 
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myelopoiesis and B lymphocyte development (Nagasawa et al., 1996, Zou et al., 
1998). 
A role for CXCL12 and CXCR4 was demonstrated in the movement of 
haemopoietic stem cells (HSCs). HSC in CXCR4 deficient mice were able to move 
to the fetal liver but not from the liver to the bone marrow (Ma et al., 1999, Zou 
et al., 1998). CXCR4 has been found to be expressed on various tissue progenitor 
cells (Ratajczak et al., 2006) as well as haemopoietic stem cells (Rosu-Myles et 
al., 2000). Similarly, CXCL12 is expressed in many different tissues and organs 
within the body, such as within the bone marrow, lymph node and muscle 
derived fibroblasts (Ratajczak et al., 2003, Zou et al., 1998). HSCs are retained 
within the bone marrow of adult mice, and this is mediated by CXCL12.  
Inactivation of CXCL12 by neutrophil derived proteases allows mobilisation of 
HSCs into the blood (McQuibban et al., 2001). Indeed, this process has been 
targeted for stem cell mobilisation to increase numbers of HSC in the blood to 
harvest for use in stem cell transplants. In addition, engraftment of HSCs after 
transplantation induced homing to the bone marrow also requires CXCL12 and 
CXCR4. CXCL12 can stimulate the arrest of CD34+ cells mediated by integrins 
(Peled et al., 1999) and proteoglycans can present immobilised CXCL12 on bone 
marrow endothelial cells which can induce CD34+ cell adhesion (Netelenbos et 
al., 2002). The CXCR4 antagonist, AMD3100 can also stimulate rapid mobilisation 
of HSCs from the bone marrow (Broxmeyer et al., 2005). Evidence suggests that 
mobilisation and homing of HSCs depend on opposing expression levels of 
chemokine receptors and adhesion molecules on HSCs and it is the balance that 
determines whether stem cells home to the bone marrow or are mobilised into 
the bloodstream (Gazitt, 2004). 
1.5.3.4 Angiogenesis 
The formation of new blood vessels, known as angiogenesis, is an important 
physiological mechanism required after tissue damage for wound repair and has 
been implicated in tumour growth and many chronic inflammatory diseases 
(Carmeliet, 2005). Angiogenesis is a process balanced by angiogenic and 
angiostatic factors, which promote or inhibit the formation of new blood vessels 
respectively. In order to form new vessel walls, the production of new 
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endothelial cells are required. Chemokines regulate this process by recruiting 
endothelial progenitor cells (EPCs) and inducing their proliferation. 
EPCs are a subtype of progenitor cells present within the bone marrow, which 
are able to migrate to the circulation and differentiate into mature endothelial 
cells. EPCs were initially isolated from adult peripheral blood (Asahara et al., 
1997) and subsequent characterisation of the phenotype of these cells revealed 
the expression of CD133, CD34 and vascular endothelial growth factor receptor-2 
(Peichev et al., 2000). One of the markers, CD133 (originally termed AC133) is a 
marker for haemopoietic stem and progenitor cells from human bone marrow 
and peripheral blood (Yin et al., 1997). Subsequently, it was discovered that a 
bone marrow derived population of CD133+ cells could also be differentiated and 
expanded into endothelial progenitor cells (Quirici et al., 2001). Additionally, a 
CD34 negative population of cells isolated from peripheral blood can also give 
rise to EPCs and this population of cells is a subset of CD14+ monocytes that are 
able to transdifferentiate into endothelial cells (Harraz et al., 2001). As a result, 
the exact definitions of EPCs remain controversial due to the different 
populations of cells within the blood that can acquire an endothelial phenotype.  
Like haemopoietic stem cells, EPCs are mobilised from the bone marrow stromal 
niche to the vascular compartment of the bone marrow and this process is 
initiated by the matrix metalloproteinase 9 (Heissig et al., 2002). An important 
trigger for the mobilisation of EPCs is the interaction between CXCL12 and 
CXCR4. Not only is CXCL12 expressed on bone marrow stromal cells but also on 
endothelial cells (Petit et al., 2007). CXCL12 gene expression is regulated by the 
transcription factor, hypoxia inducible factor-1α which is upregulated in hypoxic 
tissue (Ceradini et al., 2004) and in damaged arteries (Karshovska et al., 2007) 
which in turn recruits CXCR4+ progenitor cells. Once mobilised, EPCs can then 
home to sites of endothelial injury and ischaemia, a process regulated by 
chemokines, and contribute to endothelial regeneration and repair. 
The CXC subfamily of chemokines can regulate angiogenesis and within this 
family there are angiogenic and angiostatic members (Strieter et al., 2005). The 
CXC chemokines have an additional structural motif near the first N- terminal 
cysteine residue that determines their angiogenic or angiostatic properties. This 
motif consists of three amino acids, which are glutamic acid, leucine and 
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arginine, known as the ELR motif (Strieter et al., 1995).  Members that contain 
this motif tend to be angiogenic whereas members that lack the ELR motif tend 
to be angiostatic. CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8 are all 
angiogenic factors that mediate their effects through CXCR2 (Addison et al., 
2000). Moreover, by mutating the ELR motif in CXCL8, it was no longer 
angiogenic but in fact angiostatic (Strieter et al., 1995). Angiostatic factors 
include CXCL9 and CXCL10 (Angiolillo et al., 1995, Arenberg et al., 1996). There 
is an exception to the rule of ELR correlation within the CXC subfamily and that 
is CXCL12 which lacks the ELR motif but is angiogenic (Strieter et al., 2005). 
However, angiogenic properties are not just restricted to the CXC chemokines or 
the presence of an ELR motif. CCL11 and CX3CL1 are examples of chemokines 
outwith the CXC subfamily that are angiogenic (Lee et al., 2006, Salcedo et al., 
2001) and evidence has shown that CCL21 is angiostatic (Vicari et al., 2000).  
All of the ELR+ CXC chemokines bind to CXCR2, which is expressed on EPCs 
(Addison et al., 2000). Mice lacking CXCR2 displayed delayed wound healing 
(Devalaraja et al., 2000), illustrating that CXCR2 is a key receptor to the process 
of angiogenesis. In another study, blocking keratinocyte derived chemokine (KC/ 
CXCL1), a ligand of CXCR2, after arterial injury in ApoE deficient mice, resulted 
in inhibition of endothelial recovery (Liehn et al., 2004). The receptor through 
which CXC chemokines are thought to mediate their angiostatic effect is CXCR3. 
Ligands that can bind CXCR3 present on endothelial cells were found to mediate 
angiostatic activity (Romagnani et al., 2001). CXCR3 exists as two splice variants 
and one variant, CXCR3B was found to mediate the angiostatic activity of CXCL4, 
CXCL9 and CXCL10 (Lasagni et al., 2003) and binding to CXCR3B by CXCL4 and 
CXCL10 has been shown to activate the p38 (MAPK) pathway (Petrai et al., 
2008). A role for CCR2 and CCL2 in the homing of EPCs after endothelial injury 
has also been shown. Inflamed endothelial cells have been shown to express 
CCR2 (Weber et al., 1999). Indeed, bone marrow derived myeloid cells 
overexpressing CCL2 were infused in vivo after arterial injury and resulted in 
accelerated healing of the endothelium (Fujiyama et al., 2003). 
1.5.4 Role of chemokines and their receptors in disease 
The process of inflammation is a delicate balancing act. Acute inflammation is 
beneficial to host defence against infection and for tissue repair. However, if 
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inflammation persists and does not resolve, this leads to chronic inflammation 
(see 1.4.3). Central in many inflammatory diseases is the infiltration and 
recruitment of leukocytes mediated by chemokines. As a result, chemokines and 
their receptors have been implicated in the pathogenesis of a wide range of 
diseases from autoimmune diseases, for example multiple sclerosis, to 
inflammatory and vascular diseases such as atherosclerosis, and even tumours 
(Gerard and Rollins, 2001). 
1.5.4.1 Human immunodeficiency virus 
Human immunodeficiency virus (HIV) was identified in 1983 as a retrovirus, 
which caused acquired immunodeficiency syndrome (Gallo and Montagnier, 
2003). A clinical characteristic of advanced HIV-mediated disease is a fall in the 
number of circulating CD4+ T cells. It was later discovered that envelope 
proteins, mainly glycoprotein 120 (gp120) present on the surface of HIV could 
bind to CD4 (Dalgleish et al., 1984). This explained why the virus tended to 
infect cells expressing CD4, predominately CD4+ T cells. The entry of HIV into 
cells was demonstrated to be facilitated by chemokine receptors, CCR5 and 
CXCR4 (Deng et al., 1996, Dragic et al., 1996). Binding of gp120 to CD4 results in 
conformation changes in gp120, which in turn is then able to bind to the 
chemokine receptor (Wu et al., 1996). This subsequently results in membrane 
fusion and expulsion of viral contents into the cell. 
Originally, HIV strains were classified according to the target cellular tropism.  
M-tropic strains of HIV replicated in macrophages whilst T-tropic strains infected 
T-cells. T-tropic strains preferentially use CXCR4 and M-tropic use CCR5 to gain 
entry to the cells (Lusso, 2006). Subsequently, the HIV strains were designated 
according to the coreceptor used. For example X4 strains are CXCR4 specific, R5 
strains are CCR5 specific and R5/X4 strains are dual tropic and can use either 
CXCR4 and CCR5 to enter their target cells (Berger et al., 1998). Other 
chemokine receptors, such as CCR2B, CCR3, CCR8 and CX3CR1 have been shown 
to be used by certain HIV strains for cell entry in vitro (Lusso, 2006). 
Chemokines also play a role in HIV pathogenesis. CD8+ T cells produced 
chemokines which were able to suppress replication of HIV in CD4+ T cells (Levy 
et al., 1996). These chemokines were CCL3, CCL4 and CCL5, which are all 
capable of binding to CCR5 and therefore were reducing the ability of HIV to 
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bind to CCR5 (Cocchi et al., 1995). Indeed high levels of CCR5 binding 
chemokines are associated with slower disease progression (Ullum et al., 1998). 
Additionally, CCL3L1, a potent ligand for CCR5, has variable copy numbers in 
individuals due to duplicated isoforms of the gene which encodes CCL3 (Townson 
et al., 2002). Subsequently, low CCL3L1 copy numbers was discovered to be 
associated with increased susceptibility to HIV (Gonzalez et al., 2005).  
Interest in targeting chemokine receptors in HIV has arisen from evidence of a 
genetic polymorphism associated with the disease. A 32 base pair deletion in the 
gene encoding CCR5 results in a loss of function receptor and individuals 
homozygous for this deletion (known as CCR5∆32), which occurs in 1% of the 
Caucasian population, are resistant to HIV infection (Liu et al., 1996). However, 
20% of the Caucasian population are heterozygous for the CCR5∆32  mutation 
and in those that do get HIV, the rate of progression is slower (de Roda Husman 
et al., 1997). Other polymorphisms in CCR2, CX3CR1, CXCL12, CCL5 and CCL3 
genes have been discovered and have been associated with host resistance or  
susceptibility to HIV and disease progression (Reiche et al., 2007). 
Since individuals with the CCR5∆32 mutation developed normally and seemed 
healthy, this lead to targeting CCR5 for HIV therapy. Indeed, one drug known as 
Maraviroc has been approved for clinical use in HIV. Maraviroc is a CCR5 
antagonist, which blocks the entry of HIV into CCR5 expressing cells by 
preventing the interaction between CCR5 and gp120 (Dorr et al., 2005). Another 
drug, AMD3100 was also able to inhibit HIV activity, in particular T-tropic strains 
by acting as a CXCR4 antagonist (Schols et al., 1997). During clinical trials for 
AMD3100, it was discovered that AMD3100 resulted in an increase in circulating 
CD34+ haemopoietic stem cells (Liles et al., 2003). As a result, AMD3100, is a 
drug currently approved for use to enhance the mobilisation of stem cells into 
the blood for collection and use in autologous transplantation in patients with 
haematological malignancies (Devine et al., 2004). 
Recent evidence suggests that CCR5 does play a role within host defence. CCR5 
has been shown to play a key role in the survival of mice infected with West Nile 
virus (Glass et al., 2005). West Nile virus is a virus transmitted by mosquitoes 
which can infect humans and manifests clinically with fever and sometimes 
neurological problems, such as meningitis and encephalitis (Hayes and Gubler, 
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2006). Mice infected with West Nile virus showed increased expression of 
chemokines, in particular CCR5 ligands such as CCL3, CCL4 and CCL5, within the 
brain (Shirato et al., 2004). CCR5 was shown to be involved in mediating 
leukocyte trafficking to the brain and was crucial in eliminating the virus form 
the brain (Glass et al., 2005). Subsequently, a role for CCR5 was examined in 
humans displaying symptoms of West Nile virus infection and the frequency of 
CCR5∆32 within the cohort. It was concluded that individuals homozygous for  
CCR5∆32 were at increased risk of West Nile virus infection and that CCR5 was 
indeed protective (Glass et al., 2006). 
1.5.4.2 Cancer 
Uncontrollable cell growth can ultimately result in cancer, which involves many 
steps. Primary tumour development requires signals which allow the tumour to 
grow and escape detection from the immune system (Hanahan and Weinberg, 
2000). The formation of secondary tumours in organs at a distant site from the 
original tumour is known as metastasis. For metastasis to occur, tumours must 
invade vascular or lymphatic vessels, home to other organs, promote growth and 
survival in the new environment (Gupta and Massague, 2006). Roles for 
chemokines and their receptors in cancer have been established and play a role 
in directing cells during metastasis as well as tumour cell growth, survival and 
angiogenesis (Balkwill, 2003). 
Tumours do not only consist of cancerous cells but also contain leukocytes which 
influence the tumour microenvironment (Balkwill and Mantovani, 2001). There is 
evidence that chemokines associated with tumour cells can help evade the 
immune response and prevent rejection of the tumour (Coussens and Werb, 
2002). For example, ovarian cancer produces CCL2 and CCL5 (Negus et al., 1995, 
Negus et al., 1997) and their levels of expression were found to correlate with 
the numbers of macrophages and lymphocytes localised within the area of 
chemokine production respectively (Negus et al., 1997). Tumour cells can also 
promote an environment that helps them to survive by producing chemokines 
that preferentially select Th2 lymphocytes and evade the immune response 
against tumours (Balkwill and Mantovani, 2001). In Kaposi sarcoma, three 
chemokines,  which can attract Th2 cells, are encoded by the human kaposi 
sarcoma-associated herpes virus (Sozzani et al., 1998). There is evidence that 
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tumour associated macrophages (TAMs) are M2 polarised macrophages 
(Mantovani et al., 2004) and can release IL-10 which is immunosuppressive (Sica 
et al., 2000). TAMs also play a role in tumour progression, metastasis and 
angiogenesis (Bingle et al., 2002, Lin and Pollard, 2007). Additionally infiltrating 
leukocytes and stromal cells are thought to promote tumour progression by 
producing matrix metalloproteinases (Giraudo et al., 2004). Indeed, CCL2, CCL4 
and CCL5 can induce MMP-9 in macrophages (Robinson et al., 2002). 
Chemokines also contribute to tumour growth and the best-characterised 
chemokines for this role are CXCL1, CXCL2 and CXCL3 (also known as the growth-
related oncogene (GRO) family of chemokines). These chemokines act as 
autocrine growth factors in various cancers (Luan et al., 1997). CXCL1, CXCL2, 
CXCL3 and CXCL12 can all activate the phosphatidylinositol 3-kinase AKT 
pathway (Curnock et al., 2002) which promotes cell proliferation and survival in 
cancerous cells (Vivanco and Sawyers, 2002). Additionally, chemokines can 
either promote or inhibit angiogenesis (see 1.5.3.4). The expansion of a solid 
tumour mass requires angiogenesis as new blood vessels are required to supply 
the cancerous tissue with oxygen and nutrients from the blood to survive  
(Hanahan and Weinberg, 2000).  
Metastasis is not a random process but is actually an ordered and specific 
process (Gupta and Massague, 2006). For example, secondary tumours that 
metastasize from breast cancer tend to be found in bone marrow, lymph nodes, 
lung and liver directed by chemokines and their receptors (Muller et al., 2001). 
Indeed, in many types of cancer, malignant cells express increased levels of 
chemokine receptors, with the most widely expressed receptors being CXCR4 
and CCR7, although CCR9 and CCR10 are also expressed. Human breast cancer 
and melanoma cell lines were discovered to express chemokine receptors that 
may be characteristic for each type of cancer. CXCR4 was found to be the 
dominant chemokine receptor on metastasising breast cancer cells whilst CCR10 
was typically the highest expressed on the metastatic melanoma cell lines 
(Muller et al., 2001). Therefore, tumour cells expressing chemokine receptors 
may migrate and metastasise to sites where the ligands are expressed. 
Expression of CCR7 has been found in various cancers, including breast cancer 
(Muller et al., 2001), non-small lung cancer (Takanami, 2003) and oesophageal 
squamous cancer (Ding et al., 2003) in which expression of CCR7 was associated 
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with lymph node metastasis and correlated with poor clinical outcome. 
Transfection of B16 murine melanoma cells with CCR7, which resulted in CCR7 
being expressed higher than CCR10, resulted in the melanoma cell metastasising 
more efficiently to the lymph nodes (Wiley et al., 2001). Furthermore, 
metastasis to the lymph nodes was blocked with anti-CCL21 antibody (Wiley et 
al., 2001). The skin is a common site of metastasis for melanoma cancer cells, 
which highly express CCR10 and bind CCL27, which is also highly expressed in the 
skin (Murakami et al., 2003). Moreover, a form of T cell lymphoma known as 
cutaneous T cell-lymphoma, forms tumours within the skin and also expresses 
CCR10 (Notohamiprodjo et al., 2005). Another chemokine receptor, CCR9 is 
expressed in melanoma and prostate cancer cells (Hwang, 2004, Singh et al., 
2004) and CCR9 expression is correlated with metastasis to the small intestine 
(Letsch et al., 2004) where it’s ligand, CCL25 is expressed (Zaballos et al., 
1999). 
1.5.4.3 Psoriasis 
As well as dysregulation in keratinocyte proliferation, altered activity of immune 
cells within the skin also occurs in psoriasis (see 1.4.3.1). There is increasing 
evidence of the involvement of chemokines and their receptors in this 
dysregulation of immune cells.  
CXCL8 was one of the first chemokines to be associated with psoriasis (Schroder 
and Christophers, 1986), however CXCL1 is another chemokine that is increased 
in the lesions of psoriatic skin, interestingly it colocalises with CXCL8 (Gillitzer 
et al., 1996). Both CXCL1 and CXCL8 can bind CXCR1 and CXCR2, which are both 
predominantly expressed on neutrophils (Morohashi et al., 1995). Indeed, within 
the epidermis of psoriatic skin, overexpression of CXCR2 has been attributed to 
infiltrating neutrophils, but also keratinocytes (Kulke et al., 1998).  
Keratinocytes are capable of producing CCL2 and CCL5 upon stimulation with 
TNFα and IFNγ (Li et al., 1996). Expression of CCL2 mRNA is present within 
psoriatic lesions (Gillitzer et al., 1993) and CCL2 protein expression has been 
located to cells within the epidermis of normal and psoriatic skin (Deleuran et 
al., 1996). CCL2 can bind CCR2, a receptor that is expressed on monocytes and 
macrophages. Monocytes from peripheral blood of psoriatic patients were found 
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to have elevated levels of CCR2 expression compared to controls and CCR2 
positive cells were present in psoriatic skin biopsies (Vestergaard et al., 2004).  
T lymphocytes have been implicated in the pathogenesis of psoriasis and studies 
indicate that CCL27, CCL20, CCR10 and CCR6 play a role in recruiting T 
lymphocytes to the skin.  In inflammatory skin diseases such as psoriasis and 
atopic dermatitis, the majority of T lymphocytes infiltrating the skin express 
CCR10 (Homey et al., 2002). As mentioned in 1.5.3.2, CCL27 is produced by 
epidermal keratinocytes (Morales et al., 1999). Consistent with this, the 
interaction between CCL27 and CCR10 regulates T cell recruitment to normal 
skin as well as inflamed skin (Homey et al., 2002). Additionally skin homing T 
cells also express CCR4 (Campbell et al., 1999). Blocking CCR4 or CCL27 in mice 
prevented the migration of lymphocytes to inflamed skin (Reiss et al., 2001). 
CCL20 is another chemokine that has been shown to be associated with psoriasis. 
Homey et al., have shown that CCL20 and its receptor, CCR6 are upregulated in 
psoriatic skin (Homey et al., 2000a). In addition, this study showed that 
keratinocytes expressing CCL20 colocalised with skin infiltrating T lymphocytes 
and high levels of CCR6 were expressed on skin homing T lymphocytes (Homey et 
al., 2000a). Another receptor with a potential role in psoriasis is CXCR3, which is 
expressed on dermal lymphocytes and the ligands for CXCR3, CXCL9 and CXCL10, 
were upregulated in lesions of psoriatic skin (Rottman et al., 2001).  
1.5.4.4 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a debilitating chronic inflammatory disease (see 
1.4.3.3). Within the synovium of rheumatoid arthritis patients, the inflammatory 
infiltrate consists of a mixture of cells including macrophages, T cells, B cells, 
neutrophils, mast cells and dendritic cells. The recruitment of inflammatory 
cells to the synovial tissue is mediated by chemokines and their receptors, of 
which several have been identified in situ. The cellular infiltrate within the 
synovial tissue of rheumatic joints expresses chemokine receptors including 
CCR5, CCR2, CCR3, CXCR3 and CXCR2 (Szekanecz et al., 2003). 
Studies have shown that synovial fluid and tissues from rheumatoid arthritis 
patients express high levels of CCL2 (Koch et al., 1992). CCL2 is a chemokine 
that can attract T lymphocytes in addition to monocytes. CCL2 can also 
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stimulate cells within cartilage (chondrocytes) to produce MMP-3 which degrades 
the extracellular matrix (Borzi et al., 2000). Additionally, CCL2 and other 
chemokines such as CXCL10 and CCL13 are able to increase the proliferation of 
fibroblast like synoviocytes resulting in synovial hyperplasia (Garcia-Vicuna et 
al., 2004). Targeting CCL2 in mice resulted in a reduction in macrophage 
infiltration and reduced disease severity of arthritis (Gong et al., 1997). In a 
collagen induced arthritis model, CCR2 null mice displayed enhanced T cell 
production  and accumulation of macrophages within the joint (Quinones et al., 
2004). 
Additionally, CCL5 is another chemokine implicated in the pathogenesis of the 
disease. Expression of CCL5 is seen in the synovial lining of rheumatoid joints 
and is produced by synovial T cells (Robinson et al., 1995). In an adjuvant 
induced arthritis model in rats, blocking CCL5 was shown to ameliorate the 
disease (Barnes et al., 1998). Small molecule antagonist blocking CCR5, a 
receptor for CCL5, in a collagen induced arthritis model resulted in inhibition of 
T cell migration and reduction in disease severity (Yang et al., 2002).    
Elevated levels of CCL20 were discovered in the rheumatoid joint along with 
expression of its receptor CCR6. It was found that expression of CCL20 in the 
joint resulted in the recruitment of cells expressing CCR6 (Matsui et al., 2001).  
Th17 cells express CCR6 and have been shown to be recruited to the joint in a 
murine model of arthritis (Hirota et al., 2007b). 
In addition, synovial fluid from RA patients contains elevated levels of CXCL8 
and the production of CXCL8 in synovial tissues is mediated by macrophages 
(Koch et al., 1991). Ligands of CXCR3, CXCL9 and CXCL10 are both upregulated 
in RA synovial tissue and synovial fluid (Patel et al., 2001). As well as being 
involved in the recruitment of macrophages, both are able to enhance 
proliferation of fibroblast-like synoviocytes (Garcia-Vicuna et al., 2004). 
Increased levels of XCL1 and CX3CL1 are also present within synovial fluid of 
rheumatoid arthritis patients (Volin et al., 2001, Wang et al., 2004a) as well as 
increased expression of XCR1 on mononuclear cells in synovial tissue (Wang et 
al., 2004a). CX3CL1 is thought to be one chemokine involved in mediating 
angiogenesis in rheumatoid arthritis (Volin et al., 2001). 
Vicky King, 2010   Chapter 1, 82 
These studies show chemokines and their receptors play a pathological role in 
chronic inflammatory diseases such as psoriasis and rheumatoid arthritis. 
Targeting chemokines and their receptors within these diseases may provide 
potential therapies. 
1.6 Atypical chemokine receptors 
In recent years, there has been the discovery of atypical chemokine receptors 
(Nibbs et al., 2003), which are officially chemokine binding proteins according to 
the international union of pharmacology (IUPHAR) classification system (Murphy 
et al., 2000). These seven transmembrane spanning proteins share homology 
with true chemokine receptors and bind chemokines, but these receptors do not 
seem to signal upon ligand binding, at least not using the classical signalling 
pathways used by GPCRs (see 1.5.2.1). With no evidence of signalling, the 
atypical receptors do not receive a classical chemokine receptor name and are 
classified as chemokine binding proteins. Within this group, is the Duffy Antigen 
Receptor for Chemokines (DARC), D6 and CCX-CKR, which are alternatively 
labelled as ‘silent’ receptors (Graham, 2009). Another receptor beginning to 
emerge as a silent receptor is CXCR7. Although DARC, D6 and CCX-CKR may not 
be able to signal and induce chemotaxis, studies show that these receptors have 
an important role within immunity and inflammation (Graham, 2009). 
1.6.1 DARC 
DARC was originally known as the Duffy blood group antigen, which was found to 
be present on red blood cells and forms a blood group system (Hadley and 
Peiper, 1997). However, it was later discovered that the Duffy antigen allowed 
entry of parasites responsible for malaria, such as Plasmodium vivax (Horuk et 
al., 1993). Individuals who lack DARC on red blood cells, due to a polymorphism 
in the promoter which prevents the transcription factor GATA-1 from binding 
thus blocking expression of DARC on red blood cells, are resistant to malaria  
(Tournamille et al., 1995). It is thought that this mutation may have emerged 
due to selective pressure to prevent malaria infection.  
Following cloning, DARC was originally thought to be a nine transmembrane 
receptor (Chaudhuri et al., 1993) but was later proposed to be a seven 
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transmembrane spanning structure similar to the chemokine receptor family. 
DARC lacks the conserved DRYLAIV motif and shows no increase in intracellular 
calcium subsequent to ligand binding (Neote et al., 1994). However, DARC can 
bind 11 ligands, including those from the CC and CXC family with preference for 
the inflammatory subset within both families (Gardner et al., 2004). Chemokine 
binding to DARC is localised to the amino terminal domain of the receptor (Lu et 
al., 1995) and requires a disulphide bridge between the first and fourth cysteine 
suggesting that sequences within the pocket caused by the disulphide bond are 
important (Tournamille et al., 1997). As well as being expressed on 
erythrocytes, DARC is also expressed on vascular endothelial cells in various 
organs and within the cerebellum (Hadley et al., 1994, Horuk et al., 1996). 
Individuals who lack DARC on red blood cells still express DARC on vascular 
endothelial cells (Peiper et al., 1995) leading to suggestions that DARC may play 
an important role within this location.  
DARC on erythrocytes, may function as a ‘chemokine sink’ (Darbonne et al., 
1991) and as a result may prevent activation of circulating leukocytes. Indeed, 
DARC deficient mice also show an exaggerated response to LPS and within the 
lungs and liver of these mice, increased numbers of polymorphonuclear cells 
were found (Dawson et al., 2000). It has been suggested that DARC on 
erythrocytes plays a role in maintaining the concentration of chemokines in 
plasma. Chemokines injected intravenously were more rapidly removed from the 
circulation in DARC deficient mice compared with wild-type mice (Fukuma et 
al., 2003). In another study, DARC deficient mice displayed larger tumours in a 
model of prostate cancer compared to the tumours in wild-type mice (Shen et 
al., 2006). Individuals lacking DARC on erythrocytes are at increased risk and 
mortality of various malignant diseases, including prostate cancer (Lentsch, 
2002). 
DARC is also expressed on endothelial cells and is proposed to play a role in 
transporting chemokines across the endothelium, a process known as 
transcytosis. CXCL8 transportation across the endothelium occurs through DARC 
(Middleton et al., 2002, Lee et al., 2003b) and DARC has been found associated 
with caveolae (see 1.5.2.2) within endothelial cells (Chaudhuri et al., 1997). 
DARC has also been shown to play a role in chemokine-induced angiogenesis in 
vivo using DARC transgenic mice (Du et al., 2002). Overexpression of DARC on 
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endothelial cells within these mice resulted in a reduced angiogenic response 
(Du et al., 2002). To contrast this, endothelial DARC was able to transcytose 
chemokines in vitro and using a model of contact hypersensitivity, leukocyte 
migration across the endothelium was enhanced in DARC transgenic mice 
compared to wild-type (Pruenster et al., 2009). 
Expression of DARC has been found to be present in a variety of diseases 
including renal disease and within rheumatoid arthritis synovium (Liu et al., 
1999, Patterson et al., 2002). Indeed, upregulation of DARC on the endothelium 
has been found to take place during renal transplant rejection, pneumonia and 
in the early stages of rheumatoid arthritis (Gardner et al., 2006, Lee et al., 
2003a, Segerer et al., 2000). The role of DARC in acute renal injury was 
investigated using two neutrophil dependent models. In both models, DARC 
deficient mice were protected from renal injury. In the ischaemic perfusion 
model, the number of neutrophils recruited to the kidney was reduced (Zarbock 
et al., 2007). However, in a chronic model of renal inflammation characterised 
by the accumulation of macrophages and T cells, renal recruitment of 
macrophages and T cells still occurred in DARC deficient mice (Vielhauer et al., 
2009). These studies suggest that DARC does not play a role in monocyte and T 
cell recruitment in prolonged renal inflammation. In an LPS induced acute lung 
injury model, erythrocyte DARC was shown to limit polymorphonuclear cell 
infiltration into the lung by acting as a chemokine sink and endothelial DARC was 
shown to play a minor role in promoting leukocyte transmigration through the 
pulmonary endothelium (Reutershan et al., 2009). 
1.6.2 CCX-CKR 
CCX-CKR (ChemoCentryx chemokine receptor) has previously been named as 
CCR11 and CCRL1 (Gosling et al., 2000, Khoja et al., 2000, Schweickart et al., 
2000). Human CCX-CKR can bind CCL19, CCL21 and CCL25 (Gosling et al., 2000) 
with high affinity. These chemokines are regarded as homeostatic and are 
involved in directing cells to tissues and secondary lymphoid compartments. 
CCL19 and CCL21 are ligands for CCR7 and CCL25 was previously thought to bind 
only CCR9. CCX-CKR has structural similarities to CCR7 and CCR9 and displays 29-
35% amino acid homology with the general chemokine receptor family (Gosling 
et al., 2000). However, like DARC, this receptor was not given an official 
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chemokine receptor name because there was no evidence of signalling (Murphy, 
2002). This was later confirmed following characterisation of mouse CCX-CKR 
which showed that murine CCX-CKR in transfected cells could bind CCL19, CCL21 
and CCL25 yet did not give any signs of signalling as calcium flux did not occur 
(Townson and Nibbs, 2002). This has led to the inclusion of CCX-CKR in the 
atypical chemokine receptor family. 
Mouse CCX-CKR is highly expressed in the heart and lungs and is expressed at 
lower levels in all tissues (Townson and Nibbs, 2002). However human CCX-CKR 
was found to be highly expressed in the heart, lung and small intestine as well as 
weak expression in the brain and skeletal muscles (Gosling et al., 2000, Townson 
and Nibbs, 2002).  Although CCX-CKR does not seem to signal, the biochemical 
and trafficking properties of the receptor have been defined (Comerford et al., 
2006). This study showed that human CCX-CKR was able to internalise and 
degrade ligand more efficiently than CCR7 and was able to continue internalising 
CCL19 when CCR7 was not. Internalisation of chemokine and receptor did not 
require components of the clathrin coated mediated endocytosis pathway, such 
as β-arrestin and clathrin coated vesicles but did require dynamin and is 
suggested to require caveolae (Comerford et al., 2006).  
CCX-CKR has been proposed to act as a scavenging receptor (Comerford et al., 
2006). In a study by Heinzel et al., CCX-CKR was shown to be involved DC homing 
via the afferent lymphatics under homeostatic conditions. Reduced numbers of 
CD11c+ MHCIIhigh DCs were found in the skin draining lymph nodes of CCX-CKR 
deficient mice (Heinzel et al., 2007). Additionally, overexpression of CCX-CKR in 
thymic epithelial cells resulted in impaired migration of haemopoietic thymic 
precursors to the embryonic analage therefore further implicating a role for 
CCX-CKR in leukocyte migration under homeostatic conditions (Heinzel et al., 
2007).   
In pulmonary sarcoidosis, CCX-CKR transcripts are upregulated in 
bronchoalveolar cells and transcript levels correlated with disease severity 
alongside an increase in CCL19 levels in pulmonary sarcoidosis (lKriegova et al., 
2006). However, the exact role of CCX-CKR in this disease has not yet been 
defined. 
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1.6.3 CXCR7 
Formally known as RDC1, this receptor was cloned and characterised from mouse 
genomic DNA where it was found to show 88% amino acid similarity to the human 
RDC1 receptor. Mouse RDC1 was discovered to share 43% amino acid similarity to 
mouse CXCR2 and the RDC1 gene was localised to chromosome 1 where the 
genes for CXCR2 and CXCR4 are also located (Heesen et al., 1998). This led to 
the suggestion that RDC1 was an orphan CXC chemokine receptor. 
It was then reported that RDC1 binds to CXCL12 and CXCL11 (Balabanian et al., 
2005, Burns et al., 2006). CXCL12 binding to RDC1 in transfected cells resulted in 
calcium mobilisation and cell migration therefore it was proposed to rename it 
CXCR7 (Balabanian et al., 2005). However, another study reported that there 
was no calcium flux or cell migration after ligand binding to CXCR7/RDC1 yet 
CXCR7/RDC1 expression increased cell survival and adhesion (Burns et al., 2006). 
More recently CXCR7/RDC1 has been implicated in promoting tumour growth in 
breast, lung and prostate cancer (Miao et al., 2007, Wang et al., 2008). In the 
study by Wang et al, CXCR7/RDC1 was shown to signal via a downstream 
signalling pathway, known as the AKT pathway, which contradicted previous 
results. However, the contrasting results may be due to the use of different 
tumour cell lines and it was not ruled out that CXCL12 may have mediated 
signalling though CXCR4 heterodimerisation with CXCR7/RDC1 (Sierro et al., 
2007). Indeed, when CXCR7 and CXCR4 are coexpressed, CXCR7/CXCR4 
heterodimer formed as efficiently as receptor homodimers and it has been 
suggested that CXCR4/CXCR7 heterodimers in T cells may regulate CXCL12 
mediated chemotaxis (Levoye et al., 2009). Therefore, more studies are 
required before this chemokine receptor is either officially designated into the 
CXCR subfamily or to confirm its membership in the atypical chemokine family.  
CXCR7 was found to be highly expressed on monocytes and B cells (Infantino et 
al., 2006). Indeed the ability of B cells to differentiate into plasma cells capable 
of secreting antibodies correlated with CXCR7 expression levels (Infantino et al., 
2006). Additionally, a ligand produced from mature plasmacytoid dendritic cells, 
was found to be different from CXCL12 and CXCL11 but was able to induce 
CXCR7 internalisation on primary B cells (Infantino et al., 2006). 
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Disruption of CXCR7 in mice was lethal which illustrated a role for the receptor 
in vascular development (Sierro et al., 2007). The defects in CXCR7 null mice 
were due to defects in the heart and not due to haemopoietic problems (Sierro 
et al., 2007). Additionally expression of CXCR7 has been shown in the neurons of 
developing, and adult, rat brains although the exact role for CXCR7 at this site is 
not known (Schonemeier et al., 2008). 
In zebrafish, the migration of primordial germ cells (PGCs) was primarily known 
to be guided by CXCL12 and its receptor CXCR4 (Doitsidou et al., 2002, Knaut et 
al., 2003). Initial studies suggested that there was regulated expression of 
chemokine receptors CXCR4 and CXCR7 at the leading and trailing edge of the 
migrating primordium (Dambly-Chaudiere et al., 2007). A recent study has shown 
that CXCR7 is expressed in the somatic environment and plays a role in the 
migration of PGCs (Boldajipour et al., 2008). The authors conclude that CXCR7 
acts as a decoy receptor and is involved in PGC migration by controlling the 
levels of the chemokine CXCL12 (Boldajipour et al., 2008). 
1.6.4 D6 
The atypical chemokine receptor, D6, was originally identified in the mouse 
(Nibbs et al., 1997a). It encodes a protein of 378 amino acids containing seven 
transmembrane spanning domains with 30% identity and 60% homology to the 
murine CCR family. However, the amino acid sequence in the second 
intracellular domain, which is highly conserved among chemokine receptors, was 
found to contain the sequence DKYLEIV and not DRYLAIV. The DRYLAIV motif is 
important for G-protein coupling and chemokine receptor signalling. Human D6 
was also cloned and was discovered to be 71% identical to murine D6 and also 
contained the DKYLEIV motif (Nibbs et al., 1997b). Purification of the human D6 
protein revealed that D6 has a molecular mass of 49kDa and was sulphated and 
glycosylated at the N-terminus (Blackburn et al., 2004). 
Mouse expression of D6 is high in lung, liver and spleen and is expressed in the 
heart, brain, thymus, ovary, muscle, liver and kidney as well as the skin (Nibbs 
et al., 1997a). D6 is present on astrocytes within the brain (Neil et al., 2005). 
Expression of D6 is found within the placenta on trophoblasts, skin, lungs, on 
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endothelial cells lining the lymphatics within humans (Nibbs et al., 2001) and 
leukocytes,  in particular, B cells and dendritic cells (McKimmie et al., 2008). 
D6 displays high affinity binding to a large number of inflammatory chemokines 
within the CC chemokine subfamily including CCL2, CCL3, CCL4, CCL5, CCL7, 
CCL8, CCL11, CCL13, CCL14 (Nibbs et al., 1997b), CCL17 and CCL22. D6 does not 
bind CCL19 or CCL20, which are considered to be homeostatic chemokines 
(Bonecchi et al., 2004). Nibbs et al. also demonstrated enhanced binding of an 
isoform of human CCL3, known as CCL3L1, to D6. The enhanced binding was 
found to be due to a proline residue at position 2 (Nibbs et al., 1999). In 
addition, D6 can bind the full length CCL22 but not a truncated form of CCL22 
where the first two amino acids have been cleaved by an enzyme, CD26 
(Bonecchi et al., 2004). CD26 is a serine protease expressed by many cells and is 
selective for substrates with a proline or alanine residues at position 2 of the 
NH2 terminus (Struyf et al., 2003). Upon ligand binding, D6 does not induce 
calcium fluxes or mediate chemotaxis, signs of classical G-protein signalling 
(Nibbs et al., 1997b) and therefore has not been given a CCR name. However, 
ligand binding to D6 results in internalisation and degradation of the ligand 
leading to the proposal that D6 may act as a ‘scavenging’ or ‘decoy’ receptor for 
inflammatory CC chemokines (Fra et al., 2003). Therefore D6 may be ‘mopping 
up’ CC chemokines regulating the levels available, and limiting the numbers of 
leukocytes within an inflamed area. 
Various properties and mechanisms allow D6 to internalise CC chemokines. In the 
absence of ligand, D6 is phosphorylated and is therefore constantly ‘switched 
on’ and has the ability to internalise (Blackburn et al., 2004). Another feature is 
that only 5% of D6 is present on the cell surface and the rest is within the cell in 
intracellular vesicles (Blackburn et al., 2004). Subsequently, D6 was found to 
move to and from the cell surface in the absence of ligand binding without any 
reduction in total cell surface levels (Weber et al., 2004). D6 recycling in 
absence of ligand requires Rab4 and Rab11 (Bonecchi et al., 2008). In addition, 
D6 requires Rab5 and dynamin I to be able to internalise ligand (Weber et al., 
2004) and is dependent on β-arrestin (Galliera et al., 2004), all components of 
the clathrin coated endocytosis pathway.  An amino acid sequence in the C 
terminus of D6 is not homologous to other chemokine receptors and is conserved 
through various species. This region contains a serine cluster that controls the 
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stability, constitutive phosphorylation and trafficking of D6. The C terminus does 
not control internalisation of chemokine but does prevent subsequent 
progressive scavenging of the ligand (McCulloch et al., 2008). Ligand binding to 
D6 has been shown to increase D6 scavenging using Rab11 and increases D6 
expression on the cell membrane (Bonecchi et al., 2008). In addition, LPS can 
downregulate D6 mRNA levels whereas TGF-β can upregulate D6 mRNA levels in 
myeloid cells and D6 expression within dendritic cells was GATA-1 dependent 
(McKimmie et al., 2008). Other evidence has shown IL-1β and TNFα  can 
upregulate D6 mRNA expression in human breast cancer cell lines (Wu et al., 
2008). 
The role of D6 in vivo was examined using D6 null mice to investigate the 
hypothesis that D6 may regulate the level of inflammatory chemokines. 
Jamieson et al. used a model of cutaneous inflammation induced by phorbol 12-
myristate 13-acetate (TPA) application to murine dorsal skin on three 
consecutive days. It was found that D6 null mice could not clear inflammatory 
CC chemokines as effectively as the wild-type mice after 24 hours resulting in 
development of a pathology similar to human psoriasis. The pathology that 
developed in D6 null mice was characterised by an accumulation of T cells within 
the epidermis, mast cells in the dermis and was dependent on TNFα (Jamieson 
et al., 2005). Another study used a model of skin inflammation induced by 
injection of complete Freund’s adjuvant. In this instance, D6 null mice displayed 
an increased inflammatory response with increased numbers of leukocytes, 
angiogenesis and areas of necrosis as well as increased cellularity in lymph nodes 
(Martinez de la Torre et al., 2005). Therefore, these studies suggest that, in 
vivo, D6 plays a role in the resolution of inflammation. 
Further studies have investigated the role of D6 expression in other tissues. D6 
within the placenta plays a role in reducing fetal loss in two separate models 
induced either by systemic inflammation or anti-phospholipid antibodies 
(Martinez de la Torre et al., 2007). In a model of allergic pulmonary 
inflammation, D6 null and wild-type mice were sensitised to ovalbumin and then 
exposed to ovalbumin aerosol on a single occasion or consecutively for seven 
days (Whitehead et al., 2007). D6 was shown to scavenge certain chemokines in 
the lung in a concentration dependent way and the lungs of D6 null mice had 
increased levels of T cells, dendritic cells and eosinophils. Confusingly, despite 
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the increase in leukocyte numbers, the absence of D6 also resulted in reduced 
reactivity of the airway leading to the proposal that inhibition of D6 may help 
allergen induced asthmatic patients (Whitehead et al., 2007).   
D6 has also been shown to play a role in the development of skin tumours. A 
chemically induced skin tumour model was used in which a cutaneous 
application of 7, 12-dimethylbenz(a)anthracene (DMBA) followed by 12 2-week 
cycles of phorbol 12-myristate 13-acetate (TPA) was applied to murine skin. 
Deletion of D6 made an otherwise resistant strain susceptible to tumour 
development, which correlated with prolonged skin inflammation, including 
infiltration of epidermal T cells and dermal mast cells (Nibbs et al., 2007). In a 
tumour susceptible mouse strain, deletion of D6 resulted in enhanced 
susceptibility to papilloma formation (Nibbs et al., 2007). After discontinuing 
TPA use, which was used as a tumour promoting agent to drive tumour 
emergence after mutagenesis by DMBA, D6 deficient mice developed enlarged 
papillomas whereas papilloma size in wild-type mice did not increase (Nibbs et 
al., 2007). In a model of liver injury induced by carbon tetrachloride, D6 
deficient mice displayed prolonged liver damage with increased levels of CCL2, 
CCL3 and CCL5 after 48 hours (Berres et al., 2009). Additionally, increased 
numbers of leukocytes, in particular T cells and NK cells was found in the liver of 
D6 deficient mice compared to wild-type (Berres et al., 2009). In a model of 
colitis induced by dextran sodium sulphate, D6 deficient mice were less 
susceptible to colitis (Bordon et al., 2009). There was no difference in the level 
of pro-inflammatory chemokines released from colon explants or leukocytes 
recruited to the colon in D6 deficient mice compared to wild-type. However, D6 
deficient mice displayed higher levels of IL-17A and increased numbers of IL-17A 
γδ T cells suggesting that D6 plays a role in regulating IL-17A secretion by γδ T 
cells in the colon (Bordon et al., 2009). Another study examining D6 in 
experimental colitis induced by dextran sodium sulphate found that D6 deficient 
mice were more susceptible to colitis with higher levels of pro-inflammatory 
chemokines and increased leukocyte infiltration (Vetrano et al., 2009). 
Additionally, using chimeric mice, the ability of D6 to control intestinal 
inflammation was located to D6 expression in the stromal/lymphatic area, i.e. 
on lymphatic vessels (Vetrano et al., 2009). Also in the same study, D6 deficient 
mice were more susceptible to chronic colitis associated cancer than wild-type 
mice. 
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Other roles for D6 have been suggested. D6 null mice are relatively resistant to 
EAE due to an impaired adaptive immune response (Liu et al., 2006). In addition, 
the role of D6 in the immune response to Mycobacterium tuberculosis has been 
examined and D6 null mice were more susceptible to mortality after infection by 
Mycobacterium tuberculosis (Di Liberto et al., 2008). Mortality was associated 
with increased local and systemic inflammation, increased CC chemokine levels 
as well as infiltration of macrophages and T cells to the lungs. However blocking 
CC chemokines in D6 deficient mice resulted in prolonged survival yet 
uncontrollable growth of Mycobacterium tuberculosis within the lung (Di Liberto 
et al., 2008).  
 
Studies involving D6 in human diseases are emerging. D6 is expressed in atopic 
dermatitis and rheumatoid arthritis synovium as well as kaposi sarcoma, a form 
of malignant vascular tumour (McKimmie et al., 2008, Nibbs et al., 2001). D6 is 
also expressed in human breast cancer cell lines and tissues. Overexpression of 
D6 in breast cancer cell lines was found to inhibit proliferation and invasion 
ability of the tumour in vitro. D6 protein expression in human tissues was 
correlated positively with disease free survival (Wu et al., 2008). One study has 
shown that genetic variation in the D6 receptor correlates with the grade of liver 
inflammation in hepatitis C (Wiederholt et al., 2008). Additionally, patients with 
high levels of liver inflammation expressed lower levels of D6 mRNA (Wiederholt 
et al., 2008). To add to this, expression levels of D6 mRNA varied widely in 
control human hepatocytes suggesting that variation in D6 levels may be due to 
certain genotype variations in the D6 receptor (Wiederholt et al., 2008). 
Increased expression of D6 has also been found on lymphatic vessels and 
leukocytes within ulcerative colitis, crohns disease and colon cancer compared 
to normal colon mucosa (Vetrano et al., 2009). 
 
These studies show that D6 is a key chemokine receptor involved in the 
regulation of inflammation and the immune response. However, the precise role 
and mechanisms of D6 function in inflammation and chronic inflammatory 
diseases are still poorly understood and further work is required to clarify the 
function of D6 in these processes.  
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1.7  Aims 
The overall aim of the work within this thesis was to determine whether the 
manipulation of the expression of the atypical chemokine receptor, D6, has the 
potential to be of future therapeutic value. 
D6 was reported to play an important role in the resolution of the cutaneous 
inflammatory response in mice. Therefore, we hypothesised that increased 
expression of D6 would be able to limit inflammation in vivo.  
To test our hypothesis, K14D6 transgenic mice were generated to allow ectopic 
expression of D6 to be targeted to the epidermis. Characterisation of the K14D6 
transgenic mice was required to ensure the D6 transgene was transcribed, 
expressed at the protein level and was functional. To test whether increased 
expression of D6 within K14D6 mice could limit inflammation, a well-
characterised model of skin inflammation was used. 
Using a microarray approach, the transcriptional consequences of ligand binding 
to D6 and basal expression of D6 were examined. Primary murine keratinocytes 
from wild-type and K14D6 mice were isolated, cultured and incubated with 
either PBS or CCL3. By examining changes in the cellular transcriptome after 
ligand binding to D6, it was hoped that this would give an insight into cellular 
functions mediated by D6. 
The final aim of this thesis was to determine whether there is a correlation 
between D6 expression levels and cutaneous inflammatory diseases, in particular 
psoriasis. This was assessed by analysing D6 expression in peripheral blood and 
skin biopsies collected from psoriatic patients. Other inflammatory diseases such 
as atopic dermatitis, psoriatic arthritis and rheumatoid arthritis were also 
examined for D6 expression. 
  
 
 
 
 
 
Chapter 2  Materials and Methods 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Antibodies 
 
 
 
Abcam (Cambridge, UK) 
  
fluorescein isothiocyanate (FITC)-
conjugated mouse anti-pan cytokeratin 
BD Pharmingen (Oxford, UK) FITC-conjugated mouse IgG1 (isotype 
control) 
 
Allophycocyanin (APC)-conjugated mouse 
anti-human CD3 
 
phycoerythrin (PE)-conjugated mouse anti-
human CD14 
 
PE-conjugated mouse anti-human CD20 
 
Viaprobe 
 
Chemicon (Harrow, UK) HRP-conjugated donkey anti-chicken IgY  
 
DAKO UK  (Ely, UK) Mouse IgG2a  (isotype control) 
 
Mouse IgG1 
 
In house  
 
Mouse anti-human D6 
Miltenyi Ltd (Surrey, UK) APC-conjugated mouse anti-human CD1c 
 
APC-conjugated mouse anti-human CD304 
(BDCA) 
 
Sigma (Poole, UK) FITC-conjugated goat anti-mouse IgG (Fc 
specific) F(ab’)2 fragment 
 
Vector Laboratories 
(Peterborough, UK)  
Biotinylated anti-mouse IgG 
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2.1.2  Chemicals, reagents and solutions 
Ambion (Warrington, UK) Nuclease free water 
 
RNase Zap 
 
Biogenesis (Poole, UK) 
 
Normal Human serum 
Bioline (London, UK) 5x DNA Loading Buffer 
 
Hyperladder I 
 
Hyperladder IV 
 
BDH (Letterworth, UK) DPX mounting solution 
 
Hydrogen Peroxide 30% Solution 
 
Sodium Chloride (NaCl) 
 
Cell Path (Newtown, UK) Haematoxylin Z 
 
Putts Eosin 
 
Scotts tap water solution 
 
Fisher scientific (Loughborough, UK) Chloroform 
 
Citric Acid 
 
Diaminoethanetetra-acetic acid  
(EDTA) disodium salt  
 
Ethanol 
 
Sodium dodecyl sulfate (SDS) 
Gibco (Invitrogen, Paisley, UK) Phosphate buffered Saline (PBS) 
Invitrogen (Paisley, UK) Ethidium Bromide 
 
MES running buffer 
 
Multimark multicolour standard 
 
Nitrocellulose transfer membrane 
 
NuPage 4-12% Bis-tris gel 
 
NuPage Transfer Buffer 
 
Trizol 
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Melford (Ispwich, UK) 
 
Tris Hydrochloric acid (HCl) 
Sigma (Poole, UK) Ammonium Thiocyanate 
 
Bovine serum albumin (BSA) 
 
Dithiothreitol (DTT) 
 
Fibronectin 
 
Histopaque 1077 
 
Cell lytic-M mammalian cell lysis buffer 
 
2-Mercaptoethanol 
 
Phorbol 12-Myristate 13-Acetate 
 
Sample buffer Laemmli 2x concentrate 
 
Tween 20 
 
Surgipath (Peterborough, UK) 
 
Neutral buffered formalin 
Thermo Scientific  
(Loughborough, UK) 
 
Xylene 
 
Vector Laboratories 
(Peterborough, UK)  
 
Normal Horse Serum 
 
 
2.1.3 Chemokines 
Almac sciences (Gladsmuir, UK) Biotinylated CCL3 
 
CCL2  conjugated to Alexa-647 
 
CCL3 
 
Peprotech (London, UK) CCL22 
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2.1.4  Enzymes, kits and PCR master mix 
Abgene (Epsom, UK) Pre-aliquoted ReddyMix PCR  
master mix  
Ambion (Warrington, UK) 
 
RNase free DNase kit 
Applied Biosystems (Foster City, CA) Power SYBR Green PCR master mix 
 
BD Pharmingen (Oxford, UK) 
  
Standard Fix-Permabilisation kit 
BIOS Europe Ltd (Skelmersdale, UK) RAPI-DIFF II kit 
 
Invitrogen (Paisley, UK) Superscript First strand synthesis 
system for RT-PCR kit  
Perbio science Ltd (Cramlington, UK) bicinchoninic acid (BCA) protein assay 
 
Supersignal West Femto  
chemiluminescent substrate 
 
Supersignal West Pico 
chemiluminesent substrate 
Qiagen (Crawley, UK) QIA quick PCR purification kit 
 
RNase free DNase I 
 
RNeasy mini kit 
 
Sigma (Poole, UK) Proteinase K 
 
Vector Laboratories  
(Peterborough, UK) 
Avidin/biotin blocking kit 
 
DAB Substrate Kit, 3,3’-
diaminobenzidine 
Standard Vectastain ABC kit 
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2.1.5 Primers 
VH Bio (Gateshead, UK) 
 
Primers 
 
 
PRIMER NAME 
  
SEQUENCES 
 
mD6                                     Forward  
Reverse 
5’ AGCTTTACCTGCTGAACCTGG 3’ 
5’ AAGAAGATCATGGCCAAGAGTG 3’ 
K14mD6 Forward Forward  
Reverse 
5’ ATGACAAGCTCCAAAGAGATG 3’ 
5’ CTCTTCACTGATCTCCCTCCAC 3’ 
β-Actin Forward  
Reverse 
5’ TGAACCCTAAGGCCAACCGTG 3’ 
5’ GCTCATAGCTCTTCTCCAGGG 3’ 
CCR1 Forward  
Reverse 
5’ GCGCTCATTTCCCCTACAA 3’ 
5’ CGGCTTTGACCTTCTTCTCA 3’ 
CCR2 Forward  
Reverse 
5’ TGGGACAGAGGAAGTGGTGT 3’ 
5’ TGAGGAGGCAGAAAATAGCAG 3’ 
CCR3 Forward  
Reverse 
5’ GCAGGTGACTGAGGTGATTG 3’ 
5’ CTGTGGAAAAAGAGCCGAAG 3’ 
CCR4 Forward  
Reverse 
5’ CTCGCCTTGTTTCAGTCA 3’ 
5’ GATTTCCTCCACCCAGCA 3’ 
CCR5 Forward  
Reverse 
5’ TTTGTTCCTGCCTTCAGACC 3’ 
5’ TTGGTGCTCTGTTCCTCATCTC 3’ 
Col3a1 outer Forward  
Reverse 
5’ GGGTATCAAGGGTGAAAGTGG 3’ 
5’ AACTCCAACAATGGCAGCA 3’ 
Lzp-s outer Forward  
Reverse 
5’ AGACCGAAGCACCGACTATG 3’ 
5’ TCCTGGCTGAAGAACTGACC 3’ 
Ptx3 outer Forward  
Reverse 
5’ TTGGGTCAAAGCCACAGA 3’ 
5’ AATGAACAATGGGCAACAGAG 3’ 
Laptm5 outer Forward  
Reverse 
5’ CGCAGCCATAGGAAGTTAGG 3’ 
5’ CGGCGAGACTGTTGGACT 3’ 
CCL6 outer Forward  
Reverse 
5’ CTTTATCAGCAGGAGGGGAAC 3’ 
5’ CCCAAGAGCCCAGTTTCAG 3’ 
Npm3 outer Forward  
Reverse 
5’ ACACCCGCTCCTTCACTTT 3’ 
5’ TCCCACCCCCTATTCTCTTC 3’ 
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STEAP4 outer Forward  
Reverse 
5’ AAAGCAGCACTCGGCATACT 3’ 
5’ AGAAAGCACACCACCACTCC 3’ 
Slc6a14 outer Forward  
Reverse 
5’ TGGAGGATTTTGCCACTGTT 3’ 
5’ ATGAGCCAAGCCAGAAGAAG 3’ 
Lcn2 outer Forward  
Reverse 
5’ CCCTGTATGGAAGAACCAAGG 3’ 
5’ AGGTGGATGGGGAGTGCT 3’ 
ApoE outer Forward  
Reverse 
5’ GTGCTGTTGGTCACATTGCT 3’ 
5’ GCGTATTTGCTGGGTCTGTT 3’ 
Aldh1a7 outer Forward  
Reverse 
5’ TCAAGCCAGCAGAGCAAAC 3’ 
5’ GGACAGGGACAGCCAAATAG 3’ 
Dkk2 outer Forward  
Reverse 
5’ TCTTCCAAAGCCAGACTCCA 3’ 
5’ TTCCCTGTTCTTCAGCGTTC 3’ 
Nrk outer Forward  
Reverse 
5’ CAGATTCAAGTCGTGGAGCA 3’ 
5’ GAACCAACAGCCAGGTCAA 3’ 
Bcat1 outer Forward  
Reverse 
5’ GGATGCTGGGGTGATTGA 3’ 
5’ TTCTTCCAACTGACTGTGCTG 3’ 
Col3a1 QPCR Forward  
Reverse 
5’ AGGTTCTCCTGGTGCTGCT 3’ 
5’ TGCCCACTTGTTCCATCTTT 3’ 
Lzp-s QPCR Forward  
Reverse 
5’ GCCCATTCTGTCTCTTTCTCAC 3’ 
5’ TGTTTTGCCCTGTTTCTGCT 3’ 
Ptx3 QPCR Forward  
Reverse 
5’ ACGGAGGAGCCCAGTATGTT 3’ 
5’ TCGTCTATTACGCACCGAAGT 3’ 
Laptm5 QPCR Forward  
Reverse 
5’ GATTGTGGTGCCCGTTTG 3’ 
5’ CTCCGTTTCTATTTCTTTTTCTCCT 3’ 
CCL6 QPCR Forward  
Reverse 
5’ CCTAAGCACCCTGAAGCAAG 3’ 
5’ GGTCACTGGGGAAGACAGAA 3’ 
Npm3 QPCR Forward  
Reverse 
5’ CGGACGAGTGTAATGTGGTG 3’ 
5’ CAGGTGGTTGGAGTTGGAAA 3’ 
STEAP4 QPCR Forward  
Reverse 
5’ GGAGAAAAGCCCCAAATGA 3’ 
5’ ACCCCAAATACCCCCAGA 3’ 
Slc6a14 QPCR Forward  
Reverse 
5’ TCTTGGGCAGACGAAAACTG 3’ 
5’ GCAGGTGAGATTGCTGGTATTT 3’ 
Lcn2 QPCR Forward  
Reverse 
5’ CTGAATGGGTGGTGAGTGTG 3’ 
5’ CTTGGTATGGTGGCTGGTG 3’ 
ApoE QPCR Forward  
Reverse 
5’ GTGGCAAAGCAACCAACC 3’ 
5’ TCCGTCATAGTGTCCTCCATC 3’ 
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Aldh1a7 QPCR Forward  
Reverse 
5’ CAGATGCCGACTTGGACAG 3’ 
5’ TCCTCAACAAAAAGCCTGGA 3’ 
Dkk2 QPCR Forward  
Reverse 
5’ TTGGAATGCGGAAGAATGAG 3’ 
5’ GAGGCACATAACGGAAGCAC 3’ 
Nrk QPCR Forward  
Reverse 
5’ GCGATGAGGAAGAAAGAGGA 3’ 
5’ CACAGCAACCGCAATGTATG 3’ 
Bcat1 QPCR Forward  
Reverse 
5’ AGGTGTCTGAGGCTGGTTGT 3’ 
5’ CTATGTGCTGGGCTTTGAGG 3’ 
Mouse D6 QPCR Forward  
Reverse 
5’ TTCTCCCACTGCTGCTTCAC 3’ 
5’ TTCCATCTCAACATCACAGA 3’ 
Mouse GAPDH QPCR Forward  
Reverse 
5’ CAGCAAGGACACTGAGCAAG 3’ 
5’ TATTATGGGGGTCTGGGATG 3’ 
Human D6 QPCR Forward  
Reverse 
5’ AGGAAGGATGCAGTGGTGTC 3’ 
5’ CGGAGCAAGACGATGAGAAG 3’ 
Human GAPDH QPCR Forward  
Reverse 
5’ CAAGGCTGAGAACGGGAAG 3’ 
5’ GGTGGTGACGCCGCCAGT 3’ 
  
2.1.6 Tissue culture media and reagents 
 
 
Gibco (Invitrogen, Paisley, UK) Dulbecco’s modified Eagle’s Medium 
(DMEM) 
 
Fetal Calf Serum (FCS) 
 
Glutamine 
 
Streptomycin/Penicillin 
 
Trypsin (0.25%) 
 
Cambrex (Walkersville, MD) Keratinocyte bullet kit (keratinocyte 
growth media and supplements) 
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2.2 Methods 
2.2.1  Molecular Biology 
2.2.1.1   Preparation of genomic DNA from tail tips 
Tail tips from weaned mice were digested in screwcap eppendorfs with 100µl 
lysis buffer (100mM TrisHCl, 5mM EDTA, 0.2% SDS, 200mM NaCl) and 1µl 
(10mg/ml) proteinase K in a water bath at 55°C overnight. The tubes were 
heated for 5 minutes in a heating block at 96°C then each sample was diluted 
with 500µl of double distilled water (ddH2O). The tubes were centrifuged at 
12,000x g and stored at 4°C. For neonates, the tail tips were only incubated for 
6 hours in the water bath and were then processed as described above. 
2.2.1.2  RNA extraction using Trizol 
Trizol was used for RNA extraction from tissues following manufacturer’s 
instructions. Tissues were ‘snap frozen’ with liquid nitrogen and ground with a 
mortar and pestle. For homogenisation, 1ml Trizol was added per 50-100mg 
tissue, thoroughly mixed and left for 5 minutes to dissociate complexes. 
Chloroform, 0.2ml per ml Trizol, was added and the tubes inverted 15 times 
before incubation at room temperature for 2 minutes. The tubes were 
centrifuged (12,000x g, 15 minutes, 2-8°C) and the RNA layer (colourless 
aqueous layer) was transferred to a fresh RNase free tube. RNA was precipitated 
from the aqueous layer with isopropyl alcohol (0.5ml/1ml trizol) and incubated 
for 10 minutes at room temperature, centrifuged (10 minutes, 12,000 x g) and 
the supernatant carefully removed. The pellet was washed with 75% ethanol, 
centrifuged (7,500x g, 5 minutes, 2-8°C), supernatant removed and the RNA 
pellet left to dry. The pellet was resuspended in 100µl RNase free water. RNA 
concentration was measured using a spectophotometer. 
RNA was DNase-treated, to remove any DNA present, using the RNase-free DNase 
kit according to manufacturer’s instructions. 10x DNA buffer (5µl) was added to 
5µg RNA sample along with 1µl DNase and made up to 50µl with 
diethylpyrocarbonate (DEPC) treated water and incubated at 37°C for 30 
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minutes. DNase inactivating reagent (5µl) was added and mixed thoroughly for 
two minutes at room temperature then spun at 12,000x g at 4°C for 2 minutes. 
The DNase free RNA was transferred to a fresh clean tube. However, most of the 
RNA was DNase treated using RNeasy mini columns and on-column DNase 
treatment (see 2.2.1.4).  
2.2.1.3  RNA extraction using RNeasy Mini Kit 
The RNeasy kit technology involves the lysis of tissue or cells by using a buffer 
containing guanidinium-isothiocyanate (buffer RLT), which will denature any 
RNase enzymes present, preventing RNA from being destroyed. The kit also 
contains silica-gel-membrane columns, which allow RNA to bind, in ideal binding 
conditions with the use of ethanol, and any contaminants present are removed 
by washing and centrifuging the columns. 
Extraction of RNA from cells was performed following manufacturer’s 
instructions. In brief, cells were disrupted with either 350µl or 600µl buffer RLT 
containing 2-mercaptoethanol, depending on the number of cells. This process 
lyses the cells and inactivates any RNases present by denaturing them. The cells 
were then homogenised by passing the lysate through a 20-gauge needle at least 
five times. One volume of 70% ethanol was added to the lysate, and mixed 
thoroughly before applying to the RNeasy spin column. The columns were 
centrifuged for 15 seconds at 8,000 x g and the flow through discarded. Wash 
buffer, RW1, (350µl) was then applied to the column, centrifuged (15 seconds, 
8,000x g) and the flow through discarded followed by a 15 minute incubation 
with DNase1 at room temperature. The columns were washed with 350µl of wash 
buffer RW1, centrifuged and the flow through was discarded. Buffer RPE (500µl) 
was applied to the column, which was then centrifuged at 8,000x g. A second 
volume of RPE was added, to ensure all contaminants were removed, and the 
column was centrifuged at 8,000x g for 2 minutes. RNA was eluted in RNase-free 
water and centrifuged at 8,000x g for 1 minute before the concentration of RNA 
was measured using a spectophotometer.  
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2.2.1.4  RNA clean up 
This method was applied to RNA extracted from tissues, which was required for 
quantitative PCR (QPCR). The RNA clean up method involved DNase treatment 
using the RNeasy mini kit to remove any contaminating DNA. In brief, no more 
than 100µg RNA was loaded onto an RNeasy mini column. The sample was 
adjusted to a volume of 100µl, if required, with RNase free water. Buffer RLT 
(350µl) was added to the RNA sample and mixed thoroughly before addition of 
250µl ethanol and was applied to the RNeasy mini column. From this point on, 
the method followed was the same as in 2.2.1.3 
2.2.1.5  RNA quality test 
Once RNA was isolated from tissues or cells and had been DNase treated, a small 
sample was tested to check the quality of RNA and to ensure no degradation had 
occurred. RNA (1µl) was mixed with 3µl ddH2O and 1µl 5x loading dye and 
electrophoresed on a 1% agarose gel (see 2.2.1.8) for 20 minutes at 120V and 
visualised under a ultraviolet (UV) light for the presence of the 28s and 18s 
ribosomal bands of RNA. Intact RNA displays 2 clear and sharp bands which 
correspond to the 28s and 18s bands, with the 28s band being twice as intense as 
the 18s band. If no distinct bands but a smear appeared, this indicated that the 
RNA was degraded and was of no use.  
The quality of RNA can also be checked when quantifying RNA using a 
spectophotometer. The absorbance of the RNA is measured at 260 and 280nm 
and the ratio of these readings give an indication of the quality of the RNA and 
whether there are any contaminants such as protein or phenol. A ratio of 1.8 to 
2.1 indicates that the RNA is good quality and has limited contamination.  
2.2.1.6  cDNA synthesis from RNA 
cDNA was transcribed from RNA using Superscript first strand cDNA synthesis kit 
following manufacturer’s instructions. For each sample, a minus reverse 
transcriptase (RT) reaction was performed as a control. In brief, 1µg RNA was 
placed in an RNase free tube with 1µl dNTP and 1µl Oligo (dT) and made up to a 
final volume of 10µl in DEPC treated water, incubated at 65°C for 5 minutes and 
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placed on ice for 1 minute. An RT master mix was made up per reaction to 
contain 2µl 10xRT buffer, 4µl 25mM MgCl2, 2µl 0.1M DTT and 1µl RNase OUT 
recombinase inhibitor. Master mix (9µl) was added to each denatured RNA 
sample and incubated for 2 minutes at 42°C. Superscript II RT (1µl) or DEPC-
treated water (1µl) was added to the +RT and -RT samples respectively. All 
samples were incubated at 42°C for 50 minutes followed by a 15-minute 
incubation at 70°C to inactivate the reaction and then chilled on ice. RNase H 
(1µl) was added and the samples were incubated for 20 minutes at 37°C. The 
first strand cDNA could then be amplified by polymerase chain reaction (PCR) or 
diluted 1:5 in nuclease free water for quantitative polymerase chain reaction 
(QPCR). 
2.2.1.7  Polymerase chain reaction 
Polymerase chain reaction is a method that amplifies DNA, in which one PCR 
cycle ideally doubles the amount of the targeted sequence. Each PCR cycle 
consists of three steps, a denaturing step, an annealing step and a primer 
extension step. The denaturing step is first where the temperature is high to 
separate double stranded DNA into single strands. The annealing step involves a 
decrease in temperature and allows the primers to bind (or anneal) to the target 
DNA template. The temperature is increased in the primer extension step, to an 
optimum temperature that will allow DNA polymerase to bind and elongate the 
primers generating new DNA and the cycle starts again. After 25 to 35 cycles, 
the amplified product can be analysed. 
ReddyMix PCR master mix tubes were used for PCR applications. 1µl (or 0.4µl for 
genotyping) of each of the appropriate forward and reverse primers at a 
concentration of 10µM (20µM for murine D6) were normally used.  When the DNA 
template concentration was not known, 2µl was used unless it was for 
genotyping of primary keratinocytes where 3.75µl was added. The tubes were 
incubated in a PCR thermocycler. Primer sequences used are detailed in section 
2.1.5. 
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The PCR programmes were as follows;  
WT/K14mD6 genotyping: 96°C for 5 minutes, (96°C for 15 seconds, 55°C for 15 
seconds, 68°C for 30 seconds) x 35 cycles, 68°C for 10 minutes, using K14mD6 
primers. 
Primary keratinocyte genotyping: same as WT/ K14mD6 genotyping. 
Detection of murine D6:  94°C for 2 minutes, (92°C for 15 seconds, 55°C for 15 
seconds, 72°C for 30 seconds) x 30 cycles, 68°C for 10 minutes, using 20µM mD6 
primers. 
Detection of CCR1, 3 and 5: 94°C for 10 minutes, (94°C for 15 seconds, 59°C for 
30 seconds, 72°C for 30 seconds) x 35 cycles, 72°C for 10 minutes. 
Detection of CCR2 and 4: 94°C for 10 minutes, (94°C for 15 seconds, 61°C for 30 
seconds, 72°C) x 35 cycles, 72°C for 10 minutes. 
β-Actin: 94°C for 2 minutes, (92°C for 15 seconds, 55°C for 15 seconds, 72°C for 
30 seconds) x 30 cycles, 68°C for 10 minutes. 
2.2.1.8  Agarose gel electrophoresis 
Electrophoresis grade agarose was dissolved in 1x tris-acetate EDTA (TAE) buffer 
by heating. Ethidium bromide was added to the cooled gel to give a final 
concentration of 0.05µg/ml and then the gel was poured to set in a flat cassette 
apparatus at room temperature. Samples were run alongside a DNA ladder 
marker and, unless otherwise stated, all gels were run at 90V in 1xTAE buffer. 
DNA was visualised under UV light and the gel image captured using an Alpha 
Imager gel documentation system. 
2.2.1.9  Quantitative polymerase chain reaction 
Standard PCR gives an indication of the presence of transcripts however; it is not 
accurate in assessing quantitatively if one sample contains more transcripts than 
another sample. To do this, requires a method known as quantitative PCR or 
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real-time PCR. This QPCR protocol determined transcript number utilising a 
methodology  based on a SYBR Green master mix, which contains SYBR Green I 
dye that binds double stranded DNA resulting in a fluorescent signal being 
emitted (Morrison et al., 1998). Therefore, as SYBR Green detects new copies of 
double stranded DNA formed during the PCR reaction, the fluorescent intensity 
increases. This method involved using a standard curve, which required the 
generation and isolation of standards for the gene of interest as well as 
designing and validating primers to use in the QPCR machine.  
Designing primers 
 
Two sets of primers were required for each gene of interest in SYBR Green based 
QPCR. One is a set of ‘inner’ (nested) primers for use in the QPCR machine and 
the second set, ‘outer’ primers were designed to generate PCR products of the 
gene of interest to act as standard templates. Therefore, standard templates are 
generated by PCR using outer primers to amplify a specific part of DNA in which 
the inner primers bind. 
All primers were designed using Primer3 software and the nucleotide sequence 
of the gene of interest. Primer3 software is available at;   
(http://www.broad.mit.edu/cgi-bin/primer/primer3_www.cgi/). Primers were 
designed with QPCR specification, which are more stringent than required for 
standard PCR primers, such as optimal melting temperature of the primers (Tm), 
maximum self-complementarity and maximum 3’ self-complementarity. The 
maximum self-complementarity determines the alignment and self-
complementarity of a single primer as well as a maximum alignment score for 
the complementarity between the left and right primers as a pair. Maximum 3’ 
self-complementarity is the maximum alignment score allowed when testing a 
single primer for self-complementarity and for the complementarity between 
the 3’ of the left and right primers. Maximum 3’ self-complementarity score 
between primers gives an indication of the likelihood of primer-dimers occurring 
during PCR. The specifications of the primers were designed to the conditions of; 
• between 18 and 23 base pair (bp) in length 
 
• between 40 and 65% GC content,  
 
Vicky King, 2010   Chapter 2, 107 
• melting temperature of the primers should be between 59.5°C and 61.5°C 
with an optimal Tm of 60°C,  
 
• product size should be between 100 and 180bp,  
 
• maximum self-complementarity : 2  
 
• maximum 3’ self-complementarity: 1  
 
• avoid stretches of 4 G or C bases in a row. 
  
Primers were designed to bind within the last 1500bp of the 3’ end of the mRNA. 
Using these specifications, primers were usually generated however if no primers 
were suggested by Primer3, some conditions were relaxed until primers were 
suggested. These conditions were increasing maximum self-complementarity 
from 2 to 3, decrease the optimal melting temperature of the primers to 59°C or 
examine more of the 5’ sequence on the template until suitable primers are 
found. One condition that was not relaxed was the maximum 3’ self-
complementarity, which remained at 1. These specifications were used to design 
‘inner’ QPCR primers. Once these were designed, outer primers were designed 
to amplify the region in which inner QPCR primers would bind. The ‘outer’ 
primers were designed using the same software and similar parameters however, 
they were allowed to have higher self-complementarity and generate a larger 
product size. 
Validation of primers 
 
Both sets of primers were tested for specificity by standard PCR using cDNA 
prepared from RNA isolated from tissue or cells known to express the gene of 
interest. In general, 2µl of cDNA and 1µl of the forward and reverse primer were 
added to Reddy mix tubes. The PCR programme was 95°C for 3 minutes, (95°C 
for 15 seconds, 59°C for 20 seconds, 72°C for 20 seconds) x35 cycles, 72°C for 10 
minutes. PCR products were separated using electrophoresis on an agarose gel 
(1% for PCR products containing standards and 2% for PCR products generated 
using inner QPCR primers) and visualised using ethidium bromide under a UV 
light. Inner QPCR primers were suitable for QPCR if a single, clear and distinct 
band of the correct size occurred, therefore indicating specificity. However if 
multiple bands occurred, this suggested that the inner QPCR primers were 
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unsuitable for QPCR. However, if primer-dimer or low molecular weight bands 
occurred, then altering PCR conditions, such as increasing annealing 
temperature or decreasing primer concentration or both, could correct for 
these. On the other hand, if no product was visible, then increasing primer 
concentration and/or decreasing annealing temperature helped primers to 
produce a specific product.  
Generating standards for QPCR 
 
To quantify the levels of the gene of interest in unknown samples, the 
generation of a standard curve was required. A PCR product using the outer 
primers generated a standard DNA template for each gene of interest. The 
product generated was required to be a clear distinct band of the predicted size. 
If this was the case, the PCR product was purified using a PCR purification 
column following manufacturer’s instructions (Qiagen QIAquick PCR purification 
kit). In brief, 5 volumes of binding buffer PB were added to 1 volume of PCR 
sample and mixed. A yellow coloured sample indicated the pH was less than or 
equal to 7.5, which is optimal for DNA adsorption. The sample was applied to 
the QIAquick column and centrifuged for 30 seconds to allow binding of DNA. 
The flow through was discarded and 0.75ml Buffer PE was added to the column 
and centrifuged for 30 seconds to wash impurities through the column. The flow 
through was discarded and the column was centrifuged for a further 30 seconds 
to remove any ethanol residue then the QIAquick column was placed in a clean 
eppendorf tube. Buffer EB (50µl) was added to the centre of the QIAquick 
membrane and the column was centrifuged for 1 minute to elute DNA. The 
purified PCR products were diluted in nuclease free water to generate serial 
dilutions, each being 10 fold more dilute than the previous. The range of 
standards was from 1x10-4 fold dilution to 1x10-9 fold dilution to generate a good 
standard curve. Each of these standards was used as a template for QPCR using 
the inner QPCR primers for amplification. Using standards where different levels 
of template are present gives an indication of the range and sensitivity of the 
assay. The use of standards allows relative or absolute quantification of unknown 
transcript levels. 
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Calculating transcript numbers 
 
Relative quantification was used to determine relative differences of gene 
transcript levels between samples and was expressed as fold change. For relative 
quantification, arbitrary values were given to the standards. For example, 1x10-4 
fold dilution was given the arbitrary value of 10,000,000 copies and 1x10-9 fold 
dilution standard was given the arbitrary value of 100 copies. 
To quantify the absolute level of transcripts, the number of copies of PCR 
products within each standard was determined. To do this, 3µl of each standard 
PCR product, after purification, was mixed with 1µl ddH20 and 1µl 5x loading dye 
and run on a 1% agarose gel alongside 5µl Hyperladder I marker, where the mass 
of each band is known. The intensity of the bands in Hyperladder I and standard 
PCR products were quantified by densitometric analysis using software on the 
Alpha Imager gel documentation system. A standard curve was generated using 
the known mass of the Hyperladder band and the band’s intensity. Therefore 
using the intensity of the standard PCR product, the mass per µl was determined 
using the standard curve. Transcript copy numbers within each standard was 
calculated using a series of formulae and facts as follows.  
Firstly, the molecular weight of the standard was calculated; 
 
• Average molecular weight for double stranded nucleotide = 660 Daltons 
 
• Molecular weight of double stranded DNA = 660 Daltons x bp length 
 
The number of moles/µl was calculated; 
 
• Moles of standard = (mass/µl)/(molecular weight DNA) 
 
 
Then to convert moles into copy number, the number of molecules per mole is 
6.023x1023 copies (Avogadro’s constant) 
• Copies DNA per µl = Avogadro’s Constant x moles 
The known value of copies of DNA per µl was used to calculate the number of 
copies in each of the diluted standards.     
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Setting up SYBR green based QPCR 
 
Before starting, a plan was made of the 96 well QPCR plate, and a master mix 
was made to cover all reactions within the QPCR plate. For each reaction, 7.5µl 
of Power SYBR Green master mix, 0.6µl of primer mix and 5.4µl of nuclease free 
water were mixed together.  
Standard or sample cDNA (4.5µl) was placed in a mixing well, along with 40.5µl 
master-mix and was mixed thoroughly and carefully by pipetting up and down 
three times. Of this, 15µl was placed in three of the wells on the QPCR plate 
(each sample was applied in triplicate). A non-template control (NTC) was also 
included to determine the level of contamination and the detection limit of the 
assay. The plate was spun for 20 seconds at 400x g before being placed in the 
QPCR machine (Applied Biosystems 7900HT Real time PCR system). In general, 
the QPCR conditions were; 94°C for 10 minutes, (94°C for 3 seconds, 60°C for 30 
seconds) x 40 cycles followed by a dissociation stage. A dissociation stage for 
SYBR Green based QPCR is important, as a melt curve analysis can be 
determined at the end, which allows determination of the specificity of the PCR 
reaction.   
The software on the QPCR machine automatically works out the level of 
fluorescence that indicates exponential PCR amplification and the cycle number 
at which each well crosses the threshold. This is known as the Ct value. By using 
arbitrary or absolute copy numbers, the software can then use the Ct value to 
calculate the copy numbers in each sample taken from the standard curve. 
However, before using these values, certain analysis of the data is required. The 
standard curve should have a correlation of r2>0.97 and a slope of approximately 
3.3 (this means the PCR product has amplified 10-fold every 3.3 cycles and 
indicates the reaction was 100% efficient). The Ct value generated the NTC 
sample was noted as this signifies the sensitivity level of the assay. Examination 
of the dissociation curve should reveal one peak indicating the reaction was 
specific and no primer-dimer occurred. 
Normalising QPCR data  
 
All QPCR data was normalised using a housekeeping gene. To allow comparison 
of gene levels between samples, the amount of housekeeping gene within all 
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samples was assessed. The housekeeping gene used was glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The GAPDH gene codes for an enzyme 
(catalyses the oxidative phosphorylation of glyceraldehyde -3-phosphate to 1, 3-
diphosphoglycerate) involved in cell metabolism. The amount of transcripts of 
the gene of interest is normalised using the housekeeping gene to control for 
varying amounts of cDNA between samples due to differential rates of RNA 
degradation, varying efficiency during the RNA extraction procedure and the 
efficiency of the reverse transcription reaction.  
To calculate absolute transcript levels for the gene of interest, the data was 
normalised to GAPDH using the following calculation: 
•
 Copy number of gene of interest/ copy number of GAPDH gene x 105 
This gives the copy number of the gene of interest per 10,000 copies of GAPDH 
When calculating relative levels for the gene of interest, each sample was 
allocated a ratio of its GAPDH content compared to the 75th percentile of the 
GAPDH levels of all the samples. The levels of the gene of interest were then 
normalised by dividing by the GAPDH ratio. An example is shown below: 
 
Sample 
   Gene of interest 
(copy number) 
GAPDH 
(copy number) 
GAPDH 
ratio 
Corrected level 
of gene of 
interest 
 skin 40 14 0.86 46.4 
 skin + x 40 17 1.04 38.2 
 75th percentile 16.25   
     
WT keratinocyte 88 36 1.10 39.7 
WT keratinocyte + x 44 22 0.67 32.5 
 75th percentile 32.5   
  
Table 2-1. Example of normalisation of QPCR data using a housekeeping gene to determine 
levels of ‘gene of interest’. 
In the first example, skin and skin + x appear to express a similar level of the ‘gene of 
interest’. Once the data has been normalised, skin actually has higher levels of ‘gene of 
interest’ than skin+x. This was because the skin expressed a lower level of GAPDH (14 
copies) than skin+ x (17 copies). In the second example, initially the level of the’ gene of 
interest’ in WT keratinocytes appears to be 2-fold higher than WT keratinocyte+x. Once 
normalised, it can be seen that the difference in the levels of the ‘gene of interest’ between 
WT keratinocytes and WT keratinocytes+X is actually less. 
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2.2.2   In vivo analysis 
2.2.2.1   Maintenance of mice 
Mice were housed within the animal facility at the Central Research Facility at 
Glasgow University. All procedures performed on mice were in accordance with 
United Kingdom Home Office guidelines as well as under appropriate project and 
personal licences. 
2.2.2.2   Genotyping of mice  
A K14D6 mouse colony was maintained by crossing of K14D6 x FVB/N wild-type 
mice resulting in littermates being either K14D6 or wild-type. Weaned mice and 
neonates were tail tipped and DNA was extracted (see 2.2.1.1). Genotype was 
determined by PCR. DNA (2µl) and 0.4µl of 10µM K14mD6 primers were added to 
pre-aliquoted reddy master mix tubes. PCR conditions were 96°C for 5 minutes, 
(96°C for 15 seconds, 55°C for 15 seconds, 68°C for 30 seconds) x 35 cycles and 
68°C for 10 minutes. PCR products were electrophoresed on a 1% agarose gel 
containing ethidium bromide. A band of approximately 400bp size indicated 
K14D6 transgenic and no band indicated D6 wild-type littermate. 
2.2.2.3  Epidermal sheet preparation 
Two methods were tested to determine the best method to isolate epidermal 
sheets from mouse skin. Subcutaneous fat was removed from dorsal skin and the 
skin was cut into small sections. One method involved incubating the skin, 
dermal side down, in 0.5M ammonium thiocyanate in PBS for 10 and 20 minutes 
at 37°C. The second method involved incubating the skin, dermal side down, in 
0.025M EDTA for 2 hours at 37°C. Dermal and epidermal sections were separated 
carefully and were fixed in formalin to be stained with haematoxylin and eosin 
or were ‘snap-frozen’ in liquid nitrogen for RNA extraction following the method 
described in 2.2.1.2. 
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2.2.2.4   Harvesting of primary keratinocytes    
Neonates (from K14D6 x WT crosses) were sacrificed, placed into 70% ethanol 
and tail tipped for genotyping using K14mD6 primers (see 2.2.1.1 and 2.2.2.2). A 
clean cut of the skin was made from the tail to the head and the body was 
separated from the skin. The skin was placed dermal side down, stretched on 
the tissue culture dish with forceps and left for 20 minutes to dry before the skin 
was placed dermal side down in 0.25% trypsin overnight at 4°C. The epidermis 
was carefully peeled apart from the dermis, placed into 15ml tubes containing 
DMEM/10% FCS, and shaken for 20 minutes. The suspension was filtered through 
a gauze swab, centrifuged (1000x g for 5 minutes) and the supernatant carefully 
discarded (Yao et al., 2006). The pellet was resuspended in 1ml supplemented 
keratinocyte growth media (KGM) per skin containing 0.05mM calcium ready to 
seed and be cultured for five days for either RNA isolation, western blotting or 
flow cytometry. 
2.2.2.5  Staining of primary keratinocytes 
Keratinocytes were harvested and resuspended before seeding 500µl into 
chambered slides coated with fibronectin. The cells were fed every two days 
with fresh keratinocyte growth media. On day 5, the media was aspirated and 
the slides were allowed to dry before the sides of the chambered slides were 
broken off. Cells were fixed in methanol for 10 minutes and allowed to air dry. 
The cells were incubated in the red stain from the RAPI-Diff II kit, which is a 
staining kit similar to giemsa, for 3 minutes and 30 seconds then put into the 
blue stain for 10 seconds and rinsed in ddH2O and allowed to air dry. A coverslip 
was applied, mounted with DPX solution and dried for 24 hours. Pictures were 
taken with Axiovision software and microscope. 
2.2.2.6   Assessment of keratinocyte purity  
Keratinocytes from individual neonates were isolated and cultured for five days 
to be assessed for purity by flow cytometry. At the stage of isolation, 
keratinocytes were resuspended in 1ml KGM. 200µl of keratinocytes was 
aliquoted into wells in 24 well plate and cultured for five days. Keratinocytes 
were trypsinised in 1ml 0.25% trypsin for 5 minutes at 37°C and washed with 
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PBS/2mM EDTA/0.1% FCS (PEF) then permeabilised using a standard fix-
permeablisation kit, which permeablises cells. Keratinocytes were labelled for 
10 minutes at room temperature with 1.5µg/ml FITC-conjugated mouse anti-
cytokeratin (pan) antibody or FITC-conjugated mouse IgG1 antibody (isotype 
control). Keratinocytes were washed and analysed by flow cytometry using a 
FACS Calibur machine, in which cytokeratin expression was measured and 
compared to the isotype control.   
2.2.2.7   Incubation of keratinocytes with biotinylated CCL3 
Keratinocytes from individual neonates were isolated and cultured in 6cm 
plates. On day 5, media was aspirated from primary keratinocytes, washed with 
PBS and 1ml of fresh KGM containing 1% BSA was added.  To each plate of 
2.5x105 cells, 10nM biotinylated CCL3 (BioCCL3) was added and incubated at 
37°C. Media was sampled from the plates at various timepoints for western 
blotting. To ensure the result was D6 specific, keratinocytes were incubated 
with 10nM BioCCL3 and 100nM CCL22. Both are D6 ligands and therefore this is a 
D6-specific competition assay. Media was also sampled at various time points for 
western blotting. 
2.2.2.8   Detection of biotinylated CCL3 by western blotting  
15µl of KGM media sampled from keratinocytes incubated with BioCCL3 were 
mixed with 15µl 2x Laemmli buffer and heated at 90°C for 5 minutes. Samples 
were added to a well in a 4-12% NuPage Bis-Tris gel alongside a multimark 
multicolour standard, in the inner chamber of the tank containing MES running 
buffer with 0.1M DTT. The outer chamber of the tank was filled with MES 
running buffer and the gel set to run at 120V for one and a half hours or until the 
bromophenol blue marker was approximately ¾ of the way down the gel. The gel 
was then placed onto a nitrocellulose transfer membrane in a blot module with 
transfer buffer and run at 150mV for approximately two hours. The transfer 
membrane was left overnight in 10% powdered milk in PBS at 4°C. The 
membrane was washed several times with PBS/0.1% Tween 20 for approximately 
half an hour. The detection agent, strepavidin labelled horseradish peroxidase 
(HRP) was diluted 1:2000 and incubated with the transfer membrane for 1 hour 
before thoroughly washing with PBS/0.1% Tween 20. The chemiluminescent 
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substrate for HRP was detected by ‘west femto’ and the membrane was drained, 
exposed to x-ray film, which was then placed through a film developer. 
2.2.2.9   Assessment of CCL2 binding by keratinocytes using 
flow cytometry 
Individual keratinocytes were isolated and cultured for five days to be assessed 
in their ability to bind CCL2 by flow cytometry. At the stage of isolation, 
keratinocytes were resuspended in 1ml KGM. 200µl of keratinocytes were 
aliquoted into wells in 24 well plates and cultured for five days. On day 5, 250µl 
fresh media containing 1% BSA was added to the cells. Keratinocytes were 
incubated with either PBS, 25nM CCL2 conjugated to Alexa 647 (CCL2-alexa 647) 
or 25nM CCL2-alexa 647 and 250nM CCL3 for 100 minutes at 37°C.  Keratinocytes 
were trypsinised in 1ml 0.25% trypsin for 5 minutes at 37°C and washed twice 
with PEF (PBS/2mM EDTA/0.1% FCS). Keratinocytes were then analysed for 
binding of CCL2-alexa 647 using the FACS Calibur flow cytometry. 
2.2.2.10 Testing an anti-mouse D6 antibody 
A polyclonal antibody raised in chicken against murine D6 became available. It 
was not known whether this antibody would be specific for D6 and therefore the 
antibody was required to be tested and optimised. It was decided to test the 
antibody on cells known to express murine D6 using western blotting. A stable 
transfected cell line (Human Embryonic Kidney cells (HEKs)) expressing murine 
D6 had been made and used within our lab previously known as HEKmD6. HEKs 
and HEKmD6 were cultured in complete DMEM (containing 10% fetal calf serum, 
4mM L-glutamine, penicillin and streptomycin). Once the cells were confluent, 
the cells were trypsinised, centrifuged for 5 minutes and the cell pellet 
resuspended in 5 ml of media. The cells were counted and 2x106 cells were 
aliquoted and centrifuged again for 5 minutes. The cell pellet was lysed in 500µl 
of cell lytic-M mammalian cell lysis buffer and placed on ice for 15 minutes. The 
lysed cells were then centrifuged and the supernatant was carefully taken off. 
Total protein levels within the supernatants were measured using a bicinchoninic 
acid (BCA) protein assay following manufacturer’s instructions. In brief, 25µl 
sample or standard was added in duplicate to a 96 well plate and 200µl of 
reagent was added to each well. The plate was mixed thoroughly on a plate 
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shaker for 30 seconds and incubated at 37°C for 30 minutes before absorbance 
was measured at 562nm in a plate reader. For the western blot, 15µl of 
supernatant contained a total of 10µg protein and was mixed with 15µl HU 
buffer (8M urea, 5% SDS, 200mM Tris-HCl pH8.0, 0.1mM EDTA, 0.5% bromophenol 
blue, 100mM DTT). The gel and transfer membrane were run as described in 
2.2.2.8. The primary antibody, anti-mouse D6 antibody, was diluted and 
incubated with the transfer membrane for 1 hour at room temperature before 
thoroughly rinsing with PBS/0.1% Tween 20. The secondary antibody, donkey 
anti-chicken conjugated to HRP, was diluted 1:5000 and added to the membrane 
for 1 hour before washing with PBS/0.1% Tween. The chemiluminescent 
substrate for HRP was detected by incubation with ‘west pico’ for 5 minutes and 
then membrane was drained, exposed to x-ray film, which was then placed 
through a film developer. 
2.2.2.11 Cutaneous skin inflammation model 
The dorsal skin of mice was shaved and two days later 150µl of a 50µM solution 
of Phorbol 12-Myristate 13-Acetate, (PMA, also known as TPA) was applied to the 
dorsal skin of each mouse on three consecutive days to induce inflammation. 
2.2.2.12 Haematoxylin staining 
Mouse dorsal skin was placed into 10% neutral buffered formalin and transported 
to the University of Glasgow Veterinary School, where the sections were cut and 
stained with haematoxylin and eosin.  
2.2.2.13 Measuring skin thickness 
Haematoxylin and eosin skin sections were analysed for skin thickness, in 
particular epidermal and dermal thickness. A specialised eyepiece containing a 
grid was used in the microscope. Thickness was assessed by counting the number 
of squares the skin filled, which was then multiplied by 50 to convert the 
thickness to microns.  
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2.2.3 Keratinocyte microarray 
Microarrays allow the analysis of expression of thousands of genes in one assay. 
Microarray platforms are chips with a solid matrix consisting of fixed DNA 
sequences (probes) that correspond to specific genes, in a known order. RNA is 
harvested from the cells or tissues of interest and labelled. The labelled targets 
are hybridised to the probes, which then provides a quantitative measure of the 
abundance of RNA sequences within the target population. In this project, an 
oligonucleotide microarray was used (Affymetrix GeneChip). These chips contain 
thousands of oligonucleotides, which are single stranded probes made based on 
sequence information in databases, on a glass surface. Target RNA is 
biotinylated and added to the GeneChip. A streptavidin-phycoerythin conjugate 
recognises any hybridised probes and fluorescent signals emitted are then 
detected.      
2.2.3.1  Keratinocyte incubation and RNA extraction 
Keratinocytes were isolated from 1 neonate skin, pooled into groups of three and 
seeded into T75 flasks and cultured for 5 days. On day 5, media was removed 
and 5ml fresh KGM was added along with PBS or 10nM CCL3 in PBS and incubated 
for 6 hours at 37°C. Media was removed and RNA was extracted from cells using 
RNeasy mini kit (see 2.2.1.3). Samples were transferred to the Sir Henry 
Wellcome Functional Genomics Facility (University of Glasgow) where further 
processing of samples was carried out and the microarray analysis performed. 
RNA quantity and quality was assessed using a Nanodrop 1000 and the 
Bioanalyser 2100 respectively.  Each sample was subject to linear amplification 
before being converted to biotinylated cRNA and applied to Affymetrix GeneChip 
Mouse genome 430 2.0 Array for generation and analysis of data. 
2.2.3.2  Microarray analysis  
The data from the Affymetrix gene chips were analysed using combinations of 
Rank Products (RP) and Iterative Group Analysis (iGA). Rank Products generates 
lists of differentially expressed genes and determines statistical significance to 
each gene. Rank products are more reliable and consistent, when datasets 
contain low sample numbers or noisy datasets, than the popular method, 
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significance analysis of microarrays (SAM) for differential gene expression 
analysis (Jeffrey IB et al. 2006). The lists of genes produced by Rank products 
are processed using Iterative group analysis (iGA), which identifies functional 
changed groups of genes, assigned according to Gene Ontology 
(http://www.geneontology.org). Iterative group analysis combines the relative 
position of the genes in RP list and the number of changed genes within the 
group to determine the strength of changes within the group statistically. An 
important feature is that experimental replicates are not required because 
statistical significance can be determined by using group members as internal 
replicates. Terminology used by this software can be found in Appendix One. Full 
microarray data using Rank Products and iGA analysis can be found in Appendix 
Two and Three respectively. Validation of microarray data was performed by 
quantitative PCR. 
2.2.4 Human analysis 
2.2.4.1  Collection of human psoriasis skin biopsies 
Skin biopsies were obtained from control, psoriasis and eczema patients and 
stored in 10% neutral buffered formalin by a dermatologist, Anne Sergeant, from 
clinics at Glasgow Royal Infirmary. Some of the samples were processed and 
made into cDNA (see 2.2.1.2 and 2.2.1.6) and analysed for D6 transcripts using 
quantitative PCR. Other skin biopsies were kept for embedding into paraffin 
blocks to use for immunohistochemistry.   
 Embedding of human tissue 
 
Skin biopsy samples were placed in trays and placed in an embedding machine 
(Thermo) to be embedded in paraffin wax blocks. Samples were placed in 10% 
neutral buffered formalin for 30 minutes, 70% alcohol for 1 hour, 90% alcohol for 
1 hour, 95% alcohol for 1 hour then 5.5 hours in 100% alcohol, 3.5 hours in xylene 
and 9 hours in wax. The samples were placed in a known orientation and allowed 
to set in wax ready for sections to be cut onto poly-lysine coated slides. 
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Haematoxylin and eosin staining 
 
Sections were placed in xylene for 3 minutes, 10 dips in 100% alcohol, 10 dips in 
70% alcohol, washed in running water and placed in haematoxylin Z for 7 
minutes. The sections were then washed in running water followed by 12 dips in 
1% acid alcohol, rinsed in running water, placed in Scotts tap water solution for 
2 minutes and the sections were checked for staining microscopically. Once 
staining occurred, the sections were washed in running water and then placed in 
Putts eosin (diluted 1:2 with water) before being washed again in running water 
for 2 minutes. The sections were dehydrated in 70% alcohol, two sets of 100% 
alcohol and three sets of xylene for 1 minute each. The sections were mounted 
with coverslips using DPX mounting solution and allowed to air dry. 
 Immunohistochemistry using anti-human D6 antibody 
 
A monoclonal anti-human D6 antibody had previously been optimised for use on 
human placenta. However, none of this clone was available and therefore a 
different clone of antibody was used and required testing on human placenta 
and optimisation on human skin sections. Once optimised the protocol was as 
follows; Slides were heated in an oven at 60°C for 35 minutes, dewaxed in 
xylene for 10 minutes before being rehydrated in 100% ethanol (2x 5 minutes), 
95% ethanol (2x 5 minutes), 70% ethanol (5 minutes), PBS (5 minutes). 
Endogenous peroxidase activity was blocked by immersing slides in freshly 
prepared 0.5% hydrogen peroxide in methanol for 30 minutes then the slides 
were washed in PBS twice each for 5 minutes. To retrieve antigens, slides were 
immersed in 1mM citrate buffer (pH 6.0) and boiled in the microwave for 3x 5 
minutes. The slides were left to cool for 20 minutes before being washed in 
double distilled water for 5 minutes and then PBS (2x 5 minutes). Sections were 
blocked with 20% horse/20% human serum in PBS containing diluent of avidin D 
(from Avidin/Biotin blocking kit) for 30 minutes at room temperature in a 
humidified box. Blocking serum was tapped off and sections were incubated, in 
mouse anti-human D6 or mouse IgG2a isotype control (diluted 1:1000 to give 
final concentration 0.1µg/ml) in 2% horse serum with 4 drops/ml of Biotin (from 
Avidin/Biotin blocking kit), overnight at 4°C in a humidified box. Sections were 
washed in PBS (2x 5 minutes) and incubated for 30 minutes in biotinylated anti-
mouse IgG (diluted 1:200) in PBS containing 2% horse serum and 5% human serum 
at room temperature. An avidin biotin enzyme complex (with peroxidase as the 
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enzyme) was made (2 drops of solution A into 5mls PBS mixed followed by 2 
drops solution B, from Standard Vectastain ABC kit) and applied to the sections, 
which were then incubated at room temperature for 30 minutes. The slides were 
washed in PBS (2x 5 minutes). The substrate, DAB 3,3’-diaminobenzidine was 
made following manufacturer’s instructions (5mls distilled water, add 2 drops 
buffer, 4 drops DAB and 2 drops hydrogen peroxide and mix) and incubated on 
sections until appropriate staining was seen under the microscope. Sections were 
washed in water for 5 minutes, stained in haematoxylin for 15 seconds then 
washed in water. The sections were then dehydrated through the alcohols (70% 
alcohol, 95% alcohol, 100% alcohol) then in xylene and finally mounting sections 
with DPX and allowing to air dry before analysis. Pictures of sections were taken 
using a microscope and Axiovision software.  
2.2.4.2  Collection of peripheral blood samples 
Peripheral blood samples were collected from control, psoriasis, psoriatic 
arthritis and rheumatoid arthritis patients at various clinics. Axel Hueber, a 
rheumatologist at Glasgow Royal Infirmary and Clinical Research Fellow within 
the department, collected samples from psoriatic arthritis patients and controls. 
Hilary Wilson, a consultant at Glasgow Stobhill Hospital sent us rheumatoid 
arthritis peripheral blood samples from her clinic. Psoriasis blood samples were 
collected mainly by David Burden, a consultant dermatologist at Glasgow 
Western Infirmary as well as samples from a clinic run by Susan Holmes, a 
consultant dermatologist at Glasgow Royal Infirmary. All 10ml samples were 
collected into lithium heparin vacuettes.  
Isolation of peripheral blood mononuclear cells 
 
Blood samples were placed into sterile 50ml centrifuge tubes and an equal 
volume of PBS added and thoroughly mixed. The blood was slowly applied using 
a sterile pasteur pipette onto 4ml Histopaque 1077 in a 15ml centrifuge tube (2 
for each sample). The samples were spun at 400x g for 20 minutes, which 
separates the blood samples into different layers. The very bottom layer is red 
blood cells then histopaque, followed by a white ring layer, which is the 
peripheral blood mononuclear cell (PBMC) layer. The PBMC layer was carefully 
taken up into a pasteur pipette and transferred to a new 15ml tube and placed 
on ice. The PBMCs were mixed with PBS to wash the PBMC layer, placed in a 4°C 
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centrifuge and spun at 300x g for 5 minutes. The supernatant was carefully 
taken off, and the pellet was composed of T and B-lymphocytes, monocytes and 
dendritic cells. The PBMCs were either counted for cell surface analysis by FACS 
or RNA was extracted from them using 350µl buffer RLT containing 2-
mercaptoethanol. 
 Detection of D6 surface levels on specific PBMCs by flow cytometry. 
 
PBMCs were isolated from peripheral blood and cell numbers counted. No more 
than half a million cells were placed into various tubes to stain specific lineage 
markers for monocytes, T and B lymphocytes and myeloid and plasmacytoid 
dendritic cells. Anti-human D6 antibody or anti-human IgG2a (both 1.5µg/ml) 
were added to the appropriate tubes containing 500,000 cells and incubated 
with the cells for 10 minutes at room temperature. The cells were washed with 
PEF (PBS/2mM EDTA/0.1% FCS) and spun at 300x g for 5 minutes. The 
supernatant was removed and the cell pellets dispersed. The secondary 
antibody, FITC-conjugated goat anti-mouse IgG antibody F(ab)2 fragment, was 
added to all tubes, incubated for 10 minutes at 4°C, washed and spun (300x g, 5 
minutes). Unlabelled mouse IgG1 was added to all tubes, to block the remaining 
active sites of the secondary antibody to prevent non-specific binding, incubated 
for 10 minutes at 4°C and washed as previously stated. The next step was 
lineage specific antibodies, where four separate antibody cocktails were made. 
An APC-conjugated anti-human CD3 antibody was used for T cells, PE-conjugated 
anti-human CD20 antibody for B cells and for monocytes, a PE-conjugated anti-
human CD14 antibody was used. For myeloid and plamacytoid DCs, antibodies 
against markers on monocytes and B cells are required as these cells can also 
contain a myeloid DC marker (CD1c) and plasmacytoid DC marker (CD304) and 
therefore need to be excluded when analysing DC population for D6 staining. 
The lineage specific antibodies were added to the appropriate tubes, incubated 
for 10 minutes at 4°C. The tubes were washed with PEF and centrifuge (300x g, 5 
minutes). Before samples were run through the FACs Calibur machine, 5µl 
viaprobe was added to detect any dead cells present. 
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2.2.5 Statistical Analysis 
All graphs and statistical analysis were performed using Graphpad Prism version 
4.0. Graphs were mean ± standard error mean (SEM). Statistics used in this thesis 
were unpaired student’s t-test, a Krusal Wallis test with Dunn’s multiple 
comparison test (Figure 3-11A), two way ANOVA with Bonferroni post test (Figure 
3-9,  Figure 4-8, Figure 4-9, Figure 4-10, Figure 4-11 and Figure 4-12) and one 
way ANOVA with Bonferroni post test (Figure 5-1A, Figure 5-12 and Figure 5-22). 
A ‘p-value’ of less than or equal to 0.05 was determined statistically significant.   
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3 Characterisation of K14D6 mice 
3.1 Introduction  
Inflammation is the host’s natural response to infection and helps restore 
damaged tissue. The initiation of inflammation, which is well characterised, is 
mediated by pro-inflammatory mediators, such as chemokines and cytokines, 
involved in controlling the migration and behaviour of leukocytes in tissues. The 
resolution of inflammation occurs naturally but little is known about the 
mechanisms involved. 
D6 is an atypical chemokine receptor with high affinity for 12 pro-inflammatory 
CC chemokines (Fra et al., 2003, Nibbs et al., 1997a). In vitro studies have 
shown that D6 can reduce extracellular CC chemokines by constitutively 
recycling to and from the cell surface (Weber et al., 2004). Surface D6 binds and 
internalises ligand, targeting it for degradation within the cell (Weber et al., 
2004). In vivo studies, using a model of skin inflammation involving topical 
applications of TPA, have shown that D6 null mice demonstrate a prolonged and 
exaggerated cutaneous inflammatory response (Jamieson et al., 2005). As a 
consequence, D6 null mice demonstrated a psoriasis-like pathology, 
characterised by a large influx of mast cells into the dermis and CD3+ T cells into 
the epidermis (Jamieson et al., 2005). One mechanism proposed for the 
exaggerated inflammatory response was that D6 null mice were less effective at 
clearing bioavailable CC chemokines (Jamieson et al., 2005). As a result of the in 
vivo studies, D6 was proposed to play an important role in aiding the resolution 
of the inflammatory response.  
We hypothesised that if the absence of D6 results in exaggerated inflammation, 
then increased expression of D6 would suppress the inflammatory response. 
Therefore, the aim was to determine whether increased expression of D6 within 
murine skin, using epidermis-specific D6 transgene, would suppress the 
cutaneous inflammatory response in a skin inflammation model. This study, as a 
result, would give an indication of the therapeutic potential of D6. 
Scientific advances in genetic engineering have resulted in the production of 
genetically modified organisms in which the overexpression of molecules in 
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animals (transgenic) can now give us a better understanding of the function of 
these proteins. Within this chapter, details of how D6 transgenic mice were 
generated and the characterisation of these mice will be described. Validation 
of these mice was performed to ensure that the transgene is specifically 
transcribed where expected, that the resulting protein is functional and plays 
the biological role hypothesised. 
3.2 Generation of K14D6 transgenic mice 
D6 null mice used in the skin inflammation model were generated on a C57BL/6 
background (Jamieson et al., 2005). In addition, D6 null mice had also been 
backcrossed on to an FVB/N background, to use for a cancer model within our 
laboratory (Nibbs et al., 2007). As D6 transgenic mice were required for both the 
cancer and skin inflammation models, transgenic mice were generated on an 
FVB/N background.  
To examine the role of  increased D6 expression in the skin, a well-characterised 
keratin 14 (K14) promoter (Vassar et al., 1989) was used to drive expression of 
D6 in the basal keratinocyte layer within the skin. Murine D6 was cloned into an 
expression vector (pG32.K14 vector, gift of E.Fuchs) containing the human 
keratin 14 promoter, rabbit β-globin intron, the human K14 3' untranslated 
region and poly adenylation signal (K14pA). Figure 3.1 illustrates the construct 
used to express D6 in K14D6 transgenic mice (D.S.Gilchrist and S.Forrow 
generated these mice). The transgene construct was introduced into FVB/N 
embryos by pronuclear injection and surviving embryos were then transferred 
into psuedopregnant foster mice. Two founders were generated, known as 
Transgenic (K14mD6)1 and Transgenic (K14mD6)2. Offspring carrying the 
transgene were identified by PCR using tail tip DNA (see 2.2.1.1 and 2.2.1.7). 
Female offspring from the two founders were assessed for susceptibility to skin 
inflammation and papilloma formation. Transgenic offspring from both founders 
were protected in comparision to their wild-type littermates (Nibbs et al., 
2007). Subsequent experiments were performed using female offspring from 
Transgenic (K14mD6)1 founder.  
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Figure 3-1. K14D6 transgene construct. 
The K14D6 transgene was constructed by cloning the open reading frame of murine D6 
(mD6) into an expression vector containing the human K14 promoter (K14P), the rabbit B 
globin intron (βgint), (K14pA) the human keratin 14 3’ untranslated region and 
polyadenylation signal (Vassar et al., 1989). Transgenic mice were generated on an FVB/N 
background in which murine D6 transgene is expressed by keratin 14 promoter in basal 
keratinocytes within the epidermis. 
 
3.3 The D6 transgene is expressed in the epidermis in 
K14D6 mice 
To confirm that the transgene expression was directed to the epidermis, a 
method of separating the murine epidermis from the dermis was required before 
reverse transcription (RT)-PCR on epidermal sheets could be performed. Two 
methods of separating the epidermis were compared.  
Dorsal skin was dissected and subcutaneous fat was removed before cutting the 
skin into thin sections. Skin was placed dermal side down in either 0.5M 
ammonium thiocyanate for 10 minutes at 37°C, 0.5M ammonium thiocyanate for 
20 minutes at 37°C or 25mM EDTA for 2 hours at 37°C (Komatsu et al., 1996, 
Ratzinger et al., 2002). After incubation, the epidermis was separated from the 
dermis. Sections were fixed in 10% neutral buffered formalin and sent to 
Glasgow Veterinary School for sections to be paraffin embedded, cut and stained 
with haematoxylin and eosin (Figure 3-2). 
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The epidermis is only 1-2 cell layers thick, which consists mainly of 
keratinocytes, whilst the dermis is thicker and contains both blood and 
lymphatic vessels. By incubating the skin in ammonium thiocyanate for 10 
minutes, staining showed that separation of the skin layers was incomplete 
(Figure 3-2A). The epidermal section showed parts of the dermis were still 
present in epidermal sections (Figure 3-2A). Similarly, within the dermal 
sections, parts of the epidermis were also still attached (Figure 3-2B). By 
increasing the incubation time of the skin in ammonium thiocyanate, there were 
fewer traces of the dermis in epidermal sections (Figure 3-2C). However, within 
the dermal sheet section, no epidermis remained (Figure 3-2D). Additionally, 
when using ammonium thiocyanate, it was difficult to separate the skin 
epidermal and dermal sheets in one piece.  
When the skin was incubated in EDTA for two hours, the epidermis was easier to 
separate from the dermis and came apart in a single piece. Analysis of epidermal 
sections showed the separation looked cleaner with little evidence of the dermis 
being present (Figure 3-2E). In the dermis, there are many nucleated cells 
present (stained in blue) with no evidence of epidermis present at the surface 
(Figure3-2F).  
It was therefore concluded that separation of skin layers was best achieved by 
incubating sections in 25mM EDTA for 2 hours.  
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Figure 3-2. Optimising a method to separate the epidermis from the dermis. 
Dorsal skin was dissected, subcutaneous fat removed and cut into thin sections. Skin was 
placed dermal side down in either (A&B), 0.5M ammonium thiocyanate at 37°C for 10 
minutes at 37°C (C&D), 0.5M ammonium thiocyanate for 20 minutes at 37°C or (E&F), 25mM 
EDTA for 2 hours at 37°C. Epidermal sheets were separated from the dermis, fixed in 
formalin and stained in haematoxylin and eosin. Images of epidermal sections are shown in 
A, C and E while dermal sections are shown in B, D and F. HF indicates hair follicle. 
Magnification 100x. 
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Having decided on the best method to use, RNA was isolated from the epidermal 
sheets of wild-type and K14D6 transgenic mice and converted to cDNA to analyse 
for the expression of D6 transcripts. This was to confirm that within the K14D6 
mice, the D6 transgene was being expressed within the epidermis as anticipated.  
Using RT-PCR, D6 was detected in the epidermis of K14D6 mice whilst being 
absent from wild-type epidermis (Figure 3-3). D6 is known to be expressed 
within the skin, specifically on lymphatic endothelial cells present within the 
dermis (Nibbs et al., 2001). Extraction of RNA was attempted from dermal 
sheets, which were separated from the epidermis using 25mM EDTA however, 
obtaining intact RNA proved extremely difficult. One possible reason for this 
failure may be that as the skin sections were dermal side down in the solutions, 
RNA was degraded during processing.  
 
 
 
Figure 3-3. Transgenic expression of D6 in the epidermis of K14D6 mice.  
RNA was extracted from the epidermis of dorsal skin separated by 25mM EDTA in PBS 
(37°C for 2 hours) from wild-type (WT) and K14D6 mice. RT-PCR was performed (+/- reverse 
transcriptase (RT)) to detect mouse D6 and β-actin. Products were run on a 1% agarose gel 
and visualised by UV light. 
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3.4 The D6 transgene is expressed by K14D6 epidermal 
keratinocytes 
The next step was to confirm that D6 transgene expression was targeted 
specifically to proliferative epidermal keratinocytes within the K14D6 transgenic 
mice, which in turn would allow the functional ability of the D6 transgene to be 
assessed. 
Primary epidermal keratinocytes were isolated and cultured from the skins of 
12-24hr old neonates (Yao et al., 2006) and examined for D6 expression. 
Neonates were from K14D6 x FVB/N crosses therefore neonatal tail tips were 
obtained in which DNA was extracted and used for genotyping to determine wild-
type and K14D6 mice within the litter. Skin was taken from neonates and placed 
into individual plates dermal side down in 0.25% trypsin overnight at 4°C. The 
epidermis was carefully separated from the dermis and either placed, 
individually or pooled, in DMEM containing 10% FCS solution, shaken for 20 
minutes, then filtered and centrifuged. The keratinocyte cell pellet was 
resuspended in keratinocyte growth media and cultured for 5 days. With very 
efficient technique, one skin can yield initially approximately 2.5 million 
keratinocytes with a plating efficiency of 40%. To determine how successful the 
method was, the morphology and purity of the keratinocytes cultures was 
assessed by RAPI-DIFFII staining.  
Prior to staining, keratinocytes from individual neonates were resuspended in 
1ml of keratinocyte growth media and 500µl plated into chambered slides and 
cultured. On day 5, the media was aspirated and the cells were stained using 
RAPI-DIFFII. Staining of wild-type and K14D6 keratinocytes showed the 
morphology of K14D6 keratinocytes to be phenotypically similar to wild-type 
keratinocytes (Figure 3-4). Within both sets of cultured keratinocytes, the 
majority of the cells were round and small, features typical of keratinocytes 
(examples shown within red circle in Figure 3-4). However, there were 
occasional larger cells within both populations, which could have been 
fibroblasts (examples shown in black circle in Figure 3-4). 
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Figure 3-4. Morphology of wild-type and K14D6 epidermal keratinocytes. 
WT and K14D6 keratinocytes were harvested and cultured in chamber slides for 5 days, 
before cells were fixed with methanol then stained with RAPI-DIFFII. Magnification is 200x. 
Red circles denote keratinocytes and black circles denote fibroblasts. 
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To further assess the purity of the keratinocytes cultures, flow cytometric 
analysis was performed on cells stained with the keratinocyte-specific anti-
cytokeratin antibody. Keratinocytes were isolated from individual neonates 
(wild-type and K14D6), trypsinised, washed, permeabilised and stained with 
either FITC-conjugated mouse anti-cytokeratin (pan) antibody or FITC-
conjugated matched isotype antibody and the cell populations analysed by flow 
cytometry.  
Figure 3-5A shows the whole cell population using forward and side scatter 
detectors indicating size and granularity of the cells respectively. The majority 
of the cells are of the same size, within log 2 and 3, and the majority of the 
cells are of similar granularity, between 200 and 400 on the forward scatter. The 
keratinocyte population was gated, R1 shown in Figure 3-5A and cells within this 
gate were then analysed for antibody staining. Figure 3-5B shows in the left hand 
plot, the cell population gated by R1, stained with FITC-conjugated isotype 
control to detect non-specific binding and the baseline was set just to the right 
of log 1. The percentage of R1 gated cells stained with the FITC-conjugated 
isotype antibody, detected in the lower left quadrant, was 95.65%. The right 
plot in Figure 3-5B shows cells gated through R1 that have stained positively with 
FITC-conjugated anti-cytokeratin antibody, shown in the lower right quadrant 
indicating that the population was 96% pure epidermal keratinocytes. A 
representative overlay plot of a population of wild-type and K14D6 keratinocytes 
shows a log shift in positively stained anti-cytokeratin cells compared to isotype 
(Figure 3-5C) and therefore shows that the isolation method yields a highly pure 
keratinocyte population for wild-type and K14D6 keratinocytes. Anti-cytokeratin 
staining showed epidermal keratinocytes that were isolated to be 96% pure 
populations. 
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Figure 3-5. Purity of primary epidermal keratinocytes. 
Keratinocytes from wild-type (WT) and K14D6 mice were isolated, cultured and stained for 
intracellular cytokeratin analysed by flow cytometry. (A) Keratinocyte population was gated 
using forward and side scatter (B) The left hand plot shows keratinocytes stained with 
isotype antibody whereas the right hand plot shows keratinocytes from the same population 
stained with anti-cytokeratin. The box below shows the number of events and % gated cells 
with positive anti-cytokeratin cells appearing in lower right quadrant of plot. (C) A histogram 
plot of isotype (blue) and anti-cytokeratin (green) positive keratinocytes in WT and K14D6 
population. These are all representative examples and n=3/group. 
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To confirm the D6 transgene was targeted to proliferative epidermal 
keratinocytes within K14D6 mice, RNA was extracted from keratinocytes and 
assessed for D6 transcripts. For RNA extraction, the epidermis from 3 neonates 
were pooled together after genotype was determined and the cell pellet was 
resuspended in 3ml keratinocyte growth media and cultured for five days in a 
T75 flask.  
Using RT-PCR, D6 transcripts were detected in K14D6 epidermal keratinocytes 
but not in wild-type keratinocytes (Figure 3-6A). Quantitative PCR (QPCR) 
showed D6 transcripts were present at high levels in K14D6 compared to wild-
type epidermal keratinocytes (p<0.001), which had no detectable D6 transcripts 
above background levels (Figure 3-6B). This confirms that D6 is ectopically 
expressed in K14D6 epidermal keratinocytes, after explant and culture, at a high 
level. 
 
Figure 3-6. D6 transcripts are detected in K14D6 epidermal keratinocytes at high levels. 
RNA was extracted from epidermal keratinocytes isolated and cultured from wild-type and 
K14D6 mice. (A) RT-PCR was performed (+/- reverse transcriptase (RT)) to detect mouse D6 
and β-actin. Products were run on a 1% agarose gel and visualised using ethidium bromide 
under a UV light. (B) RNA from epidermal keratinocytes from WT and K14D6 mice was 
converted to cDNA and diluted with nuclease free water. Levels of D6 transcripts in 
epidermal keratinocytes were assessed by quantitative PCR using SYBR green. Levels were 
normalised using a ‘housekeeping’ gene, GAPDH (n=3/group, bars show mean ± SEM). 
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In this study, D6 is under the transcriptional control of the human K14 promoter. 
This promoter is able to drive expression in epithelial cells within the skin as 
well as within the thymus, tongue and oesophagus (Wang et al., 1997). 
Expression of D6 in the tongue, thymus and oesophagus is unlikely to contribute 
to skin pathology. However, thymus from K14D6 mice have been analysed by 
Professor G. Anderson and the architecture of the thymus was considered 
normal. 
3.5 Detection of mouse D6 protein 
The next step was to examine the presence of the D6 protein in K14D6 
transgenic mice either by immunohistochemistry or by western blotting. 
However, no antibody to mouse D6 was available. During this project, an anti-
mouse D6 antibody (raised in chicken) was made through collaborations. The 
antibody was required to be tested and optimised to determine whether it was 
D6 specific.  
The antibody was tested by western blotting using human embryonic kidney cells 
293 (HEK) that had been stably transfected with murine D6 (HEKmD6) and 
untransfected HEK cells as a negative control. The cells were cultured and 2x106 
cells were lysed in mammalian cell lysis buffer, centrifuged and the supernatant 
was retained. Total protein within the supernatant was analysed by a BCA 
protein assay following manufacturer’s instructions. A total of 10µg protein from 
HEK and HEKmD6 was loaded into the wells of a NuPAGE 4-12% Bis-tris gel 
alongside a multimark colour molecular weight standard. The gel was 
electrophoresed and transferred to membrane using a semi-dry transfer system 
before being incubated in different concentrations of the chicken anti-mouse D6 
antibody for 1 hour at room temperature. Primary antibody dilutions tested were 
1:50, 1:250 and 1:1000. The secondary antibody, donkey anti-chicken IgY 
conjugated to horseradish peroxidase was used at 1:5000 dilution. Horseradish 
peroxidase was detected by chemiluminescent substrate ‘west pico’(Pierce). 
The concentration of the primary antibody at 1:50 and 1:100 was too high as no 
specific bands could be determined in the blot due to high background staining 
(data not shown). However, bands were easily detected using the 1:1000 
dilution. A band of 52kDa, the approximate molecular weight of D6 was detected 
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in both HEKmD6 and the HEK negative control (Figure 3-7A). Additionally a band 
of approximately 98kDa was also detected in both HEKs and HEKmD6 (Figure 3-
7A). The experiment was repeated three times using fresh cells with the same 
result, indicating non-specific binding. To try to eliminate non-specific binding, 
the experiment was repeated with the antibodies diluted in 5% milk. A band 
appeared at approximately 52kDa and 98kDa in extracts of both HEK and 
HEKmD6 cells (Figure 3-7B). Therefore, it was concluded that the antibody was 
actually detecting some non-specific proteins and was not specific for murine 
D6. As a result, the chicken anti-mouse D6 antibody could not be used for 
further studies. 
Since the antibody was not specific, another assay was required to determine 
the presence of the D6 protein within K14D6 keratinocytes. A ligand-binding 
assay was used to determine D6 receptor expression in K14D6 transgenics.   
 
Figure 3-7. Optimising an anti-mouse D6 antibody 
Protein was extracted from human embryonic kidney (HEK) cells and HEKmD6 (HEK stably 
transfected with murine D6) and 10µg total protein was used in western blotting. The 
primary antibody, chicken anti-mouse D6 antibody, was used at 1:1000 dilution and the 
secondary antibody conjugated to horseradish peroxidase (HRP) was used at 1:5000. HRP 
was detected using West Pico. (A) Antibodies are diluted in PBS/0.1% Tween 20 (PBST) (B) 
Antibodies were diluted in 5% milk in PBST. Images are a representative of three replicate 
experiments. 
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3.6 Characterisation of chemokine receptor transcripts in 
primary keratinocytes 
Although there was no antibody against mouse D6 available to detect the 
presence of the protein, D6 transcripts were present in the transgenic 
keratinocytes and therefore the functional ability of D6 to bind and internalise a 
D6 specific ligand was assessed (McKimmie et al., 2008, McKimmie and Graham, 
2006). To examine the functional ability of D6, fluorescently labelled 
chemokines or biotinylated chemokines were used. Ligand binding to cells can 
be detected by flow cytometry using fluorescently labelled chemokines. A 
biotinylated chemokine, which could be detected by western blotting using 
streptavidin conjugated to HRP, was used to determine the capability of the D6 
transgene to internalise and degrade chemokines. 
However, before going on to examine the functional ability of D6, it was 
important to determine which chemokine receptors were present on primary 
keratinocytes, as this would help determine the most suitable ligand to use to 
assess D6 function because all D6 ligands bind other chemokine receptors. D6 
can bind many inflammatory CC chemokines, which are also capable of binding 
to other chemokine receptors, mainly CCR1, CCR2, CCR3, CCR4 and CCR5 
(summarised in Table 3-1.) It is of note that murine CCR3 is able to bind CCL3 
whilst human CCR3 is not able to (Menten et al., 2002). Studies have shown that 
CCR1 and CCR5 are present in a human keratinocyte cell line (HaCaT) and 
primary human keratinocytes express CCR3 (Petering et al., 2001, Szabo et al., 
2001). These studies indicated the possibility of the presence of CCR1, CCR3 and 
CCR5 on murine keratinocytes. 
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Chemokine 
receptor 
 D6 Ligands 
D6 CCL2 CCL3 CCL3L1 CCL4 CCL5 CCL7 CCL8 CCL11 CCL13 CCL14 CCL17 CCL22 
CCR1             
CCR2             
CCR3             
CCR4             
CCR5             
 
 
Table 3-1. Summary of D6 ligands, which CCR1, CCR2, CCR3, CCR4 and CCR5 can bind. 
D6 can bind 12 pro-inflammatory chemokines as listed. CCR1, CCR2, CCR3, CCR4 and 
CCR5 can bind several D6 ligands (indicated by grey shaded box). Murine CCR3 can bind 
CCL3 whereas human CCR3 does not (indicated by black shaded box). 
 
Wild-type and K14D6 keratinocytes were isolated and cultured in T75 flasks for 5 
days before RNA was extracted using the RNeasy mini kit. To determine a 
suitable ligand to use to test D6 function, cDNA was synthesised from 1µg RNA 
and examined for the expression of chemokine receptors CCR1-CCR5 using RT-
PCR.  
Strong expression of CCR1 transcripts was seen in the wild-type and K14D6 
keratinocytes as well as weak expression of CCR3 and CCR5 transcripts. 
Conversely, CCR2 and CCR4 transcripts were absent from both wild-type and 
K14D6 keratinocytes (Figure 3-8A). DNA from tail tips of wild-type and K14D6 
mice were used as a positive control to ensure that the primers and PCR worked. 
CCR1, CCR3 and CCR5 transcripts were quantified by quantitative PCR. There 
was no significant difference in the transcript levels of CCR1, CCR3 or CCR5 
between wild-type and K14D6 epidermal keratinocytes. This indicates that 
ectopic expression of D6 in resting epidermal keratinocytes does not affect the 
transcript levels of CCR1, CCR3 or CCR5 (Figure 3-8B). 
Therefore, to test the ability of transgenically expressed D6 to bind ligands, any 
ligand that binds CCR1, CCR3 and CCR5 were not suitable. The most suitable 
ligands would be chemokines that only bind D6 and CCR2 or CCR4, such as CCL2, 
CCL17 or CCL22.  
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Figure 3-8. Expression of chemokine receptors CCR1, CCR3 and CCR5 on primary 
epidermal keratinocytes. 
(A) RNA was extracted from WT and K14D6 epidermal keratinocytes and subjected to RT-
PCR (+/- reverse transcriptase (RT)) for chemokine receptors CCR1-5 and β-actin. DNA was 
extracted from tail tips as a positive control. Products were electrophoresed on a 1.5% 
agarose gel and visualised with ethidium bromide by UV light. (B) RNA from epidermal 
keratinocytes from WT and K14D6 mice were converted to cDNA and diluted with nuclease 
free water.  Levels of CCR1, CCR3 and CCR5 transcripts in epidermal keratinocytes were 
examined by quantitative PCR using SYBR Green. Levels were normalised against a ‘house 
keeping’ gene, GAPDH and represented as fold change in transcript level of CCR1, CCR3 
and CCR5 in K14D6 keratinocytes compared to transcript levels in WT keratinocytes 
respectively (n=3/group, bars are mean ± SEM). 
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3.7 The function of D6 in K14D6 epidermal keratinocytes 
D6 is capable of binding many inflammatory chemokines and has been proposed 
to function as a scavenging receptor (Fra et al., 2003), internalising and 
targeting chemokines for degradation (Weber et al., 2004), thereby removing CC 
chemokines from its surroundings. Therefore, the ability of D6 in K14D6 
keratinocytes to function was assessed in two ways. One was to examine the 
ability of D6 in K14D6 keratinocytes to bind a D6 ligand and the second was to 
assess the ability of D6 in K14D6 keratinocytes to remove chemokines from its 
surroundings.  
3.7.1 K14D6 keratinocytes can bind CCL2, a D6 ligand. 
To assess whether D6 from K14D6 keratinocytes was functional, the ability of 
these cells to bind a fluorescent-labelled CCL2 (CCL2-Alexa 647) was examined. 
CCL2 is a ligand for D6 (Nibbs et al., 1997a) which can also bind CCR2. To 
determine whether any binding of CCL2 by keratinocytes was specifically due to 
D6, a competition assay was set up using a 10-fold excess of CCL3, another D6 
ligand (Nibbs et al., 1997a). In this assay, it is only binding of CCL2 by D6 that 
can be outcompeted by CCL3.  
Individual populations of epidermal keratinocytes were isolated from wild-type 
and K14D6 mice, resuspended in 1ml of keratinocyte growth media and 200µl 
was seeded in triplicate into 24 well plates and cultured for five days. Fresh 
keratinocyte media was added (250µl) and cells were treated with either PBS, 
25nM fluorescent-labelled CCL2, or 25nM fluorescent-labelled CCL2 and 250nM 
CCL3, and incubated for 100 minutes at 37°C. Keratinocytes were washed, 
trypsinised, resuspended and labelled, CCL2 binding was assessed by flow 
cytometry. 
Keratinocytes were gated (R1) using forward and side scatter (Figure 3-9A) 
before going on to analyse non-specific and specific fluorescent-labelled CCL2 
binding. Figure 3-9B shows keratinocytes that have been gated through R1 and 
shows cells treated with PBS (left panel), keratinocytes stained with fluorescent-
labelled CCL2 (middle panel) and keratinocytes stained with fluorescent-labelled 
CCL2 in the presence of excess CCL3 (right panel). The top panel in Figure 3-9B 
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illustrates an example of a wild-type keratinocyte population and the bottom 
panel shows an example of K14D6 keratinocyte population. Non-specific binding 
was determined and set within the lower left quadrant of the plot for wild-type 
and K14D6 keratinocytes. In the presence of fluorescently labelled CCL2, a 
number of cells were seen to shift from the lower left quadrant to the lower 
right quadrant in K14D6 keratinocytes but not in the wild-type, indicating K14D6 
keratinocytes are positive for CCL2 binding (Figure 3-9B middle panel). In the 
presence of CCL2 and excess CCL3, wild-type keratinocytes remained within the 
lower left quadrant whereas K14D6 keratinocytes shifted from the lower right 
quadrant to the lower left quadrant (Figure 3-9B right panel). This data indicates 
that CCL2 binding in K14D6 keratinocytes was outcompeted by CCL3. Figure 3-9C 
shows an overlay plot of K14D6 keratinocytes treated with PBS, fluorescently 
labelled CCL2 and labelled CCL2 in the presence of excess CCL3 (blue, pink and 
green respectively). Figure 3-9C illustrates that K14D6 keratinocytes can bind 
the fluorescently labelled CCL2, shown by a shift in the green line compared to 
the control (blue line), yet in the presence of excess CCL3 this binding is 
inhibited, illustrated by the pink line being similar to control (blue). The data 
were quantified using the mean percentage of keratinocytes that were positively 
labelled for CCL2 under the different conditions using the percentage of cells 
gated by R1 present in the lower right quadrant. In the wild-type population, the 
percentage of keratinocytes positively labelled with CCL2 was found to be lower 
than 1% and there was no significant difference between wild-type keratinocytes 
treated with PBS, fluorescent-labelled CCL2 or fluorescent-labelled CCL2 and 
excess CCL3 (Figure 3-9D). Whereas in the K14D6 population, the percentage of 
cells positive for fluorescent-labelled CCL2 in the PBS treated group was 
significantly increased to approximately 45% in keratinocytes treated with 
fluorescently labelled CCL2 (p<0.001). In the presence of excess CCL3, the 
percentage of K14D6 keratinocytes labelled with CCL2 was significantly reduced 
from 45% to 2% (p< 0.001; shown in Figure 3-9D).  
In summary, binding of CCL2 occurred in K14D6 keratinocytes but not in wild-
type keratinocytes, indicating that CCL2 binding by K14D6 keratinocytes was due 
to D6. These data further confirmed the absence of CCR2 on primary epidermal 
keratinocytes. 
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Figure 3-9. K14D6 keratinocytes are able to bind CCL2 in a D6 dependent manner 
Keratinocytes were cultured from individual WT and K14D6 mice in 250µl KGM with 1% BSA 
and incubated with (i) PBS (ii) 25nM CCL2-alexa 647 or (iii) 25nM CCL2-alexa 647 with 250nM 
CCL3 for 100 minutes at 37°C. Keratinocytes were trypsinised and resuspended in PBS/2mM 
EDTA/0.1%FCS and samples analysed by FACS. (A) Representative plots of WT and K14D6 
keratinocytes stained with CCL2-alexa 647 under the different conditions. (B) A 
representative histogram plot of K14D6 keratinocytes showing uptake of CCL2 in untreated 
cells (blue), cells treated with CCL2 (green) and cells treated with CCL3 and CCL2 (pink). (C) 
The mean % of WT and K14D6 keratinocytes labelled with CCL2-Alexa 647; n=3/group and 
columns are mean ± SEM. 
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3.7.2 K14D6 keratinocytes can remove extracellular CCL3 from 
the media. 
D6 in K14D6 keratinocytes was able to bind CCL2 and therefore the next step 
was to determine whether D6 from the transgene was able to internalise and 
degrade ligands. D6 activity in K14D6 keratinocytes was assessed by its ability to 
deplete extracellular biotinylated CCL3, a D6 ligand. Keratinocytes were 
individually isolated and seeded into 6ml plates with 5ml of keratinocytes 
growth media. After five days, the number of keratinocytes within the plates 
was 2.5x105 cells. Wild-type and K14D6 keratinocytes were treated with 10nM 
biotinylated CCL3 and samples of supernatant were taken at various timepoints 
over 24 hours. Any remaining biotinylated CCL3 in the media was detected using 
streptavidin labelled with HRP on a western blot (McCulloch et al., 2008).  
Wild-type keratinocytes did not deplete biotinylated CCL3 from the surrounding 
media as there was no decrease in the amount of biotinylated CCL3 detected at 
0 hours from 2, 4, 6, 8, 12 and 24 hours whereas by 4 hours in the presence of 
K14D6 keratinocytes, less biotinylated CCL3 was detected than was present at 
0hrs (Figure 3-10A). By 12 hours, the levels of biotinylated CCL3 in the media in 
the presence of K14D6 keratinocytes was markedly less and very little 
biotinylated CCL3 remained after 24 hours (Figure 3-10A). Therefore, K14D6 
keratinocytes were able to remove extracellular CCL3 from the media 
progressively whereas wild-type keratinocytes did not.  
To ensure that the progressive removal of CCL3 was D6 dependent in K14D6 
keratinocytes, a competition assay was set up, with 10nM biotinylated CCL3 
added along with a 10-fold molar excess of CCL22, a high affinity D6 ligand 
(Bonecchi et al., 2004). An excess of CCL22 should bind all D6 receptors and 
prevent binding of biotinylated CCL3 to D6. As a result, excess CCL22 prevented 
depletion of biotinylated CCL3 by K14D6 keratinocytes as the levels of 
biotinylated CCL3 remained the same at 0, 2, 4, 6, 8, 12 and 24 hours, indicating 
that depletion of biotinylated CCL3 is D6 dependent (Figure 3-10B). Therefore, 
D6 in K14D6 keratinocytes is functional. 
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Figure 3-10. Transgenic expression of D6 in epidermal keratinocytes is able to degrade 
extracellular biotinylated CCL3. 
Keratinocytes from neonatal wild-type (WT) or K14D6 mice were cultured in 1ml 
keratinocyte growth media containing (A) 10nM biotinylated CCL3 (BioCCL3) or (B) 10nM 
BioCCL3 in competition with 100nM CCL22. The remaining BioCCL3 was detected by 
western blotting using streptavidin conjugated to HRP at the timepoints indicated. Data 
shown is representative of three experiments. 
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3.8 Transgenic expression of D6 dampens cutaneous 
inflammation. 
To assess the ability of the K14D6 transgene to dampen down inflammation in 
vivo, a well-characterised cutaneous inflammation model was used involving 
application of 12-O-tetradecanoyl-phorbol-13-acetate, also known as TPA 
(Stanley et al., 1991) to the skin of FVB/N wild-type and K14D6 transgenic mice. 
In this model, the lower dorsal skin of the mice was shaved two days before 
starting the TPA application. TPA was applied to the dorsal skin of the mice once 
on three consecutive days. TPA is a tumour promoter, which activates protein 
kinase C and application of the chemical on three consecutive days results in 
acute inflammation, which eventually resolves (Jamieson et al., 2005).  
This model was used previously with D6 null mice, on a C57BL/6 background, in 
which these mice demonstrated a prolonged and exaggerated inflammatory 
response (Jamieson et al., 2005). These studies showed that in comparison to 
wild-type mice, D6 null mice were unable to clear CCL5 and CCL3, both D6 
ligands, from the site of skin inflammation 24 hours after TPA application. These 
data suggested that D6 was involved in regulating chemokine levels at sites of 
inflammation by playing a role in chemokine removal. Histological analysis of the 
skin after TPA induced inflammation revealed D6 null mice demonstrated 
increased skin thickening, hyperkeratosis, epidermal hyperplasia, increased 
angiogenesis and increased infiltration of inflammatory cells, in particular 
epidermal T cells and dermal mast cells (Jamieson et al., 2005). The 
exaggerated inflammatory response was shown to be TNF-dependent, and 
histological changes within D6 null mice skin showed similar characteristics to 
those found in human psoriasis. Therefore, since absence of D6 resulted in an 
exaggerated cutaneous inflammatory response, we examined whether increased 
expression of D6 within the epidermis would suppress the inflammatory 
response. 
Four days after the final application of TPA, mice were sacrificed and the dorsal 
skin was harvested, fixed in 10% neutral buffered formalin for haematoxylin and 
eosin staining as well as for CD3 staining and astra blue staining to identify T 
cells and mast cells respectively. Skin sections were analysed for skin thickness 
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by counting the number of squares the skin filled within the grid in the eyepiece 
in which twenty random points per skin section were counted.  
There was no significant difference in skin thickness between untreated D6 null 
mice, wild-type and K14D6 mice (Figure 3-11A). Four days after the final 
application of TPA, D6 null mice demonstrated a significant increase in skin 
thickness compared to resting skin thickness (p<0.001; Figure 3-11A). Wild-type 
mice also demonstrated a significant increase in skin thickness after four days 
compared to resting skin thickness (p<0.001; Figure 3-11A). However, K14D6 
mice showed no significant difference in skin thickness four days after the final 
application of TPA compared to resting skin thickness (Figure 3-11A). This data 
illustrated that D6 null mice on a different background also demonstrated an 
exaggerated inflammatory response within the skin to TPA. Four days after the 
final application of TPA, K14D6 mice contained fewer T cells in the epidermis in 
comparison to wild-type mice (p<0.001; Figure 3-11B). K14D6 mice also 
demonstrated a significant reduction in the number of mast cells present within 
the skin in comparison to wild-type mice (p<0.001; Figure 3-11C). 
These data confirm D6 null mice demonstrate an exaggerated inflammatory 
response to TPA in comparison to wild-type mice and indicate that K14D6 mice 
can suppress in vivo inflammation due to the increased expression of D6. 
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Figure 3-11. Transgenic expression of D6 in murine epidermis limits cutaneous 
inflammation. 
(A) D6 null mice (KO), Wild-type (WT) and K14D6 mice (n=5/group) received an application of 
TPA on the dorsal skin on three consecutive days. Four days later, the skin was harvested. 
Dorsal skin from untreated mice (n=5/group) was harvested immediately. Skin sections were 
scored for epidermal thickness. (B) Skin sections from WT and K14D6 mice four days after 
the final application of TPA were stained with an anti-mouse CD3 antibody to identify T 
cells. The number of T cells within the epidermis was counted using 20 random points per 
skin section. (C) Mast cells were stained with astra blue in WT and K14D6 skin and the 
number of mast cells were counted in 20 random fields per section. 
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3.9  Summary of Chapter 3 
D6 was proposed to play a role within the resolution phase of inflammation and 
the main aim of this chapter was to test the hypothesis that increased 
expression of D6 would suppress inflammation. To test this hypothesis, 
transgenic mice were generated where D6 expression would be increased 
ectopically. Since the biological role of D6 was hypothesised using a skin 
inflammation model, it was decided to transgenically express D6 within the skin 
so that the skin inflammation model could be used to test the hypothesis. 
Therefore, K14D6 mice were generated so that increased expression of D6 would 
be targeted to the epidermal layer of murine skin under the control of the 
human K14 promoter. Therefore, the work in this chapter was to characterise 
and validate the K14D6 transgenic mice. 
In summary, K14D6 mice express D6 transcripts within the epidermis, more 
specifically within epidermal keratinocytes after explant and culture, and such 
transcripts are absent from wild-type mice. Ectopic expression of D6 within 
K14D6 keratinocytes does not change the morphology in comparison to wild-type 
keratinocytes. CCR1, CCR3 and CCR5 transcripts are present in primary murine 
keratinocytes and ectopic expression of D6 in K14D6 keratinocytes does not 
affect CCR1, CCR3 or CCR5 transcript levels. K14D6 keratinocytes are able to 
bind CCL2, a D6-specific ligand, whereas wild-type keratinocytes are not able to. 
K14D6 keratinocytes are able to progressively deplete extracellular CCL3 
whereas wild-type keratinocytes do not and therefore the K14D6 transgene is 
functional. In terms of skin inflammation, K14D6 mice were able to suppress 
inflammation in response to a topical application of a skin irritant whereas D6 
null and wild-type could not. Therefore, D6 can suppress skin inflammation and 
has the potential to be of therapeutic use. 
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4 Characterisation of the transcriptional 
consequences of D6 ligand binding 
4.1  Introduction 
Many members of the chemokine receptor family signal through the activation of 
G-proteins as they belong to the family of G-protein coupled receptors (Murphy 
et al., 2000). Conversely, there are four chemokine receptors, DARC, D6, CCX 
CKR and CXCR7, which are unconventional because there does not seem to be 
any signalling activity after high affinity ligand binding (Graham, 2009). In vitro 
studies have examined ligand dependent functional responses, such as calcium 
fluxes and chemotaxis, for both human and murine D6 and have shown that 
ligand binding to D6 does not trigger these responses (Fra et al., 2003, Nibbs et 
al., 1997a). However, the possibility that D6 may signal via a different 
mechanism other than G-protein coupling has not been investigated. Human 
lymphatic endothelial cells are known to express D6 by immunohistochemistry 
(Nibbs et al., 2001, Vetrano et al., 2009). However, D6 was not expressed on 
isolated human lymphatic endothelial cells indicating that D6 had been 
transcriptionally silenced (Amatschek et al., 2007). Within our laboratory, we 
had D6 transgenic mice (K14D6), where ectopic expression of D6 was targeted to 
epidermal keratinocytes. In the previous chapter, a method of isolating primary 
keratinocytes was utilised to characterise the level of D6 transcripts and the 
functional activity of D6 in wild-type and K14D6 mice. D6 transcripts were only 
expressed and functional in K14D6 epidermal keratinocytes (see Chapter 3). As a 
result, epidermal keratinocytes from K14D6 mice are a primary cell type that 
can be isolated and cultured whilst still expressing D6. Therefore, the aim of this 
work was, using a microarray approach, to determine any transcriptional 
consequences of ligand binding to D6. By assessing the transcriptional 
consequences, this would give an indication into cell functions mediated through 
D6 in vivo. 
The work described in this chapter exploits microarray technology to 
characterise the changes to the cellular transcriptome after ligand binding to D6 
using primary keratinocytes isolated from wild-type and K14D6 mice. It was 
hoped that the microarray analysis would yield information on altered gene 
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expression after ligand binding to D6. A second aspect was to determine if there 
were any transcriptional consequences induced by basal D6 expression, 
independent of ligand, within K14D6 keratinocytes. 
4.2 Experimental details 
Primary keratinocytes were isolated from neonatal mice and after genotyping; 
keratinocytes were pooled from three mice of the same genotype and cultured 
for 5 days in a T75 flask. On day 5, wild-type and K14D6 keratinocytes were 
incubated with 10nM CCL3, a high affinity D6 ligand, or PBS for 6 hours at 
37°C. Keratinocytes were incubated for 6 hours since transcriptional changes 
through ligand binding to chemokine receptors can occur between 2 and 8 hours 
(Valerio et al., 2004). RNA was isolated from primary keratinocytes, transcribed 
into biotinylated cRNA and applied to an Affymetrix Mouse genome 430 2.0 Array 
Gene Chip (http://www.affymetrix.com/). The data generated was analysed 
using rank products (Breitling et al., 2004b) and iterative group analysis (iGA) 
methods (Breitling et al., 2004a). The experimental design is summarised in 
Figure 4-1. 
 
 
Figure 4-1. Summary of experimental design to characterise transcriptional consequences 
of D6 ligand binding. 
Primary wild-type (WT) and K14D6 keratinocytes were isolated and cultured from neonatal 
mice. Keratinocytes were incubated with PBS or 10nM CCL3 for 6hrs. RNA was isolated 
from primary keratinocytes and prepared for application to an Affymetrix gene chip to 
measure changes in gene transcription.  
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4.3 Generation and validation of RNA for microarray 
application 
RNA was extracted from the samples and subsequently processed by staff at the 
Sir Henry Wellcome Functional Genomics Facility at the University of Glasgow 
(http://www.gla.ac.uk/faculties/fbls/functionalgenomicsfacility/) where the 
microarray analyses were performed. The RNA samples were assessed for 
quantity, using a Nanodrop ND-1000, in which 1µl of each sample was analysed 
(Table 4-1). The quality of RNA was assessed using an Agilent 2100 Bioanalyser. 
Each experimental condition was repeated in triplicate for statistical analysis.  
The concentration of the samples varied from 38.1ng/µl to 1742.4ng/µl (Table 
4-1). One sample, wild-type control 2, was below the recommended level of 2µg 
total RNA required for the microarray (Table 4-1). Therefore all samples prior to 
being transcribed into biotinylated cRNA underwent linear amplification (Phillips 
and Eberwine, 1996). If only one sample underwent linear amplification this 
would skew the data, therefore all the samples were amplified to give a fair 
comparison. The cRNA was then applied to Affymetrix GeneChip Mouse genome 
430 2.0 Array for generation and analysis of data. 
 
 
 
 
 
 
 
 
 
Table 4-1. Concentration and total yield of RNA extracted from keratinocytes analysed by a 
Nanodrop ND-1000. 
Primary keratinocytes were isolated and cultured for 5 days before addition of PBS or 10nM 
CCL3 for 6 hours at 37°C. RNA was isolated and 1µl of each sample was analysed for 
quantity using a Nanodrop ND-1000 by staff at the Functional Genomics Facility. n=3/group 
and each sample consisted of keratinocytes from 3 neonatal mice. 
Sample Concentration  
of RNA (ng/µl) 
Total yield 
RNA (µg) 
WT control 1 1742.4 52.3 
WT control 2     38.1   1.1 
WT control 3   269.9   8.1 
WT + CCL3 1 1566.5 47.0 
WT + CCL3 2   402.5 12.1 
WT + CCL3 3   421.7 12.7 
K14D6 control 1 1020.8 30.6 
K14D6 control 2   304.9   9.1 
K14D6 control 3   482.1         14.5 
K14D6 + CCL3 1   857.9 25.7 
K14D6 + CCL3 2   717.8 21.5 
K14D6 + CCL3 3   799.7 24.0 
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4.4 Analysis of microarray Data 
The analysis of the microarray was carried out in the Sir Henry Wellcome 
Functional Genomics Facility, where the data were generated and automatically 
analysed by FunAlyse, in-house microarray data analysis software. This software 
generates a directory for each project and data is normalised using the robust 
multichip average (RMA) method (Irizarry et al., 2003). The software performs 
two different sets of analysis producing two reports. These are known as the 
rank product (RP) report (Breitling et al., 2004b) and the iterative group analysis 
report (Breitling et al., 2004a). The iGA report is generated using the list of 
genes produced by the rank product analysis and identifies functional changed 
groups of genes. Terminology used by this software can be found in Appendix 
One. All data generated by the microarray can be found in Appendices Two and 
Three. The comparisons made were: 
1) WT control (baseline) versus K14D6 control 
 
2) WT control (baseline) versus WT + CCL3 
 
3) K14D6 control (baseline) versus K14D6 + CCL3 
 
4) WT + CCL3 (baseline) versus K14D6 + CCL3 
 
 
4.4.1 Rank product differential expression analysis reports 
The rank products analysis report lists genes sorted according to a measure of 
differential expression calculated using the rank product method. The rank 
products method is a non parametric statistical test where the RP score is a 
measure of differential expression based on ranks of fold changes (Breitling et 
al., 2004b). It is a biologically motivated test based on the idea that a gene is 
highly up or downregulated in one experiment but if the same gene is at the top 
of a list in a replicate experiment then it is likely that this gene is actually 
changed. Therefore rank product values are calculated using the position of the 
gene (the most strongly upregulated or downregulated gene is assigned a value 
of 1) in each of the replicate experiments sorted by increasing or decreasing fold 
change. The smaller the RP score is, the higher the likelihood the gene is up or 
downregulated. The FunAlyse software cuts the list of differentially expressed 
genes at a level of 50% false discovery rate (FDR), which is the expected 
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percentage of false positives, or the software lists the top 100 genes according 
to their rank product score, regardless of their FDR, depending on the list that is 
longer. The full rank product differential expression analysis reports can be 
found in Appendix Two. 
4.4.1.1  WT keratinocytes versus K14D6 keratinocytes 
To investigate basal differences in transcription upon D6 expression, a 
comparison between resting K14D6 keratinocytes and wild-type keratinocytes 
was made. 
i) Potential upregulated genes 
The software generated a list of the top 100 genes according to rank product 
score (The full list can be found in Appendix Two) however, only six genes were 
potentially upregulated with less than 50% false discovery rate (Table 4-2).  
Out of the six genes, only 2, chemokine binding protein 2 (Ccbp2, which is also 
known as D6) and dickkopf homolog 2 (Dkk2), changed more than 2-fold, which 
was identified as an arbitrary cut off (Table 4-2). Of the six potentially 
upregulated genes, the rank product (RP) score varied from 1.00, which was the 
highest ranked gene (Ccbp2) to an RP score of 470.76 for the lowest ranked gene 
with an FDR of less than 50%, which was tissue factor pathway inhibitor 2 
(Tfpi2). The fold change (FC), varied from 49.59 to 1.48 (Ccbp2 and branched 
chain aminotransferase 1 (Bcat1) respectively) within the top six genes shown to 
be expressed at higher levels in resting K14D6 keratinocytes by the microarray 
(Table 4-2). One gene, Ccbp2, within this comparison was found to have an RP 
score of 1.00, which is the smallest RP value that can be achieved and was found 
to be expressed at higher levels (49.59 fold change), in K14D6 keratinocytes 
compared to wild-type keratinocytes and also had a 0% false discovery rate.  
This data indicates that the gene, Ccbp2, is potentially upregulated by 49.52 
fold in K14D6 keratinocytes compared to wild-type keratinocytes. In chapter 3, 
the levels of D6 transcripts were shown to be significantly higher in K14D6 
keratinocytes compared to WT keratinocytes (see Figure 3-6). Therefore, these 
data confirm that the K14D6 transgene is expressed within K14D6 keratinocytes. 
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Table 4-2. The top 6 genes listed by RP score as potentially upregulated genes in K14D6 
keratinocytes compared to wild-type keratinocytes. 
Potentially upregulated genes were listed in order of rank product score (RP score) with 
details of % false discovery rate (FDR) and fold change (FC).  
 
ii) Potential downregulated genes 
A list of 100 potentially downregulated genes was generated by the analysis 
software according to RP scores in the comparison between K14D6 keratinocytes 
and wild-type keratinocytes; however only 81 of these genes had an FDR of less 
than 50% (Full list can be found in Appendix Two). Of the 81 genes, the RP score 
varied from 80.91 to 1158.63 with fold change varying between -2.92 and -1.02 
(Appendix Two). The top 25 potentially downregulated genes listed in the RP 
report are summarised in Table 4-3.   
Of the top 25 genes listed, only 24 genes were potentially downregulated as P 
lysozyme structural (Lzp-s) appeared twice in the RP report (Table 4-3). Of the 
24 genes, only 4 changed more than 2-fold and these were within the top 5 
ranked genes shown in Table 4-3. Lzp-s had the lowest RP score of 80.91, an FDR 
of 0% and a fold change of -2.92. Additionally, Lzp-s was third in the list with an 
RP score of 119.46, an FDR of 1.67 and a fold change of -2.73. Cathepsin S (Ctss) 
was second in the list with an RP score of 99.49 and changed by -2.81 fold. The 
other two genes found to be potentially downregulated more than 2-fold were C-
type lectin domain family member n (Clec4n) and lysosomal associated protein 
transmembrane 5 (Laptm5) which were placed 4th and 5th in the RP report with 
5.75% and 8.20% FDR respectively. This data indicates that ectopic expression of 
D6 may have a negative impact on the transcription of Lzp-s, Ctss, Clec4n and 
Laptm5. 
RP score FDR (%) FC Gene Symbol Gene Title 
1.00 0.00   49.59 Ccbp2 Chemokine binding protein 2 
206.84 15.50 2.66 Dkk2 Dickkopf homolog 2 (Xenopus laevis) 
348.58 43.33 1.81 Nrk Nik related kinase 
359.51 34.50 1.48 Bcat1 Branched chain aminotransferase 1, 
cytosolic 
389.02 32.50 1.56 Stc2 Stannocalcin 2 
470.76 47.67 1.62 Tfpi2 Tissue factor pathway inhibitor 2 
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Table 4-3. Twenty-five top genes potentially downregulated in K14D6 keratinocytes 
compared to wild-type keratinocytes. 
Genes were listed in order of rank product score (RP score) with details of % false 
discovery rate (FDR) and fold change (FC). 
 
 
 
 
 
 
 
 
 
 
 
RP score FDR (%) FC Gene Symbol Gene Title 
80.91 0.00     -2.92 Lzp-s P lysozyme structural 
99.49 0.50 -2.81 Ctss Cathepsin S 
119.46 1.67 -2.73 Lzp-s P lysozyme structural 
204.14 5.75 -2.04 Clec4n C-type lectin domain family, member n 
241.21 8.20 -2.02 Laptm5 Lysosomal associated protein 
transmembrane 5 
288.72 11.17 -1.84 Clec4d C-type lectin domain family 4, member d 
314.02 13.14 -1.94 1110014K05Rik RIKEN cDNA 1110014K05 gene 
349.82 16.00 -1.84 Fcgr3 Fc receptor, IgG, low affinity III 
391.54 19.33 -1.96 A030004J04Rik RIKEN cDNA A030004J04 gene 
395.41 17.70 -1.88 Lyzs Lysozyme 
395.62 16.09 -1.74 Ms4a11 Membrane-spanning 4-domains, 
subfamily A, member 11  
412.07 17.00 -1.79 Apoe Apolipoprotein E 
436.82 18.77 -1.76 Jarid1d Jumonji, AT rich interactive domain 1D 
(Rbp2 like) 
458.61 20.36 -1.75 Sepp1 Selenoprotein P, plasma, 1 
463.19 19.87 -1.87 2310002A05Rik RIKEN cDNA 2310002A05 gene 
464.93 19.06 -1.73 Gp49a /// Lilrb4 Glycoprotein 49A /// leukocyte 
immunoglobulin-like receptor, subfamily 
B, member 4 
529.00 26.29     -1.75 Sprrl5 Small proline rich-like 5 
530.23 24.89 -1.86 Lce5a Late cornified envelope 5A 
533.51 23.89 -1.78 Sprrl7 Small proline rich-like 7 
577.80 28.95 -1.73 1110055J05Rik RIKEN cDNA 1110055J05 gene 
601.17 30.43 -1.73 1110001M24Rik RIKEN cDNA 1110001M24 gene 
626.85 32.00 -1.60 Ddx3y DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y-linked 
639.19 32.13 -1.32 Cxcl4 Chemokine (C-X-C motif) ligand 4 
646.43 
 
31.58 -1.56 Rbm5 RNA binding motif protein 5 
648.49 30.68 -1.72 Sprrl2 Small proline rich-like 2 
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4.4.1.2  WT keratinocytes versus WT keratinocytes + CCL3 
Wild-type keratinocytes at rest and after ligand binding were compared to assess 
the basic differences in transcripts induced after ligand binding through 
chemokine receptors CCR1, CCR3 and CCR5. 
i) Potential upregulated genes 
The microarray showed higher levels of 217 genes, with an FDR of less than 50%, 
in wild-type keratinocytes incubated with CCL3 compared to control WT 
keratinocytes. The RP score varied from 145.79 to 1681.26 and the FC ranged 
from 3.72 to 1.3 (The full list can be found in Appendix Two). Of the 217 genes 
potentially upregulated using the rank product score, 71 genes demonstrated a 
2-fold change with 9 of these changing more than 3-fold (Appendix Two). Table 
4-4 lists the top 25 genes found to be potentially upregulated by CCL3 in wild-
type keratinocytes using the rank product method.  
The first five genes listed as potentially upregulated by RP score were 
membrane spanning 4-domain subfamily A member 7 (Ms4a7), chemokine (C-X-C 
motif) ligand 4 (CXCL4) also known as platelet derived factor 4, pleckstrin 
(Plek), procollagen type III alpha 1 (Col3a1) and dickkopf homolog 2 (Dkk2). 
Ms4a7 had an RP score of 145.79, a 14% FDR and a fold change of 2.46 whereas 
CXCL4 had an RP score of 171.94, a FDR of 9.5% and fold change of 2.10. Plek 
was ranked third in the list with an RP score of 189.97, an FDR of 8.33% and was 
expressed at higher levels by 2.61-fold. The fourth ranked gene was Col3a1 with 
an RP score of 224.73, a FDR of 10.25% and a fold change of 3.72 whereas the 
fifth ranked gene with an RP score of 228.64, an 8.2% FDR and changed by more 
than 3-fold was Dkk2.   
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Table 4-4. The first 25 genes listed as potentially upregulated by CCL3 in wild-type 
keratinocytes. 
Genes were listed in order of rank product score (RP score) with details of % false 
discovery rate (FDR) and fold change (FC).  
 
 
 
 
 
 
 
 
 
 
 
RP score FDR (%) FC Gene Symbol Gene Title 
145.79 14.00 2.46 Ms4a7 Membrane-spanning 4-domains, 
subfamily A, member 7 
171.94  9.50 2.10 Cxcl4 Chemokine (C-X-C motif) ligand 4 
189.97  8.33 2.61 Plek Pleckstrin 
224.73      10.25       3.72 Col3a1 Procollagen, type III, alpha 1 
228.64  8.20 3.50 Dkk2 Dickkopf homolog 2 (Xenopus laevis) 
236.57  7.00 3.11 Tfpi2 Tissue factor pathway inhibitor 2 
287.28   9.86 3.29 Lum Lumican 
288.57   8.75 2.86 Thbs2  Thrombospondin 2 
288.84   7.78 2.48 B130021B11Rik RIKEN cDNA B130021B11 gene 
269.29   7.20 2.71 Mmp2 Matrix metallopeptidase 2 
303.38   7.55 3.20 Pdgfrb Platelet derived growth factor receptor, 
beta polypeptide 
314.50   7.50 3.25 Col6a1 Procollagen, type VI, alpha 1 
319.04   7.15 2.86 Crabp1 Cellular retinoic acid binding protein 1 
322.66   7.00 2.96 Col6a2 Procollagen, type VI, alpha 2 
329.93   7.00 2.13 C1qa Complement component 1, q 
subcomponent, alpha polypeptide 
335.60   6.88 2.65 Mmp2 Matrix metallopeptidase 2 
339.17   6.71 2.78 Il1rl1 Interleukin 1 receptor-like 1 
373.12   8.39 2.55 Dpep1 Dipeptidase 1 (renal) 
394.70   9.68 2.21 Col11a1 Procollagen, type XI, alpha 1 
397.90   9.35 2.16 Ms4a6d Membrane-spanning  4-domains, 
subfamily A, member 6D 
415.35   9.67 1.88 Laptm5 Lysosomal-associated protein 
transmembrane 5 
417.60   9.32 2.82 Postn Periostin, osteoblast specific factor 
421.55   9.22 2.10 Nr2f1 Nuclear receptor subfamily 2, group F, 
member 1 
437.53 10.04 2.56 Cdh11 Cadherin 11 
439.43   9.72 1.97 F13a1 Coagulation factor XIII, A1 subunit 
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ii) Potential downregulated genes 
Addition of CCL3 to wild-type keratinocytes resulted in the potential 
downregulation of 13 genes with an FDR of less than 50%, as summarised in Table 
4-5. The RP score varied from 228.87 to 574.12 and the FC, -4.27 to -1.47, for 
the highest ranked gene and 15th ranked gene respectively (one gene, Ddx3y, 
appeared in the list three times). Of the 13 listed genes, one gene was expressed 
more than 4 fold lower, which was DEAD box polypeptide (Ddx3y). Eukaryotic 
translation initiation factor 2 (Eif2s3y) was potentially downregulated more than 
3 fold. Genes potentially downregulated more than 2 fold were jumonji (Jarid1d) 
and Ddxy3 (Table 4-5). All three of these genes are linked to the Y chromosome 
(Isensee and Ruiz Noppinger, 2007). One explanation could be that the 
population of keratinocytes treated with CCL3 were isolated, coincidentally, 
from more females than males in comparison to the keratinocyte population 
used as resting wild-type keratinocytes. 
 
 
 
 
Vicky King, 2010   Chapter 4, 160 
Table 4-5. Top 15 genes potentially downregulated gene by CCL3 in wild-type keratinocytes. 
Genes were listed in order of rank product score (RP score) with details of % false 
discovery rate (FDR) and fold change (FC). 
 
 
 
 
 
 
 
 
 
 
 
 
RP score FDR (%) FC Gene Symbol Gene Title 
228.87 45.00    -4.27 Ddx3y DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y linked 
263.41 32.50 -1.59 1110014K05Rik RIKEN cDNA 1110014K05 gene 
265.52 22.00 -1.79 Hrnr Hornerin 
302.93 23.50 -2.63 Ddx3y DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y linked 
319.33 21.20 -3.57 Eif2s3y Eukaryotic translation initiation factor 2, 
subunit 3, structural gene Y-linked 
332.57 19.83 -1.63 Sprrl5 Small proline rich-like 5 
387.48 28.00 -1.55 Lce5a Late cornified envelope 5A 
415.16 30.12 -1.58 Rptn Repetin 
443.01 32.11 -2.14 Jarid1d Jumonji, AT rich interactive domain 1D 
(Rbp2 like) 
453.86 30.90 -1.49 Sprrl7 Small proline rich-like 7 
494.01 36.36 -1.51 --- --- 
506.99 35.75 -1.84 Uty /// LOC546404 
/// LOC546411 
Ubiquitously transcribed 
tetratricopeptide repeat gene, Y 
chromosome /// similar to male-specific 
histocompatibility antigen H-YDb /// 
similar to male-specific 
histocompatibility antigen H-YDb 
508.76 33.62 -1.53 LOC433621 /// 
LOC545581 
Similar to Acidic ribosomal 
phosphoprotein P0 /// similar to Acidic 
ribosomal phosphoprotein P0 
544.39 36.79 -1.98 Ddx3y DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y linked 
574.12 38.80 -1.47 1110001M24Rik RIKEN cDNA 1110001M24 gene 
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4.4.1.3  K14D6 keratinocytes versus K14D6 + CCL3 
To assess the transcriptional consequences of ligand binding to D6, a comparison 
between resting K14D6 keratinocytes and K14D6 keratinocytes after ligand 
binding was made. 
i) Potential upregulated genes 
The microarray showed higher levels of 171 genes in K14D6 keratinocytes 
incubated with CCL3 compared to K14D6 keratinocytes at rest (see full list in 
Appendix Two). The RP score of the 171 genes varied from 97.20 to 1538.85 and 
the FC ranged from 3.31 to 1.24. Out of 171 genes, 11 genes were potentially 
differentially expressed more than 2 fold and all were within the first top 25 
genes summarised in Table 4-6. It is of note that Table 4-6 lists the top 25 
potentially upregulated genes as listed in the RP report; however only 24 genes 
are potentially upregulated as Lzp-s appears twice.  
One gene potentially differentially expressed by more than 3 fold was aldehyde 
dehydrogenase family 1 (Aldh1a7), which was also the first gene on the rank 
product list with an RP score of 97.20 and a 3% false discovery rate (Table 4-6). 
P lysozyme structural (Lzp-s) was ranked 2nd and 4th in the RP report with RP 
scores of 106.48 and 132.50 respectively, both times with an FDR of 1.5% and a 
fold change of 2.47 and 2.33 respectively. Cathepsin S (Ctss) was listed 3rd with 
an RP score of 110.66, an FDR of 1.33% and was changed by 2.33 fold. 
Nucleoplasmin 3 (Npm3) was listed 5th with an RP score of 147.22, an FDR of 
1.4% and was potentially upregulated by 2.11 fold. Selenoprotein P plasma 1 
(Sepp1) was listed 6th with an RP score of 162.85 and was potentially 
differentially expressed by 2.31 fold, followed by pentraxin related gene 3 
(Ptx3) with an RP score of 199.63, potentially upregulated by 2.18 fold and an 
FDR of 2.71%. Aldehyde dehydrogenase family 1 subfamily A1 (Aldh1a1) had an 
RP score of 210.40 and changed by 2.31 fold whereas lysosomal–associated 
protein transmembrane 5 (Laptm5) and Fc receptor IgG low affinity III (Fcrg3) 
had an RP score of 234.4 and 242.06 respectively (listed 9th and 10th) and 
changed by 1.89 and 1.97 fold respectively.  
Within the top 25 genes listed, seven genes expressed at higher levels by CCL3 in 
K14D6 keratinocytes were found to be expressed at lower levels in resting K14D6 
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keratinocytes compared to wild-type keratinocytes (Table 4-6 and 4-3 
respectively). These genes were Lzp-s, Ctss, Laptm5, Fcgr3, Lysozyme (Lyzs), 
apolipoprotein E (Apoe) and Sepp1. This suggests that in absence of ligand, basal 
D6 may have a negative impact on the transcription of these genes but CCL3 
binding may be able to induce transcription of these genes.  
  
Table 4-6. Top 25 genes potentially upregulated by CCL3 in K14D6 keratinocytes.  
Genes were listed in order of rank product score (RP score) with details of % false 
discovery rate (FDR) and fold change (FC). 
 
 
  
 
RP score FDR (%) FC Gene Symbol Gene Title 
97.20 3.00 3.31 Aldh1a7 Aldehyde dehydrogenase family1, 
subfamily A7 
106.48 1.50 2.47 Lzp-s P lysozyme structural 
110.66 1.33 2.33 Ctss Cathepsin S 
132.50 1.50 2.33 Lzp-s P lysozyme structural  
147.22 1.40 2.11 Npm3 Nucleoplasmin 3 
162.85 1.50 2.31 Sepp1 Selenoprotein P, plasma, 1 
199.63 2.71 2.18 Ptx3 Pentraxin related gene 
210.40 2.75 2.31 Aldh1a1 Aldehyde dehydrogenase family 1, 
subfamily A1 
234.40 3.67 1.89 Laptm5 Lysosomal- associated protein 
transmembrane 5 
242.06 3.90 1.97 Fcrg3 Fc receptor, IgG, low affinity III 
254.35 4.27 2.18 Col3a1 Procollagen, type III, alpha 1 
279.37 5.17 2.22 Steap4 STEAP family member 4 
296.41 6.38 1.61 Slc6a14 Solute carrier family 6 (neurotransmitter 
transporter), member 14 
302.93 6.14 2.05 2610001E17Rik RIKEN cDNA 2610001E17 gene 
305.98 5.87 1.79 Lcn2 Lipocalin 2 
313.90 5.94 1.92 Apoe Apolipoprotein E 
373.00 9.29 1.82 Ccl9 Chemokine (C-C motif) ligand 9 
398.97 11.22 1.98 Gpm6b Glycoprotein m6b 
423.63 12.68 2.11 Gtl2 /// Lphn1 GTL2, imprinted maternally expressed 
untranslated mRNA /// latrophilin 1 
427.48 12.40 1.68 Sprr2f Small proline-rich protein 2F  
430.38 12.24 1.86 Ccl6 Chemokine (C-C motif) ligand 6 
435.11 12.23 1.60 2310003F16Rik RIKEN cDNA 2310003F16 gene 
446.67 12.52 1.92 Gp49a /// Lilrb4 Glycoprotein 49 A /// leukocyte 
immunoglobulin-like receptor, subfamily 
B, member 4 
463.36 13.08 1.86 Col1a1 Procollagen, type I, alpha 1 
464.59 12.56 1.85 Lyzs Lysozyme 
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Genes potentially upregulated by CCL3 in both WT and K14D6 keratinocytes 
The microarray showed that CCL3 binding to K14D6 keratinocytes resulted in the  
potential upregulation  of 171 genes with an FDR of less than 50%, however CCL3 
ligand binding in wild-type keratinocytes resulted in the potential upregulation 
of 217 genes (Full results in Appendix Two). Eighty seven genes expressed at 
higher levels in K14D6 keratinocytes as a result of ligand binding were also 
expressed at higher levels in wild-type keratinocytes after ligand binding, 
accounting for 99 of the 217 genes listed within the wild-type + CCL3 RP report 
(some genes were listed twice).  
Comparing the first 25 ranked genes potentially upregulated by CCL3 in the wild-
type and K14D6 keratinocytes (Table 4-4 and Table 4-6 respectively), only two 
genes appear in the top 25 of both lists. The two genes are Laptm5, which is 
listed 9th in K14D6 keratinocytes (Table 4-6) and is listed 21st in wild-type 
keratinocytes (Table 4-4). The second gene is procollagen type III (Col3a1), 
found to be potentially differentially expressed by CCL3 binding in both K14D6 
and wild-type keratinocytes, was listed 11th and 4th respectively (Table 4-6 and 
Table 4-4). Other genes were potentially upregulated after CCL3 binding in both 
K14D6 keratinocytes and wild-type keratinocytes (although these genes are not 
shown in Table 4-4 but are listed in Appendix Two). These genes were, Aldh1a7, 
Lzp-s, Ctss, Sepp1, Ptx3, Aldh1a1, Fcgr3, Col3a1, Riken cDNA 2610001E17 gene, 
ApoE, CCL9, Gtl2, CCL6, glycoprotein 49a (Gp49a), Col1a1 and Lyzs. Genes 
potentially upregulated in both wild-type and K14D6 keratinocytes after ligand 
binding suggest that these may be transcriptional consequences induced through 
ligand binding to CCR1, CCR3 or CCR5. 
Genes found only to be potentially upregulated in K14D6 keratinocytes were 
Npm3, STEAP4, solute carrier family 6 member 14 (Slc6a14), lipocalin 2 (Lcn2), 
glycoprotein m6b (Gpm6b), small proline-rich protein 2F (Sprr2f) and Riken cDNA 
2310003F16 gene (Table 4-6). This suggests the possibility that these genes are 
affected by CCL3 binding to D6.  Genes found only to potentially upregulated, 
within the first 25 listed in Table 4-4, in wild-type keratinocytes after CCL3 
binding were Dkk2, Tfpi2, Riken cDNA B130021B11 gene, complement 
component 1 q subcomponent (C1qa), nuclear receptor subfamily 2 (Nr2f1) and 
coagulation factor XIII (F13a1). These genes were not expressed at higher levels 
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after CCL3 binding in K14D6 keratinocytes. This suggests the possibility that the 
presence of D6 on K14D6 keratinocytes may limit the induction of Dkk2, Tfpi2, 
RIKEN cDNA B130021B11 gene, C1qa, Nr2f1 and F13a1. 
ii) Potential downregulated genes 
The microarray showed lower levels of only four genes, with an FDR of less than 
50%, in the comparison between resting K14D6 keratinocytes and K14D6 
keratinocytes after addition of CCL3 (Table 4-7). The RP score varied from 
123.91 to 369.64 for these four genes and the FC varied from -1.85 to -1.44 
(Table 4-7). Two genes were not given a gene symbol or title but the rank 
product report has hyperlinks for each differentially expressed gene to a 
database, the Stanford Online Universal Resource for Clones and Ests (SOURCE). 
Using this hyperlink, these genes were identified as adapter related protein 
complex 2 beta 1 subunit (Ap2b1) and cannabinoid receptor 1 (Cbp1). The first 
gene, Ap2b1, had an RP score of 123.91, a 2% false discovery rate and was 
potentially downregulated by 1.85 fold. The second gene expressed at lower 
levels was sulfatase 1 with an RP score of 254.52, changed by 1.62 fold with an 
FDR of 29%. The third gene was uroplakin 1B with an RP score of 294.66, an FDR 
of 26.67% and was potentially downregulated by 1.6 fold. The fourth gene listed 
was cannabinoid receptor 1 with an RP score of 369.64 and a false discovery rate 
of 34%.  
 
 Table 4-7. Top 4 genes listed as potentially downregulated after CCL3 treatment in K14D6 
keratinocytes. 
Genes were listed in order of rank product score (RP score) with details of % false 
discovery rate (FDR) and fold change (FC).   
 
RP score FDR (%) FC Gene Symbol Gene Title 
123.91 2.00    -1.85 Ap2b1 Adapter related protein complex 2 beta 1 
subunit 
264.52 29.00 -1.62 Sulf1 Sulfatase 1 
294.66 26.67 -1.60 Upk1b Uroplakin 1B 
369.64 34.00 -1.44 Cbp1 Cannabinoid receptor 1 
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Genes potentially downregulated by CCL3 binding in both WT and K14D6 
keratinocytes 
CCL3 ligand binding in wild-type keratinocytes resulted in the potential 
downregulation of 13 genes (Table 4-5) whereas CCL3 treatment on K14D6 
keratinocytes resulted the potential downregulation of 4 genes (Table 4-7). All 
the genes expressed at lower levels in wild-type keratinocytes by CCL3 were 
different from the genes expressed at lower levels by CCL3 in K14D6 
keratinocytes. This suggests that CCL3 binding may have a negative impact on 
the gene transcripts via different mechanisms in wild-type and K14D6 
keratinocytes. 
4.4.1.4    WT + CCL3 versus K14D6 + CCL3 
This comparison would give an understanding of the genes that are potentially 
up- or downregulated after CCL3 binding in K14D6 keratinocytes compared to 
wild-type keratinocytes.  
i) Potential upregulated genes 
Seven genes, with less than 50% FDR, were expressed at higher levels after CCL3 
treatment in K14D6 keratinocytes compared to wild-type keratinocytes (Table 4-
8). The RP score varied from 1.28 to 423.42 with fold change of between 35.02 
and 1.52. Of the seven genes, 3 genes were potentially differentially expressed 
more than 2 fold. The gene with the smallest RP score of 1.28 was Ccbp2 (D6). 
This gene was potentially upregulated by 35 fold in K14D6 keratinocytes after 
incubation with CCL3 compared to wild-type keratinocytes incubated with CCL3. 
Of the seven genes potentially upregulated, three were Y-linked meaning these 
are genes encoded within the Y-chromosome. The genes were Ddx3y, which was 
ranked 2nd and 4th, Eif2s3y and Uty (Table 4-8). As these are Y-linked genes 
(Isensee and Ruiz Noppinger, 2007), this data suggests that the keratinocyte 
population used within the K14D6 + CCL3 group were isolated from more male 
neonates than the wild-type + CCL3 group.  
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Table 4-8. Genes listed as potentially upregulated after CCL3 treatment in K14D6 
keratinocytes compared to wild-type keratinocytes after CCL3 treatment. 
Genes were listed in order of rank product score (RP score) with details of % false 
discovery rate (FDR) and fold change (FC).  
 
 
Genes potentially upregulated due to ectopic expression of D6 
Ccbp2 was potentially upregulated, with an RP score of 1.28, in the wild-type + 
CCL3 versus K14D6 + CCL3 comparison (Table 4-8). However, Ccbp2 was also 
potentially upregulated and ranked 1st with an RP score of 1.00 in the WT versus 
K14D6 keratinocytes comparison (Table 4-2). Therefore, these data confirm that 
there are higher levels of D6 within K14D6 keratinocytes confirming that the D6 
transgene is expressed within K14D6 keratinocytes.  
It was noted that three Y-linked genes, Ddx3y, Eif2s3y and Uty, were potentially 
upregulated in K14D6 keratinocytes after ligand binding in comparison to wild-
type keratinocytes after CCL3 binding (Table 4-8). Ddx3y and Eif2s3y were also 
potentially downregulated in wild-type keratinocytes after CCL3 binding 
compared to wild-type keratinocytes at rest (Table 4-5). This comparison 
supports evidence that the keratinocyte population used in the wild-type + CCL3 
samples were derived from more female neonates than males. 
 
 
RP score FDR (%) FC Gene Symbol Gene Title 
1.28 0.00    35.02 Ccbp2 Chemokine binding protein 2 
90.60 12.00 3.97 Ddx3y DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y-linked 
186.44 9.00 3.73 Eif2s3y Eukaryotic translation initiation factor 2, 
subunit 3, structural gene Y-linked 
280.18 21.25 2.31 Ddx3y DEAD (Asp-Glu-Ala-Asp) box  
polypeptide 3, Y-linked 
335.66 27.20 1.55 Slc6a14 Solute carrier family 6(neurotransmitter 
transporter), member 14 
396.73 33.67 1.58 Uty /// LOC546404 
/// LOC546411 
Ubiquitously transcribed 
tetratricopeptide repeat gene, Y 
chromosome /// similar to male-specific 
histocompatibility antigen H-YDb /// 
similar to male-specific 
histocompatibility antigen H-YDb 
407.62 31.86 1.92 Jarid1d Jumonji, AT rich interactive domain 1D 
(Rbp2 like) 
423.42 32.00 1.52 Slc7a3 Solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 3 
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ii) Potential downregulated genes 
Twenty three genes, with less than 50% FDR, were found to be potentially 
downregulated with an RP score range of 145.03 to 754.73 and fold change of-
2.12 to -1.39 (Table 4-9 lists top 25 ranked genes as Lzp-s and Clec4n appear 
twice). Four genes were found to change more than 2-fold, which were 
lysosomal associated protein transmembrane 5 (Laptm5), P-lysosome structural 
(Lzp-s), C-type lectin domain family 4 member d (Clec4d) and C-type lectin 
family 4 member n (Clec4n), in which three of these were listed within the top 
four in terms of RP score (Table 4-9). 
 
Table 4-9. Top 25 ranked genes potentially downregulated in K14D6 keratinocytes treated 
with CCL3 in comparison to WT keratinocytes treated with CCL3. 
Genes were listed in order of rank product score (RP score) with details of % false 
discovery rate (FDR) and fold change (FC).  
 
 
RP score FDR (%) FC Gene Symbol Gene Title 
145.03 10.00     -2.01 Laptm5 Lysosomal-associated protein 
transmembrane 5 
154.19 5.50 -1.96 Lzp-s P lysozyme structural 
163.17 3.67 -2.04 Lzp-s P lysozyme structural 
186.83 4.50 -2.12 Clec4d C-type lectin domain family 4, member d 
204.23 4.60 -1.93 Ctss Cathepsin S 
236.28 6.33 -1.96 Plek Pleckstrin 
377.58 22.14 -1.93 Ms4a7 Membrane-spanning 4-domains, 
subfamily A, member 7 
378.78 19.62 -1.69 Cxcl4 Chemokine (C-X-C motif) ligand 4 
381.87 17.89 -1.70 Tfpi2 Tissue factor pathway inhibitor 2 
407.64 20.70 -1.82 F13a1 Coagulation factor XIII, A1 subunit 
418.00 20.82 -1.74 Ms4a11 Membrane-spanning 4-domains, 
subfamily A, member 11 
418.30 19.08 -1.77 Mrc1 Mannose receptor, C type 1 
421.12 17.92 -1.73 Ccl6 Chemokine (C-C motif) ligand 6 
421.60 16.86 -1.56 B130021B11Rik RIKEN cDNA B130021B11 gene 
427.86 16.67 -2.06 Clec4n C-type lectin domain family 4, member n 
462.57 19.31 -1.86 Fcgr2b Fc receptor, IgG, low affinity IIb 
502.33 23.24     -1.83 Ms4a6d Membrane-spanning 4-domains, 
subfamily A, member 6D 
562.57 31.33 -1.66 Lyzs Lysozyme 
565.86 30.11 -1.82 C1qa Complement component 1, q 
subcomponent, alpha polypeptide 
572.64 29.65 -1.78 Clec4n C-type lectin domain family 4, member n 
640.21 37.48 -1.75 Spp1 Secreted phosphoprotein 1 
646.39 36.95 -1.39 Dcn Decorin 
694.46 43.87 -1.75 C3ar1 Complement component 3a receptor 1 
698.40 42.71 -1.63 Cck Cholecystokinin 
730.34 46.00 -1.64 Fcgr3 Fc receptor, IgG, low affinity III 
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Genes potentially downregulated due to ectopic expression of D6 
 
Twelve of the potentially downregulated genes, summarised in Table 4-9, were 
also potentially downregulated in resting K14D6 keratinocytes in comparison to 
resting wild-type keratinocytes. Nine of the 12 genes are within the top 25 genes 
of both tables (Table 4-9 and 4-3 respectively). These were Laptm5, Lzp-s (listed 
twice), Clec4d, Ctss, CXCL4, Ms4a11, Lyzs, Clec4n and Fcgr3. The other three 
genes were mannose receptor c-type 1 (Mrc1), CCL6 and Fc receptor IgG low 
affinity IIb (Fcgr2b), listed as potentially downregulated after ligand binding in 
K14D6 keratinocytes compared to wild-type (Table 4-9). Mrc1, CCL6 and Fcgr2b 
are ranked 66th, 64th and 44th respectively in the potentially downregulated gene 
comparison between resting K14D6 and wild-type keratinocytes (Full list in 
Appendix Two). This would suggest that ectopic expression of D6 might affect 
the levels of these genes at rest. To determine a possible explanation as to why 
these genes were potentially downregulated with resting levels of D6, it was 
discovered that four of the genes, Ctss, Lyzs, Lzp-s and Laptm5 were associated 
with the lysosome. Ctss, Lzp-s and Lyz are all lysosomal proteins whereas 
Laptm5 is a transmembrane spanning protein present in the lysosome (Adra et 
al., 1996). However, only Lzp-s and Lyz were genes encoded within the same 
chromosome. This ruled out the possibility that basal D6 in absence of ligand was 
affecting the transcription of genes encoded within the same chromosome.  
However, some of these genes, Laptm5, Lzp-s, Ctss, CCL6 and Fcgr3 were 
potentially upregulated by CCL3 in K14D6 keratinocytes (Table 4-6). This 
suggests CCL3 binding in K14D6 keratinocytes may be able to induce these 
genes. However, it was noted that the potential downregulation of Laptm5, Lzp-
s, Ctss, CCL6 and Fcgr3 in K14D6 keratinocytes after ligand binding compared to 
wild-type might be due to lower levels of gene expression in resting K14D6 
keratinocytes. 
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4.4.1.5    Summary of rank product differential analysis 
reports 
From the list of potentially differentially expressed genes using the rank product 
method, the conditions under which the largest number of genes were 
potentially differentially expressed and with a false discovery rate of less than 
50% was after keratinocytes were incubated with CCL3. Two hundred and 
seventeen genes were potentially upregulated in wild-type keratinocytes and 
171 genes were potentially upregulated in K14D6 keratinocytes. The largest 
number of genes potentially downregulated was in K14D6 keratinocytes at rest 
compared to wild-type keratinocytes at rest, with 81 genes potentially 
differentially expressed.  
One gene in this analysis stood out from the rest and this was Ccbp2 (D6) with an 
RP score of 1. Ccbp2 was listed in two rank product differential expression 
analysis reports with the two smallest rank product score values in the full 
microarray analysis, along with the highest fold change and 0% false discovery 
rate (summarised in Table 4-10). These data confirm there is upregulation of D6 
with a 49.59 fold change in resting K14D6 keratinocytes compared to the wild-
type. D6 was also expressed at higher levels, with a 35.02 fold change, in K14D6 
keratinocytes compared to wild-type keratinocytes after ligand binding, however 
CCL3 does not affect the levels of D6, as the gene was not found to be 
differentially expressed in comparison to K14D6 keratinocytes not treated with 
CCL3. 
 
 
 
Table 4-10. Expression of D6 in rank product differential expression analysis reports. 
D6 (Ccbp2) was potentially upregulated in K14D6 keratinocytes at rest compared to wild-
type (WT) control keratinocytes and in K14D6 keratinocytes after incubation with CCL3 
compared to wild-type keratinocytes after CCL3 incubation. RP score is rank product score, 
FDR is the false discovery rate and FC is the fold change in the gene. 
 
 
Comparison Gene RP score FDR (%) FC 
WT control v K14D6 control Ccbp2 1.00 0.00 49.59 
 WT + CCL3 v K14D6 +CCL3 Ccbp2 1.28 0.00 35.02 
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Transcriptional changes due to ectopic expression of D6 
The microarray showed that only six genes were expressed at higher levels in 
K14D6 keratinocytes in comparison to wild-type keratinocytes. These were 
Ccbp2 (D6), Dkk2, Nrk, Bcat1, Stc2 and Tfpi2 (Table 4-2). Ccbp2 was the only 
gene with an RP score of 1 and confirmed that there is increased expression of 
D6 within K14D6 keratinocytes. 
Eighty one genes were potentially downregulated, with an FDR of less than 50%, 
in untreated K14D6 keratinocytes compared to wild-type keratinocytes 
suggesting transcriptional changes may have occurred through D6 in a ligand 
independent manner. Within this group, the 1st ranked gene potentially 
differentially expressed was Lzp-s, which had the third smallest RP score of 
80.91 in the microarray (after D6 with an RP score of 1 and 1.28).  
Effect of CCL3 binding on keratinocytes 
The largest number of genes potentially upregulated was after ligand binding 
with CCL3 in keratinocytes. CCL3 binding in wild-type keratinocytes resulted in 
217 potentially differentially expressed genes whereas 181 genes were 
potentially differentially expressed in K14D6 keratinocytes.  
When comparing both RP differential expression reports, 87 genes potentially 
upregulated in K14D6 keratinocytes by CCL3 binding were also potentially 
upregulated in wild-type keratinocytes after CCL3 binding. Two genes, Lzp-s and 
Col3a1, were listed within the top twenty five genes expressed at higher levels 
by CCL3 binding in both wild-type and K14D6 keratinocytes. Genes potentially 
upregulated in both wild-type and K14D6 keratinocytes suggests that these genes 
may be induced through CCL3 binding to common receptors, such as CCR1, CCR3 
and CCR5, shown to be present on wild-type and K14D6 keratinocytes previously 
within Chapter 3.  
The microarray showed lower levels of 13 genes in wild-type keratinocytes and 
lower levels of 4 genes in K14D6 keratinocytes after CCL3 binding. None of the 
genes potentially downregulated in wild-type and K14D6 keratinocytes were the 
same. Many of the genes potentially downregulated in wild-type keratinocytes 
after CCL3 binding were Y-linked genes and may have been due to the 
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keratinocyte populations used being isolated from more female neonates 
coincidently than the keratinocyte population used as resting wild-type. 
Differential expression of genes after CCL3 binding between WT and K14D6 
keratinocytes 
Differences in gene expression after ligand binding between wild-type and K14D6 
keratinocytes were analysed in the WT + CCL3 v K14D6 + CCL3 rank product 
report. Differential gene expression would give an indication into the effect the 
presence of D6 in K14D6 keratinocytes has on the cell transcriptome after CCL3 
binding. Only seven genes were potentially upregulated in K14D6 keratinocytes 
compared to the wild-type. One gene potentially upregulated was Ccbp2 (D6) as 
discussed above and summarised in Table 4-10. Three of the seven genes 
potentially upregulated within K14D6 keratinocytes were Y-linked genes. One 
possibility may be that the keratinocytes used for the WT + CCL3 population 
were isolated from fewer males than the K14D6 + CCL3 population. This also 
correlates with Y-linked genes being potentially downregulated in WT v WT + 
CCL3 comparison. The other two genes potentially differentially expressed were 
both solute carrier family genes, Slc6a14 and Slc7a3. These two genes were not 
potentially differentially upregulated in K14D6 keratinocytes at rest compared to 
wild-type and therefore the potential upregulation could not be explained by an 
initial higher level of gene expression in resting K14D6 keratinocytes.  
Twelve genes were potentially downregulated at rest and after ligand binding in 
K14D6 keratinocytes compared to wild-type keratinocytes (Table 4-3 and Table 
4-9 respectively). Nine out of the twelve genes were listed within the top 25 
genes in both comparisons. These genes were Laptm5, Lzp-s, Clec4d, Ctss, 
CXCL4, Ms4a11, Clec4n, Lyzs and Fcgr3. The nine genes listed were also 
potentially upregulated by CCL3 in K14D6 keratinocytes. This suggests that the 
differential expression of these genes after ligand binding between wild-type 
and K14D6 keratinocytes is due to K14D6 keratinocytes having a lower expression 
of these genes at rest than wild-type keratinocytes.  
Eleven genes potentially downregulated after ligand binding in K14D6 
keratinocytes compared to wild-type were not potentially downregulated in 
resting K14D6 keratinocytes. These were Plek, Ms4a7, Tfpi2, Fl3a1, 
B130021B11Rik, Ms4a6d, C1qa, Spp1, decorin (Dcn), C3ar1 and cholecystokinin 
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(Cck). This result indicates that the difference was potentially due to ectopic 
expression of D6 affecting the transcriptional consequence of CCL3 by inhibiting 
gene expression.  
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4.4.2 Iterative group analysis 
The lists of genes produced by rank products are further processed using 
iterative group analysis (iGA), which identifies functional changed groups of 
genes, where each gene is assigned to a functional class according to Gene 
Ontology (http://www.geneontology.org). Iterative group analysis combines the 
relative position of the genes in the RP list and the number of changed genes 
within the group to statistically determine the strength of changes within the 
group. This analysis was performed using various steps, firstly sorting the genes 
according to a differential expression method, in this case by RP score, either by 
increasing or decreasing order. The second step was to count the members of 
each functional class of interest and then for each functional class member 
determine the probability of change (p-value) for the gene member to be in that 
position by chance (Breitling et al., 2004a). The p-value for each member was 
plotted against the position of each class member within a functional group. The 
position with the smallest p-value was assigned as the ‘cut off’ point for each 
functional group. Therefore, all gene members above this position were 
determined as potentially differentially expressed and the smallest p-value was 
assigned the p value changed for the group. This was performed for all the 
functional gene classes, which were then sorted according to their p-value 
changed. The threshold of the p value changed was 1.2x10-4 and therefore 
classes with the smallest P value changed (below 1.2x10 -4) were the most 
significantly changed. An advantage of iGA analysis is that it does not require all 
members of the group change. Another important feature is that experimental 
replicates are not required because statistical significance can be determined by 
using group members as internal replicates. Full details of four iGA reports can 
be found in Appendix Three. 
 To identify functional changed groups of genes, four comparisons were made: 
1) WT control (baseline) Versus K14D6 control 
 
2) WT control (baseline) Versus WT + CCL3 
 
3) K14D6 control (baseline) Versus K14D6 + CCL3 
 
4) WT + CCL3 (baseline) Versus K14D6 + CCL3 
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4.4.2.1    WT control v K14D6 control keratinocytes 
i) Potential upregulated functional genes classes 
Ectopically expressing D6 within keratinocytes resulted in 9 classes of genes, 
which involved 18 distinct gene members, being potentially upregulated in 
K14D6 keratinocytes compared to wild-type keratinocytes at rest (Table 4-11). 
Four of these groups included genes associated with cell structure, which were 
collagen, extracellular matrix structural constituent conferring tensile strength, 
collagen triple helix repeat and extracellular matrix structural constituent. All of 
these groups involved the procollagen family of genes, which are also all 
involved in the phosphate transport group listed. Other functional gene classes 
potentially differentially expressed were transmembrane receptor protein 
tyrosine kinase signalling pathway, cadherin cytoplasmic region, intracellular 
calcium activated chloride channel activity and prostaglandin biosynthesis. 
 
Table 4-11. Potential upregulated functional gene classes in K14D6 keratinocytes compared 
to wild-type keratinocytes 
 
 
 
 
WT control V K14D6 control Group members Changed 
members 
P-value 
Changed 
5581- collagen 34 5 1.9e-07 
7169- transmembrane receptor protein tyrosine 
kinase signalling pathway 
76 6 4.3e-06 
30020- extracellular matrix structural constituent 
conferring tensile strength 
29 4 4.5e-06 
IPR008160- Collagen triple helix 65 5 5.1e-06 
IPR000233- Cadherin cytoplasmic region 12 3 7.8e-06 
6817- phosphate transport 84 5 1.8e-05 
1516- prostaglandin synthesis 9 2 2.9e-05 
5201- extracellular matrix structural constituent 47 4 3.2e-05 
5229- intracellular calcium activated chloride 
channel activity 
3 3 1.0e-04 
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Comparison with WT control V K14D6 control RP report 
Only six genes with an FDR of less than 50% were potentially upregulated in 
resting K14D6 keratinocytes in comparison to wild-type, using RP score (Table 4-
2). None of the genes were listed as changed members within the top changed 
groups in the iGA analysis report.  However, genes ranked 9th and 15th in the RP 
report, prostaglandin I2 synthase and prostaglandin-endoperoxidase synthase, 
were the two changed members within the prostaglandin synthesis group, which 
was statistically determined as potentially upregulated. Five procollagen genes 
are members within 5 of the top 9 changed groups in the iGA report. All 5 genes 
were ranked between 32 and 62 in the RP report and all had a false discovery of 
more than 50%.  
ii) Potential downregulated functional gene classes 
Gene classes found to be potentially downregulated in K14D6 keratinocytes 
compared to wild-type keratinocytes at rest included 11 groups of genes classes 
involving 21 distinct genes (Table 4-12).  
The top changed group involved the functional class of cornified envelope, 
followed by keratinisation. Other groups such as glycoside hydrolase, lysozyme 
activity, cell wall catabolism and cytolysis involved the same two members 
changing, which were P lysozyme structural (Lzp-s) and lysozyme (Lyzs). Three 
groups involving chemokines were potentially downregulated, in which four 
chemokines were consistently changed across all three groups; these were 
CXCL4, CCL9, CCL6 and CXCL2. The fifth changed member within the chemotaxis 
group was complement component 3a receptor 1 (C3ar1). The other top changed 
groups were involved in IgG binding and tyrosinase. This suggests that the 
possibility that the presence of D6 within K14D6 keratinocytes may inhibit the 
expression levels of genes within these functional gene classes. 
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Table 4-12. Potential downregulated functional gene classes in K14D6 keratinocytes 
compared to wild-type keratinocytes. 
 
 
Comparison with the RP report 
P-lysozyme structural and lysozyme were two members that changed 
consistently across 4 top changed groups in the iGA analysis and these were 
genes that were also potentially differentially expressed within the top twenty 
five genes listed in the RP report (Table 4-3). Three of the top changed groups 
contained four chemokines that changed consistently in the iGA analysis and 
three of these chemokines (CXCL4, CCL9 and CCL6) were potentially 
differentially expressed in the rank product report. Changed members within the 
cornified envelope and keratinisation group were listed within the rank product 
report. Fcgr3 was a changed member within the IgG binding group, which was 
potentially differentially expressed in the RP report. Tyrosinase was the 11th top 
changed group in the iGA analysis report yet none of the three changed 
members, dopachrome tautomerase, tyrosinase-related protein 1 and tyrosinase, 
were listed as potentially differentially expressed within the 100 genes listed in 
the RP report. 
 
 
 
 
WT control V K14D6 control 
 
Group 
members 
Changed 
members 
P-value 
Changed 
1533- cornified envelope 14 7 9.3e-13 
31424 – keratinisation 23 4 4.1e-06 
IPR001916- Glycoside hydrolase, family 22 8 2 4.6e-06 
3796- lysozyme activity 10 2 7.4e-06 
16998- cell wall catabolism 16 2 2.0e-05 
IPR001811- Small chemokine, interleukin-8 like 31 4 2.2e-05 
19835- cytolysis 20 2 3.1e-05 
19864 – IgG binding  5 2 4.1e-05 
8009- chemokine activity 38 4 5.0e-05 
6935- chemotaxis 87 5 1.1e-04 
IPR002227- Tyrosinase 3 3 1.2e-04 
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4.4.2.2   WT control v WT control + CCL3 
i) Potential upregulated functional gene classes 
CCL3 ligand binding to wild-type keratinocytes resulted in the potential 
upregulation of 22 functional gene classes in comparison to wild-type 
keratinocytes at rest. These 22 groups consisted of 42 distinct genes (Table 4-
13).  
The top three groups had the highest numbers of changed members. The 8 
changed members within the top changed group of collagen triple helix repeat 
were also seven of the members that change within the second listed changed 
gene group involved in phosphate transport. The third top changed group 
involved in extracellular matrix structural constituent contains five changed 
members that were also classified within the collagen triple helix repeat class of 
genes. Eight of the top 23 changed groups are all involved in structural support 
involving collagen and the extracellular matrix. Three groups identified involved 
chemokines, with the changed members identified as CXCL2, CXCL4, CXCL5, 
CCL2, CCL6 and CCL9. Of note, CXCL2, CXCL4, CCL6 and CCL9 were members of 
functional groups that were potentially downregulated in resting K14D6 
keratinocytes compared to wild-type keratinocytes (Table 4-12). Other gene 
class groups potentially differentially expressed in wild-type keratinocytes by 
CCL3 were phosphate transport, transmembrane receptor protein tyrosine kinase 
pathway, CD20/IgE Fc receptor beta subunit, cysteine-rich flanking region, 
heparin binding, inflammatory response pathway, eicosanoid synthesis, von 
willebrand factor, lysl oxidase, intracellular calcium activated chloride channel 
activity and positive regulation of phagocytosis. (Table 4-13). 
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WT control V  WT + CCL3 Group members Changed 
members 
P-value 
changed 
IPR008160- Collagen triple helix repeat 71 8 7.6e-11 
6817- phosphate transport 84 7 1.3e-10 
5201- extracelular matrix structural constituent 48 8 4.3e-10 
30020- extracellular matrix structural constituent 
conferring tensile strength 
29 5 1.1e-09 
5581- collagen 35 5 2.9e-09 
IPR000885- Fibrillar collagen, C-terminal 11 5 3.2e-09 
IPR-001811- small chemokine, interleukin-8 like 31 6 1.8e-08 
8009- chemokine activity 38 6 6.4e-08 
7169- transmembrane receptor protein tyrosine 
kinase signalling pathway 
76 6 4.7e-07 
IPR007237- CD20/Ig E Fc receptor beta subunit 15 4 5.5e-07 
IPR000372- Cysteine-rich flanking region, N-
terminal 
39 5 2.2e-06 
1527-microfibril 6 3 3.8e-06 
30023- extracellular matrix constituent conferring 
elasticity 
2 2 4.9e-06 
6935- chemotaxis 87 6 9.4e-06 
8201- heparin binding 57 5 2.3e-05 
Inflammatory_Response_Pathway-GenMAPP 40 3 4.1e-05 
Eicosanoid_Synthesis- GenMAPP 21 3 4.6e-05 
IPR001007- von Willebrand factor, type C 22 2 5.0e-05 
IPR001695- Lysyl oxidase 4 2 7.2e-05 
5229- intracellular calcium activated chloride 
channel activity  
3 3 9.8e-05 
50766- positive regulation of phagocytosis 21 3 1.1e-04 
5588- collagen type V 3 3 1.2e-04 
   
Table 4-13. Potential downregulated functional gene classes in Wild-type (WT) keratinocytes 
after CCL3 treatment compared to wild-type keratinocytes at rest. 
 
Comparison with the RP report 
Seven of the top changed functional groups induced by CCL3 in wild-type 
keratinocytes, reported in the iGA report, consisted of the same changed gene 
members (Full list in Appendix Three). These were Col3a1, Col6a1, Col6a2, 
C1qa, Col11a1, Col1a2 and Emilin 1. Five of these, Col3a1, Col6a1, Col6a2, C1qa 
and Col11a1, were listed within the top 25 genes in the RP report (Table 4-4). 
The other two were ranked 29th and 36th in the RP report (Full list in Appendix 
Two). Three of the top changed groups involved chemokines and these were all 
present in the RP report, CXCL4 was listed 2nd, CXCL5 was listed 39th, CCL2 was 
listed 50th, CCL6 was listed 79th, CCL9 was listed 109th and CXCL2 was 112th, all 
had an FDR of less than 50% (Full report in Appendix Two). 
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ii) Potential downregulated functional gene classes 
 
After CCL3 binding to wild-type keratinocytes, 14 functional genes classes 
involving 22 distinct genes,  were  potentially downregulated in comparison to 
wild-type keratinocytes at rest (Table 4-14). The top changed group is the 
cornified envelope and has four changed members (The full iGA analysis report is 
in Appendix Three). Members within this group are also found to be changed 
within the functional gene classes of calcium binding protein, keratinisation and 
one gene is found to be changed within the functional gene class of structural 
constituent of cytoskeleton. Four genes were found to be changed within the 
melanosome class and these genes were also classified as changed within the 
melanin biosynthesis from tyrosine and tyrosinase group. Members within the 
intermediate filament group are also the same members that have changed 
within intermediate filament protein group, sarcolemma and structural 
constituent of cytoskeleton group. Another three groups potentially 
differentially expressed with the same changed members are calcium-
independent cell-cell adhesion group, identical protein binding and the PMP-
22/EMP20 and claudin family. Another functional group potentially 
downregulated was transcription factor jumonji (Takeuchi et al., 2006), which 
involved gene members that are encoded within the Y-chromosome. 
 
WT control V WT + CCL3 
 
Group members Changed 
members 
P-value 
Changed 
1533- cornified envelope 14 4 8.0e-11 
42470- melanosome 7 4 4.6e-08 
IPR003347- Transcription factor jumonji, jmjC 18 3 6.7e-08 
5882- intermediate filament 93 8 9.3e-08 
IPR001664 – Intermediate filament protein 57 6 4.5e-07 
6583- melanin biosynthesis from tyrosine 6 3 4.4e-06 
IPR001751- Calcium binding protein, S-100/ IcaBP 
type 
14 2 7.1e-06 
IPR002227- Tyrosinase 2 2 2.5e-05 
16338- calcium-independent cell-cell adhesion 22 3 2.5e-05 
42383- sarcolemma 14 3 4.6e-05 
42802- identical protein binding 81 4 6.0e-05 
IPR004031- PMP-22/EMP/MP20 and claudin 
family 
30 3 6.5e-05 
31424 – keratinisation 23 2 8.9e-05 
5200- structural constituent of cytoskeleton 91 5 1.0e-04 
Table 4-14. Potential downregulated functional gene classes in Wild-type (WT) keratinocytes 
after CCL3 treatment compared to wild-type keratinocytes at rest. 
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Comparison with the RP report 
In the RP report, 13 genes were potentially downregulated with an FDR of less 
than 50% in wild-type keratinocytes after CCL3 binding compared to resting wild-
type keratinocytes (Table 4-5). Seven genes potentially differentially expressed 
in the RP report were also listed as changed gene members in the iGA analysis 
report. The seven genes were LOC433621, hornerin (Hrnr), repetin (Rptn), 
DEAD3y, Jarid1a, Uty and Lce5a. LOC433621, Hrnr and Rptn were the three 
changed members within the cornified envelope group. Of these three, Hrnr and 
Rptn were also changed members within the calcium binding and keratinisation 
group. DEAD3y, Jarid1a and Uty are all gene members within transcription 
factor, jumonji (Takeuchi et al., 2006). Other groups in Table 4-14, such as 
calcium independent cell-cell adhesion, all contain changed gene members that 
were listed in the RP report but with an FDR of more than 50%. 
4.4.2.3   K14D6 control v K14D6 + CCL3 
i) Potential upregulated functional gene classes 
Twenty-two functional gene classes were potentially upregulated after CCL3 
ligation in K14D6 keratinocytes compared to K14D6 keratinocytes at rest. These 
22 groups consisted of 39 distinct genes (Table 4-15). The top changed group was 
extracellular matrix structural constituent conferring tensile strength, in which 
seven members within this group changed. These were also the seven members 
that changed within the second top changed group of collagen and the fourth to 
seventh top changed groups which were extracellular matrix structural 
constituent, fibrillar collagen, collagen triple helix repeat and the phosphate 
transport group (Full list is in Appendix Three). Within this comparison, 7 genes 
involved in chemotaxis were found to be potentially upregulated after CCL3 
binding. Five of the members were also found to be changed within the gene 
class of small chemokine interleukin-8 like and chemokine activity, which 
involved CCL9, CCL6, CXCL4, CXCL2 and CCL7. CCL9, CCL6, CXCL2 and CXCL4 
were also potentially upregulated gene members within top changed groups 
after ligand binding in wild-type keratinocytes (Table 4-13). CCL3 binding to 
K14D6 keratinocytes resulted potential upregulation of genes involved in the 
positive regulation of phagocytosis, IgG binding and mast cell activation. Other 
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groups differentially expressed were glycosidase hydrolase family 22 and 
lysozyme activity involving the same two changed members and some members 
within the intracellular activated chloride channel activity group were also 
involved in the functional gene class of Von Willebrand factor. Other potentially 
differentially expressed gene classes were heparin binding, myelin proteolipid 
protein PLP, CD20/IgE Fc receptor subunit, aldehyde dehydrogenase, calcium 
binding protein and tyrosinase.  
Thirteen functional gene classes were expressed at higher levels after CCL3 
binding in both wild-type and K14D6 keratinocytes (Table 4-13 and Table 4-15 
respectively). These were three functional groups involving collagen (collagen, 
fibrillar collagen, collagen triple helix repeat) and two involved the extracellular 
matrix (extracellular matrix structural constituent conferring tensile strength 
and extracellular matrix structural constituent). The other functional groups 
were heparin binding, CD20/IgE Fc receptor subunit, intracellular calcium 
activated chloride channel activity, phosphate transport and three involved 
chemokines (chemotaxis, small chemokine interleukin-8 like and chemokine 
activity). Von willebrand factor was potentially upregulated  in both, although in 
wild-type this was type C whilst in K14D6 keratinocytes this was type A. 
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K14D6 control V K14D6 + CCL3 
 
Group members Changed 
members 
P-value 
changed 
30020- extracellular matrix structural constituent 
conferring tensile strength 
29 7 1.9e-10 
55871- collagen 35 7 6.9e-10 
82017- heparin binding 57 8 1.7e-09 
5201- extracellular matrix structural constituent 48 7 6.8e-09 
IPR000885- Fibrillar collagen, C-terminal 10 4 2.4e-08 
IPR008160- Collagen triple helix repeat 72 6 1.5e-07 
6871- phosphate transport 85 7 3.9e-07 
6935- chemotaxis 87 7 3.9e-07 
IPR001811- Small chemokine, interleukin-8 like 31 5 5.7e-07 
8009- chemokine activity 38 5 1.6e-06 
50766-positive regulation of phagocytosis 21 3 3.9e-06 
19864 – IgG binding 5 2 2.2e-05 
IPR-001614 –Myelin proteolipid protein PLP 3 2 3.1e-05 
IPR007237- CD20/IgE Fc receptor beta subunit 14 3 3.8e-05 
IPR001916- Glycoside hydrolase, family 22 8 2 5.0e-05 
IPR002086- Aldehyde dehydrogenase 26 2 5.3e-05 
45576- mast cell activation 9 2 7.7e-05 
3796- lysozyme activity 10 2 8.1e-05 
IPR001571- Calcium binding protein, S-100/ICaBP 
type 
15 3 9.3e-05 
5229- intracellular calcium activated chloride 
channel activity 
3 3 9.4e-05 
IPR002227- Tyrosinase 3 3 9.8e-05 
IPR002035- von Willebrand factor, type A 44 4 1.1e-04 
   
Table 4-15. List of potential upregulated functional gene classes in K14D6 keratinocytes 
after CCL3 treatment compared to K14D6 keratinocytes at rest. 
 
Comparison to RP report 
In the RP report, 171 genes were potentially upregulated in K14D6 keratinocytes 
after ligand binding (For full list see Appendix Two). Thirty six genes listed as 
potentially differentially expressed within the RP report were members within 
the top changed groups (Table 4-15). Of the top 25 genes listed within the RP 
report (see Table 4-6), 12 genes were found to be changed members within the 
top changed groups in Table 4-15. Genes potentially upregulated were Aldh1a7 
and Aldh1a1, both changed members within the aldehyde dehydrogenase group. 
Col3a1 and col1a1, listed as 11th and 24th in Table 4-6, are changed members 
within six functional gene groups. CCL9 and CCL6 were potentially upregulated 
in Table 4-6 and were changed members within the chemotaxis group. Ptx3 and 
Fcgr3 are changed members within the functional group positive regulation of 
phagocytosis, which were also listed in the top 25 genes in the RP report (Table 
4-6). Lzp-s and Lyzs were listed 2nd and 25th in the RP report (Table 4-6) in which 
both were changed members within the glycoside hydrolase group. 
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ii) Potential downregulated functional gene classes 
CCL3 binding in K14D6 keratinocytes resulted in 7 potentially downregulated 
functional gene classes (Table 4-16). The top changed group was plectin repeat 
with a p-value change of 3.8x10-08 in which 4 members of the group changed. 
The second top changed group with a p-value changed of  6.1x10-07 was 
sarcolemma, in which 3 members changed and are also the 3 members that 
changed within the changed groups of Z disc, response to pest pathogen or 
parasite and the intermediate filament protein group with p-value changed of 
4.8x10-06, 7.4x10-06 and 3.7x10-05 respectively. Other changed groups were 
muscle maintenance and spectrin repeat with 2 and 3 members changed 
respectively. 
CCL3 binding resulted in potential downregulation of 14 functional gene classes 
in wild-type keratinocytes whereas in K14D6 keratinocytes, only 7 functional 
groups were potentially downregulated (Table 4-14 and 4-16 respectively). Only 
two functional gene classes were expressed at lower levels after ligand binding 
in both wild-type keratinocytes and K14D6 keratinocytes, which were 
sarcolemma and intermediate filament protein (Table 4-14 and Table 4-16 
respectively). 
K14D6 control V K14D6 + CCL3 Group members Changed 
members 
P-value 
changed 
IPR001101- Plectin repeat 8 4 3.8e-08 
42383- sarcolemma 14 3 6.1e-07 
30018- Z disc 27 3 4.8e-06 
9613- response to pest, pathogen or parasite 31 3 7.4e-06 
IPR001664 – Intermediate filament protein 59 4 3.7e-05 
46716-muscle maintenance 4 2 5.7e-05 
IPR002017- Spectrin repeat 19 3 1.1e-04 
 
 
Table 4-16. Potential downregulated functional gene classes in K14D6 keratinocytes after 
CCL3 treatment compared to K14D6 keratinocytes at rest. 
 
Comparison to the RP report 
In the RP report, only four genes were potentially downregulated with an FDR of 
less than 50% after CCL3 binding in K14D6 keratinocytes (Table 4-7). None of the 
four genes listed were the changed members in any of the 7 top changed groups 
in the respective iGA analysis report. 
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4.4.2.4    WT + CCL3 v K14D6 + CCL3 
To determine the transcriptional consequences of D6 in K14D6 keratinocytes 
after ligand binding, functional gene classes were analysed for differential 
expression in a positive or negative direction in comparison to wild-type 
keratinocytes after CCL3 ligand binding.  
i) Potential upregulated functional gene classes  
Seven gene classes, which consisted of 14 distinct genes, were expressed at 
higher levels in K14D6 keratinocytes after ligand binding (Table 4-17). Four 
members changed within the top changed group of melanin biosynthesis. Within 
this group, 3 of the members were also changed members in the functional class 
involved in melanosome and 2 were changed members within the tyrosinase 
group. The second functional gene class group was involved in the cornified 
envelope, involving 5 changed members. Of these, three were members that 
changed within the keratinisation functional gene class. The third top changed 
group was transcription factor jumonji in which 3 members changed and 2 
members changed within the amino acid transporter activity group.  
None of the top changed groups in K14D6 keratinocytes after ligand binding 
(Table 4-17) were the same as the top changed groups potentially upregulated in 
resting K14D6 keratinocytes compared to wild-type keratinocytes (Table 4-11). It 
was noted that 6 of the 7 top changed groups in Table 4-17 were expressed at 
lower levels in wild-type keratinocytes after ligand binding compared to resting 
wild-type keratinocytes (Table 4-14). Therefore, CCL3 potentially induced the 
downregulation of these groups in wild-type keratinocytes but not in K14D6 
keratinocytes, this could explain why these groups are the top groups potentially 
upregulated in K14D6 keratinocytes compared to wild-type keratinocytes after 
ligand binding. 
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WT + CCL3 v K14D6 + CCL3 Group members Changed 
members 
P-value 
changed 
6583- melanin biosynthesis from tyrosine 6 4 3.4e-11 
1533- cornified envelope 14 5 1.2e-08 
IPR003347- Transcription factor jumonji, jmjC 21 3 3.9e-08 
42470- melanosome 7 3 6.8e-08 
IPR002227- Tyrosinase 2 2 1.6e-06 
15171- amino acid transporter activity 18 2 2.5e-05 
31424 – keratinisation 23 3 4.3e-05 
 
 
Table 4-17. Potential upregulated functional gene classes in K14D6 keratinocytes after CCL3 
treatment compared to Wild-type keratinocytes after CCL3 treatment. 
 
Comparison to the RP report 
Only eight genes were potentially upregulated in K14D6 keratinocytes compared 
to wild-type keratinocytes after ligand binding in the RP report (Table 4-8). 
Three genes expressed at higher levels in the RP report, Ddx3y, Uty and Jarid1d, 
are the three gene members that changed within the transcription factor 
jumonji functional gene class (Table 4-17). Slc6a14 and Slc7a3 were two genes 
listed in the RP report, which were the two changed gene members within the 
amino acid transporter activity group. Genes involved in melanin biosynthesis, 
cornified envelope, melanosome group, tyrosinase and keratinisation were not 
potentially upregulated, with an FDR of less than 50%, in the RP report. 
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ii) Potential downregulated functional gene classes 
Twelve functional gene classes were potentially downregulated involving 21 
distinct genes in K14D6 keratinocytes compared to wild-type keratinocytes after 
ligand binding by CCL3 (Table 4-18). The top changed group was CD20/IgE Fc 
receptor beta subunit in which 4 members out of 15 changed. The next three 
changed groups all involved chemokines. The second changed group was small 
chemokine interleukin-8 like with four changed members, which were also 
within the chemotaxis group and the chemokine activity group, all involving 
CXCL4, CCL6, CXCL5 and CCL9.  Chemokines were also potentially 
downregulated in K14D6 at rest compared to wild-type keratinocytes, which 
were CCL9, CCL6, CXCL4, and CXCL2 (Table 4-12). Another group that changed 
was immune cell chemotaxis, involving CXCL4 and CCR1 as two of the changed 
group members. IgG binding and mast cell activation are two other top changed 
groups with p-value changed of 1.8x10-05 and 6.5x10-05, with only two changed 
members which are the same, Fc receptor IgG low affinity IIb and Fc receptor 
IgG low affinity III. Two changed members occurred in the glycosidase hydrolase 
family 22 group and were also the two changed members within the cell wall 
catabolism group and lysozyme activity. Other functional gene classes 
potentially differentially expressed were sarcolemma and C-type lectin.  
Several functional gene classes potentially downregulated after ligand binding in 
K14D6 compared to wild-type keratinocytes were also expressed at lower levels 
in resting K14D6 keratinocytes compared to resting wild-type keratinocytes 
(Table 4-18 and 4-12 respectively). These were three groups involving 
chemokines, which were small chemokine interleukin-8 like, chemotaxis and 
chemokine activity. The other three groups potentially downregulated in both 
comparisons were glycosidase hydrolase, lysozyme activity and cell wall 
catabolism. This suggests that D6 may have a negative impact on genes 
associated with these functional groups. 
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WT + CCL3 V K14D6 + CCL3 Group members Changed 
members 
P-value 
changed 
IPR007237 – CD20/IgE Fc receptor beta subunit  15 4 8.0e-08 
IPR001811- Small chemokine, interleukin-8 like  31 4 1.4e-07 
6935- chemotaxis 87 5 2.1e-07 
8009- chemokine activity 38 4 3.3e-07 
30595- immune cell chemotaxis 5 3 3.4e-07 
19864 – IgG binding 5 2 1.8e-05 
IPR001916- Glycoside hydrolase, family 22 8 2 2.6e-05 
3796- lysozyme activity 10 2 4.2e-05 
42383- sarcolemma 14 3 5.4e-05 
IPR001304- C-type lectin 99 3 6.3e-05 
45576- mast cell activation 9 2 6.5e-05 
16988- cell wall catabolism 16 2 1.1e-04 
   
Table 4-18. Potential downregulated functional gene classes in K14D6 keratinocytes after 
CCL3 treatment compared to Wild-type keratinocytes after CCL3 treatment. 
 
 
Comparison with RP report 
Twenty-seven genes were expressed at lower levels in K14D6 keratinocytes after 
ligand binding in comparison to wild-type keratinocytes after ligand binding in 
the RP report (Table 4-9). Three of the changed members within the top 
changed CD20/IgE Fc receptor subunit group were potentially downregulated in 
the RP report. CXCL4 and CCL6 were chemokines potentially differentially 
expressed in the RP report and were found to be potentially downregulated in 
the iGA analysis as they are members within the small chemokine, chemotaxis 
and chemokine activity group. Fcg2rb and Fcgr3 are two genes potentially 
downregulated in the RP report (Table 4-9) that are also listed as changed 
members within the IgG binding and mast cell activation groups. P lysozyme 
structural (Lzp-s) and lysozyme are genes potentially downregulated in the RP 
report, which were changed members of the glycoside hydrolase, lysozyme 
activity and cell wall catabolism group in Table 4-18. Clec4d, Mrc1 and Clec4n 
are genes potentially downregulated in the RP report and are the changed 
members within the C-type lectin group.  
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4.4.2.5   Summary of iGA analysis 
To gain a better understanding of the data generated using the iGA analysis, the 
functional gene classes potentially differentially expressed between all 
comparisons were summarised in a Venn diagram for potential up- and 
downregulated changes (Figure 4-2 and Figure 4-3 respectively).  
Ectopically expressing D6 within keratinocytes resulted in 9 potentially 
upregulated functional gene classes, in which two classes were unique to this 
comparison; these were cadherin cytoplasmic region and prostaglandin synthesis 
(Figure 4-2). Genes involved in transmembrane receptor protein tyrosine kinase 
signalling and extracellular matrix structural constituent conferring tensile 
strength were also potentially upregulated by CCL3 in wild-type keratinocytes 
whereas another five functional gene classes were potentially upregulated by 
CCL3 in both K14D6 keratinocytes and wild-type keratinocytes. This suggests 
that basal D6 expression, independent of ligand within K14D6 keratinocytes may 
affect gene transcription. 
The Venn diagram illustrates that several classes of genes are induced by CCL3 in 
both wild-type and K14D6 keratinocytes demonstrating the effect of CCL3 
through receptors present on both wild-type and K14D6 keratinocytes such as 
CCR1, CCR3 and CCR5. These include 3 functional classes of genes involved in 
cell movement, CD20/IgE Fc receptor beta subunit, positive regulation of 
phagocytosis, heparin binding and fibrillar collagen group (Figure 4-2). 
Eight functional gene classes were expressed at higher levels only in K14D6 
keratinocytes after CCL3 binding in comparison to control K14D6 thus illustrating 
that genes were potentially differentially expressed because of CCL3 binding to 
D6. These were the functional gene classes of IgG binding, myelin proteolipid 
protein PLP, glycoside hydrolase family 22, aldehydrogenase, mast cell 
activation, lysozyme activity, calcium binding protein and Von Willebrand factor 
type A (Figure 4-2).   
Ectopically expressing D6 within keratinocytes resulted in the potential 
downregulation of 11 functional genes classes (Figure 4-3). Only one class of 
genes to do with cytolysis was specifically found in the comparison between 
wild-type and K14D6 keratinocytes at rest. Three groups found to be potentially 
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downregulated due to the presence of non-ligated D6 were also found to be 
potentially downregulated in the wild-type keratinocytes incubated with CCL3. 
Seven functional gene classes were potentially downregulated in the presence of 
non-ligated D6 as well as being potentially downregulated in K14D6 
keratinocytes after CCL3 treatment in comparison to wild-type. Three of these 
groups involved chemokines and the other four functional groups were IgG 
binding, glycoside hydrolase family 22, lysozyme activity and cell wall 
catabolism.  
Using the Venn diagram, 15 functional classes of genes were shown to be present 
in both the positive and negative differential expression analysis, illustrated in 
blue in Figure 4-2 and Figure 4-3 respectively. Three of these groups involving 
chemokines were found to be expressed at higher levels by CCL3 in both wild-
type and K14D6 keratinocytes indicating that CCL3 is able to induce changes in 
the gene transcripts of chemokines in both wild-type and K14D6 keratinocytes. 
However, at rest, the chemokine groups were potentially downregulated in 
K14D6 keratinocytes compared to wild-type indicating that the presence of D6 
may affect the transcription of chemokines. In addition, after ligand binding, the 
chemokine groups were potentially downregulated in K14D6 keratinocytes 
compared to wild-type. This indicates the possibility that CCL3 may be able to 
induce the transcription of genes through chemokine receptors CCR1, CCR3 and 
CCR5. However, the presence of ectopically expressed D6 within K14D6 
keratinocytes may be able to limit the transcription levels of these genes. 
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Figure 4-2. Venn diagram 
summarising potential 
upregulated functional 
gene classes using iGA 
analysis of four different 
group comparisons. 
Potential upregulated gene 
classes in each of the 
comparisons are 
represented in a 
corresponding circle. 
Functional gene classes 
found in overlapping 
regions show gene classes 
potentially upregulated in 
the other groups. Gene 
classes highlighted in blue 
are groups that are also 
found to e potentially 
downregulated. 
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Figure 4-3. Venn diagram 
summarising the potential 
downregulated functional 
gene classes using iGA 
analysis results of 4 different 
group comparisions. 
Potential downregulated gene 
classes in each of the 
comparisons are represented 
in a corresponding circle. 
Potential functional gene 
classes found in overlapping 
regions show gene classes 
potentially downregulated in 
the other groups. Functional 
gene classes shown in blue 
are groups which are also 
found to be potentially 
upregulated. 
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4.5 Validation of microarray data by QPCR 
Validation of the microarray was required to determine if the potentially 
differentially expressed genes reported in the rank product reports were 
reproducibly differentially expressed. This was performed using QPCR to 
measure changes in gene transcript levels. The main objective was to determine 
whether any transcriptional changes reported in the microarray could be 
revalidated. Therefore, genes were identified from the microarray data to be 
validated, primers were designed and validated to generate standards for each 
gene and for use in QPCR using the SYBR green based method (Morrison et al., 
1998). Fresh sets of wild-type and K14D6 primary keratinocytes were isolated 
(n=3/group in which 3 neonates were pooled to generate 1 sample), cultured 
and treated with either PBS or CCL3 as previously described for the microarray. 
RNA was extracted, quantified, converted to cDNA for QPCR. 
4.5.1 Identifying potentially upregulated genes to validate by 
QPCR 
The main objective of the microarray was to determine whether there were 
transcriptional consequences of ligand binding through D6. To obtain an 
overview of the data obtained from the microarray, genes potentially 
upregulated by CCL3 in wild-type and K14D6 keratinocytes with less than 25% 
FDR in the rank product report were summarised in a Venn diagram (Figure 4-4). 
The left hand circle shows genes that were potentially upregulated by CCL3 in 
wild-type keratinocytes and the right circle lists genes potentially upregulated 
by CCL3 in K14D6 keratinocytes. Genes listed in the overlapping region 
illustrates genes that were found to be potentially upregulated in both wild-type 
and K14D6 keratinocytes and suggests that these genes may be induced through 
CCL3 binding to receptors common to both wild-type and K14D6 keratinocytes, 
such as CCR1, CCR3 and CCR5. Genes not found in the overlapping region are 
genes that were found to be specifically potentially upregulated after CCL3 
binding in either wild-type or K14D6 keratinocytes.  
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Figure 4-4. Venn diagram of genes potentially upregulated  after CCL3 treatment in wild-type 
and K14D6 keratinocytes. 
The genes indicated in bold are genes identified for validation by QPCR. 
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i) Genes identified only in K14D6 keratinocytes after CCL3 binding 
Using the Venn diagram (Figure 4-4) and by identifying genes listed at a high 
ranking in the RP report (Table 4-6), six genes potentially upregulated only in 
K14D6 keratinocytes after CCL3 treatment were identified for validation. Genes 
found only to be potentially upregulated in K14D6 after CCL3 treatment and 
therefore potentially D6 mediated, were identified as:  
Nucleoplasmin 3 (Npm3) 
STEAP family member 4 (Steap4) 
Solute carrier family 6-member 14 (Slc6a14) 
Lipocalin 2 (Lcn2) 
Apolipoprotein E (ApoE) 
 
Nucleoplasmin 3 was the highest ranked gene, which was only potentially 
upregulated in K14D6 keratinocytes after CCL3 treatment with an RP score of 
147.22, fold change of 2.11 and a false discovery rate of 1.4% (Table 4-19). 
STEAP4 was the 11th gene listed on the RP report, with an RP score of 279.37, 
fold change of 2.22 and a false discovery rate of 5.17% (Table 4-19). Slc6a14 has 
an RP score of 296.41, a false discovery rate of 6.38% and a fold change of 1.61 
(Table 4-19). Lipocalin 2 has an RP score of 305.98, a 5.87% FDR and a 1.79 fold 
change (Table 4-19). The last gene identified for validation was apolipoprotein 
E, with an RP score of 313.19, 5.94% FDR and changed by a fold of 1.92 (Table 4-
19).   
 
 
 
 
Table 4-19. Genes potentially upregulated only in K14D6 keratinocytes after CCL3 treatment 
identified for validation. 
Genes were listed in order of Rank Product score (RP score) with details of % false 
discovery rate (FDR) and fold change (FC). Data obtained from the RP report as summarised 
in Table 4-6.  
 
 
Gene RP score FDR (%) FC 
Npm3 147.22 1.40 2.11 
STEAP4 279.37 5.17 2.22 
Slc6a14 296.41 6.38 1.61 
Lcn2 305.98 5.87 1.79 
ApoE 313.90 5.94 1.92 
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ii) Genes identified in WT and K14D6 keratinocytes after CCL3 binding 
Genes identified for validation that were potentially upregulated  in both WT 
and K14D6 keratinocytes after CCL3 ligand binding are summarised within the 
overlapping circles in the Venn diagram (Figure 4-4). Using the list of genes from 
the Venn diagram, genes were identified for validation using the highest ranked 
genes in the K14D6 + CCL3 rank product report and were identified as: 
Aldehyde dehydrogenase family 1, subfamily A7 (Aldh1a7) 
P lysozyme structural (Lzp-s) 
Pentraxin related gene (Ptx3) 
Lysosomal-associated protein transmembrane 5 (Laptm5) 
Procollagen, type III, alpha 1 (Col3a1) 
Chemokine (C-C motif) ligand 6 (CCL6) 
 
Aldehyde dehydrogenase was the first gene listed in the RP report as potentially 
differentially expressed in the comparison between K14D6 keratinocytes at rest 
and after CCL3 treatment. The RP score of Aldh1a7 was 97.2, with a fold change 
of 3.31 and a 3% false discovery rate (Table 4-20). The same gene was also 
potentially upregulated in wild-type keratinocytes after CCL3 treatment, with an 
RP score of 711.64, a 3.17 fold change and 15.65% false discovery rate (Table 4-
20). Lzp-s was potentially differentially expressed in K14D6 keratinocytes by a 
fold change of 2.7, an FDR of 1.5% and an RP score of 106.48 whereas in the 
wild-type, Lzp-s had an RP score of 740.13, an FDR of 17.28% and an FC of 1.74 
(Table 4-20). Pentraxin related gene was potentially differentially expressed by 
2.18 fold in K14D6 keratinocytes after incubation with CCL3, an RP score of 
199.63 and an FDR of 2.71%, whereas Ptx3 was potentially upregulated by 1.75 
fold in wild-type keratinocytes after CCL3 stimulation, with an RP score of 
506.88 and a 10.20% false discovery rate (Table 4-20). The fifth gene identified 
was Col3a1, which in K14D6 keratinocytes had an RP score of 254.35, a 4.27% 
FDR and increased by 2.18 fold whereas within wild-type keratinocytes, CCL3 
binding resulted in Col3a1 being potentially differentially expressed by 3.72 fold, 
with a 10.25% false discovery rate and an RP score of 224.73 (Table 4-20). The 
last gene picked for validation was CCL6. CCL6 had an RP score of 430.38, a 
12.24% FDR and changed by 1.86 fold in K14D6 keratinocytes after CCL3. CCL6 
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was also potentially upregulated by CCL3 in wild-type keratinocytes by 1.87 fold, 
an RP score of 868.30 and an FDR of 22.85% (Table 4-20). 
 WT K14D6 
Gene RP score FDR (%) FC RP score FDR (%) FC 
Aldh1a7 711.64 15.65 3.17 97.2 3.00 3.31 
Lzp-s 740.13 17.28 1.74 106.48 1.50 2.47 
Ptx3 506.88 10.20 1.75 199.63 2.71 2.18 
Laptm5 415.35  9.67 1.88 234.40 3.67 1.89 
Col3a1 224.73 10.25 3.72 254.35 4.27 2.18 
CCl6 868.30 22.85 1.87 430.38     12.24 1.86 
Table 4-20. Comparison of data from the rank product reports on six genes identified as 
potentially differentially expressed in both Wild-type and K14D6 keratinocytes after 
incubation with CCL3. 
 
iii) Genes identified in resting K14D6 keratinocytes 
 
It was also decided to validate three genes that were potentially upregulated in 
resting K14D6 keratinocytes compared to resting wild-type keratinocytes. In the 
RP analysis, only 6 genes were potentially upregulated in K14D6 keratinocytes 
compared to wild-type keratinocytes (Table 4-2).  
CCbp2 (D6) had a rank product score of 1, the smallest value that can be 
achieved using the rank product method, which indicates that the gene is 
significantly differentially expressed. Ccbp2 was chosen not to be validated 
because the microarray data confirmed that the D6 transgene was present in 
K14D6 keratinocytes at higher levels than wild-type confirming PCR and QPCR 
data in chapter 3. Therefore, it was decided to validate three of the genes listed 
after D6 in the RP report. These were dickkopf homolog 2 (Dkk2), nik related 
kinase (Nrk) and branched chain aminotransferase 1 (Bcat1; Table 4-21). The RP 
scores for these genes are much larger than one, being 206.84, 348.58 and 
359.51 for Dkk2, Nrk and Bcat1 respectively, suggesting these genes may not be 
significantly differentially expressed. 
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Gene RP score FDR % FC 
Ccbp2     1.00   0.00       49.59 
Dkk2 206.84 15.50 2.66 
Nrk 348.58 43.33 1.81 
Bcat1 359.51 34.50 1.48 
 
Table 4-21. Genes identified for validation that were potentially upregulated in K14D6 
keratinocytes in comparison to wild-type keratinocytes at rest. 
 
4.5.2 Identifying potentially downregulated genes to validate 
Overall, in the RP report, the number of genes potentially downregulated was 
far less than the number of genes potentially upregulated. None of the potential 
downregulated genes stood out with their RP score and therefore no potential 
downregulated genes were identified specifically for validation. However, 
several genes identified for validation, as potential upregulated genes induced 
by CCL3, were also present as potentially downregulated genes, for example, 
Laptm5 and Lzp-s. These two genes were potentially downregulated in two RP 
reports, one was resting K14D6 keratinocytes compared to wild-type and the 
second was K14D6 keratinocytes compared to wild-type after CCL3 binding 
(Table 4-3 and 4-9 respectively). In addition, CCL6 was a gene identified for 
validation as being potentially upregulated in both wild-type and K14D6 
keratinocytes after CCL3 binding, but was potentially downregulated in K14D6 
keratinocytes compared to wild-type keratinocytes after ligand binding (Table 4-
9). Another gene identified for validation was ApoE, which was potentially 
upregulated in K14D6 keratinocytes after ligand binding but was potentially 
downregulated in resting K14D6 keratinocytes compared to wild-type 
keratinocytes (Table 4-3). As a result, these genes could be analysed for 
potential up- or downregulation of transcripts between the different groups at 
the same time. 
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4.5.3 Design and validation of primers 
Primers were designed according to the specifications described previously in 
Chapter Two for use in QPCR. Transcript levels were quantified using a standard 
DNA template alongside samples of interest. Each specific standard DNA 
template was generated using standard PCR with ‘outer’ primers that 
incorporated the region amplified by the ‘nested’ primers, as illustrated in 
Figure 4-5. The number of transcript copies in each standard DNA template was 
calculated (See 2.2.1.9 for details) and used to determine the absolute number 
of copies of transcript in each sample of interest. 
 
 
 
Figure 4-5. A diagram illustrating the use of different primer sets for QPCR.  
(A) ‘Outer’ primers (arrows) were designed to generate a PCR product of the gene of interest 
for use in QPCR as standard DNA template. (B) The standard DNA template generated using 
the ‘outer’ primers would encode the region that would be amplified by the ‘nested’ primers 
(arrows) in QPCR. 
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4.5.4 Validation of outer primers 
The ‘outer’ primers were designed and used to generate a standard DNA 
template for each gene of interest by PCR. The ‘outer’ primers were optimised 
to produce a clear PCR product of the expected size as shown in Figure 4-6. Most 
‘outer’ primers generated a clear band using an annealing temperature of 60°C 
except for Lzp-s primers, which were required to have an annealing temperature 
of 61°C. The intensity of the bands varied, with Aldh1a7 being the most intense 
band under ultraviolet light (Figure 4-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. Specificity of ‘outer’ primers to generate standards for use in QPCR. 
PCR products were amplified from mixed WT and K14D6 keratinocytes cDNA using ‘outer’ 
primers and visualised under UV light on a 1% agarose gel. The single bands indicate the 
specificity of the primers and the specific product sizes expected are listed above. The 
products were used as reference standards in QPCR. Lane 1, Hyperladder IV; lane 2, 
Col3a1; lane 3, Lzp-s; lane 4, Ptx3; lane 5, Laptm5; lane 6, ccl6; lane 7, Npm3; lane 8, 
STEAP4; lane 9, slc6a14; lane 10, Lcn2; lane 11, Apoe; lane 12, Aldh1a7; lane 13, Dkk2; lane 
14, Nrk; lane 15, Bcat1; lane 16, Hyperladder 1.  
Lane Gene Expected product 
Size (bp) 
2 Col3a1 700 
3 Lzp-s 520 
4 Ptx3 903 
5 Laptm5 867 
6 CCl6 612 
7 Npm3 491 
8 STEAP4 630 
9 Slc6a14 413 
10 Lcn2 307 
11 ApoE 765 
12 Aldh1a7 813 
13 Dkk2 487 
14 Nrk 359 
15 Bcat1 458 
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4.5.4.1   Calculation of gene transcripts numbers within 
standards 
The bands within the DNA ladder were of a known mass (supplied by the 
manufacturer Bioline). Therefore, the intensity of the bands under UV light were 
measured using densiometric analysis. A standard curve was generated using the 
known mass of the Hyperladder band and the bands intensity. The intensity of 
each standard DNA template was measured and the mass of the DNA template 
for each gene was calculated, using the formula generated from the standard 
curve. The calculated mass for the standard DNA template was then used to 
calculate the absolute copy numbers of transcripts within the template (Table 4-
22), using a series of equations (see 2.2.1.9 for details). Using the known value 
of copy numbers of transcript in each standard, the number of copies in each of 
the diluted standards was calculated.  
 
 
Gene Mass of Product 
(ng/µl) 
Calculated Copies 
of product/µl 
Col3a1   9.84 12,831,597,359 
Lzp-s   3.54   6,212,534,965 
Ptx3 13.38 13,485,841,751 
Laptm5 10.49 10,946,698,822 
Ccl6 14.64 21,770,598,138 
Npm3 26.96 49,996,512,991 
STEAP4 23.23 33,605,964,406 
Slc6a14 30.39 66,951,683,909 
Lcn2 27.70 82,339,897,345 
Apoe 13.38 15,865,696,177 
Aldh1a7 40.92 45,909,407,730 
Dkk2   7.73 14,485,032,045 
Nrk   5.32 13,523,406,770 
Bcat1   4.22    8,408,449,120 
 
Table 4-22. Calculation of the number of transcripts within each standard for each gene of 
interest. 
For each standard, the mass was calculated using the formula from the standard curve. 
Using a series of equations, the number of gene transcripts within each standard was 
calculated from the mass.  
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4.5.5 Optimisation of ‘nested’ primers 
The ‘nested’ primers designed for use in QPCR were tested using keratinocyte 
cDNA (mixed WT and K14D6) to ensure they generated the correct size of 
product and were specific. All the ‘nested’ primers were specific and generated 
PCR products of the expected size (Figure 4-7). All QPCR assays involved SYBR 
green and a dissociation melting curve analysis was used to ensure there was no 
primer dimer formation during the reaction.  
 
 
 
 
 
Lane Gene Expected product 
Size (bp) 
2 Col3a1 114 
3 Lzp-s              104 
4 Ptx3 117 
5 Laptm5 160 
6 CCl6 102 
7 Npm3 132 
8 Steap4 103 
9 Slc6a14 117 
10 Lcn2 133 
11 ApoE 153 
12 Aldh1a7 100 
13 Dkk2 115 
14 Nrk 108 
15 Bcat1 127 
 
Figure 4-7. Nested primers used in QPCR were specific.  
PCR products were generated by amplifying mixed Wt and K14D6 keratinocyte cDNA. The 
products were electrophoresed on a 2% agarose gel and visualised under a UV light. Lane 1, 
Hyperladder IV; lane 2, Col3a1; lane 3, Lzp-s; lane 4, Ptx3; lane 5, Laptm5; lane 6, ccl6; lane 
7, Npm3; lane 8, STEAP4; lane 9, slc6a14; lane 10, Lcn2; lane 11, Apoe; lane 12, Aldh1a7; 
lane 13, Dkk2; lane 14, Nrk; lane 15, Bcat1. A single band demonstrates the specificity of 
each primer pair. The PCR product sizes expected are summarised in the table.  
 
1   2    3    4    5    6    7    8    9   10 11  12  13  14  15
200bp
100bp
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4.5.6  QPCR results 
4.5.6.1   Validation of genes potentially induced by CCL3 in 
both wild-type and K14D6 transgenic keratinocytes. 
Six genes, Aldh1a7, Col3a1, Laptm5, Lzp-s, Ptx3 and CCL6 were identified for 
validation as being potentially upregulated in both wild-type and K14D6 
keratinocytes after CCL3 treatment, suggesting that CCL3 may be regulating 
gene transcript levels through other chemokine receptors, such as CCR1.  
CCL3 treatment had no effect on the transcript levels of Col3a1 within wild-type 
or K14D6 keratinocytes (Figure 4-8A; Two-way ANOVA, WT v WT+CCL3 p>0.05, 
K14D6 v K14D6+CCL3 p>0.05). CCL3 had no significant effect on Lzp-s transcripts 
in wild-type keratinocytes or K14D6 keratinocytes (Figure 4-8B; Two-way ANOVA, 
WT v WT+CCL3 p>0.05, K14D6 v K14D6+CCL3 p>0.05). In wild-type keratinocytes, 
CCL3 did not induce any significant changes in the transcript levels of Ptx3 and 
CCL3 had no effect on the transcript levels of Ptx3 within K14D6 keratinocytes 
(Figure 4-8C; Two-way ANOVA, WT v WT+CCL3 p>0.05, K14D6 v K14D6+CCL3 
p>0.05). CCL3 had no significant effect on the transcript levels of Laptm5 within 
wild-type keratinocytes or within K14D6 keratinocytes (Figure 4-8D; Two-way 
ANOVA, WT v WT+CCL3 p>0.05, K14D6 v K14D6+CCL3 p>0.05). CCL3 had no 
significant effect on CCL6 transcript levels in wild-type or K14D6 keratinocytes 
(Figure 4-8E; Two-way ANOVA, WT v WT+CCL3 p>0.05, K14D6 v K14D6+CCL3 
p>0.05). CCL3 had no effect on the transcript levels of Aldh1a7 in either wild-
type or K14D6 keratinocytes (Figure 4-8F; Two-way ANOVA, WT v WT+CCL3 
p>0.05, K14D6 v K14D6+CCL3 p>0.05). In the microarray, Laptm5 was listed as 
potentially downregulated in resting K14D6 keratinocytes compared to WT 
keratinocytes and was identified as a gene to validate by QPCR. However, there 
was no significant difference in Laptm5 transcript levels in resting K14D6 
keratinocytes compared to control WT keratinocytes (Figure 4-8D, unpaired 
students t-test, p=0.1459). 
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Figure 4-8. Validation of gene transcripts potentially upregulated after CCL3 treatment in 
both wild-type and K14D6 keratinocytes.   
Six genes that were found to be potentially upregulated after CCL3 treatment in both wild-
type (WT) and K14D6 keratinocytes were identified for validation by QPCR. The copy 
numbers of each gene is normalised to 1x105 copies of GAPDH. (A) Col3a1, (B) Lzp-s, (C) 
Ptx3, (D) Laptm5, (E) CCL6 and (F) Aldh1a7. White column is control keratinocytes; Black 
column is keratinocytes treated with 10nM CCL3 for 6hrs at 37°C. Each column is mean ± 
SEM, n=3/group. 
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Although the data was not significant, the CCL6 and Laptm5 QPCR were 
repeated with more samples by including RNA from two sets of keratinocytes 
used in the microarray. The assay was also repeated on fresh sets (n=3/group 
with 3 neonates pooled per sample) of keratinocytes using 30nM concentration of 
CCL3 instead of 10nM. 
By including keratinocyte samples that were involved in the microarray, sample 
size was increased from three to five and the QPCR was repeated. In the 
increased sample group, CCL3 had no significant effect on CCL6 transcript levels 
in both wild-type and K14D6 keratinocytes (Figure 4-9A; Two-way ANOVA, WT v 
WT+CCL3 p>0.05, K14D6 v K14D6+CCL3 p>0.05). Increasing the concentration of 
CCL3 to 30nM also had no effect on CCL6 transcripts within wild-type 
keratinocytes or K14D6 keratinocytes (Figure 4-9B; Two-way ANOVA, WT v 
WT+CCL3 p>0.05, K14D6 v K14D6+CCL3 p>0.05). These data suggest that CCL3 
binding did not have an impact on CCL6 transcript levels in wild-type or K14D6 
keratinocytes. 
 
 
 
 
 
 
 
 
Figure 4-9. Repeated QPCR for validation of CCL6 
Wild-type (WT) and K14D6 keratinocytes were treated with either PBS (white) or CCL3 
(black) for 6hrs at 37°C. QPCR measuring absolute c opy numbers was performed. The copy 
numbers of each gene is normalised to 1x105 copies of GAPDH. (A) 10nM CCL3 was used, 
n=5/group (B) The concentration of CCL3 was increased to 30nM n=3/group. Each column is 
mean ± SEM.  
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Transcript levels of Laptm5 were re-examined with increased sample size by 
including samples used within the microarray. CCL3 did not induce any 
transcriptional changes in Laptm5 in wild-type keratinocytes or K14D6 
keratinocytes (Figure 4-10A; Two-way ANOVA, WT v WT+CCL3 p>0.05, K14D6 v 
K14D6+CCL3 p>0.05). Additionally, there was no significant difference in the 
transcript levels of Laptm5 in resting K14D6 keratinocytes compared to wild-type 
(Figure 4-10A; unpaired student’s t-test, p=0.22). Increasing the concentration 
of CCL3 to 30nM did not have any significant effect on Laptm5 transcripts within 
WT or K14D6 keratinocytes (Figure 4-10B, Two-way ANOVA WT v WT+CCL3 
p>0.05, K14D6 v K14D6+CCL3 p>0.05). There was no difference in transcripts 
levels of Laptm5 in resting wild-type or K14D6 keratinocytes (Figure 4-10B; 
unpaired students t-test, p=0.41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10. Repeated QPCR for validation of Laptm5 
Wild-type (WT) and K14D6 keratinocytes were treated with either PBS (white) or CCL3 
(black) for 6hrs at 37°C. QPCR measuring absolute c opy numbers was performed. The copy 
numbers of each gene is normalised to 1x105 copies of GAPDH. (A) 10nM CCL3 was used, 
n=5/group. (B) The concentration of CCL3 was increased to 30nM, n=3/group. Each column 
is mean ± SEM. 
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At rest, there was no significant difference in the transcript levels of Col3a1, 
Lzp-s, Ptx3, Laptm5, CCL6 or Aldh1a7 transcript levels between wild-type and 
K14D6 keratinocytes (Figure 4-8A, B, C, D, E and F respectively; students t-test, 
all p>0.05), illustrating that ectopic expression of D6 did not affect the 
expression levels of these genes.  
4.5.6.2   Validation of genes potentially induced by CCL3 only 
in K14D6 keratinocytes 
Potential upregulation of gene transcript levels through D6 was investigated by 
identifying five genes from the microarray that were potentially upregulated in 
only K14D6 keratinocytes after CCL3 treatment. These genes were Npm3, 
STEAP4, slc6a14, Lcn2 and ApoE. CCL3 treatment caused no significant effect on 
the transcript levels of Npm3, STEAP4, Lcn2, Apoe or Slc6a14 in K14D6 
keratinocytes or wild-type keratinocytes (Figure 4-11A, B, C, D and E 
respectively; Two-way ANOVA, WT v WT+CCL3 p>0.05, K14D6 v K14D6+CCL3 
p>0.05 for all genes). Additionally, there were also no significant differences in 
the transcript levels of Npm3, STEAP4, Slc6a14, Lcn2 or ApoE between wild-type 
and K14D6 keratinocytes at rest (Figure 4-11, student’s t-test, p>0.05). These 
QPCR data would suggest that CCL3 binding to D6 in K14D6 keratinocytes does 
not have an impact on the transcription of these genes. 
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Figure 4-11. Validation of gene transcripts identified as potentially upregulated after CCL3 
treatment in K14D6 keratinocytes but not wild-type (WT) keratinocytes.   
Five genes that were found to be potentially upregulated after CCL3 treatment in K14D6 
keratinocytes only were identified for validation. QPCR measuring absolute copy numbers 
was performed. The copy numbers of each gene is normalised to 1x105 copies of GAPDH. 
(A) Npm3, (B) Steap4, (C) slc6a14, (D) Lcn2, (E) Apoe. White column is control 
keratinocytes; Black column is keratinocytes treated with 10nM CCL3 for 6hrs at 37°C. Each 
column is mean of three samples ± SEM, n=3/group. 
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4.5.6.3 Validation of genes potentially upregulated between 
wild-type and K14D6 keratinocytes at rest 
To determine whether transgenic overexpression of D6 had any effect on 
keratinocytes at rest, the transcript levels of the top three genes after D6 
reported in the microarray were validated. Out of the three genes identified for 
validation, Dkk2 had a fold change above 2, however the RP score varied from 
206.84 to 359.51 with FDR between 15.5 and 43.3% (Table 4-2). The QPCR data 
showed there was no significant difference in the transcript levels of Dkk2 in 
K14D6 keratinocytes compared to  wild-type keratinocytes at rest (Figure 4-12A, 
student’s t-test, p=0.122). There was a non-significant difference in the 
transcript levels of Bcat1 between wild-type and K14D6 keratinocytes at rest 
(Figure 4-12B, student’s t-test, p=0.119). The transcript levels of Nrk were not 
significantly different in K14D6 keratinocytes compared to wild-type 
keratinocytes (Figure 4-12C; student’s t-test, p=0.159). Additionally, treatment 
of wild-type and K14D6 keratinocytes with CCL3 had no effect on the 
transcriptional levels of Dkk2, Nrk and Bcat1 in comparison to the control 
keratinocytes (Figure 4-12; Two-way ANOVA, WT v WT+CCL3 p>0.05, K14D6 v 
K14D6+CCL3 p>0.05). These QPCR data would suggest that transgenic expression 
in absence of ligand had no impact on the level of transcription of Dkk2, Nrk and 
Bcat1. 
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Figure 4-12. Validation of the transcript levels of three genes potentially upregulated 
between wild-type (WT) and K14D6 keratinocytes. 
Three genes potentially upregulated in K14D6 keratinocytes compared to wild-type in the 
microarray data were validated by QPCR. Copy numbers of each gene is normalised to 
1x105 copies of GAPDH, a housekeeping gene. (A) DKK2 (B), Nrk (C) Bcat1. White columns 
are control keratinocytes. Black columns are keratinocytes treated with 10nM CCL3 for 6 hrs 
at 37°C. Each column is mean ± SEM, n=3/group. 
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4.5.7 Summary of quantitative PCR results 
Various genes were identified from the microarray using the rank products 
method to validate by QPCR. Six genes were identified that were listed as 
potentially upregulated in both wild-type and K14D6 keratinocytes after ligand 
binding. However, by QPCR, none of the genes identified showed any significant 
changes in gene expression due to CCL3 ligand binding (Figure 4-8). By QPCR, 
CCL3 did not significantly upregulate any of the genes identified for validation 
that were identified as potentially upregulated only in K14D6 after ligand 
binding in the microarray (Figure 4-11). Resting K14D6 keratinocytes did not 
show any significant upregulation of Dkk2, Nrk or Bcat transcript levels, which 
were three genes identified for validation from the RP report (Figure 4-12). In 
the microarray, Laptm5 was potentially downregulated in resting K14D6 
keratinocytes compared to wild-type keratinocytes. However, there was no 
difference in Laptm5 transcript levels between WT and K14D6 keratinocytes by 
QPCR (Figure 4-10). 
No significant differences were found in any of the individual genes validated by 
QPCR and this correlates with the microarray results. One of the methods for the 
analysis of microarray data was rank products, in which the smaller the RP value 
the more likely the gene is up- or downregulated (Breitling et al., 2004b). Many 
of the genes identified for validation had high RP scores, for example, the 
smallest RP score (excluding D6) was 97.2 and increased to 868, which suggests 
the likelihood that these genes were not actually differentially expressed in the 
microarray. 
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4.6 Discussion of Chapter 4 
To date, in vitro studies have determined that D6 does not seem to signal by 
analysing functional responses after ligand binding using cell lines (Nibbs RJ et 
al., 1997; Fra AM et al., 2003). In this study, we have taken the approach one 
step further in that we are using primary cells, which contain high levels of 
ectopically expressed D6. These cells are keratinocytes from wild-type or K14D6 
transgenic mice. By analysing the transcriptional consequences of ligand binding 
in wild-type and K14D6 keratinocytes, it was hoped that this would give an 
insight into any altered gene expression after ligand binding to D6. In addition, 
information would also be gained on the transcriptional consequences induced 
through D6 in a ligand independent manner by comparing the cell transcriptome 
in resting wild-type and K14D6 keratinocytes. 
Examination of the transcriptional data generated using the rank product 
differential analysis method revealed that the largest number of genes 
potentially upregulated was after ligand binding in both wild-type and K14D6 
keratinocytes. Conversely, the largest number of genes potentially 
downregulated occurred in resting K14D6 keratinocytes. Of note, the most 
strongly differentially expressed gene in the microarray was D6 in K14D6 
keratinocytes compared to wild-type. These data confirm that D6 is expressed 
from the transgene driven by the keratin 14 promoter in K14D6 keratinocytes. 
Within the RP report, many Y-linked genes were listed when a certain population 
of keratinocytes was used (WT+CCL3). This result added an extra complication to 
the analysis of the microarray data and therefore an improvement to the design 
of the experiment would be to ensure that the keratinocytes populations used 
were all isolated from the same ratio of male to female neonates. 
Analysis of the transcriptional data generated using the iGA analysis provided a 
number of insights into the functional differences induced by non-ligated D6 and 
ligand binding through D6. CCL3 binding in both wild-type and K14D6 
keratinocytes resulted in the potential upregulation of genes encoding 
chemokines,  genes involved in CD20/IgE Fc receptor subunit, positive regulation 
of phagocytosis and intracellular calcium activated chloride channel activity. 
This suggests the possibility that CCL3 exerts these effects through common 
receptors on both wild-type and K14D6 keratinocytes.  
Vicky King, 2010   Chapter 4, 212 
It was noted that in wild-type keratinocytes, other genes potentially upregulated 
by CCL3 were genes involved in transmembrane receptor protein kinase 
signalling pathway, genes involved in the inflammatory response pathway and 
eicosanoid synthesis pathways. This suggests the possibility that CCL3 in wild-
type keratinocytes activated chemokine receptors capable of signalling and 
induced genes involved in inflammation. Since these groups were not potentially 
upregulated in K14D6 keratinocytes, this suggests that ectopic expression of D6 
has prevented these genes from being activated. One mechanism may be that D6 
removed CCL3 from its surroundings and targeted it for degradation. In turn, this 
may prevent the ligand binding to chemokine receptors, which would activate 
the genes involved in the inflammatory response. In addition to this, genes 
involved in chemokines and CD20/IgE Fc receptor subunit was in fact found to be 
potentially downregulated in K14D6 keratinocytes compared to wild-type 
keratinocytes after ligand binding suggesting that ectopic expression of D6 may 
be able to limit transcriptional consequences of CCL3 binding. 
Analysis of the transcriptional consequences of non-ligated D6 revealed potential 
upregulation of genes involved with transmembrane receptor protein tyrosine 
kinase receptor pathway, as well as phosphate transport and intracellular 
calcium activated chloride channel activity. Interestingly, non-ligated D6 in 
K14D6 keratinocytes resulted in the potential downregulation of functional genes 
classes involving chemokines. 
Although this microarray has given an insight and indication of the 
transcriptional consequences of D6 after ligand binding, it has to be kept in mind 
that D6 is ectopically expressed within these keratinocytes. Therefore, these 
results may be specific to this cell type and whether the same transcriptional 
consequences occur in a cell that naturally expresses D6 remains to be seen. 
Another point is that only one ligand was used within this study and does not 
take into account that in vivo many different chemokines are within the local 
proximity of D6 that may affect the transcriptional consequences of ligand 
binding. However, this study is one step forward in analysing the functional 
response of D6 in vitro. 
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4.7 Conclusion of Chapter 4 
In summary, the main aim of the work within this chapter was to characterise 
the transcriptional consequences of ligand binding through D6 in ectopically 
expressed primary keratinocytes. A second aim was to determine if there was 
any transcriptional consequence of ectopic expression of D6 within K14D6 
keratinocytes. The microarray results suggested that CCL3 induced the largest 
transcriptional changes in both wild-type and K14D6 keratinocytes mediated 
through common chemokine receptors such as CCR1. However, at the individual 
gene expression level, one conclusion was D6 is expressed at higher levels in 
K14D6 keratinocytes compared to wild-type keratinocytes. As a whole, there did 
not seem to be any significant transcriptional consequences of ligand binding 
through D6 at the individual gene level, however by analysing functional gene 
classes, data suggests the possibility that non-ligated D6 and ligated D6 is able to 
downregulate the gene expression level of chemokines. Therefore, these data 
suggests that D6 within keratinocytes does not seem to affect the cellular 
transcriptome as there was no significant upregulation of gene transcripts after 
ligand binding yet D6 may play a role in limiting the expression levels of genes. 
In the presence of ligand, D6 may reduce these levels by removal of the ligand 
leaving less ligand available to bind to other chemokine receptors.  
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5 D6 in human psoriasis 
5.1 Introduction 
Psoriasis is a common inflammatory relapsing skin disease, which varies in 
location and severity (Naldi and Gambini, 2007). Clinical symptoms of psoriasis 
appear as lesions on the skin, which in the most common form of psoriasis, 
generally appear as red plaques. Pathological and histological changes occur 
within psoriatic lesions and these make up the hallmark features of the disease. 
Psoriasis has characteristic features that consist of epidermal thickening caused 
by the increased proliferation of keratinocytes, hyperkeratosis, epidermal 
hyperplasia, angiogenesis and an influx of leukocytes (Murphy et al., 2007). In 
addition, patients with psoriasis can also develop inflammatory joint disease 
(arthritis), known as psoriatic arthritis (Kleinert et al., 2007). Although the 
trigger of psoriasis is unknown, the key mediators currently thought to drive 
psoriasis are T cells (Austin et al., 1999) in particular Th1 and Th17 cells (Lowes 
et al., 2008), cytokines such as TNFα, IFNγ, IL-23 (Chan et al., 2006) and 
keratinocytes (Zenz et al., 2005).  
Pathology similar to human psoriasis was demonstrated in mice lacking the 
atypical chemokine receptor, D6 (Jamieson et al., 2005). In the study, by 
Jamieson et al., D6 null mice demonstrated an exaggerated inflammatory 
response within the skin in response to a chemical irritant, TPA, although skin 
inflammation in D6 null mice did eventually resolve. Histological analysis of skin 
from D6 null mice revealed several characteristics similar to human psoriasis, 
such as hyperkeratosis, epidermal hyperproliferation and increased angiogenesis 
(Jamieson et al., 2005). The pathology displayed in D6 null mice was dependent 
on TNF (Jamieson et al., 2005) as well as IL-15 and IL-17 (personal 
communication Professor G.J.Graham), which are all hallmarks of human 
psoriasis. Thus, D6 null mice displayed psoriasis-like pathology suggesting 
possible involvement of D6-dysfunction, as a contributing factor in the 
pathogenesis of the disease. 
The aim of the work in this chapter was to determine whether there was any 
correlation between D6 expression levels and cutaneous disease development. 
D6 expression levels were examined in human skin biopsies from control 
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subjects, atopic dermatitis patients and patients with psoriasis. In psoriasis 
patients, skin biopsies from psoriatic lesions and uninvolved skin from the same 
patient were also examined. Samples were taken from atopic dermatitis patients 
because atopic dermatitis is another chronic inflammatory disease of the skin. 
Diagnosis of atopic dermatitis is based on presentation of skin lesions that are 
dry (eczema), very itchy (puritus) and chronic lesions display lichenification of 
the skin (Beltrani, 1999). Atopic dermatitis is thought to be induced by the skin 
in individuals who are hypersensitive to allergens, resulting in increased Th2 
type cytokines, increased serum IgE levels and eosinophilia (Leung, 1995).  
Specifically, the levels of D6 transcripts were examined by quantitative PCR. The 
presence and location of D6 within the human skin biopsies was examined by 
immunohistochemistry using an antibody available for human D6 (Nibbs et al., 
2001). The main aim of this work was to gain further understanding of the role 
for D6 in the pathogenesis of human cutaneous inflammatory disorders. 
5.2 Collection of human skin samples 
To examine the association of D6 with human psoriasis, patient samples were 
required. Skin samples were taken from volunteers at a Dermatology clinic in 
Glasgow Royal Infirmary. Skin biopsies were taken from various parts of the body 
from psoriatic, atopic dermatitis patients and controls. Control samples were 
obtained from various types of patients, such as patients having a naevus 
removed, patients with atypical fibroxanthoma or patients with basal cell 
carcinoma. These skin samples are considered normal by dermatologists. 
Psoriasis patients had a skin biopsy taken from the centre of a psoriatic lesion 
and a biopsy taken from uninvolved skin (non-lesional) from the same part of the 
body. Skin samples were either ‘snap frozen’ and RNA was extracted from the 
biopsies for quantitative PCR or samples were placed in 10% neutral buffered 
formalin and embedded in paraffin wax blocks for immunohistochemistry. 
 
 
 
Vicky King, 2010   Chapter 5, 217 
5.3 D6 transcripts in human skin 
RNA was extracted from human skin biopsies using Trizol and was DNase treated, 
(see 2.2.1.2 and 2.2.1.4). RNA was obtained from 9 control samples, 9 atopic 
dermatitis samples, 10 uninvolved psoriatic samples and 13 lesional psoriatic 
samples. RNA was transcribed into cDNA (by a dermatologist, Anne Sergeant) and 
used for QPCR. Using QPCR, human skin samples were examined for D6 transcript 
levels to determine any correlation between presence of disease and D6 
expression.  
There was no significant difference in D6 transcripts levels between atopic 
dermatitis samples and control samples or between psoriatic lesions and control. 
However, D6 transcript levels in uninvolved skin from psoriatic patients were 
significantly higher than control, atopic dermatitis and psoriatic lesional skin 
(Figure 5.1A). Uninvolved skin from psoriasis patients contained an 8-fold 
increase in D6 transcript levels in comparison to control skin (Figure 5-1A). D6 
transcript levels were also 8-fold higher in uninvolved skin from psoriasis 
patients compared to lesional skin of psoriasis patients (Figure 5-1A). In 
individual psoriasis patients (where matching samples were obtained), 9 out of 
the 10 patients had higher D6 levels in uninvolved skin than within psoriatic 
lesions (Figure 5-1B). Conversely, one patient (patient 25) had higher D6 
transcript levels in psoriatic lesions than in uninvolved skin, illustrated by the 
red dotted box in Figure 5-1B. In addition, patient 29 only had slightly higher 
levels of D6 transcripts within non-lesional skin compared to lesional skin (Figure 
5.1B). These results indicate a consistent pattern of expression within psoriasis 
patients suggesting that D6 is abnormally expressed within uninvolved skin (non-
lesional) of psoriasis patients. 
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Figure 5-1. D6 transcript levels in human skin. 
Levels of D6 transcripts were examined in human skin biopsies from control individuals, 
atopic dermatitis patients and psoriasis patients (lesions and uninvolved skin). (A) Levels of 
D6 transcripts are normalised to GAPDH, a housekeeping gene, and expressed as fold 
change in D6 transcripts compared to control samples. Control n=9, psoriasis non-lesional 
n=10, psoriatic lesional n=13 and atopic dermatitis n=9, columns show mean ± SEM. (B) The 
individual transcript levels of D6 in non-lesional skin and lesion of each patient. Transcript 
levels were normalised to GAPDH and expressed as fold change normalised to control 
samples with a fold change of 1 (shown by black dotted line). Blue column is psoriatic non-
lesional and green column is psoriatic lesional skin. 
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5.4 D6 protein in human skin 
Within our laboratory, monoclonal antibodies to human D6 had been generated 
(Nibbs et al., 2001). In brief, human D6 was transfected into a murine cell line 
(L1.2) and used to immunise C57BL/6 mice. Spleen cells from the immunised 
mice were fused with myeloma SP2/0 cells to generate hybridomas. 
Supernatants from the hybridomas were screened and several clones that 
specifically stained for D6 were further subcloned, expanded and the 
supernatant collected.  
As anti-human D6 antibodies were available for use, human skin biopsies were 
obtained to stain for the presence of D6 in control human skin and psoriatic skin 
(within lesions and uninvolved skin). Staining for D6, using 
immunohistochemistry would allow us to determine the location of D6 within the 
skin. Human placental samples were used as a positive control as D6 is highly 
expressed within human placenta, specifically on syncytiotrophoblasts (Martinez 
de la Torre et al., 2007). Previous studies using one of the monoclonal antibodies 
generated revealed the presence of D6 on lymphatic endothelial cells by 
immunohistochemistry (Nibbs et al., 2001). This study used a new clone of 
antibody and as a result required optimisation for use in immunohistochemistry. 
Human skin biopsy samples were obtained from patients and collected into 10% 
neutral buffered formalin. Samples were processed, embedded in paraffin wax 
blocks and cut into 4-micron sections to stain either with haematoxylin and eosin 
or with the anti-human D6 antibody. In sections stained with the anti-human D6 
antibody (or isotype control), a biotinylated secondary antibody was used. Bound 
antibodies were detected using the avidin-biotin- horseradish peroxidase method 
(Vector Laboratories) and DAB substrate, which results in brown staining. 
Sections of placenta were used to test the clone of anti-human D6 antibody, 
initially following the previously optimised protocol.  
Firstly, placental sections were cut and then to enable identification of 
placental structure, sections were stained with haematoxylin and eosin.  Figure 
5-2 illustrates aspects of the placental structure, which consists of chorionic villi 
surrounded by maternal blood in the intervillous space. The villus area consists 
mainly of connective tissue and contains umbilical blood vessels linked to the 
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fetus. The outer lining of the villus is lined with syncytiotrophoblasts, which are 
the interface between the mother and the fetus.   
To test the clone of antibody, placental sections were stained with high 
concentrations of the primary antibody using dilutions of 1:10 and 1:50 (stock 
concentration was 100µg/ml). No brown staining was seen anywhere within the 
placental sections using 1:10 or 1:50 dilutions of either IgG2a antibody or anti-
human D6 antibody (Figure 5-3). This suggested that the conditions used for 
staining the placental sections were not optimal. 
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Figure 5-2. Haematoxylin and eosin staining in human placenta 
Placental sections were processed and sections cut for staining with haematoxylin and 
eosin to identify placental features, such as chorionic villus, intervillous space (IVS) and 
syncytiotrophoblasts (ST) lining the villi. Magnification is 100x.  
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Figure 5-3. Optimisation of D6 antibody on placental sections. 
Placental sections were stained with either anti-human D6 antibody (4a5) or Isotype IgG2a 
using either 1:50 or 1:10 dilutions. Magnification is 100x. 
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There are many factors, which can contribute to staining not occurring in 
immunohistochemistry, and it was decided to try a different antigen retrieval 
step. In the next set of staining, the antigen retrieval step was changed from 
EDTA pH 8 to 1mM citrate buffer pH 6. As a result, brown staining was present in 
the placental section stained with the anti-human D6 antibody (Figure 5-4). This 
was evident in the connective tissue within the villus as well as the 
syncytiotrophoblast layer (Figure 5-4). However, placenta stained with the 
isotype IgG2a antibody, as a negative control, also displayed brown staining 
within the villi as well as within syncytiotrophoblasts, indicating high non-
specific staining (Figure 5-4).  
To reduce background staining, the primary antibody concentration was 
reduced. Using a 1:50 dilution of the anti-human D6 antibody, brown staining 
was present in the connective tissue of the villus as well as in the outer layer of 
the villus (Figure 5-5). However, within the negative control section using an 
isotype antibody, the connective tissue of the villi and the syncytiotrophoblast 
layer also stained brown, illustrating high non-specific binding had occurred 
(Figure 5-5). As a result, a 1:250 dilution of primary antibody was tested and 
resulted in strong specific D6 staining within syncytiotrophoblast cells in the 
placenta, as the isotype stained section contained no brown staining within the 
syncytiotrophoblast layer (Figure 5-5). Since the syncytiotrophoblast layer was 
only brown in sections stained with the anti-human D6 antibody and was not 
seen using the isotype control, this suggested that the anti-human D6 antibody 
(4a5 clone) was working and was specific for D6. This staining confirmed that D6 
is expressed on syncytiotrophoblasts within the placenta.  
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Figure 5-4. Change of antigen retrieval method. 
Placental sections were stained with either anti-human D6 antibody (4a5) or Isotype IgG2a 
using 1:10 dilutions. IVS; intervillous space, ST; syncytiotrophoblasts, Magnification 100x. 
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Figure 5-5. Different concentrations of primary antibody on placental sections. 
Sections were stained with either 1:50 or 1:250 dilution of isotype IgG2a or anti-human D6 
antibody.  IVS; intervillous space, ST; syncytiotrophoblasts. Magnification x100. 
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Since the anti-human D6 antibody was shown to be specific for D6 in the 
placenta, it was decided to stain human skin sections and use placental sections 
as a positive control. First, skin sections were cut then stained with 
haematoxylin and eosin to ensure the skin biopsy was embedded in the correct 
orientation. The structure and features within a control skin sample are 
illustrated in Figure 5-6. Features illustrated within this sample are the multi-
layered epidermis including the outermost layer, known as the stratum corneum. 
Below the epidermis is the dermis, in which blood vessels, hair follicles and 
sebaceous glands can be identified (Figure 5-6).  
It was decided to test the anti-human D6 antibody on skin sections using a 1:250 
dilution. This concentration of antibody resulted in brown staining within the 
epidermis as well as within the connective tissue in the dermis (Figure 5-7). The 
isotype control stained skin section did not display any brown staining, which 
would suggest that the brown staining seen in the anti-human D6 antibody 
stained section is due to primary antibody binding (anti-human D6 antibody). 
However, in the D6 stained section, brown staining covered the whole tissue and 
as a result indicated that the staining was non-specific (Figure 5-7).  
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Figure 5-6. Structure and features of human skin 
A skin biopsy was taken from a control patient, processed and sections were cut and 
stained with haematoxylin and eosin. Annotations illustrate epidermal and dermal 
compartments of skin as well as stratum corneum (SC), blood vessels (BV), hair follicles 
(HF) and sebaceous glands (SG). Magnification 100x. 
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Figure 5-7. D6 staining in skin section 
Control skin sections were stained with either isotype IgG2a or anti-human D6 antibody 
(1:250 dilution).Magnification 100x. 
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To optimise the anti-human D6 antibody for staining in human skin sections, 
decreasing concentrations of anti-human D6 antibody were tested using 1:300, 
1:400 and 1:500 dilutions (Figure 5-8; 1:400 dilution not shown). Using 1:300 
dilution of antibody, D6 was specifically expressed on syncytiotrophoblasts 
within placental sections as no brown staining appeared on syncytiotrophoblasts 
with the negative control, which was stained with isotype IgG2a antibody (Figure 
5-8A). On the other hand, in the skin sections, brown staining was present in the 
epidermis and in hair follicles with no brown staining appearing in dermal 
connective tissues (Figure 5-8A). As no brown staining appeared in the negative 
control skin section, this suggested that the anti-human D6 antibody was working 
but possibly not specific to D6 and potentially cross-reacting to other proteins, 
for example in hair follicles. (Figure 5-8A). The 1:500 dilution of antibody also 
resulted in similar staining to the 1:300 dilution where brown staining occurring 
in the epidermis as well as hair follicles and no brown staining occurred in the 
negative control (Figure 5-8B). In addition, it was noted that in both 1:300 and 
1:500 stained skin sections, the dermal connective tissue did not stain brown in 
comparison to the staining seen previously with a 1:250 dilution of antibody 
(Figure 5-7). This suggested that by increasing the dilution of the antibody, non-
specific binding had been reduced slightly.  
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Figure 5-8. Different concentrations of primary antibody on human placenta and skin 
sections.  
Placental and skin sections were stained with either isotype IgG2a antibody or anti-human 
D6 antibody. (A) Antibodies were used at 1:300 dilution (B) Antibodies were used at 1:500 
dilution. HF indicates hair follicles. Magnification 50x. 
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To determine optimal conditions for D6 staining within skin sections and to 
reduce non-specific binding within the tissue, further dilutions, 1:750 and 1:1000 
were tested. In the 1:750 dilution, D6 was seen to be expressed within the 
placenta indicated by brown staining using the anti-human D6 antibody (Figure 
5-9A). Within the skin, brown staining was present within the epidermis (Figure 
5-9A) however, it was noted that this was less intense than when the 1:500 
dilution was used (Figure 5-8). This indicated that non-specific staining was 
reduced by using a lower concentration of anti-human D6 antibody. In the 1:1000 
antibody dilution, brown staining still occurred in the epidermis and surrounding 
hair follicles in skin sections stained with the anti-human D6 antibody although 
no brown staining was seen in the negative control (Figure 5-9B). However, it 
was noted that several cells within the skin were stained brown and others did 
not (within black circle in Figure 5-9B). On closer examination, it was noted that 
there was non-specific staining in the epidermal tissue (indicated by the red 
arrow in Figure 5-10) yet not all the cells within the epidermis were stained 
brown (example within black circle in Figure 5-10). Within the dermis, there was 
a mixture of cells that had stained brown (examples in red circle in Figure 5-10), 
which could possibly be leukocytes and others cells did not. These data 
indicated that the D6 antibody may be specific for D6 expressing cells but there 
was still some staining within the epidermis, which was likely to be non-specific, 
and indicates cross-reactivity with other proteins within the epidermis.  
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Figure 5-9. Optimisation of primary antibody on human placenta and human skin sections 
using 1:750 and 1:1000 dilutions. 
Human placenta and skin sections were stained with either isotype IgG2a or anti-human D6 
antibody (A) Sections were stained with primary antibody at 1:750 dilution (B) Primary 
antibody was used at 1:1000 dilution. Black circle contains some cells, which have stained 
brown which indicates that these cells express D6. Magnification 100x. 
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Figure 5-10. D6 staining within human skin 
Human skin section was stained with anti-human D6 antibody (1:1000 dilution) and 
examined for positive brown staining. BV indicates a blood vessel. Red arrow denotes 
background staining in the epidermis. Red circles illustrate positive brown stained cells 
indicating D6 protein expression. Black circle highlights that some cells in the epidermis did 
not stain brown (negative for D6).  Magnification x200. 
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In order to reduce non-specific staining within the epidermis, sections were 
tested with the extra steps of blocking endogenous biotin as well as reducing the 
time the tissues were incubated in DAB. There was less epidermal staining in 
both sets of skin sections, indicating that non-specific staining was reduced by 
the amount of time DAB was incubated with the samples and not by the use of 
avidin-biotin block in this case (Figure 5-11). Once again, there are positive 
stained cells within the epidermis and the dermis (Figure 5-11B).However, with 
non-specific staining still present in the epidermis, there is the possibility that 
positive brown stained cells are not D6 expressing cells and the antibody is cross-
reactive with proteins on these cells. If these cells are positive for D6, they 
could be leukocytes as D6 has been reported to be expressed on B cells and 
dendritic cells as well as within atopic dermatitis (McKimmie et al., 2008, 
McKimmie and Graham, 2006). Further staining would be required to confirm the 
cell types. As for cells positively stained within the epidermis, this would suggest 
that D6, or the antibody is cross-reacting with proteins, expressed on 
keratinocytes, melanocytes and merkel cells or possibly by resident immune 
cells within the skin. Blood vessels did not stain positively for D6 and it was 
noted that using his clone of anti-human D6 antibody, positive brown staining 
was not seen on lymphatic vessels within control skin. With non-specific staining 
occurring in the skin, this clone of antibody may not be optimal for 
immunohistochemistry on skin.  
Whilst trying to optimise the anti-human D6 antibody, the next step was to 
obtain, embed and cut psoriasis skin biopsies ready for immunohistochemistry 
staining. There were only five psoriasis patient samples available (lesional and 
non-lesional) however; several attempts to cut sections were unsuccessful. 
While trying to cut sections, the skin would ribbon, tear or the section would 
split down the middle, therefore not giving good sections to stain. To try to 
improve this, a new blade was used, embedded sections were left on ice longer 
but sections were still difficult to cut. Another possibility could be that the 
sections were not in the exact correct orientation during the embedding 
procedure.   
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Figure 5-11. Comparison using avidin/biotin block during D6 staining on human skin. 
Skin sections were stained using 1:1000 dilution of anti-human D6 antibody. (A) Skin 
stained section without or without the use of avidin/biotin block. Magnification 200x (B) Skin 
sections with/without avidin biotin block, showing brown staining on some cells within the 
tissue. Same pictures as in (A) but magnification is 400x. 
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5.5 D6 transcripts in peripheral blood 
As described in section 5.3, D6 transcripts were elevated in psoriatic uninvolved 
skin compared to control skin. Therefore, it was decided to examine D6 
transcript levels within the peripheral blood of psoriasis patients to determine if 
PBMCs had enhanced D6 expression compared to healthy controls. These cells 
may contribute to the enhanced expression of D6 within psoriatic uninvolved skin 
due to increased leukocyte infiltration. It was also decided to extend the 
analysis of D6 transcripts within peripheral blood to other inflammatory 
diseases, such as psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Psoriatic 
arthritis is a chronic inflammatory disease that involves joint inflammation as 
well as the presence of psoriasis. Over time, cartilage within the joints is 
reduced and erosion of the bone occurs resulting in joint deformities leading to a 
reduced function and quality of life (Gladman et al., 2005). Rheumatoid arthritis 
is also chronic inflammatory disease that leads to swelling and destruction 
within the joints. The lining of the synovium becomes inflamed and hyperplastic 
due to infiltration of inflammatory cells (Sweeney and Firestein, 2004). Joint 
destruction occurs through cartilage damage and bone erosion leading to severe 
disability (Goldring, 2003). PsA and RA can be distinguished from each other by 
the psoriatic component and by the joints that are affected.  
A small sample of peripheral blood was collected from control (n=12), psoriatic 
(n=12), psoriatic arthritis (n=15) and RA patients (n=15). Cells from peripheral 
blood were isolated and RNA was extracted from total PBMCs, which includes 
monocytes, T cells, B cells, myeloid dendritic cells and plasmacytoid dendritic 
cells, and analysed for D6 transcripts by QPCR. In the PBMCs from psoriasis 
patients, D6 transcripts were increased 2.3-fold compared to control PBMCs but 
the change was not significant (Figure 5-12). There was no significant difference 
in D6 transcripts in PBMCs within PsA patients compared to controls. However, 
there was a significant 2-fold decrease found in PBMCs from RA patients in 
comparison to controls (Figure 5-12). There was large variation in D6 transcripts 
within psoriasis patients and it is not known whether this variation correlates 
with disease severity at the time (Figure 5-12). In PsA patients, there are two 
distinct populations and it may be possible that these correlate with the 
presence of psoriatic lesions (Figure 5-12).  
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Figure 5-12. Levels of D6 transcripts in peripheral blood from human inflammatory diseases. 
RNA was extracted from peripheral blood cells of control, psoriatic, psoriatic arthritis (PsA) 
or rheumatoid arthritis (RA) patients and examined for D6 transcripts. Levels were 
normalised using GAPDH as a housekeeping gene. D6 transcripts levels are expressed as 
fold change in comparison to controls. Control n=12, psoriasis n=12, psoriatic arthritis 
(PsA) n=15 and rheumatoid arthritis (RA) n=15. 
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5.6 D6 surface expression on peripheral blood cells 
D6 transcript levels were found to be lower in peripheral blood of RA patients 
than in healthy controls. As a result, it was decided to examine PBMCs in more 
detail to determine which cell types were responsible for lower D6 expression in 
RA patients. 
PBMCs were extracted from control or RA patient blood and examined for D6 
expression on the cell surface by flow cytometry using an anti-human D6 
antibody (McKimmie et al., 2008). To identify cell types, antibodies against 
lineage specific markers were used. CD3 was used to identify T cells, CD20 was 
used to identify B cells and monocytes were identified by CD14. Myeloid DCs 
were identified by CD1c expression and plasmacytoid DCs were identified by 
CD304 (BDCA4) expression. 
PBMCs were profiled using forward and side scatter and the main population of 
cells were gated as show in Figure 5-13.  
 
 
Figure 5-13. Profile of peripheral blood mononuclear cells from a healthy control patient. 
Peripheral blood mononuclear cells were profiled by flow cytometry using forward and side 
scatter. The main population of cells were gated for further analysis. 
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Control PBMCs were stained with viaprobe to detect and exclude dead cells. Live 
cells do not stain positive for viaprobe. Live T lymphocytes were gated (R2) by 
selecting cells which were negative for viaprobe and stained positive for CD3 
using an anti-human CD3 antibody, as shown in Figure 5-14A. The plots shown in 
Figure 5-14 are from one representative sample. A profile of CD3 positive T cells 
stained with isotype antibody or anti-human D6 antibody is shown in Figure 5-
14B. T cells stained with isotype antibody had a mean fluorescent intensity (MFI) 
of 1.79 whereas D6 expressing CD3 positive cells had an MFI of 3.36. The 
corresponding histogram plot shows that T cells from a control patient weakly 
express D6 on their surface (Figure 5-14B). Live B cells were gated on CD20 
positive cells (R2; Figure 5-14C) and were then analysed using either isotype 
antibody staining or anti-human D6 antibody. Isotype stained B cells had an MFI 
of 1.74 whereas B cells express different levels of surface D6 (fluorescent 
intensity spread is 3-3865) with an MFI of 49.76 (Figure 5-14D). Control B cells 
express surface D6 at various levels with some B cells expressing D6 at high 
levels.  
Monocytes from controls were gated (R2) using an anti-human CD14 antibody 
(Figure 5-15A). Cells positively expressing CD14 were gated and analysed for 
expression of D6 (Figure 5-15A). In a representative sample, isotype stained 
monocytes had an MFI of 5.09 whereas D6 positive cells had an MFI of 53.83 
(Figure 5-15B). It can be concluded that monocytes express surface D6 (Figure 5-
11B).  
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Figure 5-14. Analysis of D6 expression on control human T and B cells. 
(A) Live positive CD3 T cells were gated using R2. (B) T cells gated through R2 were 
analysed using isotype or anti-human D6 antibody. A representative histogram showing T 
cells intensity for isotype (purple) and D6 (green). (C) Live B cells were gated using an anti-
human CD20 antibody. (D) A representative plot of cells positive for CD20 and stained with 
either isotype control or anti-human D6 antibody. A representative overlay is shown plotting 
B cell fluorescent intensity for isotype (purple) and D6 (green). 
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Figure 5-15. Analysis of D6 expression on control monocytes. 
(A) Monocytes were gated using an anti-human CD14 antibody (R2) (B) Cells were gated 
through R2 and analysed for isotype and D6 expression. A representative histogram shows 
fluorescent intensity for isotype (purple) and D6 (green) positive monocytes. 
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There are two subtypes of dendritic cells in human PBMCs, myeloid and 
plasmacytoid dendritic cells, which are characterised by distinct lineage markers 
(Shortman and Liu, 2002). For mDCs, an antibody against CD1c was used and for 
pDCs, an antibody against CD304 (BDCA-4) was used. However, monocytes and B 
cells can also express these surface molecules and therefore identification of 
monocytes and B cells was required in order to exclude them from further 
analysis of dendritic cells. Cells were stained with a cocktail of antibodies in 
order to identify dendritic cells. Cells negative for CD14 and CD20 were gated 
through R2, therefore excluding monocytes and B cells respectively (Figure 5-
16A). Cells gated in R2, which were positive for CD1c, were classed as mDCs (R3; 
Figure 5-16B). In a representative sample, mDCs, which stained positive for 
isotype control had an MFI of 3.32 whereas D6 positive cells gave an MFI of 44.21 
(Figure 5-16B). Myeloid DCs express a range of D6 on their surface with some 
expressing very little D6 and some with high expression of D6, the fluorescent 
intensity ranged from 3 to 5474 (Figure 5-16B). Plasmacytoid DCs were also 
gated through R2, to exclude monocytes and B cells. Positively stained BDCA-4 
(CD304) cells indicated that these cells were pDCs and were gated (R3) for 
further analysis (Figure 5-16C). Plasmacytoid DCs, in a representative sample, 
express very high levels of D6 (MFI is between 5 and 2916 with a mean of 268.3) 
as shown in Figure 5-16D. 
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Figure 5-16. Analysis of D6 expression on control myeloid and plasmacytoid dendritic cells. 
(A) Live cells were gated (R2) to exclude monocytes and B cells using anti-human CD14 and 
anti-human CD20 antibody and positive CD1c cells were gated (R3) as myeloid DCs. (B) 
Cells were gated through R3 and analysed for isotype and D6 expression. A representative 
histogram plot shows fluorescent intensity for isotype stained mDCs (purple) and D6 
positive mDCs (green). (C) Live pDCs were gated to exclude monocytes and B cells (R2) and 
were gated using an anti-human BDCA-4 antibody (R3). (D) Representative plots of cells 
positive for CD20 and stained with either isotype control or anti-human D6 antibody. A 
representative histogram plot shows fluorescent intensity for isotype stained pDCs (purple) 
and D6 positive pDCs (green). 
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Peripheral blood was taken from RA patients and PBMCs were isolated. PBMCs 
were stained with antibodies specific for lineage markers to identify monocytes, 
T and B lymphocytes, myeloid and plasmacytoid dendritic cells as well as 
staining for surface D6 expression. PBMCs from RA patients were all gated using 
the same antibodies and parameters as the control peripheral mononuclear 
cells. A profile of PBMCs from one RA patient is shown in Figure 5-17, which is 
similar to control PBMCs although the profile will vary slightly from patient to 
patient.  
 
 
 
 
Figure 5-17. Cell profile of peripheral blood mononuclear cells from a rheumatoid arthritis 
patient using flow cytometry. 
Peripheral blood mononuclear cells were profiled by flow cytometry using forward and side 
scatter. The main population of cells were gated for further analysis. 
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Live T cells were identified using the anti-human CD3 antibody and were gated 
as shown in Figure 5-18A.  T cells from one RA patient expressed low levels of 
D6, as the MFI was 3.65 and only shifted to 7.32 for D6 positive T cells (Figure 5-
18B). B cells were gated using CD20 and an MFI of 3.52 was obtained with cells 
stained with isotype antibody whereas cells stained with anti-human D6 antibody 
resulted in an MFI of 190.16 with a spread of 12 to 1322. High levels of D6 was 
expressed on B cells from RA patients shown by a 2 log fold shift in the MFI of D6 
positive cells compared to isotype stained cells (Figure 5-18D). 
Monocytes from RA patient peripheral blood were gated using an anti-human 
CD14 antibody (Figure 5-19A). In a representative sample, isotype stained 
monocytes had an MFI of 8.55 and moved to 100.67 on D6 stained monocytes. 
The corresponding histogram shows that monocytes expressing D6 resulted in a 
log fold shift of the MFI compared to the isotype control. Therefore, D6 is 
expressed on monocytes within the peripheral blood of RA patients (Figure 5-
19B).  
Live mDCs from a RA patient were gated (Figure 5-20A) and isotype stained 
mDCs had an MFI of 5.22 whereas mDCs positively bound to D6 antibody yielded 
an MFI of 44.56 with a spread of 53-1241, resulting in a log-fold shift (Figure 5-
20B). Although there were low numbers of mDCs, they express moderate levels 
of D6. Low numbers of pDCs were also seen yet pDCs express a broad and high 
range of D6 expression levels. In a representative sample, the MFI was 4.09 for 
isotype stained pDCs and positively D6 stained pDCs varied from 5-4598 with a 
mean of 359.34 resulting in a 2-log fold shift compared to the isotype control 
(Figure 5-20D). 
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Figure 5-18.  Analysis of D6 expression on T and B cells from a RA patient. 
(A) Positive CD3 cells were gated and selected as T cells. (B) Cells were gated through R2 
and analysed for isotype or D6 expression. A representative histogram plotting T cells 
intensity for isotype (purple) and D6 (green). (D) Live B cells were gated using an anti-
human CD20 antibody. (E) Representative plots of cells positive for CD20 and stained with 
either isotype control or anti-human D6 antibody with a histogram plot showing T cell 
intensity for isotype (purple) and D6 (green). 
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Figure 5-19. Analysis of D6 expression on monocytes from a RA patient. 
Cells were gated through R1 and live cells were detected using viaprobe. (A) Monocytes 
were selected using an anti-human CD14 antibody and gated (R2) (B) Cells were gated 
through R2 and analysed for isotype control or D6 expression. A representative histogram 
shows fluorescent intensity for isotype (purple) and D6 (green) positive monocytes. 
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Figure 5-20. Analysis of D6 expression on myeloid and plasmacytoid dendritic cells from a 
RA patient. 
Cells were gated through R1 and live cells were detected using viaprobe. (A) Live cells were 
gated using R2 to exclude monocytes and B cells and positive CD1c cells were gated and 
selected as myeloid DCs (R3). (B) Cells were gated through R3 and analysed for isotype and 
D6 expression. A representative overlay plotting fluorescent intensity for isotype positive 
(purple) and D6 positive (green) monocytes. (C) Live pDCs were gated to exclude 
monocytes and B cells (R2) and was gated using an anti-human BDCA-4 antibody (R3). (D) 
A representative overlay plot of cells positive for CD20 and stained with either isotype 
control or anti-human D6 antibody. 
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To compare D6 expression levels between healthy samples and RA patients, the 
corrected mean fluorescent intensity was calculated, by subtracting the MFI 
from the isotype control from MFI of D6, for each cell type. Overall, in control 
peripheral blood, pDCs and B cells expressed the highest levels of D6 on their 
surface, followed by mDCs and monocytes whereas T cells expressed very weak 
levels of D6 (Figure 5-21). This trend in levels of expression was similar to D6 
expression  found on leukocytes (McKimmie et al., 2008, McKimmie and Graham, 
2006). In peripheral blood from RA patients, the trend of D6 expression on the 
same cell types was similar, in that B cells and pDCs expressed highest levels of 
surface D6 followed by mDCs and monocytes then T cells (Figure 5-21). However, 
D6 expression on B cells and mDCs was found to be significantly higher in RA 
patients than in healthy control patients (Figure 5-21). In addition, D6 expression 
was increased on T cells, monocytes and pDCs from RA patients compared to 
healthy control but were not significant (Figure 5-21). As a result, these data 
contradicted the D6 transcript levels data obtained earlier (Figure 5-12), where 
in peripheral blood, D6 transcript levels were lower in RA patients than in 
healthy controls. 
 
Figure 5-21. Analysis of D6 expression on peripheral blood cells in control and RA patients. 
Peripheral blood cells were isolated from control (white) and RA patients (black) stained for 
specific lineage markers to identify T cells, B cells, monocytes, myeloid DCs and 
plasmacytoid DCs. D6 surface expression on these cells was detected by an anti-human D6 
antibody and expression levels are represented as mean fluorescent intensity (MFI). Control 
n=6, RA n=9, column is mean ± SEM. 
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Due to the apparent contradiction in these data, it was decided to reanalyse the 
QPCR data to try to find a possible explanation. Upon doing so, it was seen that 
the housekeeping gene, GAPDH, was significantly higher in peripheral blood of 
RA patients compared to healthy controls (Figure 5-22). Housekeeping genes are 
used to normalise sample cDNA levels to allow comparison of gene levels 
between samples. Having significantly higher levels of housekeeping gene within 
a sample group would skew the data because this would result in the transcript 
levels of D6 in the RA samples to be calculated lower than they actually are. 
This suggests that GAPDH is not the most suitable housekeeping gene to use in 
order to normalise the data, as an ideal housekeeping gene should be expressed 
at a constant level between control and test sample. There is evidence that 
GAPDH transcript levels can vary in nucleated blood cells between individuals 
(Bustin et al., 1999) as well as in whole blood from healthy and in pulmonary 
tuberculosis samples (Dheda et al., 2004). To correct for this, it would be more 
suitable to use a housekeeping gene that does not significantly change between 
peripheral blood of RA patients and control samples. 
 
 
Figure 5-22 Copy numbers of GAPDH in control, psoriatic arthritis (PsA), rheumatoid 
arthritis (RA) and psoriasis patients. 
RNA was extracted from peripheral blood cells converted to cDNA and diluted with nuclease 
free water. Levels of GAPDH transcripts were assessed by QPCR using SYBR Green. 
Control n=12, Psoriatic arthritis n=15, RA n=15 and psoriasis n=12. Columns are mean ± 
SEM, 
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5.7 Summary of Chapter 5 
In a cutaneous model of inflammation, absence of D6 results an exaggerated 
inflammatory response resulting in pathology similar to human psoriasis 
(Jamieson et al., 2005). This led to the hypothesis that D6 dysfunction may play 
a role in the pathogenesis of human psoriasis. To examine this possibility, the 
aim of the work within this chapter was to examine the expression of D6 within 
human psoriasis and other inflammatory diseases. 
Analysis of skin biopsies from psoriatic (uninvolved and lesional samples) as well 
as control and atopic dermatitis samples revealed that D6 transcript expression 
was increased in psoriatic uninvolved skin. This suggests that D6 is dysfunctional 
within psoriatic patients in that D6 expression may be upregulated in uninvolved 
skin to limit skin inflammation. Anti-human D6 antibody was tested for use with 
psoriatic skin however obtaining good skin sections from these biopsies was 
difficult and results suggest that the antibody may not be ideal to use on skin by 
immunohistochemistry. Examination of D6 transcripts within peripheral blood 
revealed a non-significant 2.3 fold increase in D6 transcripts within psoriatic 
blood, no change in psoriatic arthritis blood and a 2 fold decrease in RA blood 
compared to control. However, it was discovered that GAPDH may not be a 
suitable housekeeping gene for peripheral blood from RA patients and that the 
2-fold decrease in transcript levels was a false result. This was confirmed by the 
analysis of D6 expression on isolated cells from RA blood indicating that in fact B 
cells and mDCs expressed significantly higher levels of surface D6 in comparison 
to healthy control.  
To conclude, the work within this chapter suggests that more studies are 
required to determine the correlation between D6 and inflammatory diseases 
especially regarding the mechanisms underlying the dysregulation of D6 in 
uninvolved skin of psoriasis patients. 
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6 General Discussion 
Inflammation is the body’s response to internal or external insults such as tissue 
injury or infection (Medzhitov, 2008). Chemokines are key players in the 
inflammatory process by controlling the migration of leukocytes into tissues 
(Charo and Ransohoff, 2006). In particular, pro-inflammatory CC chemokines are 
involved, which signal through chemokine receptors present on various 
leukocytes (Murphy et al., 2000). A controlled inflammatory response results in 
the tissue returning to its normal physiological state and is beneficial to the 
body (Serhan et al., 2007). When inflammation becomes dysregulated, this can 
be detrimental as demonstrated by chronic inflammatory diseases. Although the 
initiation and maintenance of inflammatory processes is well understood, the 
mechanisms responsible for the resolution of inflammation are only just 
beginning to emerge.  
D6 is an atypical chemokine receptor, which has the ability to bind inflammatory 
CC chemokines (Graham, 2009). D6 does not seem to signal (Graham, 2009) but 
studies suggest that D6 sequesters CC chemokines by constitutively moving to 
and from the cell surface in a ligand independent manner (Weber et al., 2004). 
Evidence has shown that D6 is a key mediator in the resolution of inflammation. 
D6 null mice display enhanced skin inflammation in response to TPA and 
complete Freund’s adjuvant  (Martinez de la Torre et al., 2005, Jamieson et al., 
2005). Additionally, D6 null mice are susceptible to inflammation dependent 
tumour development (Nibbs et al., 2007). During skin inflammation, D6 has been 
shown to be involved in the clearance of CC chemokines at the site of 
inflammation (Jamieson et al., 2005). D6 null mice displayed enhanced 
recruitment of leukocytes to the lung after allergen exposure (Whitehead et al., 
2007) and infection with Mycobacterium tuberculosis leads to enhanced local 
and systemic inflammation with increased CC chemokines and leukocyte 
infiltration (Di Liberto et al., 2008). In inflammation induced miscarriage models 
using LPS or anti-phospholipid antibodies, enhanced susceptibility to miscarriage 
occurs in D6 null mice and is associated with enhanced chemokines and 
leukocyte infiltration in the placenta (Martinez de la Torre et al., 2007). D6 has 
been implicated in the development of experimental colitis and is thought to 
regulate the production of IL-17A by γδ T cells in the later stages of the disease 
(Bordon et al., 2009). 
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Evidence indicated that D6 was involved in controlling cutaneous inflammation 
therefore, we hypothesised that increased expression of D6, using a transgenic 
approach, should be able to suppress cutaneous inflammation in vivo. To test 
this, transgenic mice were generated, in which the expression of D6 was 
targeted to epidermal keratinocytes. Validation studies confirmed ectopic 
expression of D6 in the epidermis and in keratinocytes from K14D6 mice, whilst 
D6 transcripts were absent from wild-type epidermis. In addition, D6 expressed 
from the transgene in K14D6 keratinocytes was functional, as demonstrated by 
the ability of K14D6 keratinocytes to bind CCL2 and progressively remove 
extracellular CCL3, both D6 ligands, in a D6 dependent manner. It is of note that 
only 45% of K14D6 keratinocytes were able to bind CCL2. These primary 
keratinocytes were isolated and cultured in keratinocytes growth media 
containing low concentrations of calcium and no fetal calf serum. As a result, 
culture of these keratinocytes should generate a homogenous population, which 
would proliferate but not differentiate due to the low concentration of calcium 
(Hennings et al., 1980). An explanation as to why only 45% keratinocytes were 
able to bind CCL2 is that the majority of D6 expression is inside the cell 
(Blackburn et al., 2004) and keratinocytes expressing low levels of surface D6 
were not identified i.e. these cells were not able to bind high levels of CCL2. 
Retrospectively, it may have been of interest to confirm that D6 positive 
keratinocytes were keratin 14 expressing cells. 
Having characterised the K14D6 transgenic mice, we examined whether ectopic 
expression of D6 within the skin was able to dampen down inflammation. We 
used a well-characterised model of skin inflammation previously used by 
colleagues, which involved application of TPA to murine dorsal skin once a day 
for three consecutive days (Jamieson et al., 2005). Work presented here shows 
that D6 null mice demonstrated an exaggerated cutaneous inflammatory 
response and wild-type mice had increased skin thickness four days after the last 
application of TPA compared to resting thickness. This was consistent with 
previous findings in a different strain of mice (Jamieson et al., 2005). K14D6 
mice displayed no significant difference in skin thickness four days after the 
final application of TPA compared to resting skin thickness. In addition, the 
numbers of mast cells and epidermal T cells were reduced in inflamed K14D6 
skin compared to inflamed wild-type skin. Within the skin, D6 is involved in 
regulating the levels of CC chemokines (Jamieson et al., 2005) and therefore the 
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most likely explanation is that by increasing D6 levels in K14D6 mice, lower 
levels of CC chemokines were present than in wild-type skin. As a result, this 
directly affected the recruitment of mast cells and T cells into the skin and 
subsequent inflammation. 
In the epidermis, keratinocytes and Langerhans cells are rich sources of various 
chemokines, which can drain into the dermis. Following TPA stimulation, 
keratinocytes produce CCL3 and CCL5 (personal communication, Prof. 
G.Graham). Murine mast cells express CCR1, CCR2, CCR3 and CCR5 (Ma et al., 
2002, Oliveira and Lukacs, 2001), which are all capable of supporting migration 
towards ligands which also bind to D6. Human mast cells also express a range of 
chemokine receptors. One of these is CCR3 (de Paulis et al., 2001) which is able 
to support migration towards CCL11 and CCL5 in the skin (Romagnani et al., 
1999), both of which are D6 ligands. Activated T cells express various chemokine 
receptors (Bonecchi et al., 1998) including CCR4, which is implicated in the 
homing of T cells into inflamed skin (Reiss et al., 2001). In addition, activated T 
cells recruited into the skin during inflammation may release CXCL12 which 
influences the migration of mast cells (Brill et al., 2004), through the presence 
of CXCR4 on mast cells (Oliveira and Lukacs, 2001). Therefore, it is feasible that 
a reduction in mast cells and T cells recruited into the skin was due to a lower 
abundance of CC chemokines. 
D6 may not just have an impact on the level of chemokines but also indirectly 
affect nearby leukocytes. In turn, this may affect the function and recruitment 
of leukocytes into the skin. Degranulation of mast cells can be mediated by 
chemokines, such as CCL3 binding to CCR1 (Miyazaki et al., 2005). One 
possibility is that D6 may affect degranulation of mast cells by scavenging CCL3 
resulting in a reduction of the levels of histamine secreted from mast cells. 
Histamine mediates vasodilatation and is required for leukocyte infiltration into 
tissues.  
The ability of K14D6 mice to dampen down cutaneous inflammation suggests 
that D6 has the potential to be therapeutic. By generating K14D6 transgenic 
mice, we have used a prophylactic approach. Therefore, the therapeutic ability 
of D6 remains to be examined. To assess this, one approach would be to induce 
and establish skin inflammation in the D6 null mice and assess whether D6 can 
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rescue the phenotype of the D6 null mice, i.e. dampen down the exaggerated 
skin inflammation. This could be tested using a ‘gene gun’, also known as 
particle mediated gene delivery (Yang et al., 2001). This method involves gold 
particles coated with plasmid DNA and directly delivered at high speed into the 
target tissue. In D6 null mice, skin inflammation would be initiated using the TPA 
induced inflammation model and then D6 would be expressed in the skin of the 
D6 null mice using the gene gun. The type of promoter used within the plasmid 
would determine the location of transgene expression. For example, using a CMV 
promoter, genes are expressed in the epidermis and dermis of the skin whereas 
when using a K14 promoter, genes are only expressed in the epidermis (Lin et 
al., 2001a). The gene gun technology has been used to deliver cytokines in vivo 
(Sun et al., 1995) and studies using IL-23 and IL-18 cDNA delivered by the gene 
gun have been shown to have anti-tumour effects in the skin (Wang et al., 
2004b). 
If D6 was indeed therapeutic, it may be useful in a variety of inflammatory 
diseases. In particular, pathologies involving CC chemokines could be targeted 
with D6. These include psoriasis, atopic dermatitis, rheumatoid arthritis, 
asthma, inflammatory bowel disease (as reviewed by D'Ambrosio et al., 2003). 
CC chemokines have also been implicated in atherosclerosis (Sheikine and 
Hansson, 2004) and transplantation (Colvin and Thomson, 2002) 
In order to use D6 as a therapeutic agent against these diseases, development of 
additional methods to deliver D6 would be required. This could involve the use 
of viral delivery systems. Viral vectors are modified where their own viral genes 
are replaced with a gene of choice. The most common types of viruses used as 
vectors for gene therapy are retroviruses, adenoviruses and adeno-associated 
viruses, all with different properties and length of time in which the transgene is 
expressed. There is evidence that CC chemokines can be targeted using viral 
based gene therapy in a murine model of atherosclerosis. A chemokine binding 
protein derived from Vaccinia virus can block chemokine activity (Alcami et al., 
1998) and gene therapy using an adenoviral mediated delivery system blocked 
CC chemokines (Bursill et al., 2006), inhibited recruitment of macrophages and 
reduced atherosclerotic plaque formation in vivo (Bursill et al., 2004). As 
adenoviral gene therapy results in short-term transgene expression, the viral 
chemokine binding protein has also been transferred using lentivirus 
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demonstrating that long-term inhibition of CC chemokines resulted in reduction 
of atherosclerotic plaques (Bursill et al., 2009). Alternative methods of gene 
delivery, which are non-viral, have also been developed. Non-viral methods 
include the use of naked plasmid DNA and synthetic vectors (Li and Huang, 
2000). So far, although these non-viral methods are thought to be safer, the 
transfection efficiency of non-viral therapy is lower than viral delivery methods. 
Another approach altogether would be to use peptides, based on a short linear 
sequence from D6. Peptides have been derived based on the sequences of 
chemokine receptors. One example is  the synthesis of a peptide using a short N-
terminal fragment of CCR5 sequence (Chain et al., 2008). The peptide was used 
to generate antibodies which would be specific for CCR5 to reduce HIV 
infectivity (Chain et al., 2008). CCR3 is another receptor where peptides were 
synthesised based on the N-terminus of the receptor to characterise the binding 
properties between CCR3 and CCL11 (Ye et al., 2000). The development of the 
best delivery method for D6 may depend on the type of disease, where D6 is to 
be targeted and whether expression of the transgene is only required for short-
term or longer. 
In vitro studies suggest that D6 does not seem to have the ability to signal (Fra 
et al., 2003) however, D6 may signal via other mechanisms that do not elicit a 
calcium flux response. We have begun to examine this by isolating murine 
keratinocytes that express D6 ectopically at high levels and to determine the 
transcriptional consequences of ligand binding using microarray technology. 
Keratinocytes are capable of producing chemokines such as CCL5 and CCL2 upon 
stimulation with IFN-γ or TNF-α (Li et al., 1996), which contribute to recruiting 
leukocytes into the skin during inflammation. Therefore, D6 may have had an 
impact on cellular transcription within these cells or scavenged the chemokines 
produced from it. 
By analysing individual differential gene expression using rank products (Breitling 
et al., 2004b), one conclusion can be made from our microarray experiment. D6 
was expressed at higher levels in K14D6 keratinocytes compared to wild-type. 
This was an expected result. By analysing groups of functional gene classes, our 
results from the microarray suggests that non-ligated D6 may have an impact on 
the transcription of some genes, in particular, chemokines. Although we do not 
provide firm evidence of this, it would be intriguing to examine whether D6’s 
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ability to reduce the levels of CC chemokines, also regulates the transcription of 
these genes. It is of note that as a functional gene class, chemokines were 
downregulated in keratinocytes in the presence of non-ligated D6 (using iGA 
analysis) particularly CXCL4, CCL6 and CCL9. CXCL4 is involved in the migration 
of T lymphocytes mediated by CXCR3B, a splice variant of CXCR3 (Lasagni et al., 
2003, Mueller et al., 2008). CCL6 and CCL9 are chemokines which to date have 
only been found in rodents, both which are able to bind to CCR1 (Lean et al., 
2002, Ma et al., 2004). It is interesting to note that CCL6 and CCL9 both contain 
an extended N-terminal domain. Whilst there are no direct human homologues 
of CCL6 and CCL9, two chemokines CCL15 and CCL23 also contain extended N-
termini and have only been found in humans (Berger et al., 1993, Youn et al., 
1998). Studies have shown that all four can be truncated by proteases at their N-
termini, which increases their signalling and chemotaxis ability through CCR1 
(Berahovich et al., 2005). In addition, N-terminal truncated CCL15 and CCL23 
are detected at high levels in synovial fluid from rheumatoid arthritis patients 
(Berahovich et al., 2005). One possibility may be that D6 inhibits the 
transcription of these genes, although the mechanisms are unclear, to prevent 
their release and limit the levels of potential potent chemoattractants during 
the inflammatory response. It may be that D6 it is unable to scavenge these 
chemokines once they are cleaved by proteases during inflammation. Evidence 
has shown that D6 is not able to scavenge a truncated form of CCL22 (Bonecchi 
et al., 2004) although it is of note that neither human nor murine D6 has been 
shown to bind CCL6, CCL9, CCL15 or CCL23. However, by inhibiting the 
transcription of genes for CCL6, CCL9 and CXCL4, D6 may indirectly affect the 
recruitment of cells into the tissue.  
Other studies have examined the downstream consequences induced by CCL5 in 
human monocytes (Locati et al., 2002). CCL5 induced the upregulation of genes 
but did not suppress the transcription of any genes. CCL5 induced gene 
expression of several chemokines including CCL2, CCL3, CCL4 and CXCL8 as well 
as CCR1 and induced expression of molecules involved in matrix degradation, 
potentially amplifying leukocyte recruitment (Locati et al., 2002). Additionally, 
gene transcripts induced by CCL5 binding to CCR5 in human neuronal cells has 
also been examined. Upregulated genes induced by CCL5 included those involved 
in cell signalling and CCL5 in this context induced the downregulation of several 
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genes (Valerio et al., 2004). Therefore, depending on the cell type and the 
environment, chemokines can induce different transcriptional responses.  
The microarray data generated in this study used primary cells that did not 
normally express D6. Human lymphatic endothelial cells express D6 (Nibbs et al., 
2001, Vetrano et al., 2009) however D6 expression is lost when lymphatic 
endothelial cells have been cultured (Amatschek et al., 2007). It would be more 
suitable to use primary cells that express D6.  In keeping with this consideration, 
leukocytes and murine B cells derived from the spleen have been found to 
express D6 (McKimmie et al., 2008) and in a separate study, expression of D6 on 
splenic B cells was located in marginal zone B cells (Kin et al., 2008). Although 
what role D6 has on B cells remains to be determined. 
Studies performed in our lab illustrated that D6 was important in regulating the 
resolution of inflammation (Jamieson et al., 2005). Jamieson et al., 
demonstrated that D6 null mice had enhanced levels of CC chemokines within 
the skin, which resulted in a psoriasis-like pathology. We decided to determine 
whether there was any association between D6 levels and human psoriasis. We 
obtained skin biopsies from control, psoriatic and atopic dermatitis patients. In 
some psoriatic patients, we obtained lesional and uninvolved skin from the same 
patient. Within this study, examination of D6 transcript levels revealed that 
there was no significant difference in D6 transcripts between atopic dermatitis, 
lesional psoriatic skin and control skin. Interestingly, D6 expression in psoriatic 
uninvolved skin was 8-fold higher than control and psoriatic lesional skin. 
Analysis of individual psoriatic patients, where we had matching uninvolved and 
lesional skin, revealed that 9 out of the 10 patients had increased expression of 
D6 mRNA in their uninvolved skin compared to their lesional skin. These data 
suggest that D6 expression is dysregulated in psoriatic uninvolved skin. These 
data were obtained from matched samples in psoriatic patients and therefore 
are internally controlled, further strengthening the evidence of the 
dysregulation of D6 expression in psoriatic uninvolved skin. 
This led us to hypothesise that D6 is upregulated in uninvolved skin of psoriatic 
patients in order to suppress ongoing inflammation in the area. Gene expression 
profiles have revealed that there are differences between psoriatic lesional and 
uninvolved skin as well as psoriatic uninvolved and healthy skin (Itoh et al., 
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2005, Zhou et al., 2003). Differences have also been shown in cytokines levels 
such as TNF-α and IL-1β (Uyemura et al., 1993) and expression levels of CXCL8 
and CCL5 higher in uninvolved skin than normal skin have been shown as well as 
increased mRNA expression of IL-17 and IFN-γ (Lowes et al., 2008). In addition, 
psoriatic lesional skin has increased transcript levels of IL-17A, IL-17F, IL-22 and 
IL-26, all Th17 derived cytokines, compared to normal skin (Wilson et al., 2007). 
Keratinocyte treatment with IL-22 and IL-17 resulted in upregulation of 
antimicrobial peptides such as β-defensins (Liang et al., 2006) suggesting a 
protective role for these cytokines in the skin. Indeed psoriatic lesions contain 
higher levels of antimicrobial peptides than normal skin (Harder and Schroder, 
2005). However, in addition to anti-microbial properties, β-defensins can also 
bind CCR6 (Yang et al., 1999) and attract CCR6+ T cells, such as Th17 cells into 
the skin. Additionally, Th17 cytokines can also stimulate CCL20 from 
keratinocytes (Harper et al., 2009) which can also bind CCR6, in turn this 
recruits more CCR6+ Th17 cells into the skin and contributes to skin pathology. 
Subcutaneous injection of IL-23, a cytokine which enhances the proliferation of 
Th17 cells (Aggarwal et al., 2003), induced a psoriasis-like pathology in vivo 
(Chan et al., 2006) and IL-22 is a downstream mediator in this process (Zheng et 
al., 2007). IL-15 secretion can induce IL-17 (McInnes and Gracie, 2004) and has 
been implicated in psoriasis. Indeed, the use of anti-IL-15 antibodies in vivo 
resulted in resolution of psoriatic lesions (Villadsen et al., 2003). It is of note 
that the pathology displayed in D6 null mice after induction of inflammation by a 
chemical stimulant was dependent on IL-15 and IL-17 (personal communication 
Prof. G. Graham) therefore further confirming its similarity to human psoriasis. 
The presence of inflammatory cytokines and chemokines present within the 
uninvolved skin of psoriatic patients suggests the presence of ongoing low-level 
inflammation. As a result, D6 may be enhanced in uninvolved psoriatic skin to 
prevent a psoriatic lesion occurring. This then raises the question of how 
psoriatic lesions occur in these individuals, i.e. if D6 prevents psoriatic lesions in 
some areas, why does D6 not work in all areas. One possibility is that there is 
low-level ongoing inflammation in the psoriatic skin and lesions form when a 
reduction in the expression level of D6 occurs. D6 can be dynamically regulated, 
McKimmie et al., have shown that LPS can downregulate D6 expression 
(McKimmie et al., 2008). Others have also shown that inflammatory mediators 
can upregulate D6 in a breast cancer cell line (Wu et al., 2008). This suggests 
the possibility that in the skin of psoriatic patients, an infection or trauma may 
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result in the downregulation of D6 levels and, in turn, a psoriatic lesion may 
erupt. A recent study revealed that D6 regulates the levels of IL-17 production 
by γδ T cells in the later stages of colitis (Bordon et al., 2009) therefore it may 
be possible that the lack of D6 in the skin may lead to the dysregulation of the 
IL-17 levels in the skin and contribute to the pathology of psoriasis. 
Having examined the mRNA expression of D6 within psoriatic skin, we went on to 
examine the expression of the D6 protein within the skin. Previous studies 
revealed D6 protein to be expressed on lymphatic endothelial cells within the 
skin (Nibbs et al., 2001) and others have shown D6 expression on leukocytes 
within atopic dermatitis skin (McKimmie et al., 2008). In this study, the clone of 
antibody used is an alternative clone to that used previously to reveal D6 
staining on lymphatic endothelial cells (Nibbs et al., 2001). The clone used in 
this study has been validated using HEK293 cells stably transfected with human 
D6 and detected by western blotting and flow cytometry (McCulloch et al., 
2008). For use in immunohistochemistry, anti-human D6 staining was optimised 
using placental sections as a positive control and on control skin sections. 
Staining of control skin sections revealed positive D6 staining on leukocytes 
however, lymphatic endothelial vessels did not stain positive for D6. An 
explanation for this may be the use of different clones of antibody. One clone of 
antibody was specific for D6 expressed on lymphatic endothelial cells (Nibbs et 
al., 2001) whilst the other seems to be specific for D6 on leukocytes (McKimmie 
et al., 2008). This suggests that the different clones of the anti-human D6 
antibodies have slightly altered specificities and bind different D6 epitopes on 
lymphatic endothelial cells and leukocytes. Different epitopes of D6 may occur 
because the N-terminus of D6 is glycosylated and also contains tyrosine residues 
which are sulphated (Blackburn et al., 2004). Therefore, the antibody used in 
this study may be specific for one epitope revealed on leukocytes for which the 
other antibody has lower affinity. Different antibody specificities using different 
clones of antibodies have also been demonstrated for another atypical 
chemokine receptor, DARC (Chaudhuri et al., 1997, Nielsen et al., 1997). It 
would be interesting to determine the location and number of leukocytes 
expressing D6 in psoriatic skin, including uninvolved and lesional skin biopsies, 
compared to control skin. To determine the specific leukocyte subset expressing 
D6, sections could be co-stained using antibodies specific for each subset of 
leukocytes. This would identify the leukocytes involved in the enhanced D6 
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expression in uninvolved psoriatic skin. The level of D6 protein expression by 
individual subsets of leukocytes could be determined by flow cytometry. 
With enhanced D6 expression in uninvolved skin of psoriatic patients compared 
to controls, we decided to examine peripheral blood to determine if enhanced 
expression within the skin was a general phenomenon or only located within the 
skin in psoriatic patients. We also extended the study into other inflammatory 
diseases such as PsA and RA and examined D6 expression within these diseases. 
Peripheral blood mononuclear cells (PBMCs) from psoriasis patients displayed a 
non-significant 2.3-fold increase in D6 mRNA expression over normal PBMCs 
whereas PsA PBMCs showed no significant change in mRNA expression and RA 
PBMCs showed a significant 2-fold decrease. However, GAPDH levels in PBMCs 
from RA patients were increased compared to control peripheral blood 
mononuclear cells. Retrospectively, the housekeeping gene, GAPDH was not a 
suitable choice for a housekeeping gene for RA patients. In addition, there is 
evidence that GAPDH varies in nucleated blood cells between individuals (Bustin 
et al., 1999) and in peripheral blood cells from tuberculosis patients (Dheda et 
al., 2004). Subsequently, since completion of this work, a colleague has 
continued the research into psoriasis. The QPCR of peripheral blood from 
psoriasis patients has been repeated using TATA binding protein as the 
housekeeping gene and with increased sample size. In doing so, PBMCs from 
psoriatic patients displayed a 10-fold increase in D6 mRNA expression compared 
to controls, which correlates with the enhanced D6 expression observed in 
psoriatic uninvolved skin. Further work is required to determine whether 
enhanced expression of D6 in psoriatic peripheral blood is restricted to a distinct 
subset of leukocytes. 
As mentioned above, before we had determined the problematic issue regarding 
GAPDH in this context, we had observed a 2-fold decrease in D6 transcripts 
within peripheral blood of RA patients. We resolved to examine surface D6 
expression on specific leukocytes within peripheral blood to determine which 
cell types were expressing D6. Examination of D6 expression on specific subsets 
of leukocytes by flow cytometry revealed that expression of D6 was highest on B 
cells and dendritic cells. The trends in D6 expression on leukocyte subsets within 
control peripheral blood correlated with previous findings (McKimmie et al., 
2008). Surface expression of D6 on B cells and mDCs from RA patients was 
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significantly increased on these cells compared to control B cells and mDCs. This 
data contradicted the QPCR data, which suggested that D6 transcripts in 
peripheral blood of RA patients were 2-fold lower than control peripheral blood. 
Retrospectively, it may have been useful to examine D6 transcript expression in 
each of the subpopulations of leukocytes from the same samples in which D6 
protein expression was analysed.  
All leukocytes analysed by flow cytometry revealed that D6 expression was 
increased on all cells in RA peripheral blood but this was only significantly 
different in B cells and mDCs compared to control. One reason for this enhanced 
D6 expression may be that RA can be considered a systemic inflammatory 
disease (with increased inflammatory mediators in the blood). Many chemokines 
and their receptors are implicated in the pathology of RA (Szekanecz et al., 
2003). Within the blood, there are increased levels of inflammatory mediators 
and chemokines.  Increased levels of CCR1 and CCR5 on RA peripheral blood 
monocytes and increased levels of CCL5 and CCL15 have also been reported in 
rheumatoid arthritis peripheral blood compared to controls (Haringman et al., 
2006). An inflammatory environment surrounds PBMCs and it is possible that D6 
is upregulated in the peripheral blood of RA patients to try to counteract the 
systemic inflammation. It would be interesting to correlate the expression of D6 
on leukocytes from RA patients with the circulating levels of chemokines within 
their blood. This could be analysed by collecting peripheral blood from RA 
patients and using half to isolate PBMCs to examine surface D6 expression by 
flow cytometry and from the other half, plasma would be extracted to examine 
the levels of multiple chemokine at the same time. The chemokines and 
cytokines would be analysed using Luminex technology. In addition, as 
mentioned, a significant increase in D6 protein expression was observed in B 
cells and mDCs in RA patients compared to controls. Both these cells are 
involved in the adaptive response and play a role in antigen presentation. 
Therefore, D6 may be involved in the adaptive immune response. A recent study 
has revealed D6 expression on leukocytes within human rheumatoid synovium 
suggesting that D6 is involved in the pathogenesis of rheumatoid arthritis 
(McKimmie et al., 2008). The exact role of D6 in human or murine models of 
arthritis has not yet been determined. 
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Inflammation is an important mechanism within the body. However, there are 
many diseases driven by chronic inflammation, which are detrimental to our 
body. The work presented here shows that increased expression of D6 can 
suppress cutaneous inflammation in vivo; therefore, D6 has the potential to be 
of therapeutic value. Our microarray studies have indicated that non-ligated D6 
may have a negative impact on the transcription of certain genes. Further work 
using a primary cell that naturally expresses D6 is required to determine the 
transcriptional response of cells to D6 after ligand binding. Additionally, this 
study shows evidence to suggest that D6 is dysregulated in inflammatory diseases 
suggesting D6 is involved in the pathogenesis of these inflammatory diseases. 
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Appendix One  
Terminology used on the web pages automatically generated by FunAlyse, 
microarray data analysis software 
http://www.gla.ac.uk/functionalgenomics/rp/termin.html 
 
Experiment report 
  
Software 
This refers to software that actually runs the whole analysis automatically. In 
particular it:  
• •         Generates a directory structure for a project and its experiments  
• •         Manages the security of the project 
• •         Performs RMA low-level analysis  
• •         Performs RP identification of differentially expressed genes for a 
number of between-group comparisons  
• •         Functionally annotates the list of RP-identified top genes  
• •         Performs iGA to find differentially expressed functional classes of 
genes (written by Rainer Breitling).  
• •         Presents the RP and iGA results in form of web pages and/or 
downloadable tab-delimited text files suitable for reading in Excel. 
The software has been written and implemented by Pawel Herzyk in the Autumn 
2003 – Spring 2004. 
 
Project  
Project refers to data that belongs to a particular researcher or a group of 
researchers. Each PI (principal investigator) can only have one project that can be 
divided into many experiments. Each project has associated:  
• •         Name - this is usually constructed from the PI's name e.g. john_dav 
would be a name of a project owned by John Davis.  
• •         Class - this could be Microarray or Proteomics  
• •         Type - e.g. Affymetrix or Spotted depending on the type of 
microarrays used  
  
Experiment  
Each project can be divided into experiments. Each experiment contains data from 
a number of replicated (or not) samples corresponding to different conditions. 
 
Array  
This refers to an identifiable type of array e.g. U133 is the Affymetrix human array 
HG-U133. 
 
Chip  
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Some Affymetrix arrays may consist of several subarrays. E.g. HG-U133 array is in 
fact represented by two arrays HG-U133A and HG-U133B. In this case we say that 
the array has two chips A and B. If the array has only one chip it is denoted as N 
(for none). 
 
 
 
Normalisation  
This really is a shorthand for low-level analysis. In case of Affymetrix data this 
consists of  
• •         Background correction  
• •         Multichip normalisation on the probe level  
• •         Summary of the log-normalised probe level data into a probe-set level 
data  
By default we use Robust Multichip Average (RMA) method implemented in 
module Affy in the Bioconductor microarray analysis software. 
 
Differential Expression  
A method of identification of differentially expressed genes between two groups of 
replicated samples. We use the RankProducts method(RP) developed in University 
of Glasgow. 
 
Differentially expressed gene classes  
A method for identification of functional gene classes that are differentially 
expressed in a given comparison. We use the Iterative Group Analysis method 
developed in the University of Glasgow.  
 
Baseline  
For every comparison between two groups of replicated samples we select one of 
the groups as a reference (baseline). This is usually done upon suggestion from a 
researcher who owns the data.  
 
Treatment  
This refers to the group of replicated samples that has not been selected as baseline. 
The software analyses the expression of a treatment group with respect to the 
baseline. 
 
Direction  
This refers to the direction of the differential expression of the treatment with 
respect to the baseline:  
• •         Positive - means a list of genes with significantly higher expression in 
the treatment group than in the baseline group  
• •         Negative - means a list of genes with significantly lower expression in 
the treatment group than in the baseline group  
RPhtml  
Results of RP in html format 
 
RPtext  
Results of RP in tab-delimited text format 
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iGAcla 
Results of iGA in Classic mode (html format). Look at paragraph Mode in section 
iGA report for more explanations. 
 
iGArep 
Results of iGA in Representative mode (html format). Look at paragraph Mode in 
section iGA report for more explanations. 
RP report 
Comparison  
This refers to a comparison between two groups of replicated samples. E.g.: 
Samples: A,B,C vs Samples: D,E,F means that samples A,B,C 
correspond to the treatment group and D,E,F correspond to the baseline group. 
 
Probe-set ID  
The Affymetrix probe-set identificator 
 
RPscore  
This is a measure of differential expression calculated by the RP method. For every 
gene this is calculated as a geometric mean of fold-change ranks over the number 
of all possible between-chip comparisons contributing to a given between-group 
comparison. 
 
FDR  
This is a conservative estimate of False Discovery Rate. If you cut the differentially 
expressed gene-list at the particular position associated with a particular FDR then 
it shows the expected percentage of false positives. 
 
FCrma  
Before FunAlyse version 1.4.1 this is a mean fold-change over all possible 
between-chip comparisons contributing to a given between-group comparison.  
From FunAlyse version 1.4.1 onwards this is calculated as an antilog of a mean 
log-fold-change over all possible between-chip comparisons contributing to a given 
between-group comparison.  
In both cases if you have two groups of three Affymetrix chips the FCrma is 
calculated over all nine comparisons.  
 
FCnom  
It has been demonstrated in the experiment where selected genes were spiked-in at 
known concentrations on the HG-U95A chip that the fold-changes calculated after 
RMA low-level analysis are significantly lower than the nominal fold-changes 
calculated from the spiked-in gene concentrations. The relation between these two 
fold-changes was calculated by a fitting procedure:  
log2(rma FC) = 0.61 x log2(nominal FC)  
Consequently, the FCnom corresponds to the mean nominal fold-change obtained 
from the rma fold-changes using the above equation over all possible between-chip 
comparisons contributing to a given between-group comparison. Please, treat it 
with caution as it is not known how universal the above equation is. Consult Figure 
6 in the original paper Cope et al. 2003 (PubMed abstract).  
 
Gene annotation database  
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This is a database that contains functional annotation of your genes. Every gene in 
the reported list of differentially expressed genes has a hyperlink to it. Currently, 
we use the following databases:  
• •         Human, Mouse and Rat - SOURCE database  
• •         Arabidopsis - MIPS and TAIR databases  
• •         Drosophila - FlyBase  
• •         Yeast - SGD database  
  
 
Gene symbol  
Common gene symbol used by biologists. 
 
Gene ID  
Publicly used gene identificator. 
 
Title  
Short functional annotation of a gene. This is very brief, you shouldn't rely on it too 
much. 
iGA report 
Mode  
The iGA module in the FunAlyse software can work in two modes: Classic - all 
probe-sets on the chip are taking part in the iGA calculations. Representative - 
only one probe-set per gene is selected. This is to remove a bias towards a 
particular groups in case more then one probe-set represent a gene contributing to 
this group. A probe set producing the best RPscore in a given comparison 
(calculated seperately for positive and negative expression) is selected as a 
representative for that gene. The non-redundant set of genes is defined differently 
for different organisms. For Human, Mouse and Rat they are defined using Unigene 
IDs, for Arabidopsis and Yeast they are defined on the base of gene IDs whilst for 
Drosophila it is based on gene symbols. 
 
Number of probe-sets on the chip  
A number of Affymetrix probe-sets on a given chip. In the Classic mode some 
probe-sets may refer to the same gene. 
 
Number of annotated probe-sets  
A number of probe-sets on a given chip that have functional annotation in the 
current Affymetrix annotation file that has been used for functional group 
construction. 
 
Number of groups  
A total number of functionally annotated gene-groups. They are pre-constructed 
independently of the microarray experiment. Usually we use GeneOntology (GO) 
annotations present in the Affymetrix annotation file but you may advise us to use 
other annotation sources. 
 
Number of singletons  
A number of functionally annotated gene-groups that contain a single gene. These 
are not particularly useful for iGA. 
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Significance threshold  
A threshold for P-value changed. P-values lower than the threshold are considered 
statistically significant. (see also P-value changed) 
 
File Name  
A name of the input file that contains full list of genes sorted by RankProducts 
score RPscore that is our measure of gene differential expression.  
Annotations  
This is a name of the Affymetrix functional annotation file used for the functional 
group construction. 
 
Top changed groups  
A list of significantly differentially expressed gene-groups. 
 
Group Members  
Number of probe-sets that belong to a particular group. 
 
Changed Members  
Number of group members that have actually contributed to achieving a given P-
value changed for this group. 
 
P-value changed  
This tells you what is a probability of a random event that 'that many' of changed 
members out of 'that many' group members has been found 'that high' on the RP 
list of 'that many' sorted genes. This is calculated from the hyper-geometric 
distribution. Consult Figure 1 in the original paper 
 
P-value  
Going down from the top of the RP list, for every encountered subset of a particular 
gene group we calculate the p-value that tells you how probable a random event is 
that such subset was found 'that high' on the RP list. This is calculated from the 
hyper-geometric distribution. In this context P-value changed is a smallest p-value 
over all the above subsets. Consult Figure 1 in the original paper 
 
Percent changed  
This is simply changed members over group members times 100. 
Rank  
This is rank of a particular gene in the list of differentially expressed genes. This 
list was created from the RP list by exclusion of genes that are not assigned to the 
functional gene-groups. 
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Appendix Two 
The Rank Product (RP) differential expression analysis report 
 
 
 
General Information 
Experiment  VK1mouse4302 
Normalisation  rma across replicates 
Chip  one chip only 
Comparison  Treatment samples: K14D6 Control vs Baseline samples: WT Control 
RP comparison  not paired 
Direction  Positive 
 
0 Probe-set ID RPscore FDR FC_rma FC_nom "SOURCE" "EntrezGene" Gene Symbol Title 
1 1422111_at 1.00 0.00 49.59 603.20 BE631540 59289 Ccbp2 chemokine binding protein 2 
2 1420512_at 206.84 15.50 2.66 4.96 NM_020265 56811 Dkk2 dickkopf homolog 2 (Xenopus laevis) 
3 1450079_at 348.58 43.33 1.81 2.65 AK012873 27206 Nrk Nik related kinase 
4 1450871_a_at 359.51 34.50 1.48 1.90 X17502 12035 Bcat1 
branched chain 
aminotransferase 1, 
cytosolic 
5 1449484_at 389.02 32.20 1.56 2.08 AF031035 20856 Stc2 stanniocalcin 2 
6 1418547_at 470.76 47.67 1.62 2.21 NM_009364 21789 Tfpi2 tissue factor pathway inhibitor 2 
7 1437935_at 507.32 NA 1.57 2.09 BB821151 75033 4930486G11Rik RIKEN cDNA 4930486G11 gene 
8 1420991_at 511.93 NA 1.55 2.05 AK009959 107765 Ankrd1 
ankyrin repeat 
domain 1 (cardiac 
muscle) 
9 1448816_at 529.66 NA 1.75 2.51 NM_008968 19223 Ptgis 
prostaglandin I2 
(prostacyclin) 
synthase 
10 1421038_a_at 531.04 NA 1.12 1.20 NM_008433 16534 Kcnn4 
potassium 
intermediate/small 
conductance calcium-
activated channel, 
subfamily N, member 
4 
11 1416405_at 607.93 NA 1.71 2.41 BC019502 12111 Bgn biglycan 
12 1448323_a_at 643.49 NA 1.71 2.40 BC019502 12111 Bgn biglycan 
13 1416200_at 667.15 NA 1.65 2.27 NM_133775 77125 9230117N10Rik RIKEN cDNA 9230117N10 gene 
14 1423607_at 680.73 NA 1.94 2.96 AK014312 17022 Lum lumican 
15 1427262_at 691.34 NA 1.87 2.78 L04961 213742 Xist inactive X specific transcripts 
16 1418815_at 723.08 NA 1.43 1.79 BC022107 12558 Cdh2 cadherin 2 
17 1454672_at 798.97 NA 1.87 2.78 BE952212 --- --- --- 
18 1436448_a_at 821.49 NA 1.60 2.15 AA833146 19224 Ptgs1 
prostaglandin-
endoperoxide 
synthase 1 
19 1455626_at 829.09 NA 1.07 1.12 AA987181 15405 Hoxa9 homeo box A9 
20 1451016_at 832.05 NA 1.38 1.69 BB540964 15983 Ifrd2 interferon-related 
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developmental 
regulator 2 
21 1416778_at 841.85 NA 1.68 2.34 BE197945 20324 Sdpr serum deprivation 
response 
22 1434278_at 855.72 NA 1.34 1.62 BG976607 17772 Mtm1 X-linked myotubular 
myopathy gene 1 
23 1424186_at 887.84 NA 1.44 1.82 BG074158 67896 2610001E17Rik RIKEN cDNA 2610001E17 gene 
24 1439774_at 913.38 NA 1.62 2.20 BB051738 18933 Prrx1 paired related homeobox 1 
25 1415834_at 946.19 NA 1.24 1.42 NM_026268 67603 Dusp6 dual specificity phosphatase 6 
26 1416072_at 956.02 NA 1.45 1.85 NM_133654 12490 Cd34 CD34 antigen 
27 1425458_a_at 966.35 NA 1.37 1.67 AF022072 14783 Grb10 growth factor receptor bound protein 10 
28 1436319_at 980.06 NA 1.31 1.55 BB751459 240725 Sulf1 sulfatase 1 
29 1434877_at 984.15 NA 1.53 2.01 AI152800 18164 Nptx1 neuronal pentraxin 1 
30 1453252_at 994.13 NA 1.34 1.61 AK010138 71916 Dus4l 
dihydrouridine 
synthase 4-like (S. 
cerevisiae) 
31 1428960_at 1004.42 NA 1.35 1.63 AK017056 71233 4933434I06Rik RIKEN cDNA 4933434I06 gene 
32 1436936_s_at 1014.15 NA 1.74 2.49 BG806300 213742 Xist inactive X specific transcripts 
33 1425415_a_at 1016.60 NA 1.36 1.65 U75214 20510 Slc1a1 
solute carrier family 1 
(neuronal/epithelial 
high affinity glutamate 
transporter, system 
Xag), member 1 
34 1427610_at 1020.80 NA 1.39 1.72 BC026631 109620 Dsp desmoplakin 
35 1449519_at 1023.57 NA 1.36 1.65 NM_007836 13197 Gadd45a 
growth arrest and 
DNA-damage-
inducible 45 alpha 
36 1415998_at 1035.12 NA 1.38 1.69 NM_011694 22333 Vdac1 voltage-dependent 
anion channel 1 
37 1437889_x_at 1046.43 NA 1.57 2.09 AI931862 12111 Bgn biglycan 
38 1427263_at 1065.74 NA 1.35 1.63 L04961 213742 Xist inactive X specific transcripts 
39 1428944_at 1089.81 NA 1.42 1.78 BB417360 231380 5730469D23Rik RIKEN cDNA 5730469D23 gene 
40 1448590_at 1187.50 NA 1.63 2.24 NM_009933 12833 Col6a1 procollagen, type VI, 
alpha 1 
41 1436698_x_at 1189.66 NA 1.26 1.47 AV167328 407831 BC054438 cDNA sequence BC054438 
42 1423606_at 1208.13 NA 1.57 2.09 BI110565 50706 Postn periostin, osteoblast 
specific factor 
43 1438989_s_at 1236.84 NA 1.31 1.56 BB386167 320860 B130021B11Rik RIKEN cDNA B130021B11 gene 
44 1455121_at 1248.43 NA 1.30 1.54 BB553784 212391 A630025C20Rik RIKEN cDNA A630025C20 gene 
45 1454904_at 1261.59 NA 1.29 1.52 BG976607 17772 Mtm1 X-linked myotubular 
myopathy gene 1 
46 1421917_at 1262.81 NA 1.47 1.88 AW537708 18595 Pdgfra 
platelet derived 
growth factor 
receptor, alpha 
polypeptide 
47 1423271_at 1266.24 NA 1.31 1.57 AV239646 14619 Gjb2 
gap junction 
membrane channel 
protein beta 2 
48 1423110_at 1271.66 NA 1.67 2.32 BF227507 --- --- --- 
49 1450196_s_at 1289.33 NA 1.31 1.56 NM_030678 14936 14937 Gys1 /// Gys3 
glycogen synthase 1, 
muscle /// glycogen 
synthase 3, brain 
50 1431295_a_at 1318.68 NA 1.31 1.56 AK016910 71116 Stx18 syntaxin 18 
51 1416121_at 1323.10 NA 1.72 2.43 M65143 16948 Lox lysyl oxidase 
52 1450757_at 1324.74 NA 1.38 1.69 NM_009866 12552 Cdh11 cadherin 11 
53 1444368_at 1328.00 NA 1.30 1.54 BE956442 110834 Chrna3 Cholinergic receptor, 
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nicotinic, alpha 
polypeptide 3 
(Chrna3), mRNA 
54 1420992_at 1331.31 NA 1.45 1.85 AK009959 107765 Ankrd1 
ankyrin repeat 
domain 1 (cardiac 
muscle) 
55 1450857_a_at 1334.16 NA 1.81 2.64 BF227507 12843 Col1a2 procollagen, type I, 
alpha 2 
56 1452445_at 1339.62 NA 1.33 1.60 BC026874 338365 Slc41a2 solute carrier family 41, member 2 
57 1453783_at 1344.55 NA 1.32 1.59 BE864772 70733 6330411E07Rik RIKEN cDNA 6330411E07 gene 
58 1449735_at 1372.35 NA 1.31 1.56 BG074689 --- --- --- 
59 1418601_at 1383.54 NA 0.96 0.94 NM_011921 26358 Aldh1a7 
aldehyde 
dehydrogenase 
family 1, subfamily A7 
60 1415802_at 1390.45 NA 1.29 1.51 NM_009196 20501 Slc16a1 
solute carrier family 
16 (monocarboxylic 
acid transporters), 
member 1 
61 1442845_at 1412.33 NA 1.27 1.48 AV320517 320395 C130075A20Rik RIKEN cDNA C130075A20 gene 
62 1435945_a_at 1437.93 NA 0.95 0.92 BG865910 16534 Kcnn4 
potassium 
intermediate/small 
conductance calcium-
activated channel, 
subfamily N, member 
4 
63 1418736_at 1456.53 NA 1.32 1.58 BC003835 26879 B3galt3 
UDP-Gal:betaGlcNAc 
beta 1,3-
galactosyltransferase, 
polypeptide 3 
64 1454174_a_at 1465.43 NA 1.29 1.51 AK021190 77644 C330007P06Rik RIKEN cDNA C330007P06 gene 
65 1456292_a_at 1479.27 NA 1.43 1.79 AV147875 22352 Vim vimentin 
66 1421817_at 1481.12 NA 1.20 1.35 AK019177 14782 Gsr glutathione reductase 1 
67 1422995_at 1485.51 NA 1.29 1.52 NM_138313 171543 Bmf Bcl2 modifying factor 
68 1419404_s_at 1487.00 NA 1.27 1.49 NM_009173 20437 20438 Siah1a /// Siah1b 
seven in absentia 1A 
/// seven in absentia 
1B 
69 1435831_at 1515.03 NA 1.09 1.15 BB427704 22268 Upk1b uroplakin 1B 
70 1449475_at 1541.88 NA 1.31 1.55 NM_138652 192113 Atp12a 
ATPase, H+/K+ 
transporting, 
nongastric, alpha 
polypeptide 
71 1428796_at 1554.27 NA 1.29 1.53 AK017436 74503 5530401J07Rik RIKEN cDNA 5530401J07 gene 
72 1425092_at 1559.88 NA 1.16 1.28 AF183946 320873 Cdh10 cadherin 10 
73 1452250_a_at 1581.58 NA 1.38 1.69 BI455189 12834 Col6a2 procollagen, type VI, 
alpha 2 
74 1423744_x_at 1589.37 NA 1.31 1.56 BC006682 26905 Eif2s3x 
eukaryotic translation 
initiation factor 2, 
subunit 3, structural 
gene X-linked 
75 1449244_at 1621.01 NA 1.35 1.63 BC022107 12558 Cdh2 cadherin 2 
76 1418157_at 1625.70 NA 1.32 1.58 NM_010151 13865 Nr2f1 
nuclear receptor 
subfamily 2, group F, 
member 1 
77 1430676_at 1636.38 NA 1.30 1.54 AK019854 12823 Col19a1 procollagen, type XIX, alpha 1 
78 1450315_at 1638.11 NA 1.28 1.49 NM_030736 81011 V1rd14 vomeronasal 1 
receptor, D14 
79 1451090_a_at 1643.54 NA 1.30 1.53 BC006682 26905 Eif2s3x 
eukaryotic translation 
initiation factor 2, 
subunit 3, structural 
gene X-linked 
80 1437672_at 1643.85 NA 1.27 1.48 AV286336 16369 Irs3 insulin receptor 
substrate 3 
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81 1418926_at 1648.07 NA 1.36 1.66 NM_011546 21417 Zfhx1a zinc finger homeobox 1a 
82 1427883_a_at 1666.33 NA 1.28 1.50 AW550625 12825 Col3a1 procollagen, type III, 
alpha 1 
83 1440910_at 1680.56 NA 1.35 1.64 AW495307 Mm.381907 --- CDNA clone IMAGE:5252333 
84 1450004_at 1685.90 NA 1.08 1.14 NM_021367 53603 Tslp thymic stromal lymphopoietin 
85 1426255_at 1696.96 NA 1.29 1.52 M20480 18039 Nefl neurofilament, light polypeptide 
86 1446584_at 1706.52 NA 1.29 1.52 BB485470 76299 Txndc4 
Thioredoxin domain 
containing 4 
(endoplasmic 
reticulum) (Txndc4), 
mRNA 
87 1422567_at 1709.08 NA 1.29 1.51 NM_022018 63913 Niban niban protein 
88 1459085_at 1711.18 NA 1.27 1.49 BG066528 52305 D1Ertd259e 
DNA segment, Chr 1, 
ERATO Doi 259, 
expressed 
89 1420650_at 1717.02 NA 1.27 1.48 NM_007496 11906 Atbf1 AT motif binding factor 1 
90 1430342_at 1717.63 NA 1.28 1.51 BF011273 67589 4930518J20Rik RIKEN cDNA 4930518J20 gene 
91 1433491_at 1728.77 NA 1.27 1.49 BE951907 13822 Epb4.1l2 erythrocyte protein band 4.1-like 2 
92 1437219_at 1729.38 NA 1.33 1.59 AW553541 16001 Igf1r 
Insulin-like growth 
factor I receptor 
(Igf1r), mRNA 
93 1416473_a_at 1735.26 NA 1.32 1.58 NM_020043 56741 Nope neighbor of Punc E11 
94 1449351_s_at 1736.95 NA 1.18 1.31 NM_019971 54635 Pdgfc 
platelet-derived 
growth factor, C 
polypeptide 
95 1450078_at 1760.15 NA 1.32 1.57 AK012873 27206 Nrk Nik related kinase 
96 1460039_at 1760.67 NA 1.30 1.53 BB035924 243653 Clec1a C-type lectin domain family 1, member a 
97 1437556_at 1761.93 NA 1.32 1.58 BF147593 80892 Zfhx4 zinc finger homeodomain 4 
98 1458640_at 1768.52 NA 1.29 1.51 BB284122 Mm.37652 --- 
6 days neonate skin 
cDNA, RIKEN full-
length enriched 
library, 
clone:A030007I19 
product:hypothetical 
protein, full insert 
sequence 
99 1438148_at 1774.82 NA 1.10 1.17 BB829808 330122 Gm1960 gene model 1960, (NCBI) 
100 1451332_at 1786.80 NA 1.22 1.39 BC021376 225207 Zfp521 zinc finger protein 521 
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The Rank Product (RP) differential expression analysis report 
 
 
General Information 
Experiment  VK1mouse4302 
Normalisation  rma across replicates 
Chip  one chip only 
Comparison  Treatment samples: WT + CCL3 vs Baseline samples: WT Control 
RP comparison  not paired 
Direction  Positive 
 
 
0 Probe-set ID RPscore FDR FC_r
ma 
FC_no
m 
"SOURCE" "EntrezGe
ne" 
Gene Symbol Title 
1 1424754_at 145.79 14.00 2.46 4.38 BC024402 109225 Ms4a7 
membrane-spanning 
4-domains, subfamily 
A, member 7 
2 1448995_at 171.94 9.50 2.10 3.39 NM_019932 56744 Cxcl4 chemokine (C-X-C 
motif) ligand 4 
3 1448748_at 189.97 8.33 2.61 4.83 AF181829 56193 Plek pleckstrin 
4 1427883_a_at 224.73 10.25 3.72 8.61 AW550625 12825 Col3a1 procollagen, type III, 
alpha 1 
5 1420512_at 228.64 8.20 3.50 7.79 NM_020265 56811 Dkk2 dickkopf homolog 2 (Xenopus laevis) 
6 1418547_at 236.57 7.00 3.11 6.44 NM_009364 21789 Tfpi2 tissue factor pathway inhibitor 2 
7 1423607_at 287.28 9.86 3.29 7.06 AK014312 17022 Lum lumican 
8 1450663_at 288.57 8.75 2.86 5.61 NM_011581 21826 Thbs2 thrombospondin 2 
9 1438989_s_at 288.84 7.78 2.48 4.42 BB386167 320860 B130021B11Rik 
RIKEN cDNA 
B130021B11 gene 
10 1416136_at 296.29 7.20 2.71 5.12 NM_008610 17390 Mmp2 matrix 
metallopeptidase 2 
11 1436970_a_at 303.38 7.55 3.20 6.74 AA499047 18596 Pdgfrb 
platelet derived 
growth factor 
receptor, beta 
polypeptide 
12 1448590_at 314.50 7.50 3.25 6.91 NM_009933 12833 Col6a1 procollagen, type VI, 
alpha 1 
13 1448326_a_at 319.04 7.15 2.86 5.59 NM_013496 12903 Crabp1 cellular retinoic acid binding protein I 
14 1452250_a_at 322.66 7.00 2.96 5.92 BI455189 12834 Col6a2 procollagen, type VI, 
alpha 2 
15 1417381_at 329.93 7.00 2.13 3.47 NM_007572 12259 C1qa 
complement 
component 1, q 
subcomponent, alpha 
polypeptide 
16 1439364_a_at 335.60 6.88 2.65 4.95 BF147716 17390 Mmp2 matrix 
metallopeptidase 2 
17 1422317_a_at 339.17 6.71 2.78 5.34 NM_010743 17082 Il1rl1 interleukin 1 receptor-like 1 
18 1435943_at 373.12 8.39 2.55 4.63 AI647687 13479 Dpep1 dipeptidase 1 (renal) 
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19 1449154_at 394.70 9.68 2.21 3.68 NM_007729 12814 Col11a1 procollagen, type XI, 
alpha 1 
20 1419598_at 397.90 9.35 2.16 3.53 NM_026835 68774 Ms4a6d 
membrane-spanning 
4-domains, subfamily 
A, member 6D 
21 1436905_x_at 415.35 9.67 1.88 2.82 BB218107 16792 Laptm5 
lysosomal-associated 
protein 
transmembrane 5 
22 1423606_at 417.60 9.32 2.82 5.47 BI110565 50706 Postn periostin, osteoblast 
specific factor 
23 1418157_at 421.55 9.22 2.10 3.38 NM_010151 13865 Nr2f1 
nuclear receptor 
subfamily 2, group F, 
member 1 
24 1450757_at 437.53 10.04 2.56 4.67 NM_009866 12552 Cdh11 cadherin 11 
25 1448929_at 439.43 9.72 1.97 3.03 NM_028784 74145 F13a1 coagulation factor XIII, A1 subunit 
26 1419100_at 455.66 10.42 2.15 3.51 NM_009252 20716 Serpina3n 
serine (or cysteine) 
peptidase inhibitor, 
clade A, member 3N 
27 1416414_at 461.95 10.37 1.85 2.75 NM_133918 100952 Emilin1 elastin microfibril interfacer 1 
28 1449368_at 469.99 10.50 2.97 5.97 NM_007833 13179 Dcn decorin 
29 1450857_a_at 470.68 10.17 3.18 6.68 BF227507 12843 Col1a2 procollagen, type I, 
alpha 2 
30 1416121_at 472.91 9.97 3.12 6.45 M65143 16948 Lox lysyl oxidase 
31 1438672_at 475.20 9.87 1.96 3.02 BI134721 170736 Parvb Parvin, beta (Parvb), 
mRNA 
32 1421425_a_at 476.88 9.62 1.80 2.61 NM_030598 53901 Dscr1l1 
Down syndrome 
critical region gene 1-
like 1 
33 1435477_s_at 482.60 9.64 2.03 3.19 BM224327 14130 Fcgr2b Fc receptor, IgG, low 
affinity IIb 
34 1416405_at 489.25 9.65 2.93 5.82 BC019502 12111 Bgn biglycan 
35 1418666_at 506.88 10.20 1.75 2.50 NM_008987 19288 Ptx3 pentraxin related gene 
36 1423110_at 506.90 9.92 2.96 5.91 BF227507 --- --- --- 
37 1424186_at 539.75 11.89 2.80 5.40 BG074158 67896 2610001E17Rik RIKEN cDNA 2610001E17 gene 
38 1437558_at 540.30 11.61 1.85 2.74 BM119919 320860 B130021B11Rik 
RIKEN cDNA 
B130021B11 gene 
39 1419728_at 546.18 11.62 1.93 2.95 NM_009141 20311 Cxcl5 chemokine (C-X-C 
motif) ligand 5 
40 1418454_at 549.59 11.47 2.01 3.15 NM_015776 50530 Mfap5 microfibrillar 
associated protein 5 
41 1448323_a_at 549.62 11.22 2.98 5.99 BC019502 12111 Bgn biglycan 
42 1420498_a_at 552.08 11.05 2.16 3.53 NM_023118 13132 Dab2 disabled homolog 2 (Drosophila) 
43 1419473_a_at 566.01 11.88 1.99 3.10 NM_031161 12424 Cck cholecystokinin 
44 1423537_at 566.36 11.61 2.13 3.45 BB622036 14432 Gap43 growth associated protein 43 
45 1421917_at 569.08 11.51 2.40 4.22 AW537708 18595 Pdgfra 
platelet derived 
growth factor 
receptor, alpha 
polypeptide 
46 1436698_x_at 575.44 11.67 1.92 2.91 AV167328 407831 BC054438 cDNA sequence BC054438 
47 1416200_at 582.79 11.77 1.90 2.87 NM_133775 77125 9230117N10Rik RIKEN cDNA 9230117N10 gene 
48 1452905_at 585.62 11.65 2.60 4.79 AV015833 17263 330814 Gtl2 /// Lphn1 
GTL2, imprinted 
maternally expressed 
untranslated mRNA /// 
latrophilin 1 
49 1419248_at 591.51 11.67 2.01 3.13 AF215668 19735 Rgs2 regulator of G-protein 
signaling 2 
50 1420380_at 628.06 13.48 2.33 3.99 AF065933 20296 Ccl2 chemokine (C-C 
motif) ligand 2 
51 1437889_x_at 657.21 15.35 2.68 5.04 AI931862 12111 Bgn biglycan 
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52 1422571_at 657.44 15.06 2.69 5.06 NM_011581 21826 Thbs2 thrombospondin 2 
53 1420804_s_at 659.19 14.89 1.80 2.63 NM_010819 17474 Clec4d C-type lectin domain family 4, member d 
54 1416221_at 661.34 14.85 2.60 4.80 BI452727 14314 Fstl1 follistatin-like 1 
55 1448228_at 661.58 14.60 2.53 4.58 M65143 16948 Lox lysyl oxidase 
56 1448816_at 664.14 14.50 2.23 3.73 NM_008968 19223 Ptgis 
prostaglandin I2 
(prostacyclin) 
synthase 
57 1426947_x_at 667.96 14.46 2.20 3.65 BI455189 12834 Col6a2 procollagen, type VI, 
alpha 2 
58 1450430_at 672.42 14.72 1.74 2.47 NM_008625 17533 Mrc1 mannose receptor, C type 1 
59 1452141_a_at 680.30 14.97 1.95 3.00 BC001991 20363 Sepp1 selenoprotein P, plasma, 1 
60 1418599_at 682.21 14.87 1.77 2.55 NM_007729 12814 Col11a1 procollagen, type XI, 
alpha 1 
61 1448162_at 694.27 15.39 1.91 2.90 BB250384 22329 Vcam1 vascular cell adhesion 
molecule 1 
62 1448925_at 701.70 15.76 2.09 3.36 NM_007855 13345 Twist2 twist homolog 2 (Drosophila) 
63 1437165_a_at 704.76 15.70 2.35 4.05 BB250811 18542 Pcolce 
procollagen C-
endopeptidase 
enhancer protein 
64 1436448_a_at 706.91 15.59 2.24 3.77 AA833146 19224 Ptgs1 
prostaglandin-
endoperoxide 
synthase 1 
65 1418601_at 711.64 15.65 3.17 6.64 NM_011921 26358 Aldh1a7 
aldehyde 
dehydrogenase family 
1, subfamily A7 
66 1451978_at 721.02 16.06 2.24 3.75 AF357006 16949 Loxl1 lysyl oxidase-like 1 
67 1439426_x_at 740.13 17.28 1.74 2.48 AV058500 17110 Lzp-s P lysozyme structural 
68 1447862_x_at 752.36 17.85 2.00 3.13 BB233297 21826 Thbs2 thrombospondin 2 
69 1438405_at 763.85 18.36 2.41 4.22 BB791906 14178 Fgf7 fibroblast growth factor 7 
70 1415983_at 766.61 18.29 1.57 2.10 NM_008879 18826 Lcp1 lymphocyte cytosolic protein 1 
71 1450652_at 770.50 18.41 2.28 3.87 NM_007802 13038 Ctsk cathepsin K 
72 1436996_x_at 783.94 19.10 1.66 2.29 AV066625 17110 Lzp-s P lysozyme structural 
73 1450641_at 805.95 20.26 2.13 3.45 M24849 22352 Vim vimentin 
74 1425575_at 811.40 20.24 1.76 2.54 M68513 13837 Epha3 Eph receptor A3 
75 1425528_at 821.92 20.69 2.20 3.63 L06502 18933 Prrx1 paired related homeobox 1 
76 1418990_at 822.12 20.43 1.76 2.52 NM_025658 66607 Ms4a4d 
membrane-spanning 
4-domains, subfamily 
A, member 4D 
77 1456292_a_at 853.38 22.35 2.11 3.39 AV147875 22352 Vim vimentin 
78 1449254_at 853.87 22.12 2.22 3.70 NM_009263 20750 Spp1 secreted phosphoprotein 1 
79 1417266_at 868.30 22.85 1.87 2.80 BC002073 20305 Ccl6 chemokine (C-C 
motif) ligand 6 
80 1418736_at 870.45 22.73 1.70 2.39 BC003835 26879 B3galt3 
UDP-Gal:betaGlcNAc 
beta 1,3-
galactosyltransferase, 
polypeptide 3 
81 1425145_at 871.16 22.47 2.23 3.73 D13695 17082 Il1rl1 interleukin 1 receptor-like 1 
82 1425810_a_at 875.10 22.50 1.60 2.16 BF124540 13007 Csrp1 cysteine and glycine-
rich protein 1 
83 1448259_at 885.57 22.84 2.41 4.24 BI452727 14314 Fstl1 follistatin-like 1 
84 1418945_at 889.73 22.88 1.95 2.99 NM_010809 17392 Mmp3 matrix 
metallopeptidase 3 
85 1460227_at 894.34 22.94 1.95 2.98 BC008107 21857 Timp1 tissue inhibitor of 
metalloproteinase 1 
86 1448591_at 897.68 22.99 1.61 2.17 NM_021281 13040 Ctss cathepsin S 
87 1418815_at 900.46 22.91 1.68 2.35 BC022107 12558 Cdh2 cadherin 2 
88 1440397_at 908.51 23.31 1.74 2.47 BB464523 --- --- --- 
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89 1448620_at 920.24 23.66 1.76 2.53 NM_010188 14131 Fcgr3 Fc receptor, IgG, low 
affinity III 
90 1449244_at 933.40 24.27 1.73 2.46 BC022107 12558 Cdh2 cadherin 2 
91 1419599_s_at 937.95 24.34 1.58 2.12 NM_026835 64382 Ms4a11 
membrane-spanning 
4-domains, subfamily 
A, member 11 
92 1439774_at 941.15 24.33 2.29 3.89 BB051738 18933 Prrx1 paired related homeobox 1 
93 1460419_a_at 942.93 24.22 1.66 2.29 X59274 18751 Prkcb1 protein kinase C, beta 1 
94 1427086_at 954.53 24.83 1.83 2.68 BM570006 --- --- --- 
95 1416168_at 964.23 25.19 1.97 3.04 NM_011340 20317 Serpinf1 
serine (or cysteine) 
peptidase inhibitor, 
clade F, member 1 
96 1418492_at 967.73 25.18 2.19 3.62 NM_011825 23893 Grem2 
gremlin 2 homolog, 
cysteine knot 
superfamily (Xenopus 
laevis) 
97 1451867_x_at 982.96 26.14 2.00 3.13 AF177664 11856 Arhgap6 Rho GTPase 
activating protein 6 
98 1427262_at 984.23 25.98 1.94 2.95 L04961 213742 Xist inactive X specific transcripts 
99 1448293_at 985.81 25.81 1.88 2.83 BB125261 13591 Ebf1 early B-cell factor 1 
100 1447830_s_at 990.58 25.97 1.82 2.67 BB034265 19735 Rgs2 regulator of G-protein 
signaling 2 
101 1417936_at 995.22 26.11 1.58 2.12 AF128196 20308 Ccl9 chemokine (C-C 
motif) ligand 9 
102 1418511_at 1004.36 26.59 1.76 2.52 NM_019759 56429 Dpt Dermatopontin 
103 1434423_at 1014.89 27.27 1.70 2.38 BB138485 --- --- --- 
104 1423311_s_at 1023.04 27.63 1.44 1.82 BQ177165 21983 Tpbg trophoblast glycoprotein 
105 1449408_at 1026.36 27.55 1.52 1.99 NM_023844 67374 Jam2 junction adhesion 
molecule 2 
106 1438009_at 1038.87 28.45 1.42 1.79 W91024 319171 Hist1h2ao histone 1, H2ao 
107 1423477_at 1039.21 28.21 1.69 2.37 BB361162 22771 Zic1 zinc finger protein of the cerebellum 1 
108 1437673_at 1039.26 27.95 1.60 2.15 AV164956 Mm.257714 --- Transcribed locus 
109 1460208_at 1043.57 28.02 2.12 3.42 NM_007993 14118 Fbn1 fibrillin 1 
110 1452296_at 1044.06 27.82 2.10 3.37 BM570006 20564 Slit3 slit homolog 3 (Drosophila) 
111 1429022_at 1044.37 27.57 1.82 2.67 AK013587 11517 Adcyap1r1 
adenylate cyclase 
activating polypeptide 
1 receptor 1 
112 1449984_at 1047.97 27.60 1.53 2.00 NM_009140 20310 Cxcl2 chemokine (C-X-C 
motif) ligand 2 
113 1426640_s_at 1050.29 27.55 1.91 2.90 BB354684 217410 Trib2 tribbles homolog 2 (Drosophila) 
114 1438118_x_at 1057.27 27.73 1.95 2.99 AV147875 22352 Vim Vimentin 
115 1426236_a_at 1071.93 28.56 1.67 2.32 AI391218 14645 Glul 
glutamate-ammonia 
ligase (glutamine 
synthetase) 
116 1440910_at 1084.85 29.08 1.65 2.27 AW495307 Mm.381907 --- 
CDNA clone 
IMAGE:5252333 
117 1454830_at 1091.86 29.35 1.47 1.88 AV010392 14119 Fbn2 fibrillin 2 
118 1423326_at 1092.49 29.13 1.97 3.03 BI151440 12495 Entpd1 
ectonucleoside 
triphosphate 
diphosphohydrolase 1 
119 1451332_at 1097.99 29.24 1.78 2.57 BC021376 225207 Zfp521 zinc finger protein 521 
120 1416740_at 1100.12 29.12 2.04 3.22 AW744319 12831 Col5a1 procollagen, type V, 
alpha 1 
121 1425357_a_at 1102.12 29.03 1.70 2.39 BC015293 23892 Grem1 gremlin 1 
122 1437726_x_at 1102.12 28.80 1.57 2.10 BB111335 12260 C1qb 
complement 
component 1, q 
subcomponent, beta 
polypeptide 
123 1424542_at 1102.94 28.61 1.78 2.58 D00208 20198 S100a4 S100 calcium binding 
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protein A4 
124 1448942_at 1113.88 29.19 1.89 2.85 NM_025331 66066 Gng11 
guanine nucleotide 
binding protein (G 
protein), gamma 11 
125 1420992_at 1116.76 29.22 1.82 2.67 AK009959 107765 Ankrd1 
ankyrin repeat 
domain 1 (cardiac 
muscle) 
126 1455494_at 1131.87 29.91 2.15 3.50 BI794771 12842 Col1a1 procollagen, type I, 
alpha 1 
127 1419693_at 1144.97 30.70 1.89 2.83 NM_130449 140792 Colec12 collectin sub-family 
member 12 
128 1457042_at 1147.07 30.63 1.73 2.45 BB328287 58871 AI256396 EST AI256396 
129 1448606_at 1150.23 30.65 1.72 2.43 U70622 14745 Edg2 
endothelial 
differentiation, 
lysophosphatidic acid 
G-protein-coupled 
receptor, 2 
130 1423271_at 1150.59 30.44 1.65 2.28 AV239646 14619 Gjb2 
gap junction 
membrane channel 
protein beta 2 
131 1418892_at 1162.74 30.97 2.02 3.17 AF309564 80837 Rhoj ras homolog gene family, member J 
132 1455426_at 1172.64 31.50 1.97 3.04 AV226618 13837 Epha3 Eph receptor A3 
133 1439380_x_at 1173.55 31.34 2.02 3.18 BB093563 17263 Gtl2 
GTL2, imprinted 
maternally expressed 
untranslated mRNA 
134 1429273_at 1174.13 31.18 1.87 2.80 AK014221 73230 Bmper BMP-binding 
endothelial regulator 
135 1448919_at 1178.48 31.22 1.85 2.74 NM_025422 66205 Cd302 CD302 antigen 
136 1437360_at 1179.09 31.04 1.74 2.48 BB053591 279653 Pcdh19 protocadherin 19 
137 1448201_at 1180.52 30.89 1.55 2.06 NM_009144 20319 Sfrp2 
secreted frizzled-
related sequence 
protein 2 
138 1416778_at 1182.06 30.72 1.84 2.72 BE197945 20324 Sdpr serum deprivation 
response 
139 1435459_at 1185.11 30.68 1.87 2.79 BM936480 55990 Fmo2 flavin containing 
monooxygenase 2 
140 1436791_at 1186.03 30.51 1.64 2.25 BB067079 22418 Wnt5a 
wingless-related 
MMTV integration site 
5A 
141 1425951_a_at 1188.07 30.39 1.81 2.65 AF240358 56620 Clec4n C-type lectin domain family 4, member n 
142 1427919_at 1188.31 30.20 1.67 2.32 BC028307 68792 Srpx2 
sushi-repeat-
containing protein, X-
linked 2 
143 1442257_at 1192.88 30.28 1.56 2.08 BI134319 Mm.204306 --- 
12 days embryo 
female mullerian duct 
includes surrounding 
region cDNA, RIKEN 
full-length enriched 
library, 
clone:6820438B06 
product:unclassifiable
, full insert sequence 
144 1420991_at 1194.70 30.18 1.44 1.81 AK009959 107765 Ankrd1 
ankyrin repeat 
domain 1 (cardiac 
muscle) 
145 1420394_s_at 1197.25 30.08 1.75 2.50 U05264 14727 14728 Gp49a /// Lilrb4 
glycoprotein 49 A /// 
leukocyte 
immunoglobulin-like 
receptor, subfamily B, 
member 4 
146 1456046_at 1198.63 30.01 1.62 2.20 AV319144 17064 C1qr1 
complement 
component 1, q 
subcomponent, 
receptor 1 
147 1452183_a_at 1204.70 30.21 1.75 2.50 Y13832 17263 Gtl2 
GTL2, imprinted 
maternally expressed 
untranslated mRNA 
148 1456014_s_at 1209.43 30.34 1.65 2.26 BB113173 108101 BC032204 cDNA sequence 
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BC032204 
149 1452445_at 1213.81 30.38 1.76 2.53 BC026874 338365 Slc41a2 solute carrier family 41, member 2 
150 1422124_a_at 1214.38 30.20 1.50 1.94 NM_011210 19264 Ptprc 
protein tyrosine 
phosphatase, 
receptor type, C 
151 1455688_at 1226.72 30.73 2.17 3.55 BB795075 98434 LOC98434 hypothetical LOC98434 
152 1450241_a_at 1231.15 30.84 1.78 2.56 NM_010161 14017 Evi2a ecotropic viral integration site 2a 
153 1421045_at 1241.21 31.37 1.88 2.82 BB528408 17534 Mrc2 mannose receptor, C type 2 
154 1439327_at 1246.77 31.51 1.68 2.34 BB197647 320924 Ccbe1 
collagen and calcium 
binding EGF domains 
1 
155 1416072_at 1256.35 31.96 2.02 3.16 NM_133654 12490 Cd34 CD34 antigen 
156 1452366_at 1258.53 31.87 1.56 2.07 AV371987 234356 4732435N03Rik RIKEN cDNA 4732435N03 gene 
157 1449473_s_at 1259.58 31.71 1.60 2.17 NM_011611 21939 Cd40 CD40 antigen 
158 1424131_at 1267.67 32.21 1.70 2.40 AF064749 12835 Col6a3 procollagen, type VI, 
alpha 3 
159 1423547_at 1267.81 32.02 1.63 2.23 AW208566 17105 Lyzs Lysozyme 
160 1434877_at 1268.95 31.91 2.11 3.40 AI152800 18164 Nptx1 neuronal pentraxin 1 
161 1416468_at 1276.93 32.25 1.89 2.85 NM_013467 11668 Aldh1a1 
aldehyde 
dehydrogenase family 
1, subfamily A1 
162 1439181_at 1277.63 32.12 1.46 1.86 AV020760 210104 BC043301 cDNA sequence BC043301 
163 1428432_at 1283.31 32.37 1.55 2.06 BB813478 71918 2310047A01Rik RIKEN cDNA 2310047A01 gene 
164 1433695_at 1284.05 32.23 1.62 2.21 BQ174762 380686 1500041B16Rik RIKEN cDNA 1500041B16 gene 
165 1437056_x_at 1287.99 32.23 1.51 1.97 BB558800 78892 Crispld2 
cysteine-rich 
secretory protein 
LCCL domain 
containing 2 
166 1436936_s_at 1289.80 32.15 1.75 2.49 BG806300 213742 Xist inactive X specific transcripts 
167 1450826_a_at 1292.53 32.15 1.81 2.64 NM_011315 20210 Saa3 serum amyloid A 3 
168 1448194_a_at 1307.72 32.86 1.40 1.75 NM_023123 14955 H19 H19 fetal liver mRNA 
169 1437385_at 1309.05 32.76 1.85 2.74 AV264768 320924 Ccbe1 
collagen and calcium 
binding EGF domains 
1 
170 1450684_at 1318.88 33.22 1.70 2.38 NM_007960 14009 Etv1 ets variant gene 1 
171 1424382_at 1321.77 33.29 1.88 2.82 BC025602 52377 Rcn3 
reticulocalbin 3, EF-
hand calcium binding 
domain 
172 1451161_a_at 1330.77 33.72 1.42 1.78 U66888 13733 Emr1 
EGF-like module 
containing, mucin-
like, hormone 
receptor-like 
sequence 1 
173 1434298_at 1331.24 33.55 1.59 2.14 BQ174116 24136 Zfhx1b zinc finger homeobox 1b 
174 1419442_at 1335.10 33.75 1.50 1.95 BC005429 17181 Matn2 matrilin 2 
175 1452339_at 1343.82 34.11 1.52 1.98 AL359935 108153 Adamts7 
a disintegrin-like and 
metallopeptidase 
(reprolysin type) with 
thrombospondin type 
1 motif, 7 
176 1448433_a_at 1347.37 34.24 1.75 2.50 NM_008788 18542 Pcolce 
procollagen C-
endopeptidase 
enhancer protein 
177 1420772_a_at 1362.23 35.11 1.40 1.74 NM_010286 14605 Tsc22d3 TSC22 domain family 3 
178 1456475_s_at 1367.93 35.22 1.58 2.13 BB216074 19088 Prkar2b 
protein kinase, cAMP 
dependent regulatory, 
type II beta 
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179 1417649_at 1371.14 35.28 1.87 2.79 NM_009876 12577 Cdkn1c 
cyclin-dependent 
kinase inhibitor 1C 
(P57) 
180 1428642_at 1376.30 35.43 1.57 2.09 AK018094 76157 Slc35d3 solute carrier family 35, member D3 
181 1437903_at 1380.77 35.54 1.50 1.94 BB820958 16948 Lox lysyl oxidase 
182 1423327_at 1392.35 36.16 1.67 2.33 AK005645 68172 4930517K11Rik RIKEN cDNA 4930517K11 gene 
183 1449314_at 1406.49 36.84 1.71 2.41 NM_011766 22762 Zfpm2 zinc finger protein, 
multitype 2 
184 1420249_s_at 1412.65 37.03 1.68 2.34 AV084904 20305 Ccl6 chemokine (C-C 
motif) ligand 6 
185 1436659_at 1419.14 37.39 1.90 2.86 BB757120 13175 Dcamkl1 
Double cortin and 
calcium/calmodulin-
dependent protein 
kinase-like 1, mRNA 
(cDNA clone 
IMAGE:5006471) 
186 1427076_at 1420.25 37.26 1.65 2.27 L20315 17476 Mpeg1 macrophage 
expressed gene 1 
187 1427300_at 1421.31 37.15 1.81 2.65 D49658 16875 Lhx8 LIM homeobox protein 8 
188 1451289_at 1426.94 37.30 1.87 2.78 AW105916 13175 Dcamkl1 
double cortin and 
calcium/calmodulin-
dependent protein 
kinase-like 1 
189 1420688_a_at 1428.63 37.24 1.52 1.98 NM_011360 20392 Sgce sarcoglycan, epsilon 
190 1460292_a_at 1437.47 37.61 1.42 1.78 NM_053123 93761 Smarca1 
SWI/SNF related, 
matrix associated, 
actin dependent 
regulator of 
chromatin, subfamily 
a, member 1 
191 1452382_at 1439.22 37.55 1.83 2.68 BB542096 --- --- --- 
192 1450079_at 1442.66 37.59 1.73 2.45 AK012873 27206 Nrk Nik related kinase 
193 1457753_at 1461.09 38.58 1.54 2.03 BI655907 279572 Tlr13 toll-like receptor 13 
194 1421228_at 1472.68 39.19 1.67 2.33 AF128193 20306 Ccl7 chemokine (C-C 
motif) ligand 7 
195 1424659_at 1507.79 41.70 1.77 2.56 BG963150 20563 Slit2 slit homolog 2 (Drosophila) 
196 1433885_at 1507.90 41.49 1.72 2.44 BM240173 544963 Iqgap2 
IQ motif containing 
GTPase activating 
protein 2 
197 1417148_at 1546.39 44.16 1.51 1.96 NM_008809 18596 Pdgfrb 
platelet derived 
growth factor 
receptor, beta 
polypeptide 
198 1450852_s_at 1563.76 45.34 1.76 2.54 BQ173958 14062 F2r coagulation factor II (thrombin) receptor 
199 1451016_at 1573.54 45.88 1.31 1.55 BB540964 15983 Ifrd2 
interferon-related 
developmental 
regulator 2 
200 1438530_at 1577.96 45.97 1.46 1.86 BB756069 21788 Tfpi tissue factor pathway inhibitor 
201 1450004_at 1598.64 47.40 1.21 1.36 NM_021367 53603 Tslp thymic stromal lymphopoietin 
202 1416805_at 1599.80 47.27 1.52 1.98 NM_133187 68659 1110032E23Rik RIKEN cDNA 1110032E23 gene 
203 1434325_x_at 1606.07 47.50 1.58 2.11 BB274009 19085 Prkar1b 
protein kinase, cAMP 
dependent regulatory, 
type I beta 
204 1422748_at 1619.25 48.26 1.74 2.48 NM_015753 24136 Zfhx1b zinc finger homeobox 1b 
205 1440969_at 1622.67 48.29 1.32 1.58 BE944957 407797 BC030308 cDNA sequence BC030308 
206 1442082_at 1635.09 48.95 1.55 2.05 BB333624 12267 C3ar1 
complement 
component 3a 
receptor 1 
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207 1424086_at 1638.55 48.96 1.52 1.99 BC025514 102644 D9Ucla1 
DNA segment, Chr 9, 
University of 
California at Los 
Angeles 1 
208 1431079_at 1641.74 48.98 1.59 2.13 BF148029 69183 C1qtnf2 
C1q and tumor 
necrosis factor related 
protein 2 
209 1432466_a_at 1647.20 49.19 1.48 1.89 AK019319 11816 Apoe apolipoprotein E 
210 1455393_at 1651.60 49.27 1.49 1.92 BB009037 --- --- --- 
211 1427263_at 1653.60 49.18 1.39 1.73 L04961 213742 Xist inactive X specific transcripts 
212 1429514_at 1654.13 49.00 1.56 2.08 AW111876 67916 Ppap2b phosphatidic acid phosphatase type 2B 
213 1443673_x_at 1659.77 49.19 1.30 1.54 BB710847 --- --- --- 
214 1432517_a_at 1664.55 49.35 1.41 1.76 AK006371 18113 Nnmt nicotinamide N-
methyltransferase 
215 1456389_at 1669.64 49.54 1.47 1.88 BB244754 24136 Zfhx1b zinc finger homeobox 1b 
216 1418826_at 1678.82 49.93 1.60 2.15 NM_027209 69774 Ms4a6b 
membrane-spanning 
4-domains, subfamily 
A, member 6B 
217 1446085_at 1681.26 49.93 1.35 1.63 BB022048 216233 Socs2 
Suppressor of 
cytokine signaling 2 
(Socs2), mRNA 
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The Rank Product (RP) differential expression analysis report 
 
 
 
 
General Information 
Experiment  VK1mouse4302 
Normalisation  rma across replicates 
Chip  one chip only 
Comparison  Treatment samples: K14D6 + CCL3 vs Baseline samples: TG Control 
RP comparison  not paired 
Direction  Positive 
 
 
 
0 Probe-set ID RPscore FDR FC_rma FC_nom "SOURCE" "EntrezGene" Gene Symbol Title 
1 1418601_at 97.20 3.00 3.31 7.11 NM_011921 26358 Aldh1a7 
aldehyde 
dehydrogenase 
family 1, 
subfamily A7 
2 1436996_x_at 106.48 1.50 2.47 4.41 AV066625 17110 Lzp-s P lysozyme 
structural 
3 1448591_at 110.66 1.33 2.33 4.01 NM_021281 13040 Ctss cathepsin S 
4 1439426_x_at 132.50 1.50 2.33 4.01 AV058500 17110 Lzp-s P lysozyme 
structural 
5 1423522_at 147.22 1.40 2.11 3.39 BB811478 18150 Npm3 nucleoplasmin 3 
6 1452141_a_at 162.85 1.50 2.31 3.96 BC001991 20363 Sepp1 selenoprotein P, plasma, 1 
7 1418666_at 199.63 2.71 2.18 3.58 NM_008987 19288 Ptx3 pentraxin related gene 
8 1416468_at 210.40 2.75 2.31 3.94 NM_013467 11668 Aldh1a1 
aldehyde 
dehydrogenase 
family 1, 
subfamily A1 
9 1436905_x_at 234.40 3.67 1.89 2.85 BB218107 16792 Laptm5 
lysosomal-
associated protein 
transmembrane 5 
10 1448620_at 242.06 3.90 1.97 3.04 NM_010188 14131 Fcgr3 Fc receptor, IgG, low affinity III 
11 1427883_a_at 254.35 4.27 2.18 3.59 AW550625 12825 Col3a1 procollagen, type III, alpha 1 
12 1460197_a_at 279.37 5.17 2.22 3.71 NM_054098 117167 Steap4 STEAP family 
member 4 
13 1420504_at 296.41 6.38 1.61 2.18 AF320226 56774 Slc6a14 
solute carrier 
family 6 
(neurotransmitter 
transporter), 
member 14 
14 1424186_at 302.93 6.14 2.05 3.26 BG074158 67896 2610001E17Rik RIKEN cDNA 2610001E17 gene 
15 1427747_a_at 305.98 5.87 1.79 2.61 X14607 16819 Lcn2 lipocalin 2 
16 1432466_a_at 313.90 5.94 1.92 2.92 AK019319 11816 Apoe apolipoprotein E 
17 1417936_at 373.00 9.29 1.82 2.66 AF128196 20308 Ccl9 chemokine (C-C 
motif) ligand 9 
18 1423091_a_at 398.97 11.22 1.98 3.05 AK016567 14758 Gpm6b glycoprotein m6b 
19 1452905_at 423.63 12.68 2.11 3.40 AV015833 17263 330814 Gtl2 /// Lphn1 
GTL2, imprinted 
maternally 
expressed 
untranslated 
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mRNA /// 
latrophilin 1 
20 1449833_at 427.48 12.40 1.68 2.34 NM_011472 20760 Sprr2f small proline-rich protein 2F 
21 1417266_at 430.38 12.24 1.86 2.77 BC002073 20305 Ccl6 chemokine (C-C 
motif) ligand 6 
22 1425087_at 435.11 12.23 1.60 2.16 BC021588 67693 2310003F16Rik RIKEN cDNA 2310003F16 gene 
23 1420394_s_at 446.67 12.52 1.92 2.90 U05264 14727 14728 Gp49a /// Lilrb4 
glycoprotein 49 A 
/// leukocyte 
immunoglobulin-
like receptor, 
subfamily B, 
member 4 
24 1455494_at 463.36 13.08 1.86 2.77 BI794771 12842 Col1a1 procollagen, type I, alpha 1 
25 1423547_at 464.59 12.56 1.85 2.73 AW208566 17105 Lyzs lysozyme 
26 1452250_a_at 482.72 13.31 1.90 2.85 BI455189 12834 Col6a2 procollagen, type VI, alpha 2 
27 1435477_s_at 496.59 13.89 1.72 2.43 BM224327 14130 Fcgr2b Fc receptor, IgG, low affinity IIb 
28 1419100_at 508.00 14.46 1.85 2.75 NM_009252 20716 Serpina3n 
serine (or 
cysteine) 
peptidase 
inhibitor, clade A, 
member 3N 
29 1422939_at 508.61 13.97 1.53 2.01 NM_009126 383548 Serpinb3b 
serine (or 
cysteine) 
peptidase 
inhibitor, clade B 
(ovalbumin), 
member 3B 
30 1448590_at 512.09 13.70 1.85 2.74 NM_009933 12833 Col6a1 procollagen, type VI, alpha 1 
31 1420503_at 535.10 14.87 1.49 1.92 AF320226 56774 Slc6a14 
solute carrier 
family 6 
(neurotransmitter 
transporter), 
member 14 
32 1435459_at 539.54 14.88 1.85 2.74 BM936480 55990 Fmo2 flavin containing 
monooxygenase 2 
33 1422940_x_at 583.05 18.36 1.53 2.01 NM_009126 383548 Serpinb3b 
serine (or 
cysteine) 
peptidase 
inhibitor, clade B 
(ovalbumin), 
member 3B 
34 1423271_at 591.98 18.88 1.45 1.83 AV239646 14619 Gjb2 
gap junction 
membrane 
channel protein 
beta 2 
35 1433530_at 613.80 20.00 1.51 1.96 BI694945 70164 2210411K19Rik RIKEN cDNA 2210411K19 gene 
36 1423537_at 615.70 19.67 1.87 2.79 BB622036 14432 Gap43 growth associated protein 43 
37 1448326_a_at 627.16 20.08 1.75 2.51 NM_013496 12903 Crabp1 
cellular retinoic 
acid binding 
protein I 
38 1424754_at 644.48 21.11 1.55 2.05 BC024402 109225 Ms4a7 
membrane-
spanning 4-
domains, 
subfamily A, 
member 7 
39 1448259_at 653.72 21.44 1.76 2.52 BI452727 14314 Fstl1 follistatin-like 1 
40 1424843_a_at 663.67 21.62 1.48 1.89 BC004622 14455 Gas5 growth arrest 
specific 5 
41 1438405_at 665.38 21.44 1.86 2.77 BB791906 14178 Fgf7 fibroblast growth factor 7 
42 1449154_at 671.67 21.45 1.86 2.78 NM_007729 12814 Col11a1 procollagen, type XI, alpha 1 
43 1436970_a_at 682.68 21.84 1.73 2.45 AA499047 18596 Pdgfrb platelet derived 
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growth factor 
receptor, beta 
polypeptide 
44 1418599_at 696.26 22.52 1.81 2.65 NM_007729 12814 Col11a1 procollagen, type XI, alpha 1 
45 1420804_s_at 720.74 24.69 1.57 2.09 NM_010819 17474 Clec4d 
C-type lectin 
domain family 4, 
member d 
46 1448756_at 729.95 25.20 1.40 1.74 NM_009114 20202 S100a9 
S100 calcium 
binding protein A9 
(calgranulin B) 
47 1448748_at 730.24 24.68 1.55 2.05 AF181829 56193 Plek pleckstrin 
48 1417785_at 734.92 24.60 1.58 2.12 NM_134102 85031 Pla1a phospholipase A1 
member A 
49 1416221_at 735.00 24.12 1.74 2.48 BI452727 14314 Fstl1 follistatin-like 1 
50 1452296_at 738.70 24.00 1.72 2.43 BM570006 20564 Slit3 slit homolog 3 (Drosophila) 
51 1448475_at 739.77 23.61 1.64 2.25 NM_133859 99543 Olfml3 olfactomedin-like 3 
52 1424265_at 742.77 23.38 1.51 1.97 BC022734 74091 Npl 
N-
acetylneuraminate 
pyruvate lyase 
53 1426947_x_at 743.55 22.98 1.75 2.51 BI455189 12834 Col6a2 procollagen, type VI, alpha 2 
54 1440739_at 753.02 23.33 1.63 2.24 AW228853 22341 Vegfc 
vascular 
endothelial growth 
factor C 
55 1423110_at 757.87 23.31 1.76 2.53 BF227507 --- --- --- 
56 1418892_at 764.07 23.25 1.72 2.44 AF309564 80837 Rhoj ras homolog gene family, member J 
57 1448228_at 776.52 23.63 1.86 2.77 M65143 16948 Lox lysyl oxidase 
58 1419627_s_at 777.85 23.34 1.67 2.31 NM_020001 56620 Clec4n 
C-type lectin 
domain family 4, 
member n 
59 1419394_s_at 794.29 24.37 1.42 1.77 NM_013650 20201 S100a8 
S100 calcium 
binding protein A8 
(calgranulin A) 
60 1435943_at 807.08 25.17 1.89 2.84 AI647687 13479 Dpep1 dipeptidase 1 (renal) 
61 1448995_at 827.30 26.46 1.65 2.28 NM_019932 56744 Cxcl4 chemokine (C-X-C motif) ligand 4 
62 1451718_at 827.63 26.06 1.45 1.84 BB768495 18823 Plp1 proteolipid protein (myelin) 1 
63 1423259_at 834.40 26.32 1.56 2.07 BB121406 15904 Id4 inhibitor of DNA binding 4 
64 1450857_a_at 834.80 25.92 1.71 2.41 BF227507 12843 Col1a2 procollagen, type I, alpha 2 
65 1417649_at 835.68 25.65 1.86 2.76 NM_009876 12577 Cdkn1c 
cyclin-dependent 
kinase inhibitor 
1C (P57) 
66 1449984_at 838.10 25.42 1.56 2.06 NM_009140 20310 Cxcl2 chemokine (C-X-C motif) ligand 2 
67 1448293_at 858.04 26.76 1.58 2.12 BB125261 13591 Ebf1 early B-cell factor 1 
68 1424382_at 861.21 26.69 1.67 2.31 BC025602 52377 Rcn3 
reticulocalbin 3, 
EF-hand calcium 
binding domain 
69 1457040_at 863.35 26.49 1.47 1.88 BE947711 246316 Lgi2 
leucine-rich 
repeat LGI family, 
member 2 
70 1419599_s_at 866.01 26.29 1.58 2.12 NM_026835 64382 Ms4a11 
membrane-
spanning 4-
domains, 
subfamily A, 
member 11 
71 1416121_at 870.48 26.28 1.71 2.42 M65143 16948 Lox lysyl oxidase 
72 1443790_x_at 902.84 28.36 1.37 1.68 AV208084 78108 4930414L22Rik RIKEN cDNA 4930414L22 gene 
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73 1448194_a_at 909.59 28.47 1.50 1.94 NM_023123 14955 H19 H19 fetal liver 
mRNA 
74 1429273_at 914.94 28.57 1.70 2.39 AK014221 73230 Bmper 
BMP-binding 
endothelial 
regulator 
75 1419417_at 915.86 28.24 1.59 2.14 NM_009506 22341 Vegfc 
vascular 
endothelial growth 
factor C 
76 1437517_x_at 918.09 27.99 1.37 1.68 BB699605 20248 Serpinb3a 
serine (or 
cysteine) 
peptidase 
inhibitor, clade B 
(ovalbumin), 
member 3A 
77 1449368_at 922.52 27.90 1.67 2.32 NM_007833 13179 Dcn decorin 
78 1450757_at 925.19 27.76 1.56 2.07 NM_009866 12552 Cdh11 cadherin 11 
79 1439380_x_at 928.28 27.68 1.75 2.51 BB093563 17263 Gtl2 
GTL2, imprinted 
maternally 
expressed 
untranslated 
mRNA 
80 1457642_at 932.93 27.65 1.38 1.70 BB255999 70622 5730507N06Rik 
RIKEN cDNA 
5730507N06 
gene 
81 1420867_at 945.78 28.28 1.37 1.67 BB609648 56334 Tmed2 
transmembrane 
emp24 domain 
trafficking protein 
2 
82 1437165_a_at 956.17 28.85 1.62 2.20 BB250811 18542 Pcolce 
procollagen C-
endopeptidase 
enhancer protein 
83 1460250_at 971.86 30.01 1.57 2.10 BC021458 66042 Sostdc1 sclerostin domain 
containing 1 
84 1448397_at 974.60 29.90 1.28 1.50 BC016507 14623 Gjb6 
gap junction 
membrane 
channel protein 
beta 6 
85 1420249_s_at 977.46 29.84 1.51 1.97 AV084904 20305 Ccl6 chemokine (C-C 
motif) ligand 6 
86 1419463_at 978.22 29.53 1.55 2.04 AF108501 80797 Clca2 
chloride channel 
calcium activated 
2 
87 1430655_at 988.47 29.91 1.47 1.88 BE685884 70800 4631405K08Rik RIKEN cDNA 4631405K08 gene 
88 1450652_at 993.62 30.05 1.63 2.24 NM_007802 13038 Ctsk cathepsin K 
89 1419483_at 1011.87 31.35 1.38 1.70 NM_009779 12267 C3ar1 
complement 
component 3a 
receptor 1 
90 1448323_a_at 1017.20 31.40 1.52 1.99 BC019502 12111 Bgn biglycan 
91 1443897_at 1022.26 31.38 1.44 1.82 BB200603 13198 Ddit3 
DNA-damage 
inducible 
transcript 3 
92 1432517_a_at 1022.64 31.12 1.51 1.97 AK006371 18113 Nnmt nicotinamide N-
methyltransferase 
93 1438069_a_at 1027.87 31.16 1.38 1.70 BE446879 83486 Rbm5 RNA binding motif protein 5 
94 1419598_at 1033.12 31.26 1.54 2.03 NM_026835 68774 Ms4a6d 
membrane-
spanning 4-
domains, 
subfamily A, 
member 6D 
95 1427086_at 1033.55 30.94 1.58 2.12 BM570006 --- --- --- 
96 1438403_s_at 1033.62 30.63 1.41 1.75 BF537798 80291 BC003324 
CDNA sequence 
BC003324, 
mRNA (cDNA 
clone MGC:7036 
IMAGE:3156139) 
97 1450826_a_at 1039.65 30.82 1.61 2.18 NM_011315 20210 Saa3 serum amyloid A 3 
98 1424903_at 1043.42 30.77 1.58 2.12 AF127244 20592 Jarid1d jumonji, AT rich 
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interactive domain 
1D (Rbp2 like) 
99 1423606_at 1051.64 31.16 1.71 2.42 BI110565 50706 Postn 
periostin, 
osteoblast specific 
factor 
100 1420499_at 1055.47 31.16 1.43 1.79 NM_008102 14528 Gch1 GTP 
cyclohydrolase 1 
101 1439766_x_at 1058.94 31.08 1.52 1.99 BB089170 22341 Vegfc 
vascular 
endothelial growth 
factor C 
102 1433695_at 1062.92 31.13 1.51 1.97 BQ174762 380686 1500041B16Rik RIKEN cDNA 1500041B16 gene 
103 1420676_at 1070.91 31.50 1.38 1.71 NM_025984 67127 Sprrl3 small proline rich-like 3 
104 1455607_at 1087.25 32.29 1.55 2.05 BG072958 72780 Rspo3 
R-spondin 3 
homolog 
(Xenopus laevis) 
105 1429297_at 1090.31 32.27 1.41 1.75 AK009018 71869 Serpinb12 
serine (or 
cysteine) 
peptidase 
inhibitor, clade B 
(ovalbumin), 
member 12 
106 1421228_at 1129.88 35.33 1.69 2.37 AF128193 20306 Ccl7 chemokine (C-C 
motif) ligand 7 
107 1416779_at 1130.25 35.03 1.46 1.86 BE197945 20324 Sdpr serum deprivation 
response 
108 1435934_at 1144.23 35.91 1.43 1.80 AI643884 70316 Ndufab1 
NADH 
dehydrogenase 
(ubiquinone) 1, 
alpha/beta 
subcomplex, 1 
109 1434479_at 1161.59 37.06 1.49 1.93 AV246911 12831 Col5a1 
Procollagen, type 
V, alpha 1 
(Col5a1), mRNA 
110 1416077_at 1162.52 36.79 1.54 2.03 NM_009627 11535 Adm adrenomedullin 
111 1422963_at 1167.55 36.90 1.31 1.56 NM_011475 20763 Sprr2i small proline-rich protein 2I 
112 1425357_a_at 1176.66 37.24 1.52 1.99 BC015293 23892 Grem1 gremlin 1 
113 1460259_s_at 1182.29 37.41 1.52 1.99 AF108501 12722 80797 Clca1 /// Clca2 
chloride channel 
calcium activated 
1 /// chloride 
channel calcium 
activated 2 
114 1435639_at 1183.14 37.14 1.43 1.80 BF580962 70045 2610528A11Rik RIKEN cDNA 2610528A11 gene 
115 1451939_a_at 1186.41 37.15 1.35 1.64 AB028050 51795 Srpx sushi-repeat-
containing protein 
116 1436055_at 1204.38 38.34 1.52 1.99 AI506528 74488 Lrrc15 leucine rich repeat 
containing 15 
117 1421492_at 1208.73 38.34 1.36 1.66 NM_019455 54486 Ptgds2 
prostaglandin D2 
synthase 2, 
hematopoietic 
118 1448303_at 1210.06 38.14 1.41 1.76 NM_053110 93695 Gpnmb 
glycoprotein 
(transmembrane) 
nmb 
119 1422571_at 1215.82 38.34 1.69 2.35 NM_011581 21826 Thbs2 thrombospondin 2 
120 1424542_at 1217.79 38.22 1.40 1.75 D00208 20198 S100a4 S100 calcium binding protein A4 
121 1452138_a_at 1219.78 38.05 1.38 1.69 BB497528 70008 Ace2 
angiotensin I 
converting 
enzyme (peptidyl-
dipeptidase A) 2 
122 1450618_a_at 1228.45 38.52 1.34 1.61 NM_011468 20755 Sprr2a small proline-rich protein 2A 
123 1416136_at 1242.21 39.27 1.71 2.41 NM_008610 17390 Mmp2 
matrix 
metallopeptidase 
2 
124 1417256_at 1246.90 39.42 1.22 1.39 NM_008607 17386 Mmp13 matrix 
metallopeptidase 
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13 
125 1417852_x_at 1252.74 39.53 1.40 1.74 AF047838 12722 Clca1 
chloride channel 
calcium activated 
1 
126 1419665_a_at 1253.73 39.26 1.38 1.69 NM_019738 56312 Nupr1 nuclear protein 1 
127 1435343_at 1255.50 39.16 1.53 2.00 BF715043 210293 Dock10 dedicator of 
cytokinesis 10 
128 1448061_at 1264.04 39.57 1.48 1.91 AA183642 --- --- --- 
129 1416405_at 1265.70 39.38 1.45 1.85 BC019502 12111 Bgn biglycan 
130 1418492_at 1266.15 39.11 1.52 1.99 NM_011825 23893 Grem2 
gremlin 2 
homolog, cysteine 
knot superfamily 
(Xenopus laevis) 
131 1448925_at 1268.43 38.96 1.54 2.02 NM_007855 13345 Twist2 twist homolog 2 (Drosophila) 
132 1449314_at 1270.69 38.87 1.46 1.86 NM_011766 22762 Zfpm2 zinc finger protein, 
multitype 2 
133 1443768_at 1273.77 38.83 1.41 1.75 BG101505 11848 Rhoa 
Ras homolog 
gene family, 
member A 
(Rhoa), mRNA 
134 1417494_a_at 1273.90 38.54 1.55 2.06 BB332449 12870 Cp ceruloplasmin 
135 1456379_x_at 1274.42 38.31 1.34 1.61 BB038556 227325 Dner 
delta/notch-like 
EGF-related 
receptor 
136 1420380_at 1282.63 38.65 1.67 2.32 AF065933 20296 Ccl2 chemokine (C-C 
motif) ligand 2 
137 1417210_at 1294.04 39.26 1.55 2.05 NM_012011 26908 Eif2s3y 
eukaryotic 
translation 
initiation factor 2, 
subunit 3, 
structural gene Y-
linked 
138 1450430_at 1297.13 39.17 1.47 1.89 NM_008625 17533 Mrc1 mannose 
receptor, C type 1 
139 1422837_at 1299.90 39.14 1.24 1.43 NM_022886 64929 Scel sciellin 
140 1419247_at 1311.81 39.72 1.45 1.84 AF215668 19735 Rgs2 regulator of G-protein signaling 2 
141 1416740_at 1314.96 39.72 1.47 1.88 AW744319 12831 Col5a1 procollagen, type V, alpha 1 
142 1422317_a_at 1327.48 40.41 1.74 2.48 NM_010743 17082 Il1rl1 interleukin 1 
receptor-like 1 
143 1426302_at 1327.77 40.16 1.33 1.59 BC021368 214523 Tmprss4 transmembrane protease, serine 4 
144 1417009_at 1334.11 40.38 1.48 1.90 NM_023143 50909 C1r 
complement 
component 1, r 
subcomponent 
145 1455426_at 1342.39 40.70 1.51 1.96 AV226618 13837 Epha3 Eph receptor A3 
146 1423634_at 1354.58 41.49 1.28 1.50 AI506986 57911 Gsdm1 gasdermin 1 
147 1444176_at 1375.02 42.96 1.32 1.58 AV204216 242341 Atp6v0d2 
ATPase, H+ 
transporting, V0 
subunit D, isoform 
2 
148 1420498_a_at 1377.68 42.91 1.53 2.00 NM_023118 13132 Dab2 disabled homolog 2 (Drosophila) 
149 1421194_at 1383.73 43.09 1.42 1.78 NM_010576 16401 Itga4 integrin alpha 4 
150 1455431_at 1391.19 43.42 1.35 1.63 AV371434 20537 Slc5a1 
solute carrier 
family 5 
(sodium/glucose 
cotransporter), 
member 1 
151 1434195_at 1405.67 44.29 1.45 1.83 BB042892 244954 Prss35 protease, serine, 35 
152 1428642_at 1410.00 44.40 1.41 1.75 AK018094 76157 Slc35d3 
solute carrier 
family 35, 
member D3 
153 1416072_at 1415.04 44.40 1.46 1.85 NM_133654 12490 Cd34 CD34 antigen 
154 1450783_at 1415.15 44.11 1.30 1.54 NM_008331 15957 Ifit1 interferon-induced 
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protein with 
tetratricopeptide 
repeats 1 
155 1455930_at 1424.05 44.67 1.30 1.54 BI651113 --- --- --- 
156 1455899_x_at 1427.58 44.75 1.31 1.56 BB241535 12702 Socs3 
suppressor of 
cytokine signaling 
3 
157 1436530_at 1429.16 44.57 1.44 1.83 AA666504 Mm.24097 --- 
CDNA clone 
MGC:107680 
IMAGE:6766535 
158 1421045_at 1443.93 45.50 1.48 1.91 BB528408 17534 Mrc2 mannose 
receptor, C type 2 
159 1439364_a_at 1450.22 45.77 1.62 2.20 BF147716 17390 Mmp2 
matrix 
metallopeptidase 
2 
160 1449254_at 1464.84 46.70 1.36 1.66 NM_009263 20750 Spp1 secreted phosphoprotein 1 
161 1437658_a_at 1475.87 47.36 1.33 1.60 AW552536 83673 Rnu22 RNA, U22 small 
nucleolar 
162 1418266_at 1478.82 47.39 1.26 1.45 NM_009659 11686 Alox12b 
arachidonate 12-
lipoxygenase, 
12R type 
163 1444061_at 1482.07 47.46 1.29 1.51 BB150166 109314 A030004J04Rik RIKEN cDNA A030004J04 gene 
164 1417516_at 1492.32 48.02 1.31 1.56 NM_007837 13198 Ddit3 
DNA-damage 
inducible 
transcript 3 
165 1455573_at 1494.80 47.92 1.34 1.62 BE197934 16664 Krt1-14 keratin complex 1, 
acidic, gene 14 
166 1448162_at 1495.67 47.71 1.46 1.86 BB250384 22329 Vcam1 
vascular cell 
adhesion 
molecule 1 
167 1416593_at 1501.01 47.82 1.40 1.74 AF276917 93692 Glrx1 glutaredoxin 1 (thioltransferase) 
168 1454830_at 1502.75 47.65 1.41 1.76 AV010392 14119 Fbn2 fibrillin 2 
169 1451332_at 1511.71 48.01 1.43 1.79 BC021376 225207 Zfp521 zinc finger protein 521 
170 1416200_at 1524.31 48.78 1.20 1.36 NM_133775 77125 9230117N10Rik 
RIKEN cDNA 
9230117N10 
gene 
171 1429504_at 1538.85 49.65 1.36 1.65 BE134108 67225 Rnpc3 
RNA-binding 
region (RNP1, 
RRM) containing 
3 
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The Rank Product (RP) differential expression analysis report 
 
 
 
 
General Information 
Experiment  VK1mouse4302 
Normalisation  rma across replicates 
Chip  one chip only 
Comparison  Treatment samples: K14D6 + CCL3 vs Baseline samples: WT + CCL3 
RP comparison  not paired 
Direction  Positive 
 
0 Probe-set ID RPscore FDR FC_rma FC_nom "SOURCE" "EntrezGene" Gene Symbol Title 
1 1422111_at 1.28 0.00 35.02 340.86 BE631540 59289 Ccbp2 chemokine binding protein 2 
2 1426438_at 186.44 12.00 3.97 9.59 AA210261 26900 Ddx3y 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
3, Y-linked 
3 1417210_at 190.60 9.00 3.73 8.67 NM_012011 26908 Eif2s3y 
eukaryotic translation 
initiation factor 2, 
subunit 3, structural 
gene Y-linked 
4 1452077_at 280.18 21.25 2.31 3.95 AA210261 26900 Ddx3y 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
3, Y-linked 
5 1420504_at 335.66 27.20 1.55 2.05 AF320226 56774 Slc6a14 
solute carrier family 6 
(neurotransmitter 
transporter), member 
14 
6 1426598_at 396.73 33.67 1.58 2.12 BB742957 
22290 
546404 
546411 
Uty /// 
LOC546404 
/// 
LOC546411 
ubiquitously 
transcribed 
tetratricopeptide 
repeat gene, Y 
chromosome /// 
similar to male-
specific 
histocompatibility 
antigen H-YDb /// 
similar to male-
specific 
histocompatibility 
antigen H-YDb 
7 1424903_at 407.62 31.86 1.92 2.92 AF127244 20592 Jarid1d 
jumonji, AT rich 
interactive domain 
1D (Rbp2 like) 
8 1417022_at 423.42 32.00 1.52 1.99 NM_007515 11989 Slc7a3 
solute carrier family 7 
(cationic amino acid 
transporter, y+ 
system), member 3 
9 1426439_at 612.17 NA 1.80 2.62 AA210261 26900 Ddx3y 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
3, Y-linked 
10 1423522_at 627.90 NA 1.50 1.95 BB811478 18150 Npm3 nucleoplasmin 3 
11 1449484_at 698.90 NA 1.44 1.82 AF031035 20856 Stc2 stanniocalcin 2 
12 1437935_at 710.40 NA 1.46 1.85 BB821151 75033 4930486G11Rik 
RIKEN cDNA 
4930486G11 gene 
13 1415862_at 729.26 NA 1.36 1.66 BB762957 22178 Tyrp1 tyrosinase-related protein 1 
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14 1420503_at 789.24 NA 1.38 1.69 AF320226 56774 Slc6a14 
solute carrier family 6 
(neurotransmitter 
transporter), member 
14 
15 1421003_at 826.18 NA 1.38 1.69 AA024025 56809 Gmeb1 
glucocorticoid 
modulatory element 
binding protein 1 
16 1455626_at 917.50 NA 1.14 1.24 AA987181 15405 Hoxa9 homeo box A9 
17 1420901_a_at 948.05 NA 1.36 1.65 NM_010438 15275 Hk1 hexokinase 1 
18 1418666_at 956.11 NA 1.22 1.38 NM_008987 19288 Ptx3 pentraxin related gene 
19 1422523_at 973.05 NA 1.30 1.54 NM_021882 20431 Si silver 
20 1422481_at 977.84 NA 1.28 1.50 NM_008473 16678 Krt2-1 keratin complex 2, basic, gene 1 
21 1437445_at 1076.16 NA 1.23 1.41 BB770967 17364 Trpm1 
transient receptor 
potential cation 
channel, subfamily 
M, member 1 
22 1452315_at 1120.02 NA 1.36 1.66 BB827235 16551 Kif11 kinesin family 
member 11 
23 1417649_at 1128.63 NA 1.23 1.41 NM_009876 12577 Cdkn1c 
cyclin-dependent 
kinase inhibitor 1C 
(P57) 
24 1415861_at 1141.68 NA 1.24 1.43 BB762957 22178 Tyrp1 tyrosinase-related protein 1 
25 1456095_at 1150.01 NA 1.19 1.33 BB769772 22173 Tyr tyrosinase 
26 1418028_at 1186.33 NA 1.26 1.46 NM_010024 13190 Dct dopachrome tautomerase 
27 1426065_a_at 1196.86 NA 1.36 1.65 BC012955 228775 Trib3 tribbles homolog 3 (Drosophila) 
28 1421830_at 1228.50 NA 1.33 1.60 NM_009647 11639 Ak3l1 adenylate kinase 3 
alpha-like 1 
29 1456225_x_at 1241.53 NA 1.35 1.64 BB508622 228775 Trib3 tribbles homolog 3 (Drosophila) 
30 1439409_x_at 1294.88 NA 1.23 1.40 BB006219 22178 Tyrp1 tyrosinase-related protein 1 
31 1448397_at 1302.50 NA 1.25 1.44 BC016507 14623 Gjb6 
gap junction 
membrane channel 
protein beta 6 
32 1453252_at 1304.65 NA 1.33 1.59 AK010138 71916 Dus4l 
dihydrouridine 
synthase 4-like (S. 
cerevisiae) 
33 1452514_a_at 1305.71 NA 1.27 1.49 X65997 16590 Kit kit oncogene 
34 1421487_a_at 1318.38 NA 1.34 1.62 NM_010878 17973 Nck1 
non-catalytic region 
of tyrosine kinase 
adaptor protein 1 
35 1417717_a_at 1323.95 NA 1.24 1.41 NM_011661 22173 Tyr tyrosinase 
36 1425415_a_at 1375.67 NA 1.32 1.58 U75214 20510 Slc1a1 
solute carrier family 1 
(neuronal/epithelial 
high affinity 
glutamate 
transporter, system 
Xag), member 1 
37 1448152_at 1414.85 NA 1.34 1.61 NM_010514 16002 Igf2 insulin-like growth factor 2 
38 1450618_a_at 1420.44 NA 1.28 1.50 NM_011468 20755 Sprr2a small proline-rich protein 2A 
39 1426634_at 1471.30 NA 1.33 1.59 BB010989 230612 Slc5a9 
solute carrier family 5 
(sodium/glucose 
cotransporter), 
member 9 
40 1419906_at 1473.87 NA 1.32 1.58 AV026552 15446 Hpgd 
Hydroxyprostaglandi
n dehydrogenase 15 
(NAD), mRNA (cDNA 
clone MGC:14001 
IMAGE:4208980) 
41 1442153_at 1480.86 NA 1.47 1.87 BB206087 Mm.385427 --- 
0 day neonate 
thymus cDNA, 
RIKEN full-length 
enriched library, 
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clone:A430072F05 
product:unclassifiable
, full insert sequence 
42 1437125_at 1503.50 NA 1.30 1.54 BB476448 12322 Camk2a 
calcium/calmodulin-
dependent protein 
kinase II alpha 
43 1448235_s_at 1517.76 NA 1.32 1.58 BF166000 
114675 
15289 
213440 
432959 
433238 
434174 
544824 
545506 
545555 
546331 
Hmgb1 /// 
4932431P20R
ik /// Hmgb1l 
/// 
LOC432959 
/// 
LOC433238 
/// 
LOC434174 
/// 
LOC544824 
/// 
LOC545506 
/// 
LOC545555 
/// 
LOC546331 
high mobility group 
box 1 /// RIKEN 
cDNA 4932431P20 
gene /// high mobility 
group box 1-like /// 
similar to High 
mobility group protein 
1 (HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) /// similar 
to High mobility 
group protein 1 
(HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) /// similar 
to High mobility 
group protein 1 
(HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) /// similar 
to Ac2-008 /// similar 
to High mobility 
group protein 1 
(HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) /// similar 
to High mobility 
group protein 1 
(HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) /// similar 
to High mobility 
group protein 1 
(HMG-1) (High 
mobility group protein 
B1) (Amphoterin) 
(Heparin-binding 
protein p30) 
44 1448745_s_at 1519.00 NA 1.13 1.22 NM_008508 16939 Lor loricrin 
45 1446990_at 1553.36 NA 1.30 1.53 AW556192 18027 Nfia nuclear factor I/A 
46 1430635_at 1563.59 NA 1.21 1.37 BB774399 77836 Mlana melan-A 
47 1415998_at 1574.94 NA 1.32 1.57 NM_011694 22333 Vdac1 voltage-dependent 
anion channel 1 
48 1429460_at 1583.55 NA 1.24 1.41 AK019508 78249 Gpr115 G protein-coupled 
receptor 115 
49 1451718_at 1591.23 NA 1.13 1.23 BB768495 18823 Plp1 proteolipid protein (myelin) 1 
50 1447625_at 1594.11 NA 1.26 1.47 BB286270 13559 E2f5 E2F transcription factor 5 
51 1429565_s_at 1598.37 NA 1.02 1.03 AK004318 66203 Lce5a late cornified 
envelope 5A 
52 1449347_a_at 1603.63 NA 1.28 1.50 NM_021365 27083 434794 Xlr4b /// Xlr4a 
X-linked lymphocyte-
regulated 4B /// X-
linked lymphocyte-
regulated 4A 
53 1429067_at 1612.21 NA 1.29 1.52 AK009171 69543 Capns2 calpain, small subunit 2 
54 1449540_at 1628.21 NA 1.30 1.55 NM_023894 104384 Rhox9 
reproductive 
homeobox on X 
chromosome, 9 
344 
 
55 1450976_at 1633.42 NA 1.28 1.50 AI987929 17988 Ndrg1 N-myc downstream 
regulated gene 1 
56 1450079_at 1633.77 NA 1.09 1.15 AK012873 27206 Nrk Nik related kinase 
57 1448107_x_at 1655.08 NA 1.29 1.51 BC010754 16612 Klk6 kallikrein 6 
58 1451613_at 1672.90 NA 1.10 1.17 AY027660 68723 Hrnr hornerin 
59 1419409_at 1700.51 NA 1.15 1.26 NM_026822 68720 Sprrl5 small proline rich-like 5 
60 1417516_at 1703.92 NA 1.30 1.53 NM_007837 13198 Ddit3 DNA-damage inducible transcript 3 
61 1427663_a_at 1708.03 NA 1.30 1.55 BG921314 12750 Clk4 CDC like kinase 4 
62 1448185_at 1724.45 NA 1.30 1.53 NM_022331 64209 Herpud1 
homocysteine-
inducible, 
endoplasmic 
reticulum stress-
inducible, ubiquitin-
like domain member 
1 
63 1452138_a_at 1747.88 NA 1.29 1.52 BB497528 70008 Ace2 
angiotensin I 
converting enzyme 
(peptidyl-dipeptidase 
A) 2 
64 1419905_s_at 1792.82 NA 1.07 1.11 AV026552 15446 Hpgd 
hydroxyprostaglandin 
dehydrogenase 15 
(NAD) 
65 1420676_at 1794.82 NA 1.05 1.08 NM_025984 67127 Sprrl3 small proline rich-like 3 
66 1448612_at 1809.06 NA 1.31 1.55 NM_018754 55948 Sfn stratifin 
67 1416778_at 1837.15 NA 1.22 1.39 BE197945 20324 Sdpr serum deprivation 
response 
68 1416691_at 1841.81 NA 1.29 1.52 NM_019581 56055 Gtpbp2 GTP binding protein 2 
69 1453218_at 1888.02 NA 1.01 1.01 AK003705 73719 1110014K05Rik 
RIKEN cDNA 
1110014K05 gene 
70 1420867_at 1891.78 NA 1.28 1.50 BB609648 56334 Tmed2 
transmembrane 
emp24 domain 
trafficking protein 2 
71 1451064_a_at 1893.43 NA 1.28 1.49 BC004827 107272 Psat1 phosphoserine 
aminotransferase 1 
72 1432032_a_at 1895.53 NA 1.29 1.52 AK015393 11876 Artn artemin 
73 1423271_at 1932.34 NA 1.15 1.26 AV239646 14619 Gjb2 
gap junction 
membrane channel 
protein beta 2 
74 1422989_a_at 1941.79 NA 1.28 1.50 NM_032418 13400 Dmpk 
dystrophia 
myotonica-protein 
kinase 
75 1450387_s_at 1943.45 NA 1.24 1.43 NM_009647 11639 Ak3l1 adenylate kinase 3 
alpha-like 1 
76 1420431_at 1953.13 NA 0.99 0.98 NM_009100 20129 Rptn repetin 
77 1420332_x_at 1953.24 NA 1.02 1.03 NM_027137 69611 Sprrl7 small proline rich-like 7 
78 1422639_at 1963.56 NA 1.13 1.23 NM_054084 116903 Calcb calcitonin-related polypeptide, beta 
79 1419591_at 1971.27 NA 1.21 1.36 NM_031378 83492 Mlze 
melanoma-derived 
leucine zipper, extra-
nuclear factor 
80 1418283_at 1979.65 NA 1.29 1.51 NM_009903 12740 Cldn4 claudin 4 
81 1448364_at 1979.87 NA 1.21 1.36 U95826 12452 Ccng2 cyclin G2 
82 1416934_at 1988.26 NA 1.27 1.49 NM_019926 17772 Mtm1 X-linked myotubular 
myopathy gene 1 
83 1457449_at 1991.14 NA 1.29 1.52 AW550676 241447 Lass6 
Longevity assurance 
homolog 6 (S. 
cerevisiae), mRNA 
(cDNA clone 
MGC:67674 
IMAGE:4224547) 
84 1419254_at 1991.99 NA 1.29 1.51 BG076333 17768 Mthfd2 
methylenetetrahydrof
olate dehydrogenase 
(NAD+ dependent), 
methenyltetrahydrofol
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ate cyclohydrolase 
85 1437703_at 1997.64 NA 1.26 1.47 BM229128 382156 LOC382156 
similar to F-box- and 
WD40-repeat-
containing protein 
86 1444515_at 1999.14 NA 1.28 1.49 BM247709 338367 Myo1d Myosin ID (Myo1d), 
mRNA 
87 1429602_at 2011.21 NA 1.26 1.47 AK009888 69655 Cd164l2 D164 sialomucin-like 2 
88 1437306_at 2022.54 NA 1.17 1.30 BG071013 232035 C130092O11Rik 
RIKEN cDNA 
C130092O11 gene 
89 1457040_at 2026.45 NA 1.21 1.38 BE947711 246316 Lgi2 leucine-rich repeat LGI family, member 2 
90 1436058_at 2041.03 NA 1.28 1.49 BB132493 58185 Rsad2 
radical S-adenosyl 
methionine domain 
containing 2 
91 1437809_x_at 2045.19 NA 1.26 1.46 AV296703 23872 Ets2 
E26 avian leukemia 
oncogene 2, 3' 
domain 
92 1430112_at 2045.22 NA 1.30 1.54 AK016965 269701 545804 
Wdr66 /// 
LOC545804 
WD repeat domain 
66 /// similar to 
hypothetical protein 
MGC33630 
93 1444000_at 2052.19 NA 1.28 1.49 BB448693 319786 B930059L03Rik 
RIKEN cDNA 
B930059L03 gene 
94 1424332_at 2054.71 NA 1.28 1.49 AF422144 224624 Rab40c Rab40c, member RAS oncogene family 
95 1436055_at 2071.43 NA 1.19 1.32 AI506528 74488 Lrrc15 leucine rich repeat 
containing 15 
96 1418599_at 2077.45 NA 1.10 1.16 NM_007729 12814 Col11a1 procollagen, type XI, 
alpha 1 
97 1422247_a_at 2095.05 NA 1.09 1.15 NM_009484 22290 546404 
Uty /// 
LOC546404 
ubiquitously 
transcribed 
tetratricopeptide 
repeat gene, Y 
chromosome /// 
similar to male-
specific 
histocompatibility 
antigen H-YDb 
98 1425880_x_at 2096.27 NA 1.26 1.46 AF290196 236537 Zfp352 zinc finger protein 352 
99 1449033_at 2098.87 NA 1.12 1.20 AB013898 18383 Tnfrsf11b 
tumor necrosis factor 
receptor superfamily, 
member 11b 
(osteoprotegerin) 
100 1429297_at 2107.08 NA 1.17 1.29 AK009018 71869 Serpinb12 
serine (or cysteine) 
peptidase inhibitor, 
clade B (ovalbumin), 
member 12 
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The Rank Product (RP) differential expression analysis report 
 
 
 
 
General Information 
Experiment  VK1mouse4302 
Normalisation  rma across replicates 
Chip  one chip only 
Comparison  Treatment samples: K14D6 Control vs Baseline samples: WT Control 
RP comparison  not paired 
Direction  Negative 
 
0 Probe-set ID RPscore FDR FC_rma FC_nom "SOURCE" "EntrezGene" Gene Symbol Title 
1 1436996_x_at 80.91 0.00 -2.92 -5.79 AV066625 17110 Lzp-s P lysozyme 
structural 
2 1448591_at 99.49 0.50 -2.81 -5.44 NM_021281 13040 Ctss cathepsin S 
3 1439426_x_at 119.46 1.67 -2.73 -5.20 AV058500 17110 Lzp-s P lysozyme 
structural 
4 1419627_s_at 204.14 5.75 -2.04 -3.22 NM_020001 56620 Clec4n 
C-type lectin 
domain family 4, 
member n 
5 1436905_x_at 241.21 8.20 -2.02 -3.18 BB218107 16792 Laptm5 
lysosomal-
associated 
protein 
transmembrane 5 
6 1420804_s_at 288.72 11.17 -1.84 -2.73 NM_010819 17474 Clec4d 
C-type lectin 
domain family 4, 
member d 
7 1453218_at 314.02 13.14 -1.94 -2.97 AK003705 73719 1110014K05Rik 
RIKEN cDNA 
1110014K05 
gene 
8 1448620_at 349.82 16.00 -1.84 -2.71 NM_010188 14131 Fcgr3 Fc receptor, IgG, low affinity III 
9 1444061_at 391.54 19.33 -1.96 -3.01 BB150166 109314 A030004J04Rik 
RIKEN cDNA 
A030004J04 
gene 
10 1423547_at 395.41 17.70 -1.88 -2.81 AW208566 17105 Lyzs lysozyme 
11 1419599_s_at 395.62 16.09 -1.74 -2.49 NM_026835 64382 Ms4a11 
membrane-
spanning 4-
domains, 
subfamily A, 
member 11 
12 1432466_a_at 412.07 17.00 -1.79 -2.60 AK019319 11816 Apoe apolipoprotein E 
13 1424903_at 436.82 18.77 -1.76 -2.53 AF127244 20592 Jarid1d 
jumonji, AT rich 
interactive 
domain 1D (Rbp2 
like) 
14 1452141_a_at 458.61 20.36 -1.75 -2.50 BC001991 20363 Sepp1 selenoprotein P, plasma, 1 
15 1456248_at 463.19 19.87 -1.87 -2.79 AV076385 69520 2310002A05Rik 
RIKEN cDNA 
2310002A05 
gene 
16 1420394_s_at 464.93 19.06 -1.73 -2.45 U05264 14727 14728 Gp49a /// Lilrb4 
glycoprotein 49 A 
/// leukocyte 
immunoglobulin-
like receptor, 
subfamily B, 
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member 4 
17 1419409_at 529.00 26.29 -1.75 -2.50 NM_026822 68720 Sprrl5 small proline rich-like 5 
18 1429565_s_at 530.23 24.89 -1.86 -2.76 AK004318 66203 Lce5a late cornified 
envelope 5A 
19 1420332_x_at 533.51 23.89 -1.78 -2.57 NM_027137 69611 Sprrl7 small proline rich-like 7 
20 1420550_at 577.80 28.95 -1.73 -2.46 AV014636 67828 1110055J05Rik 
RIKEN cDNA 
1110055J05 
gene 
21 1428980_at 601.17 30.43 -1.73 -2.46 AK003253 73731 1110001M24Rik 
RIKEN cDNA 
1110001M24 
gene 
22 1452077_at 626.85 32.00 -1.60 -2.15 AA210261 26900 Ddx3y 
DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 3, Y-
linked 
23 1448995_at 639.19 32.13 -1.32 -1.58 NM_019932 56744 Cxcl4 chemokine (C-X-C motif) ligand 4 
24 1438069_a_at 646.43 31.58 -1.56 -2.07 BE446879 83486 Rbm5 RNA binding 
motif protein 5 
25 1420350_at 648.49 30.68 -1.72 -2.44 NM_028625 73722 Sprrl2 small proline rich-like 2 
26 1420676_at 662.44 31.35 -1.70 -2.38 NM_025984 67127 Sprrl3 small proline rich-like 3 
27 1438558_x_at 665.94 30.52 -1.63 -2.22 AV009267 15220 Foxq1 Forkhead box Q1 (Foxq1), mRNA 
28 1417808_at 667.50 29.68 -1.67 -2.31 NM_025621 66533 2310050C09Rik 
RIKEN cDNA 
2310050C09 
gene 
29 1423505_at 674.00 29.52 -1.49 -1.93 BB114067 21345 Tagln transgelin 
30 1417936_at 686.95 30.53 -1.61 -2.19 AF128196 20308 Ccl9 chemokine (C-C 
motif) ligand 9 
31 1449265_at 718.21 34.00 -1.54 -2.03 BC008152 12362 Casp1 caspase 1 
32 1420431_at 719.47 33.00 -1.59 -2.14 NM_009100 20129 Rptn repetin 
33 1423522_at 723.58 32.58 -1.57 -2.09 BB811478 18150 Npm3 nucleoplasmin 3 
34 1417275_at 731.55 32.50 -1.31 -1.55 NM_010762 17153 Mal 
myelin and 
lymphocyte 
protein, T-cell 
differentiation 
protein 
35 1432828_at 737.75 32.57 -1.52 -1.98 BF607489 --- --- --- 
36 1426438_at 764.20 35.17 -1.54 -2.04 AA210261 26900 Ddx3y 
DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 3, Y-
linked 
37 1420741_x_at 791.06 37.41 -1.65 -2.28 NM_029667 76585 2310069N01Rik 
RIKEN cDNA 
2310069N01 
gene 
38 1427735_a_at 805.16 38.18 -1.53 -2.00 M12233 11459 Acta1 actin, alpha 1, 
skeletal muscle 
39 1431554_a_at 806.43 37.38 -1.60 -2.15 AK003395 71790 Anxa9 annexin A9 
40 1422963_at 808.90 36.98 -1.61 -2.19 NM_011475 20763 Sprr2i small proline-rich protein 2I 
41 1425951_a_at 814.54 36.80 -1.51 -1.97 AF240358 56620 Clec4n 
C-type lectin 
domain family 4, 
member n 
42 1457777_at 817.53 36.43 -1.58 -2.11 AV240142 57911 Gsdm1 gasdermin 1 
43 1449833_at 833.07 37.70 -1.59 -2.14 NM_011472 20760 Sprr2f small proline-rich protein 2F 
44 1435477_s_at 834.99 37.02 -1.58 -2.11 BM224327 14130 Fcgr2b Fc receptor, IgG, low affinity IIb 
45 1423634_at 852.30 38.13 -1.58 -2.12 AI506986 57911 Gsdm1 gasdermin 1 
46 1449071_at 854.10 37.59 -1.50 -1.95 NM_022879 17898 Myl7 
myosin, light 
polypeptide 7, 
regulatory 
47 1456001_at 854.64 36.83 -1.60 -2.17 AV071932 Mm.387664 --- CDNA clone MGC:118457 
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IMAGE:30288561 
48 1426598_at 863.01 37.17 -1.48 -1.90 BB742957 
22290 
546404 
546411 
Uty /// 
LOC546404 /// 
LOC546411 
ubiquitously 
transcribed 
tetratricopeptide 
repeat gene, Y 
chromosome /// 
similar to male-
specific 
histocompatibility 
antigen H-YDb /// 
similar to male-
specific 
histocompatibility 
antigen H-YDb 
49 1423542_at 869.86 37.16 -1.56 -2.08 BB283507 23993 Klk7 
kallikrein 7 
(chymotryptic, 
stratum corneum) 
50 1417210_at 874.20 36.80 -1.48 -1.91 NM_012011 26908 Eif2s3y 
eukaryotic 
translation 
initiation factor 2, 
subunit 3, 
structural gene Y-
linked 
51 1453092_at 875.77 36.14 -1.66 -2.29 AK009010 74175 2300002G24Rik 
RIKEN cDNA 
2300002G24 
gene 
52 1418188_a_at 879.22 36.19 -1.50 -1.95 AF146523 72289 Malat1 
metastasis 
associated lung 
adenocarcinoma 
transcript 1 (non-
coding RNA) 
53 1416468_at 881.14 35.64 -1.40 -1.75 NM_013467 11668 Aldh1a1 
aldehyde 
dehydrogenase 
family 1, 
subfamily A1 
54 1440966_at 882.57 35.20 -1.43 -1.79 BB248730 57438 March7 
membrane-
associated ring 
finger (C3HC4) 7 
55 1448291_at 890.87 35.47 -1.40 -1.74 NM_013599 17395 Mmp9 
matrix 
metallopeptidase 
9 
56 1427910_at 890.93 34.84 -1.61 -2.18 AK003744 73720 Cst6 cystatin E/M 
57 1418601_at 896.13 34.77 -1.04 -1.06 NM_011921 26358 Aldh1a7 
aldehyde 
dehydrogenase 
family 1, 
subfamily A7 
58 1420677_x_at 931.87 38.52 -1.57 -2.10 NM_025984 67127 Sprrl3 small proline rich-like 3 
59 1460569_x_at 933.90 38.10 -1.47 -1.87 AW611462 12739 Cldn3 claudin 3 
60 1438403_s_at 944.91 38.80 -1.46 -1.86 BF537798 80291 BC003324 
CDNA sequence 
BC003324, 
mRNA (cDNA 
clone MGC:7036 
IMAGE:3156139) 
61 1455900_x_at 948.87 38.64 -1.59 -2.14 BB041811 21817 Tgm2 transglutaminase 2, C polypeptide 
62 1437277_x_at 957.49 38.84 -1.49 -1.92 BB550124 21817 Tgm2 transglutaminase 2, C polypeptide 
63 1449902_at 961.33 38.57 -1.50 -1.95 AV014636 66195 1110058A15Rik 
RIKEN cDNA 
1110058A15 
gene 
64 1417266_at 967.76 38.66 -1.72 -2.43 BC002073 20305 Ccl6 chemokine (C-C 
motif) ligand 6 
65 1435934_at 984.76 39.83 -1.43 -1.80 AI643884 70316 Ndufab1 
NADH 
dehydrogenase 
(ubiquinone) 1, 
alpha/beta 
subcomplex, 1 
66 1450430_at 1019.27 43.24 -1.50 -1.95 NM_008625 17533 Mrc1 mannose 
receptor, C type 1 
67 1432558_a_at 1032.55 44.00 -1.22 -1.39 AK019046 17153 Mal 
myelin and 
lymphocyte 
protein, T-cell 
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differentiation 
protein 
68 1457254_x_at 1041.76 44.28 -1.63 -2.22 BB302103 432460 LOC432460 
similar to RIKEN 
cDNA 
6330442E10 
gene 
69 1456211_at 1061.10 45.87 -1.48 -1.90 BB003937 --- --- --- 
70 1447807_s_at 1066.37 45.89 -1.44 -1.82 AV336001 211945 Plekhh1 
pleckstrin 
homology domain 
containing, family 
H (with MyTH4 
domain) member 
1 
71 1419549_at 1071.67 45.93 -1.35 -1.63 NM_007482 11846 Arg1 arginase 1, liver 
72 1420377_at 1074.00 45.62 -1.27 -1.48 BG071333 20450 St8sia2 
ST8 alpha-N-
acetyl-
neuraminide 
alpha-2,8-
sialyltransferase 
2 
73 1417061_at 1090.52 46.88 -1.46 -1.86 AF226613 53945 Slc40a1 
solute carrier 
family 40 (iron-
regulated 
transporter), 
member 1 
74 1427268_at 1091.98 46.50 -1.55 -2.04 J03458 433621 545581 
LOC433621 /// 
LOC545581 
similar to Acidic 
ribosomal 
phosphoprotein 
P0 /// similar to 
Acidic ribosomal 
phosphoprotein 
P0 
75 1435906_x_at 1103.69 47.03 -1.46 -1.85 BE197524 14469 Gbp2 
guanylate 
nucleotide 
binding protein 2 
76 1454849_x_at 1104.74 46.59 -1.38 -1.69 BB433678 12759 Clu clusterin 
77 1452378_at 1116.67 47.32 -1.47 -1.88 AW012617 72289 Malat1 
metastasis 
associated lung 
adenocarcinoma 
transcript 1 (non-
coding RNA) 
78 1451601_a_at 1121.06 47.27 -1.54 -2.02 BC025823 216892 BC011467 cDNA sequence BC011467 
79 1426439_at 1135.14 48.33 -1.50 -1.95 AA210261 26900 Ddx3y 
DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 3, Y-
linked 
80 1451613_at 1142.37 48.46 -1.48 -1.89 AY027660 68723 Hrnr hornerin 
81 1448982_at 1158.63 49.88 -1.50 -1.94 NM_011177 19144 Prss18 protease, serine, 18 
82 1448169_at 1202.81 NA -1.31 -1.56 NM_010664 16668 Krt1-18 keratin complex 1, acidic, gene 18 
83 1449959_x_at 1203.90 NA -1.50 -1.95 NM_026335 67718 Sprrl9 small proline rich-like 9 
84 1435462_at 1214.16 NA -1.46 -1.86 BQ176176 433022 LOC433022 hypothetical LOC433022 
85 1437458_x_at 1221.73 NA -1.37 -1.67 AV075715 12759 Clu clusterin 
86 1419605_at 1240.04 NA -1.44 -1.81 NM_010796 17312 Mgl1 
macrophage 
galactose N-
acetyl-
galactosamine 
specific lectin 1 
87 1450633_at 1243.32 NA -1.48 -1.91 NM_020036 80796 Calm4 calmodulin 4 
88 1427963_s_at 1246.05 NA -1.47 -1.88 BE979765 103142 Rdh9 retinol dehydrogenase 9 
89 1429540_at 1247.88 NA -1.49 -1.92 AK008979 72383 Cnfn cornifelin 
90 1422837_at 1249.20 NA -1.43 -1.80 NM_022886 64929 Scel sciellin 
91 1429060_at 1255.39 NA -1.42 -1.77 AK020483 72289 Malat1 
metastasis 
associated lung 
adenocarcinoma 
transcript 1 (non-
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coding RNA) 
92 1429230_at 1256.39 NA -1.46 -1.87 AK003996 68668 1110030O19Rik 
RIKEN cDNA 
1110030O19 
gene 
93 1421398_at 1264.34 NA -1.37 -1.67 NM_053166 94089 Trim7 tripartite motif protein 7 
94 1450792_at 1273.33 NA -1.38 -1.69 NM_011662 22177 Tyrobp 
TYRO protein 
tyrosine kinase 
binding protein 
95 1418283_at 1274.46 NA -1.34 -1.62 NM_009903 12740 Cldn4 claudin 4 
96 1418626_a_at 1277.22 NA -1.34 -1.61 NM_013492 12759 Clu clusterin 
97 1436917_s_at 1289.32 NA -1.34 -1.62 BB491018 67839 Gpsm1 
G-protein 
signalling 
modulator 1 
(AGS3-like, C. 
elegans) 
98 1417917_at 1307.06 NA -1.38 -1.69 NM_009922 12797 Cnn1 calponin 1 
99 1436329_at 1314.80 NA -1.42 -1.79 AV346607 13655 Egr3 early growth 
response 3 
100 1429537_at 1315.93 NA -1.34 -1.61 BG277020 66625 5730406M06Rik 
RIKEN cDNA 
5730406M06 
gene 
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The Rank Product (RP) differential expression analysis report 
 
 
 
 
 
General Information 
Experiment  VK1mouse4302 
Normalisation  rma across replicates 
Chip  one chip only 
Comparison  Treatment samples: WT + CCL3 vs Baseline samples: WT Control 
RP comparison  not paired 
Direction  Negative 
 
 
 
 
0 Probe-set ID RPscore FDR FC_rma FC_nom "SOURCE" "EntrezGene" Gene Symbol Title 
1 1426438_at 228.87 45.00 -4.27 -10.81 AA210261 26900 Ddx3y 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 3, 
Y-linked 
2 1453218_at 263.41 32.50 -1.59 -2.15 AK003705 73719 1110014K05Rik 
RIKEN cDNA 
1110014K05 gene 
3 1451613_at 265.52 22.00 -1.70 -2.39 AY027660 68723 Hrnr Hornerin 
4 1452077_at 302.93 23.50 -2.63 -4.88 AA210261 26900 Ddx3y 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 3, 
Y-linked 
5 1417210_at 319.33 21.20 -3.57 -8.06 NM_012011 26908 Eif2s3y 
eukaryotic translation 
initiation factor 2, 
subunit 3, structural 
gene Y-linked 
6 1419409_at 332.57 19.83 -1.63 -2.22 NM_026822 68720 Sprrl5 small proline rich-like 5 
7 1429565_s_at 387.48 28.00 -1.55 -2.05 AK004318 66203 Lce5a late cornified envelope 5A 
8 1420431_at 415.16 30.12 -1.58 -2.11 NM_009100 20129 Rptn Repetin 
9 1424903_at 443.01 32.11 -2.14 -3.49 AF127244 20592 Jarid1d 
jumonji, AT rich 
interactive domain 1D 
(Rbp2 like) 
10 1420332_x_at 453.86 30.90 -1.49 -1.92 NM_027137 69611 Sprrl7 small proline rich-like 7 
11 1452292_at 494.01 36.36 -1.51 -1.97 AV271093 --- --- --- 
12 1426598_at 506.99 35.75 -1.84 -2.72 BB742957 
22290 
546404 
546411 
Uty /// 
LOC54640
4 /// 
LOC54641
1 
ubiquitously transcribed 
tetratricopeptide repeat 
gene, Y chromosome /// 
similar to male-specific 
histocompatibility 
antigen H-YDb /// 
similar to male-specific 
histocompatibility 
antigen H-YDb 
13 1427268_at 508.76 33.62 -1.53 -2.00 J03458 433621 545581 
LOC43362
1 /// 
LOC54558
1 
similar to Acidic 
ribosomal 
phosphoprotein P0 /// 
similar to Acidic 
ribosomal 
phosphoprotein P0 
14 1426439_at 544.39 36.79 -1.98 -3.07 AA210261 26900 Ddx3y DEAD (Asp-Glu-Ala-
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Asp) box polypeptide 3, 
Y-linked 
15 1428980_at 574.12 38.80 -1.47 -1.87 AK003253 73731 1110001M24Rik 
RIKEN cDNA 
1110001M24 gene 
16 1448745_s_at 646.92 NA -1.45 -1.84 NM_008508 16939 Lor Loricrin 
17 1420350_at 652.06 NA -1.42 -1.78 NM_028625 73722 Sprrl2 small proline rich-like 2 
18 1417275_at 698.11 NA -1.44 -1.82 NM_010762 17153 Mal 
myelin and lymphocyte 
protein, T-cell 
differentiation protein 
19 1419906_at 708.68 NA -1.46 -1.86 AV026552 15446 Hpgd 
Hydroxyprostaglandin 
dehydrogenase 15 
(NAD), mRNA (cDNA 
clone MGC:14001 
IMAGE:4208980) 
20 1429996_at 786.08 NA -1.42 -1.77 BB207765 70760 6330417A16Rik 
RIKEN cDNA 
6330417A16 gene 
21 1459635_at 854.52 NA -1.41 -1.76 BG144294 13383 Dlgh1 
Discs, large homolog 1 
(Drosophila) (Dlgh1), 
mRNA 
22 1417808_at 911.39 NA -1.45 -1.84 NM_025621 66533 
2310050C
09Rik 
RIKEN cDNA 
2310050C09 gene 
23 1420677_x_at 949.26 NA -1.38 -1.69 NM_025984 67127 Sprrl3 small proline rich-like 3 
24 1444472_at 961.17 NA -1.39 -1.72 BB154631 235344 Sik2 SNF1-like kinase 2 (Snf1lk2), mRNA 
25 1442153_at 962.32 NA -1.57 -2.10 BB206087 Mm.385427 --- 
0 day neonate thymus 
cDNA, RIKEN full-
length enriched library, 
clone:A430072F05 
product:unclassifiable, 
full insert sequence 
26 1420550_at 1016.33 NA -1.34 -1.61 AV014636 67828 1110055J05Rik 
RIKEN cDNA 
1110055J05 gene 
27 1420183_at 1037.45 NA -1.37 -1.67 AI036317 16939 Lor Loricrin (Lor), mRNA 
28 1432558_a_at 1074.86 NA -1.36 -1.65 AK019046 17153 Mal 
myelin and lymphocyte 
protein, T-cell 
differentiation protein 
29 1452315_at 1119.09 NA -1.31 -1.56 BB827235 16551 Kif11 kinesin family member 11 
30 1429772_at 1124.63 NA -1.35 -1.64 BB085537 18845 Plxna2 plexin A2 
31 1453405_at 1164.96 NA -1.38 -1.70 AK019180 78390 2610311B01Rik 
RIKEN cDNA 
2610311B01 gene 
32 1457065_at 1166.06 NA -1.49 -1.93 BB530943 22268 Upk1b uroplakin 1B 
33 1423952_a_at 1173.29 NA -1.45 -1.84 BC010337 110310 Krt2-7 
keratin complex 2, 
basic, gene 7 
34 1441100_at 1188.84 NA -1.37 -1.68 BB496952 103537 Mbtd1 mbt domain containing 1 
35 1420377_at 1217.31 NA -1.22 -1.39 BG071333 20450 St8sia2 
ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 2 
36 1419905_s_at 1217.46 NA -1.31 -1.55 AV026552 15446 Hpgd 
hydroxyprostaglandin 
dehydrogenase 15 
(NAD) 
37 1437782_at 1225.80 NA -1.36 -1.67 BE651445 66797 Cntnap2 contactin associated protein-like 2 
38 1423320_at 1241.37 NA -1.41 -1.76 AI507229 66705 Dnase1l2 deoxyribonuclease 1-like 2 
39 1419549_at 1252.27 NA -1.44 -1.82 NM_007482 11846 Arg1 arginase 1, liver 
40 1420676_at 1258.55 NA -1.28 -1.51 NM_025984 67127 Sprrl3 small proline rich-like 3 
41 1449451_at 1259.55 NA -1.34 -1.62 NM_025867 66957 Serpinb11 
serine (or cysteine) 
peptidase inhibitor, 
clade B (ovalbumin), 
member 11 
42 1421316_at 1264.83 NA -1.38 -1.69 NM_025413 66195 
1110058A1
5Rik 
RIKEN cDNA 
1110058A15 gene 
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43 1420741_x_at 1275.58 NA -1.30 -1.53 NM_029667 76585 
2310069N
01Rik 
RIKEN cDNA 
2310069N01 gene 
44 1418855_at 1285.55 NA -1.37 -1.68 NM_028628 73730 
1110008K0
4Rik 
RIKEN cDNA 
1110008K04 gene 
45 1449902_at 1286.42 NA -1.32 -1.57 AV014636 66195 1110058A15Rik 
RIKEN cDNA 
1110058A15 gene 
46 1424927_at 1315.09 NA -1.35 -1.63 BC025083 73690 Glipr1 GLI pathogenesis-
related 1 (glioma) 
47 1440789_at 1329.47 NA -1.35 -1.64 BB243938 18007 Neo1 Neogenin 
48 1440966_at 1338.11 NA -1.37 -1.67 BB248730 57438 March7 membrane-associated 
ring finger (C3HC4) 7 
49 1456248_at 1352.60 NA -1.29 -1.52 AV076385 69520 2310002A05Rik 
RIKEN cDNA 
2310002A05 gene 
50 1448393_at 1356.41 NA -1.42 -1.78 BC008104 53624 Cldn7 claudin 7 
51 1416613_at 1364.07 NA -1.10 -1.17 BI251808 13078 Cyp1b1 
cytochrome P450, 
family 1, subfamily b, 
polypeptide 1 
52 1430440_at 1368.33 NA -1.34 -1.61 AK015363 74660 4930442J19Rik 
RIKEN cDNA 
4930442J19 gene 
53 1455464_x_at 1377.32 NA -1.41 -1.76 BB427704 --- --- --- 
54 1422760_at 1398.06 NA -1.28 -1.49 NM_011061 18602 Padi4 
peptidyl arginine 
deiminase, type IV 
55 1420413_at 1405.23 NA -1.34 -1.62 NM_011990 26570 Slc7a11 
solute carrier family 7 
(cationic amino acid 
transporter, y+ system), 
member 11 
56 1447625_at 1406.24 NA -1.30 -1.54 BB286270 13559 E2f5 E2F transcription factor 5 
57 1456001_at 1416.63 NA -1.34 -1.61 AV071932 Mm.387664 --- 
CDNA clone 
MGC:118457 
IMAGE:30288561 
58 1460569_x_at 1420.12 NA -1.37 -1.68 AW611462 12739 Cldn3 claudin 3 
59 1444192_at 1434.52 NA -1.32 -1.58 BB460651 --- --- --- 
60 1450633_at 1435.50 NA -1.34 -1.62 NM_020036 80796 Calm4 calmodulin 4 
61 1418283_at 1436.80 NA -1.31 -1.57 NM_009903 12740 Cldn4 claudin 4 
62 1439845_at 1440.73 NA -1.33 -1.60 BQ174438 Mm.348429 --- Transcribed locus 
63 1419529_at 1441.16 NA -1.20 -1.34 NM_031252 83430 Il23a 
interleukin 23, alpha 
subunit p19 
64 1457077_at 1456.56 NA -1.34 -1.61 BB306048 245683 --- 
PREDICTED: similar to 
hypothetical protein 
FLJ34960 [Mus 
musculus], mRNA 
sequence 
65 1453252_at 1459.43 NA -1.27 -1.48 AK010138 71916 Dus4l dihydrouridine synthase 4-like (S. cerevisiae) 
66 1438558_x_at 1519.98 NA -1.31 -1.55 AV009267 15220 Foxq1 Forkhead box Q1 (Foxq1), mRNA 
67 1454299_at 1522.69 NA -1.31 -1.55 AV250295 74587 4833422B07Rik 
RIKEN cDNA 
4833422B07 gene 
68 1454632_at 1530.52 NA -1.32 -1.58 AV328515 268567 6330442E10Rik 
RIKEN cDNA 
6330442E10 gene 
69 1449071_at 1534.40 NA -1.37 -1.68 NM_022879 17898 Myl7 
myosin, light 
polypeptide 7, 
regulatory 
70 1445916_at 1537.46 NA -1.34 -1.62 BG070994 11964 Atp6v1a1 
ATPase, H+ 
transporting, V1 subunit 
A1, mRNA (cDNA clone 
MGC:6531 
IMAGE:2651677) 
71 1418496_at 1549.18 NA -1.36 -1.65 NM_008259 15375 Foxa1 forkhead box A1 
72 1451601_a_at 1553.22 NA -1.30 -1.53 BC025823 216892 BC011467 
cDNA sequence 
BC011467 
73 1416368_at 1580.84 NA -1.23 -1.40 NM_010357 14860 Gsta4 
glutathione S-
transferase, alpha 4 
74 1459415_at 1594.42 NA -1.31 -1.56 BB204258 --- --- --- 
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75 1458871_at 1611.25 NA -1.34 -1.62 BB148290 243084 Tmprss11e transmembrane protease, serine 11e 
76 1427593_at 1632.56 NA -1.31 -1.55 BB620112 93679 Trim8 tripartite motif protein 8 
77 1418423_s_at 1637.78 NA -1.30 -1.53 AF425083 
20709 20710 
544923 
93806 
Serpinb9f 
/// 
Serpinb9e 
/// 
Serpinb9g 
/// 
LOC54492
3 
serine (or cysteine) 
peptidase inhibitor, 
clade B, member 9f /// 
serine (or cysteine) 
peptidase inhibitor, 
clade B, member 9e /// 
serine (or cysteine) 
peptidase inhibitor, 
clade B, member 9g /// 
similar to 
OTTMUSP0000000064
1 
78 1442750_at 1639.79 NA -1.30 -1.54 BG067768 97884 D230016N13Rik 
UDP-
GalNAc:betaGlcNAc 
beta 1,3-
galactosaminyltransfera
se, polypeptide 2, 
mRNA (cDNA clone 
MGC:103263 
IMAGE:30735904) 
79 1425671_at 1644.06 NA -1.31 -1.56 AF093257 26556 Homer1 homer homolog 1 (Drosophila) 
80 1444562_at 1655.13 NA -1.32 -1.58 BE690666 100763 Ube3c 
Ubiquitin protein ligase 
E3C, mRNA (cDNA 
clone IMAGE:5353408) 
81 1419619_at 1661.35 NA -1.32 -1.57 NM_028770 74127 
1200016G
03Rik 
RIKEN cDNA 
1200016G03 gene 
82 1444349_at 1661.40 NA -1.24 -1.42 BG071091 --- --- --- 
83 1422639_at 1680.58 NA -1.32 -1.57 NM_054084 116903 Calcb 
calcitonin-related 
polypeptide, beta 
84 1420647_a_at 1681.19 NA -1.25 -1.44 
NM_03117
0 
16691 
434261 
Krt2-8 /// 
LOC43426
1 
keratin complex 2, 
basic, gene 8 /// similar 
to cytokeratin EndoA – 
mouse 
85 1422247_a_at 1685.22 NA -1.28 -1.50 
NM_00948
4 
22290 
546404 
Uty /// 
LOC54640
4 
ubiquitously transcribed 
tetratricopeptide repeat 
gene, Y chromosome /// 
similar to male-specific 
histocompatibility 
antigen H-YDb 
86 1447807_s_at 1688.22 NA -1.34 -1.62 AV336001 211945 Plekhh1 
pleckstrin homology 
domain containing, 
family H (with MyTH4 
domain) member 1 
87 1446570_at 1692.91 NA -1.31 -1.56 BB469236 --- --- --- 
88 1448169_at 1698.16 NA -1.23 -1.40 NM_010664 16668 Krt1-18 
keratin complex 1, 
acidic, gene 18 
89 1415861_at 1699.74 NA -1.22 -1.39 BB762957 22178 Tyrp1 tyrosinase-related protein 1 
90 1445477_at 1711.48 NA -1.31 -1.55 BE952410 Mm.26390 --- Retrotransposon ETn insertion in p53 mRNA 
91 1435831_at 1713.42 NA -1.42 -1.79 BB427704 22268 Upk1b uroplakin 1B 
92 1435321_at 1719.91 NA -1.34 -1.61 BM117827 77569 3732412D22Rik 
RIKEN cDNA 
3732412D22 gene 
93 1444202_at 1743.05 NA -1.30 -1.54 BI965268 546051 LOC546051 
similar to hypothetical 
protein LOC80139 
94 1455679_at 1748.59 NA -1.29 -1.51 BE457727 109019 5830411E10Rik 
RIKEN cDNA 
5830411E10 gene 
95 1438216_at 1751.69 NA -1.27 -1.48 BG143502 68750 1110037N09Rik 
PREDICTED: 
hypothetical protein 
LOC68750 [Mus 
musculus], mRNA 
sequence 
96 1435154_at 1760.27 NA -1.24 -1.43 AV099404 245128 LOC245128 
similar to solute carrier 
family 7 (cationic amino 
acid transporter, y+ 
system), member 3 
97 1426941_at 1764.77 NA -1.26 -1.47 BC020027 --- --- --- 
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98 1420371_at 1787.33 NA -1.29 -1.52 BI646094 20650 Sntb2 syntrophin, basic 2 
99 1443915_at 1788.56 NA -1.30 -1.55 BE957160 74600 Mrpl47 mitochondrial ribosomal protein L47 
100 1436686_at 1789.49 NA -1.31 -1.55 AA165749 68036 Zfp706 zinc finger protein 706 
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The Rank Product (RP) differential expression analysis report 
  
 
 
 
General Information 
Experiment  VK1mouse4302 
Normalisation  rma across replicates 
Chip  one chip only 
Comparison  Treatment samples: K14D6 + CCL3 vs Baseline samples: K14D6 Control 
RP comparison  not paired 
Direction  Negative 
 
 
0 Probe-set ID RPscore FDR FC_rma FC_nom "SOURCE" "EntrezGene" Gene Symbol Title 
1 1452292_at 123.91 2.00 -1.85 -2.74 AV271093 --- --- --- 
2 1436319_at 264.52 29.00 -1.62 -2.21 BB751459 240725 Sulf1 sulfatase 1 
3 1435831_at 294.66 26.67 -1.60 -2.17 BB427704 22268 Upk1b uroplakin 1B 
4 1434172_at 360.64 34.00 -1.44 -1.81 BQ177934 --- --- --- 
5 1450377_at 538.35 NA -1.55 -2.04 AI385532 21825 Thbs1 thrombospondin 1 
6 1446481_at 543.55 NA -1.49 -1.93 BB534411 11787 Apbb2 
Amyloid beta (A4) 
precursor protein-
binding, family B, 
member 2, mRNA 
(cDNA clone 
MGC:100042 
IMAGE:30550087) 
7 1435989_x_at 576.03 NA -1.52 -1.99 AW322280 434261 LOC434261 
similar to 
cytokeratin EndoA 
- mouse 
8 1457479_at 603.21 NA -1.44 -1.81 AW536823 22596 Xrcc5 
X-ray repair 
complementing 
defective repair in 
Chinese hamster 
cells 5, mRNA 
(cDNA clone 
IMAGE:2647262) 
9 1427262_at 649.58 NA -1.42 -1.77 L04961 213742 Xist inactive X specific transcripts 
10 1456661_at 657.15 NA -1.50 -1.94 BM293452 16468 Jarid2 
Jumonji, AT rich 
interactive domain 
2, mRNA (cDNA 
clone 
IMAGE:3589616) 
11 1427610_at 674.96 NA -1.47 -1.88 BC026631 109620 Dsp desmoplakin 
12 1417275_at 680.37 NA -1.46 -1.85 NM_010762 17153 Mal 
myelin and 
lymphocyte 
protein, T-cell 
differentiation 
protein 
13 1424598_at 683.47 NA -1.44 -1.81 BC021452 13209 Ddx6 
DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 6 
14 1455464_x_at 694.70 NA -1.47 -1.88 BB427704 --- --- --- 
15 1445641_at 703.61 NA -1.47 -1.88 BB727879 --- --- --- 
16 1427263_at 741.08 NA -1.32 -1.58 L04961 213742 Xist inactive X specific transcripts 
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17 1440722_at 771.22 NA -1.39 -1.72 BB284387 52013 D19Ertd386e 
DNA segment, Chr 
19, ERATO Doi 
386, expressed 
(D19Ertd386e), 
mRNA 
18 1420377_at 813.18 NA -1.24 -1.41 BG071333 20450 St8sia2 
ST8 alpha-N-
acetyl-neuraminide 
alpha-2,8-
sialyltransferase 2 
19 1433902_at 819.15 NA -1.36 -1.66 BB469300 243574 Kbtbd8 
kelch repeat and 
BTB (POZ) domain 
containing 8 
20 1460302_at 852.47 NA -1.42 -1.77 AI385532 21825 Thbs1 thrombospondin 1 
21 1420647_a_at 861.38 NA -1.45 -1.83 NM_031170 16691 434261 
Krt2-8 /// 
LOC434261 
keratin complex 2, 
basic, gene 8 /// 
similar to 
cytokeratin EndoA 
- mouse 
22 1438200_at 874.34 NA -1.42 -1.78 BB065799 240725 Sulf1 sulfatase 1 
23 1443393_at 878.47 NA -1.44 -1.81 BB201890 75788 Smurf1 
SMAD specific E3 
ubiquitin protein 
ligase 1, mRNA 
(cDNA clone 
MGC:28022 
IMAGE:3660965) 
24 1440014_at 917.67 NA -1.41 -1.76 AW553510 107975 Pacs1 
Phosphofurin 
acidic cluster 
sorting protein 1 
(Pacs1), mRNA 
25 1425092_at 920.21 NA -1.27 -1.49 AF183946 320873 Cdh10 cadherin 10 
26 1454904_at 923.49 NA -1.34 -1.61 BG976607 17772 Mtm1 
X-linked 
myotubular 
myopathy gene 1 
27 1423691_x_at 923.68 NA -1.44 -1.82 M21836 16691 Krt2-8 keratin complex 2, basic, gene 8 
28 1437219_at 951.33 NA -1.42 -1.77 AW553541 16001 Igf1r 
Insulin-like growth 
factor I receptor 
(Igf1r), mRNA 
29 1439760_x_at 963.24 NA -1.37 -1.68 BB219662 22268 Upk1b uroplakin 1B 
30 1442961_at 969.72 NA -1.37 -1.67 BG071782 --- --- --- 
31 1456712_at 981.56 NA -1.34 -1.62 AV231984 209707 A830039H10Rik RIKEN cDNA A830039H10 gene 
32 1436039_at 1012.68 NA -1.32 -1.58 BM245957 Mm.85165 --- 
Transcribed locus, 
moderately similar 
to XP_488601.1 
PREDICTED: 
hypothetical 
protein 
XP_488601 [Mus 
musculus] 
33 1454544_at 1035.15 NA -1.38 -1.70 AK020650 78850 9530078B04Rik RIKEN cDNA 9530078B04 gene 
34 1421811_at 1059.53 NA -1.37 -1.68 AI385532 21825 Thbs1 thrombospondin 1 
35 1447408_at 1082.37 NA -1.42 -1.79 BM201377 71175 4933421G18Rik 
Nipped-B homolog 
(Drosophila) 
(Nipbl), transcript 
variant B, mRNA 
36 1445642_at 1088.29 NA -1.36 -1.65 AV156411 213409 Lemd1 LEM domain 
containing 1 
37 1439843_at 1107.13 NA -1.34 -1.62 AI840829 12326 Camk4 
calcium/calmodulin
-dependent protein 
kinase IV 
38 1457429_s_at 1114.50 NA -1.33 -1.59 BB549174 226866 Gm106 gene model 106, (NCBI) 
39 1442535_at 1123.07 NA -1.38 -1.70 BB533591 Mm.216110 --- 
Adult male 
hypothalamus 
cDNA, RIKEN full-
length enriched 
library, 
clone:A230075A13 
product:unclassifia
ble, full insert 
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sequence 
40 1438148_at 1133.18 NA -1.18 -1.30 BB829808 330122 Gm1960 gene model 1960, (NCBI) 
41 1455134_at 1137.25 NA -1.34 -1.62 AF031164 242474 D730040F13Rik 
RIKEN cDNA 
D730040F13 gene 
(D730040F13Rik), 
mRNA 
42 1436982_at 1143.42 NA -1.35 -1.63 BB788270 213988 Tnrc6b trinucleotide repeat 
containing 6b 
43 1427072_at 1147.74 NA -1.38 -1.69 BM119481 236920 Stard8 START domain 
containing 8 
44 1427056_at 1173.34 NA -1.35 -1.64 AV228731 235130 Adamts15 
a disintegrin-like 
and 
metallopeptidase 
(reprolysin type) 
with 
thrombospondin 
type 1 motif, 15 
45 1441629_at 1191.73 NA -1.31 -1.55 BB451601 --- --- --- 
46 1416368_at 1195.00 NA -1.31 -1.56 NM_010357 14860 Gsta4 
glutathione S-
transferase, alpha 
4 
47 1445786_at 1208.94 NA -1.34 -1.61 BB539247 109880 Braf Braf transforming gene 
48 1454672_at 1232.33 NA -1.36 -1.65 BE952212 --- --- --- 
49 1427537_at 1236.24 NA -1.37 -1.67 BC026387 223650 Eppk1 epiplakin 1 
50 1450988_at 1265.15 NA -1.30 -1.54 BB751088 14160 Lgr5 
leucine rich repeat 
containing G 
protein coupled 
receptor 5 
51 1441501_at 1268.76 NA -1.32 -1.58 AV382262 66870 Serbp1 Serpine1 mRNA binding protein 1 
52 1459443_at 1273.18 NA -1.31 -1.56 BM248133 16535 Kcnq1 
KCNQ1b mRNA 
for Q1-type 
potassium channel 
spliced variant 
53 1455059_at 1297.80 NA -1.31 -1.55 BB104941 109278 9430093I07Rik RIKEN cDNA 9430093I07 gene 
54 1421038_a_at 1306.61 NA -1.38 -1.70 NM_008433 16534 Kcnn4 
potassium 
intermediate/small 
conductance 
calcium-activated 
channel, subfamily 
N, member 4 
55 1427982_s_at 1313.46 NA -1.34 -1.61 BF582734 --- --- --- 
56 1446196_at 1314.47 NA -1.29 -1.52 BB105328 15364 Hmga2 high mobility group AT-hook 2 
57 1437534_at 1318.78 NA -1.34 -1.63 AU019880 106529 Gpsn2 
ES cells cDNA, 
RIKEN full-length 
enriched library, 
clone:2410016D23 
product:SC2 
homolog [Rattus 
sp], full insert 
sequence 
58 1435945_a_at 1339.40 NA -1.36 -1.67 BG865910 16534 Kcnn4 
potassium 
intermediate/small 
conductance 
calcium-activated 
channel, subfamily 
N, member 4 
59 1458068_at 1355.02 NA -1.33 -1.60 BB374785 74370 4932417H02Rik 
Raptor mRNA for 
p150 target of 
rapamycin (TOR)-
scaffold protein 
containing WD-
repeats 
60 1446616_at 1357.47 NA -1.30 -1.55 AW551961 --- --- --- 
61 1430425_at 1368.44 NA -1.34 -1.61 AW493494 237979 Sdk2 sidekick homolog 2 (chicken) 
62 1431528_at 1375.82 NA -1.34 -1.61 BE225800 76042 5830427D02Rik RIKEN cDNA 
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5830427D02 gene 
63 1440343_at 1385.12 NA -1.31 -1.55 BQ174267 73086 Rps6ka5 
ribosomal protein 
S6 kinase, 
polypeptide 5 
64 1418480_at 1432.73 NA -1.29 -1.52 NM_023785 57349 Cxcl7 chemokine (C-X-C 
motif) ligand 7 
65 1424112_at 1435.45 NA -1.33 -1.60 BG092290 16004 Igf2r insulin-like growth factor 2 receptor 
66 1439129_at 1466.83 NA -1.31 -1.55 AW495734 68813 1110060D06Rik RIKEN cDNA 1110060D06 gene 
67 1447294_at 1470.87 NA -1.34 -1.61 BB730861 103583 Fbxw11 F-box and WD-40 domain protein 11 
68 1439545_at 1478.26 NA -1.31 -1.55 BM240227 18181 Nrf1 
Nuclear respiratory 
factor 1, mRNA 
(cDNA clone 
MGC:5646 
IMAGE:3496661) 
69 1457262_at 1479.82 NA -1.34 -1.62 BB024162 233789 2610207I05Rik RIKEN cDNA 2610207I05 gene 
70 1441652_at 1489.70 NA -1.27 -1.48 BB185152 12168 Bmpr2 
bone morphogenic 
protein receptor, 
type II 
(serine/threonine 
kinase) 
71 1453125_at 1492.31 NA -1.25 -1.44 BM508495 20666 Sox11 SRY-box 
containing gene 11 
72 1432358_at 1495.44 NA -1.30 -1.54 AK003577 73732 1110008I14Rik RIKEN cDNA 1110008I14 gene 
73 1458663_at 1502.50 NA -1.35 -1.64 AI552833 16795 Large 
Like-
glycosyltransferas
e (Large), mRNA 
74 1448169_at 1520.27 NA -1.38 -1.69 NM_010664 16668 Krt1-18 keratin complex 1, 
acidic, gene 18 
75 1455965_at 1521.30 NA -1.21 -1.37 BG064671 --- --- --- 
76 1418547_at 1532.31 NA -0.89 -0.82 NM_009364 21789 Tfpi2 tissue factor pathway inhibitor 2 
77 1439571_at 1535.73 NA -1.30 -1.53 BB820889 319683 E230008J23Rik RIKEN cDNA E230008J23 gene 
78 1438575_a_at 1538.08 NA -1.32 -1.58 BG143413 Mm.254833 --- Transcribed locus 
79 1455377_at 1542.74 NA -1.28 -1.49 BB795572 70892 4921517B04Rik RIKEN cDNA 4921517B04 gene 
80 1424927_at 1546.63 NA -1.27 -1.49 BC025083 73690 Glipr1 GLI pathogenesis-
related 1 (glioma) 
81 1444218_at 1549.04 NA -1.29 -1.52 AI117684 76539 D19Ertd737e 
DNA segment, Chr 
19, ERATO Doi 
737, expressed 
82 1428719_at 1549.16 NA -1.28 -1.50 AK008551 
207685 
547243 
70018 
2010309G21Rik 
/// LOC207685 
/// LOC547243 
RIKEN cDNA 
2010309G21 gene 
/// hypothetical 
protein 
LOC207685 /// 
similar to Ig 
lambda-2 chain 
83 1423071_x_at 1585.19 NA -1.28 -1.50 AW549928 
270335 
434328 
544983 
545175 
545584 
546326 
LOC270335 /// 
LOC434328 /// 
LOC544983 /// 
LOC545175 /// 
LOC545584 /// 
LOC546326 
hypothetical gene 
supported by 
BC019681; 
BC027236 /// 
hypothetical 
LOC434328 /// 
similar to RIKEN 
cDNA 
2610524H06 gene 
/// similar to 
LOC381508 
protein /// similar to 
LOC381508 
protein /// similar to 
LOC381508 
protein 
84 1450923_at 1592.44 NA -1.30 -1.53 BF144658 21808 Tgfb2 
transforming 
growth factor, beta 
2 
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85 1436790_a_at 1598.23 NA -1.27 -1.48 BG072739 20666 Sox11 SRY-box 
containing gene 11 
86 1433201_at 1599.52 NA -1.26 -1.45 AK010214 70290 2310079F09Rik RIKEN cDNA 2310079F09 gene 
87 1416612_at 1605.67 NA -1.21 -1.37 BI251808 13078 Cyp1b1 
cytochrome P450, 
family 1, subfamily 
b, polypeptide 1 
88 1422324_a_at 1615.75 NA -1.17 -1.29 NM_008970 19227 Pthlh 
parathyroid 
hormone-like 
peptide 
89 1445943_at 1617.75 NA -1.28 -1.49 BG071766 --- --- --- 
90 1460571_at 1618.37 NA -1.27 -1.48 BM208197 192119 Dicer1 
Double-strand-
specific 
ribonuclease 
MDCR 
91 1428944_at 1625.90 NA -1.23 -1.41 BB417360 231380 5730469D23Rik RIKEN cDNA 5730469D23 gene 
92 1416613_at 1628.60 NA -1.17 -1.29 BI251808 13078 Cyp1b1 
cytochrome P450, 
family 1, subfamily 
b, polypeptide 1 
93 1459646_at 1631.73 NA -1.16 -1.27 BM899994 328779 Hs3st6 
heparan sulfate 
(glucosamine) 3-
O-sulfotransferase 
6 
94 1457065_at 1646.08 NA -1.30 -1.53 BB530943 22268 Upk1b uroplakin 1B 
95 1435154_at 1648.01 NA -1.26 -1.46 AV099404 245128 LOC245128 
similar to solute 
carrier family 7 
(cationic amino 
acid transporter, 
y+ system), 
member 3 
96 1458657_at 1648.43 NA -1.29 -1.52 AA822260 69538 Antxr1 
Tumor endothelial 
marker 8 precursor 
(Tem8) 
97 1437554_at 1666.56 NA -1.30 -1.54 BM232239 18810 Plec1 plectin 1 
98 1441688_at 1671.69 NA -1.29 -1.52 AV343428 319654 6430537I21Rik RIKEN cDNA 6430537I21 gene 
99 1447143_at 1683.35 NA -1.35 -1.64 BM115076 --- --- --- 
100 1458021_at 1684.30 NA -1.29 -1.51 BB550531 69024 Snx15 
Sorting nexin 15, 
mRNA (cDNA 
clone MGC:27611 
IMAGE:4503873) 
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The Rank Product (RP) differential expression analysis report 
 
 
 
 
 
0 Probe-set ID RPscore FDR FC_rma FC_nom "SOURCE" "EntrezGene" Gene Symbol Title 
1 1436905_x_at 145.03 10.00 -2.01 -3.15 BB218107 16792 Laptm5 
lysosomal-
associated protein 
transmembrane 5 
2 1436996_x_at 154.19 5.50 -1.96 -3.01 AV066625 17110 Lzp-s P lysozyme 
structural 
3 1439426_x_at 163.17 3.67 -2.04 -3.21 AV058500 17110 Lzp-s P lysozyme 
structural 
4 1420804_s_at 186.83 4.50 -2.12 -3.43 NM_010819 17474 Clec4d 
C-type lectin 
domain family 4, 
member d 
5 1448591_at 204.23 4.60 -1.93 -2.95 NM_021281 13040 Ctss cathepsin S 
6 1448748_at 236.28 6.33 -1.96 -3.01 AF181829 56193 Plek pleckstrin 
7 1424754_at 377.58 22.14 -1.93 -2.93 BC024402 109225 Ms4a7 
membrane-
spanning 4-
domains, subfamily 
A, member 7 
8 1448995_at 378.78 19.62 -1.69 -2.36 NM_019932 56744 Cxcl4 chemokine (C-X-C 
motif) ligand 4 
9 1418547_at 381.87 17.89 -1.70 -2.39 NM_009364 21789 Tfpi2 tissue factor pathway inhibitor 2 
10 1448929_at 407.64 20.70 -1.82 -2.68 NM_028784 74145 F13a1 coagulation factor XIII, A1 subunit 
11 1419599_s_at 418.00 20.82 -1.74 -2.49 NM_026835 64382 Ms4a11 
membrane-
spanning 4-
domains, subfamily 
A, member 11 
12 1450430_at 418.30 19.08 -1.77 -2.55 NM_008625 17533 Mrc1 mannose receptor, C type 1 
13 1417266_at 421.12 17.92 -1.73 -2.46 BC002073 20305 Ccl6 chemokine (C-C 
motif) ligand 6 
14 1438989_s_at 421.60 16.86 -1.56 -2.08 BB386167 320860 B130021B11Rik RIKEN cDNA B130021B11 gene 
15 1425951_a_at 427.86 16.67 -2.06 -3.28 AF240358 56620 Clec4n 
C-type lectin 
domain family 4, 
member n 
16 1435477_s_at 462.57 19.31 -1.86 -2.77 BM224327 14130 Fcgr2b Fc receptor, IgG, low affinity IIb 
17 1419598_at 502.33 23.24 -1.83 -2.69 NM_026835 68774 Ms4a6d 
membrane-
spanning 4-
domains, subfamily 
A, member 6D 
18 1423547_at 562.57 31.33 -1.66 -2.30 AW208566 17105 Lyzs lysozyme 
19 1417381_at 565.86 30.11 -1.82 -2.68 NM_007572 12259 C1qa complement 
component 1, q 
General Information 
Experiment  VK1mouse4302 
Normalisation  rma across replicates 
Chip  one chip only 
Comparison  Treatment samples: K14D6 + CCL3 vs Baseline samples: WT + CCL3 
RP comparison  not paired 
Direction  Negative 
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subcomponent, 
alpha polypeptide 
20 1419627_s_at 572.64 29.65 -1.78 -2.57 NM_020001 56620 Clec4n 
C-type lectin 
domain family 4, 
member n 
21 1449254_at 640.21 37.48 -1.75 -2.50 NM_009263 20750 Spp1 secreted phosphoprotein 1 
22 1449368_at 646.39 36.95 -1.39 -1.71 NM_007833 13179 Dcn decorin 
23 1442082_at 694.46 43.87 -1.75 -2.51 BB333624 12267 C3ar1 
complement 
component 3a 
receptor 1 
24 1419473_a_at 698.40 42.71 -1.63 -2.23 NM_031161 12424 Cck cholecystokinin 
25 1448620_at 730.34 46.00 -1.64 -2.25 NM_010188 14131 Fcgr3 Fc receptor, IgG, low affinity III 
26 1419728_at 740.66 45.88 -1.53 -2.02 NM_009141 20311 Cxcl5 chemokine (C-X-C 
motif) ligand 5 
27 1427262_at 754.73 46.93 -1.47 -1.88 L04961 213742 Xist inactive X specific transcripts 
28 1417936_at 783.45 NA -1.41 -1.75 AF128196 20308 Ccl9 chemokine (C-C 
motif) ligand 9 
29 1434172_at 791.18 NA -1.58 -2.12 BQ177934 --- --- --- 
30 1437558_at 793.08 NA -1.45 -1.84 BM119919 320860 B130021B11Rik RIKEN cDNA B130021B11 gene 
31 1420394_s_at 840.89 NA -1.58 -2.11 U05264 14727 14728 Gp49a /// Lilrb4 
glycoprotein 49 A 
/// leukocyte 
immunoglobulin-
like receptor, 
subfamily B, 
member 4 
32 1444176_at 840.89 NA -1.71 -2.41 AV204216 242341 Atp6v0d2 
ATPase, H+ 
transporting, V0 
subunit D, isoform 
2 
33 1443673_x_at 888.70 NA -1.38 -1.70 BB710847 --- --- --- 
34 1456858_at 912.26 NA -1.42 -1.77 BB075339 229357 Gpr149 G protein-coupled 
receptor 149 
35 1440969_at 918.41 NA -1.40 -1.74 BE944957 407797 BC030308 cDNA sequence BC030308 
36 1438672_at 929.31 NA -1.42 -1.77 BI134721 170736 Parvb Parvin, beta (Parvb), mRNA 
37 1436568_at 929.37 NA -1.62 -2.20 AU016127 67374 Jam2 junction adhesion 
molecule 2 
38 1427263_at 952.72 NA -1.37 -1.67 L04961 213742 Xist inactive X specific transcripts 
39 1452141_a_at 985.76 NA -1.48 -1.90 BC001991 20363 Sepp1 selenoprotein P, plasma, 1 
40 1415983_at 985.90 NA -1.49 -1.92 NM_008879 18826 Lcp1 lymphocyte 
cytosolic protein 1 
41 1443775_x_at 995.49 NA -1.39 -1.71 AV165539 380993 Zfp406 zinc finger protein 406 
42 1434877_at 1003.29 NA -1.31 -1.56 AI152800 18164 Nptx1 neuronal pentraxin 1 
43 1418511_at 1011.43 NA -1.49 -1.92 NM_019759 56429 Dpt dermatopontin 
44 1441688_at 1032.11 NA -1.37 -1.68 AV343428 319654 6430537I21Rik RIKEN cDNA 6430537I21 gene 
45 1420249_s_at 1057.30 NA -1.60 -2.16 AV084904 20305 Ccl6 chemokine (C-C 
motif) ligand 6 
46 1427268_at 1059.33 NA -1.15 -1.26 J03458 433621 545581 
LOC433621 /// 
LOC545581 
similar to Acidic 
ribosomal 
phosphoprotein P0 
/// similar to Acidic 
ribosomal 
phosphoprotein P0 
47 1425575_at 1062.51 NA -1.50 -1.95 M68513 13837 Epha3 Eph receptor A3 
48 1448169_at 1089.52 NA -1.47 -1.88 NM_010664 16668 Krt1-18 keratin complex 1, 
acidic, gene 18 
49 1451289_at 1091.74 NA -1.44 -1.82 AW105916 13175 Dcamkl1 double cortin and 
calcium/calmodulin-
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dependent protein 
kinase-like 1 
50 1423477_at 1107.54 NA -1.45 -1.85 BB361162 22771 Zic1 zinc finger protein 
of the cerebellum 1 
51 1422340_a_at 1114.62 NA -1.45 -1.83 NM_009610 11468 Actg2 
actin, gamma 2, 
smooth muscle, 
enteric 
52 1416811_s_at 1118.89 NA -1.33 -1.59 NM_007796 13024 13025 Ctla2a /// Ctla2b 
cytotoxic T 
lymphocyte-
associated protein 
2 alpha /// cytotoxic 
T lymphocyte-
associated protein 
2 beta 
53 1422135_at 1132.40 NA -1.36 -1.65 NM_011980 26465 Zfp146 zinc finger protein 146 
54 1419872_at 1139.33 NA -1.50 -1.94 AI323359 12978 Csf1r colony stimulating factor 1 receptor 
55 1442257_at 1142.86 NA -1.38 -1.70 BI134319 Mm.204306 --- 
12 days embryo 
female mullerian 
duct includes 
surrounding region 
cDNA, RIKEN full-
length enriched 
library, 
clone:6820438B06 
product:unclassifia
ble, full insert 
sequence 
56 1418826_at 1150.73 NA -1.56 -2.07 NM_027209 69774 Ms4a6b 
membrane-
spanning 4-
domains, subfamily 
A, member 6B 
57 1448471_a_at 1190.30 NA -1.33 -1.59 NM_007796 13024 Ctla2a 
cytotoxic T 
lymphocyte-
associated protein 
2 alpha 
58 1450652_at 1201.01 NA -1.36 -1.66 NM_007802 13038 Ctsk cathepsin K 
59 1422124_a_at 1203.52 NA -1.40 -1.74 NM_011210 19264 Ptprc 
protein tyrosine 
phosphatase, 
receptor type, C 
60 1418157_at 1236.99 NA -1.31 -1.56 NM_010151 13865 Nr2f1 
nuclear receptor 
subfamily 2, group 
F, member 1 
61 1435943_at 1256.04 NA -1.22 -1.38 AI647687 13479 Dpep1 dipeptidase 1 (renal) 
62 1427115_at 1268.28 NA -1.32 -1.58 M74753 17883 Myh3 
myosin, heavy 
polypeptide 3, 
skeletal muscle, 
embryonic 
63 1419609_at 1270.76 NA -1.43 -1.79 AV231648 12768 Ccr1 chemokine (C-C 
motif) receptor 1 
64 1427076_at 1270.97 NA -1.59 -2.14 L20315 17476 Mpeg1 macrophage 
expressed gene 1 
65 1423505_at 1271.94 NA -1.37 -1.67 BB114067 21345 Tagln transgelin 
66 1416613_at 1274.71 NA -1.18 -1.31 BI251808 13078 Cyp1b1 
cytochrome P450, 
family 1, subfamily 
b, polypeptide 1 
67 1440145_at 1317.38 NA -1.38 -1.70 BB831986 15101 H60 
PREDICTED: 
histocompatibility 
60 [Mus musculus], 
mRNA sequence 
68 1423691_x_at 1322.52 NA -1.43 -1.79 M21836 16691 Krt2-8 keratin complex 2, basic, gene 8 
69 1440295_at 1329.05 NA -1.36 -1.65 BB130189 68832 1110057K04Rik RIKEN cDNA 1110057K04 gene 
70 1434129_s_at 1340.14 NA -1.50 -1.95 BG917242 218454 Lhfpl2 lipoma HMGIC fusion partner-like 2 
71 1456046_at 1342.16 NA -1.53 -2.00 AV319144 17064 C1qr1 
complement 
component 1, q 
subcomponent, 
receptor 1 
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72 1429693_at 1354.44 NA -1.44 -1.82 AK017619 13132 Dab2 disabled homolog 2 (Drosophila) 
73 1439364_a_at 1380.07 NA -1.18 -1.32 BF147716 17390 Mmp2 matrix 
metallopeptidase 2 
74 1435989_x_at 1384.32 NA -1.42 -1.77 AW322280 434261 LOC434261 
similar to 
cytokeratin EndoA - 
mouse 
75 1416136_at 1387.90 NA -1.20 -1.34 NM_008610 17390 Mmp2 matrix 
metallopeptidase 2 
76 1454656_at 1389.76 NA -1.38 -1.69 AV271736 219140 Spata13 spermatogenesis 
associated 13 
77 1433525_at 1395.56 NA -1.44 -1.82 AW558570 13617 Ednra endothelin receptor type A 
78 1451161_a_at 1448.52 NA -1.41 -1.75 U66888 13733 Emr1 
EGF-like module 
containing, mucin-
like, hormone 
receptor-like 
sequence 1 
79 1456014_s_at 1456.21 NA -1.53 -2.02 BB113173 108101 BC032204 cDNA sequence BC032204 
80 1458299_s_at 1458.03 NA -1.40 -1.75 BB820441 18037 Nfkbie 
nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor, epsilon 
81 1420498_a_at 1458.52 NA -1.35 -1.63 NM_023118 13132 Dab2 disabled homolog 2 (Drosophila) 
82 1436970_a_at 1465.52 NA -1.39 -1.72 AA499047 18596 Pdgfrb 
platelet derived 
growth factor 
receptor, beta 
polypeptide 
83 1426236_a_at 1466.34 NA -1.40 -1.74 AI391218 14645 Glul 
glutamate-
ammonia ligase 
(glutamine 
synthetase) 
84 1452382_at 1471.67 NA -1.34 -1.62 BB542096 --- --- --- 
85 1456475_s_at 1475.79 NA -1.41 -1.76 BB216074 19088 Prkar2b 
protein kinase, 
cAMP dependent 
regulatory, type II 
beta 
86 1424443_at 1476.00 NA -1.43 -1.79 AV378394 107769 29877 
Hdgfrp3 /// 
Tm6sf1 
hepatoma-derived 
growth factor, 
related protein 3 /// 
transmembrane 6 
superfamily 
member 1 
87 1444061_at 1484.12 NA -1.18 -1.32 BB150166 109314 A030004J04Rik RIKEN cDNA A030004J04 gene 
88 1435343_at 1488.16 NA -1.41 -1.77 BF715043 210293 Dock10 dedicator of 
cytokinesis 10 
89 1420431_at 1495.23 NA -1.01 -1.02 NM_009100 20129 Rptn repetin 
90 1429210_at 1498.92 NA -1.44 -1.83 BE290548 237759 Col23a1 procollagen, type XXIII, alpha 1 
91 1437726_x_at 1518.53 NA -1.39 -1.71 BB111335 12260 C1qb 
complement 
component 1, q 
subcomponent, 
beta polypeptide 
92 1427883_a_at 1520.30 NA -1.33 -1.60 AW550625 12825 Col3a1 procollagen, type III, alpha 1 
93 1432466_a_at 1521.93 NA -1.37 -1.69 AK019319 11816 Apoe apolipoprotein E 
94 1451867_x_at 1535.31 NA -1.57 -2.09 AF177664 11856 Arhgap6 Rho GTPase 
activating protein 6 
95 1438975_x_at 1543.90 NA -1.32 -1.59 AV361868 224454 Zdhhc14 
zinc finger, DHHC 
domain containing 
14 
96 1419090_x_at 1558.48 NA -1.31 -1.55 NM_010644 16618 Klk26 kallikrein 26 
97 1449038_at 1558.98 NA -1.31 -1.56 NM_008288 15483 Hsd11b1 
hydroxysteroid 11-
beta 
dehydrogenase 1 
98 1448061_at 1560.02 NA -1.43 -1.80 AA183642 --- --- --- 
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99 1427484_at 1561.14 NA -1.31 -1.55 BB650819 319670 Eml5 
echinoderm 
microtubule 
associated protein 
like 5 
100 1455660_at 1567.23 NA -1.61 -2.19 BB769628 12983 Csf2rb1 
colony stimulating 
factor 2 receptor, 
beta 1, low-affinity 
(granulocyte-
macrophage) 
 
366 
 
Appendix Three 
Iterative Group Analysis (iGA) report on the differentially 
expressed functional gene classes 
 
 
 
General Information 
Mode Representative 
Number of genes on chip  23155 
Number of annotated genes  15986 
Number of groups  8092 
Number of singletons  2867 
Significance threshold  1.2e-04 
File name  K14D6 Control v WT Control positive 
 
Top Changed Groups  Group Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
5581 - collagen 34 5 1.9e-07 14.71 
7169 - transmembrane receptor protein tyrosine kinase 
signaling pathway 76 6 4.3e-06 7.89 
30020 - extracellular matrix structural constituent 
conferring tensile strength 29 4 4.5e-06 13.79 
IPR008160 - Collagen triple helix repeat 65 5 5.1e-06 7.69 
IPR000233 - Cadherin cytoplasmic region 12 3 7.8e-06 25.00 
6817 - phosphate transport 84 5 1.8e-05 5.95 
1516 - prostaglandin biosynthesis 9 2 2.9e-05 22.22 
5201 - extracellular matrix structural constituent 47 4 3.2e-05 8.51 
5229 - intracellular calcium activated chloride channel 
activity 3 3 1.0e-04 100.00 
 
Changed group breakdown: 
Group P-value  Probe-set ID  Rank Gene ID  Gene Symbol  Title  
5581 - collagen 6.6e-02 1448590_at 32 NM_009933 Col6a1 procollagen, type VI, 
alpha 1 
 3.8e-03 1450857_a_at 43 BF227507 Col1a2 procollagen, type I, alpha 2 
 2.1e-04 1452250_a_at 55 BI455189 Col6a2 procollagen, type VI, 
alpha 2 
 6.7e-06 1430676_at 58 AK019854 Col19a1 procollagen, type XIX, 
alpha 1 
show the whole group 1.9e-07 1427883_a_at 62 AW550625 Col3a1 procollagen, type III, 
alpha 1 
7169 - transmembrane 
receptor protein tyrosine 
kinase signaling pathway 
1.6e-01 1421917_at 36 AW537708 Pdgfra 
platelet derived growth 
factor receptor, alpha 
polypeptide 
 1.5e-02 1416121_at 40 M65143 Lox lysyl oxidase 
 1.1e-03 1450857_a_at 43 BF227507 Col1a2 procollagen, type I, alpha 2 
 3.2e-04 1437219_at 69 AW553541 Igf1r Insulin-like growth factor I 
receptor (Igf1r), mRNA 
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 3.0e-05 1436970_a_at 76 AA499047 Pdgfrb 
platelet derived growth 
factor receptor, beta 
polypeptide 
show the whole group 4.3e-06 1419248_at 90 AF215668 Rgs2 regulator of G-protein 
signaling 2 
30020 - extracellular matrix 
structural constituent 
conferring tensile strength 
5.7e-02 1448590_at 32 NM_009933 Col6a1 procollagen, type VI, 
alpha 1 
 2.7e-03 1450857_a_at 43 BF227507 Col1a2 procollagen, type I, alpha 2 
 1.3e-04 1452250_a_at 55 BI455189 Col6a2 procollagen, type VI, 
alpha 2 
show the whole group 4.5e-06 1427883_a_at 62 AW550625 Col3a1 procollagen, type III, 
alpha 1 
IPR008160 - Collagen triple 
helix repeat 1.2e-01 1448590_at 32 NM_009933 Col6a1 
procollagen, type VI, 
alpha 1 
 1.3e-02 1450857_a_at 43 BF227507 Col1a2 procollagen, type I, alpha 2 
 1.4e-03 1452250_a_at 55 BI455189 Col6a2 procollagen, type VI, 
alpha 2 
 9.0e-05 1430676_at 58 AK019854 Col19a1 procollagen, type XIX, 
alpha 1 
show the whole group 5.1e-06 1427883_a_at 62 AW550625 Col3a1 procollagen, type III, 
alpha 1 
IPR000233 - Cadherin 
cytoplasmic region 1.0e-02 1418815_at 14 BC022107 Cdh2 cadherin 2 
 4.2e-04 1450757_at 41 NM_009866 Cdh11 cadherin 11 
show the whole group 7.8e-06 1425092_at 54 AF183946 Cdh10 cadherin 10 
6817 - phosphate transport 1.6e-01 1448590_at 32 NM_009933 Col6a1 procollagen, type VI, 
alpha 1 
 2.1e-02 1450857_a_at 43 BF227507 Col1a2 procollagen, type I, alpha 2 
 3.0e-03 1452250_a_at 55 BI455189 Col6a2 procollagen, type VI, 
alpha 2 
 2.4e-04 1430676_at 58 AK019854 Col19a1 procollagen, type XIX, 
alpha 1 
show the whole group 1.8e-05 1427883_a_at 62 AW550625 Col3a1 procollagen, type III, 
alpha 1 
1516 - prostaglandin 
biosynthesis 4.5e-03 1448816_at 8 NM_008968 Ptgis 
prostaglandin I2 
(prostacyclin) synthase 
show the whole group 2.9e-05 1436448_a_at 15 AA833146 Ptgs1 prostaglandin-
endoperoxide synthase 1 
5201 - extracellular matrix 
structural constituent 9.0e-02 1448590_at 32 NM_009933 Col6a1 
procollagen, type VI, 
alpha 1 
 7.1e-03 1450857_a_at 43 BF227507 Col1a2 procollagen, type I, alpha 2 
 5.6e-04 1452250_a_at 55 BI455189 Col6a2 procollagen, type VI, 
alpha 2 
show the whole group 3.2e-05 1427883_a_at 62 AW550625 Col3a1 procollagen, type III, 
alpha 1 
5229 - intracellular calcium 
activated chloride channel 
activity 
2.7e-02 1460259_s_at 144 AF108501 Clca1 /// Clca2 
chloride channel calcium 
activated 1 /// chloride 
channel calcium activated 
2 
 4.0e-04 1419463_at 164 AF108501 Clca2 chloride channel calcium 
activated 2 
 1.0e-04 1417853_at 343 AF047838 Clca1 chloride channel calcium 
activated 1 
 
 
 
Iterative Group Analysis (iGA) report on the differentially 
expressed functional gene classes 
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General Information 
Mode Representative 
Number of genes on chip  23155 
Number of annotated genes  16003 
Number of groups  8107 
Number of singletons  2867 
Significance threshold  1.2e-04 
File name  WT +CCL3 V WT Control Positive 
 
Top Changed Groups  Group Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
IPR008160 - Collagen triple helix repeat 71 8 7.6e-11 11.27 
6817 - phosphate transport 84 7 1.3e-10 8.33 
5201 - extracellular matrix structural constituent 48 8 4.3e-10 16.67 
30020 - extracellular matrix structural constituent 
conferring tensile strength 29 5 1.1e-09 17.24 
5581 - collagen 35 5 2.9e-09 14.29 
IPR000885 - Fibrillar collagen, C-terminal 11 5 3.2e-09 45.45 
IPR001811 - Small chemokine, interleukin-8 like 31 6 1.8e-08 19.35 
8009 - chemokine activity 38 6 6.4e-08 15.79 
7169 - transmembrane receptor protein tyrosine kinase 
signaling pathway 76 6 4.7e-07 7.89 
IPR007237 - CD20/IgE Fc receptor beta subunit 15 4 5.5e-07 26.67 
IPR000372 - Cysteine-rich flanking region, N-terminal 39 5 2.2e-06 12.82 
1527 - microfibril 6 3 3.8e-06 50.00 
30023 - extracellular matrix constituent conferring 
elasticity 2 2 4.9e-06 100.00 
6935 - chemotaxis 87 6 9.4e-06 6.90 
8201 - heparin binding 57 5 2.3e-05 8.77 
Inflammatory_Response_Pathway - GenMAPP 40 3 4.1e-05 7.50 
Eicosanoid_Synthesis - GenMAPP 21 3 4.6e-05 14.29 
IPR001007 - von Willebrand factor, type C 22 2 5.0e-05 9.09 
IPR001695 - Lysyl oxidase 4 2 7.2e-05 50.00 
5229 - intracellular calcium activated chloride channel 
activity 3 3 9.8e-05 100.00 
50766 - positive regulation of phagocytosis 21 3 1.1e-04 14.29 
5588 - collagen type V 3 3 1.2e-04 100.00 
 
Changed group breakdown: 
Group P-value  Probe-set ID  Rank Gene ID  Gene Symbol  Title  
IPR008160 - Collagen triple helix 
repeat 1.8e-02 1427883_a_at 4 AW550625 Col3a1 
procollagen, type III, 
alpha 1 
 1.0e-03 1448590_at 11 NM_009933 Col6a1 procollagen, type VI, 
alpha 1 
 2.3e-05 1452250_a_at 13 BI455189 Col6a2 procollagen, type VI, 
alpha 2 
 3.4e-07 1417381_at 14 NM_007572 C1qa 
complement 
component 1, q 
subcomponent, 
alpha polypeptide 
 8.9e-09 1449154_at 17 NM_007729 Col11a1 procollagen, type XI, 
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alpha 1 
 1.1e-09 1416414_at 25 NM_133918 Emilin1 elastin microfibril interfacer 1 
 1.0e-10 1450857_a_at 27 BF227507 Col1a2 procollagen, type I, 
alpha 2 
show the whole group 7.6e-11 1423110_at 34 BF227507 --- --- 
6817 - phosphate transport 2.1e-02 1427883_a_at 4 AW550625 Col3a1 procollagen, type III, 
alpha 1 
 1.5e-03 1448590_at 11 NM_009933 Col6a1 procollagen, type VI, 
alpha 1 
 3.8e-05 1452250_a_at 13 BI455189 Col6a2 procollagen, type VI, 
alpha 2 
 6.8e-07 1417381_at 14 NM_007572 C1qa 
complement 
component 1, q 
subcomponent, 
alpha polypeptide 
 2.1e-08 1449154_at 17 NM_007729 Col11a1 procollagen, type XI, 
alpha 1 
 2.9e-09 1416414_at 25 NM_133918 Emilin1 elastin microfibril interfacer 1 
show the whole group 1.3e-10 1450857_a_at 27 BF227507 Col1a2 procollagen, type I, 
alpha 2 
5201 - extracellular matrix structural 
constituent 1.2e-02 1427883_a_at 4 AW550625 Col3a1 
procollagen, type III, 
alpha 1 
 4.8e-04 1448590_at 11 NM_009933 Col6a1 procollagen, type VI, 
alpha 1 
 7.1e-06 1452250_a_at 13 BI455189 Col6a2 procollagen, type VI, 
alpha 2 
 1.6e-07 1449154_at 17 NM_007729 Col11a1 procollagen, type XI, 
alpha 1 
 1.5e-08 1450857_a_at 27 BF227507 Col1a2 procollagen, type I, 
alpha 2 
 2.2e-07 1460208_at 87 NM_007993 Fbn1 fibrillin 1 
 1.1e-08 1454830_at 93 AV010392 Fbn2 fibrillin 2 
show the whole group 4.3e-10 1416740_at 96 AW744319 Col5a1 procollagen, type V, 
alpha 1 
30020 - extracellular matrix 
structural constituent conferring 
tensile strength 
7.2e-03 1427883_a_at 4 AW550625 Col3a1 procollagen, type III, 
alpha 1 
 1.7e-04 1448590_at 11 NM_009933 Col6a1 procollagen, type VI, 
alpha 1 
 1.5e-06 1452250_a_at 13 BI455189 Col6a2 procollagen, type VI, 
alpha 2 
 2.0e-08 1449154_at 17 NM_007729 Col11a1 procollagen, type XI, 
alpha 1 
show the whole group 1.1e-09 1450857_a_at 27 BF227507 Col1a2 procollagen, type I, 
alpha 2 
5581 - collagen 8.7e-03 1427883_a_at 4 AW550625 Col3a1 procollagen, type III, 
alpha 1 
 2.5e-04 1448590_at 11 NM_009933 Col6a1 procollagen, type VI, 
alpha 1 
 2.7e-06 1452250_a_at 13 BI455189 Col6a2 procollagen, type VI, 
alpha 2 
 4.5e-08 1449154_at 17 NM_007729 Col11a1 procollagen, type XI, 
alpha 1 
show the whole group 2.9e-09 1450857_a_at 27 BF227507 Col1a2 procollagen, type I, 
alpha 2 
IPR000885 - Fibrillar collagen, C-
terminal 2.7e-03 1427883_a_at 4 AW550625 Col3a1 
procollagen, type III, 
alpha 1 
 5.8e-05 1449154_at 17 NM_007729 Col11a1 procollagen, type XI, 
alpha 1 
 7.0e-07 1450857_a_at 27 BF227507 Col1a2 procollagen, type I, 
alpha 2 
 5.6e-09 1423110_at 34 BF227507 --- --- 
show the whole group 3.2e-09 1416740_at 96 AW744319 Col5a1 procollagen, type V, 
alpha 1 
IPR001811 - Small chemokine, 3.9e-03 1448995_at 2 NM_019932 Cxcl4 chemokine (C-X-C 
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interleukin-8 like motif) ligand 4 
 2.1e-03 1419728_at 35 NM_009141 Cxcl5 chemokine (C-X-C 
motif) ligand 5 
 8.8e-05 1420380_at 45 AF065933 Ccl2 chemokine (C-C 
motif) ligand 2 
 7.6e-06 1417266_at 66 BC002073 Ccl6 chemokine (C-C 
motif) ligand 6 
 4.5e-07 1417936_at 81 AF128196 Ccl9 chemokine (C-C 
motif) ligand 9 
show the whole group 1.8e-08 1449984_at 90 NM_009140 Cxcl2 chemokine (C-X-C 
motif) ligand 2 
8009 - chemokine activity 4.7e-03 1448995_at 2 NM_019932 Cxcl4 chemokine (C-X-C 
motif) ligand 4 
 3.1e-03 1419728_at 35 NM_009141 Cxcl5 chemokine (C-X-C 
motif) ligand 5 
 1.6e-04 1420380_at 45 AF065933 Ccl2 chemokine (C-C 
motif) ligand 2 
 1.8e-05 1417266_at 66 BC002073 Ccl6 chemokine (C-C 
motif) ligand 6 
 1.3e-06 1417936_at 81 AF128196 Ccl9 chemokine (C-C 
motif) ligand 9 
show the whole group 6.4e-08 1449984_at 90 NM_009140 Cxcl2 chemokine (C-X-C 
motif) ligand 2 
7169 - transmembrane receptor 
protein tyrosine kinase signaling 
pathway 
4.7e-02 1436970_a_at 10 AA499047 Pdgfrb 
platelet derived 
growth factor 
receptor, beta 
polypeptide 
 7.2e-03 1450857_a_at 27 BF227507 Col1a2 procollagen, type I, 
alpha 2 
 3.1e-04 1416121_at 28 M65143 Lox lysyl oxidase 
 3.8e-05 1421917_at 40 AW537708 Pdgfra 
platelet derived 
growth factor 
receptor, alpha 
polypeptide 
 2.0e-06 1419248_at 44 AF215668 Rgs2 regulator of G-protein signaling 2 
show the whole group 4.7e-07 1425575_at 62 M68513 Epha3 Eph receptor A3 
IPR007237 - CD20/IgE Fc receptor 
beta subunit 9.4e-04 1424754_at 1 BC024402 Ms4a7 
membrane-spanning 
4-domains, subfamily 
A, member 7 
 1.2e-04 1419598_at 18 NM_026835 Ms4a6d 
membrane-spanning 
4-domains, subfamily 
A, member 6D 
 2.7e-05 1418990_at 64 NM_025658 Ms4a4d 
membrane-spanning 
4-domains, subfamily 
A, member 4D 
show the whole group 5.5e-07 1419599_s_at 74 NM_026835 Ms4a11 
membrane-spanning 
4-domains, subfamily 
A, member 11 
IPR000372 - Cysteine-rich flanking 
region, N-terminal 1.7e-02 1423607_at 7 AK014312 Lum lumican 
 1.8e-03 1449368_at 26 NM_007833 Dcn decorin 
 6.3e-05 1416405_at 32 BC019502 Bgn biglycan 
 4.8e-05 1423311_s_at 83 BQ177165 Tpbg trophoblast glycoprotein 
show the whole group 2.2e-06 1452296_at 88 BM570006 Slit3 slit homolog 3 (Drosophila) 
1527 - microfibril 1.3e-02 1418454_at 36 NM_015776 Mfap5 microfibrillar 
associated protein 5 
 4.3e-04 1460208_at 87 NM_007993 Fbn1 fibrillin 1 
show the whole group 3.8e-06 1454830_at 93 AV010392 Fbn2 fibrillin 2 
30023 - extracellular matrix 
constituent conferring elasticity 3.1e-03 1416414_at 25 NM_133918 Emilin1 
elastin microfibril 
interfacer 1 
 4.9e-06 1418454_at 36 NM_015776 Mfap5 microfibrillar 
associated protein 5 
6935 - chemotaxis 1.1e-02 1448995_at 2 NM_019932 Cxcl4 chemokine (C-X-C 
motif) ligand 4 
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 1.5e-02 1419728_at 35 NM_009141 Cxcl5 chemokine (C-X-C 
motif) ligand 5 
 1.9e-03 1420380_at 45 AF065933 Ccl2 chemokine (C-C 
motif) ligand 2 
 4.5e-04 1417266_at 66 BC002073 Ccl6 chemokine (C-C 
motif) ligand 6 
 7.8e-05 1417936_at 81 AF128196 Ccl9 chemokine (C-C 
motif) ligand 9 
show the whole group 9.4e-06 1449984_at 90 NM_009140 Cxcl2 chemokine (C-X-C 
motif) ligand 2 
8201 - heparin binding 7.1e-03 1448995_at 2 NM_019932 Cxcl4 chemokine (C-X-C 
motif) ligand 4 
 3.4e-04 1450663_at 8 NM_011581 Thbs2 thrombospondin 2 
 4.7e-05 1423606_at 20 BI110565 Postn periostin, osteoblast 
specific factor 
 2.3e-05 1416221_at 47 BI452727 Fstl1 follistatin-like 1 
show the whole group 2.3e-05 1416740_at 96 AW744319 Col5a1 procollagen, type V, 
alpha 1 
Inflammatory_Response_Pathway - 
GenMAPP 1.0e-02 1427883_a_at 4 AW550625 Col3a1 
procollagen, type III, 
alpha 1 
 2.2e-04 1416136_at 9 NM_008610 Mmp2 matrix 
metallopeptidase 2 
show the whole group 4.1e-05 1450857_a_at 27 BF227507 Col1a2 procollagen, type I, 
alpha 2 
Eicosanoid_Synthesis - GenMAPP 2.1e-02 1435943_at 16 AI647687 Dpep1 dipeptidase 1 (renal) 
 1.8e-03 1448816_at 48 NM_008968 Ptgis 
prostaglandin I2 
(prostacyclin) 
synthase 
show the whole group 4.6e-05 1436448_a_at 54 AA833146 Ptgs1 
prostaglandin-
endoperoxide 
synthase 1 
IPR001007 - von Willebrand factor, 
type C 5.5e-03 1427883_a_at 4 AW550625 Col3a1 
procollagen, type III, 
alpha 1 
show the whole group 5.0e-05 1450663_at 8 NM_011581 Thbs2 thrombospondin 2 
IPR001695 - Lysyl oxidase 7.0e-03 1416121_at 28 M65143 Lox lysyl oxidase 
show the whole group 7.2e-05 1451978_at 56 AF357006 Loxl1 lysyl oxidase-like 1 
5229 - intracellular calcium activated 
chloride channel activity 3.2e-02 1419463_at 172 AF108501 Clca2 
chloride channel 
calcium activated 2 
 7.0e-04 1417852_x_at 230 AF047838 Clca1 chloride channel 
calcium activated 1 
 9.8e-05 1460259_s_at 262 AF108501 Clca1 /// Clca2 
chloride channel 
calcium activated 1 
/// chloride channel 
calcium activated 2 
50766 - positive regulation of 
phagocytosis 4.0e-02 1435477_s_at 31 BM224327 Fcgr2b 
Fc receptor, IgG, low 
affinity IIb 
 8.5e-04 1418666_at 33 NM_008987 Ptx3 pentraxin related gene 
show the whole group 1.1e-04 1448620_at 73 NM_010188 Fcgr3 Fc receptor, IgG, low 
affinity III 
5588 - collagen type V 1.8e-02 1416740_at 96 AW744319 Col5a1 procollagen, type V, 
alpha 1 
 6.3e-04 1422437_at 215 AV229424 Col5a2 procollagen, type V, 
alpha 2 
 1.2e-04 1419703_at 492 NM_016919 Col5a3 procollagen, type V, 
alpha 3 
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Iterative Group Analysis (iGA) report on the differentially 
expressed functional gene classes 
 
 
 
General Information 
Mode Representative 
Number of genes on chip  23155 
Number of annotated genes  15988 
Number of groups  8102 
Number of singletons  2879 
Significance threshold  1.2e-04 
File name  K14D6 + CCL3 v K14D6 control positive 
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Top Changed Groups  Group Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
30020 - extracellular matrix structural constituent 
conferring tensile strength 29 7 1.9e-10 24.14 
5581 - collagen 35 7 6.9e-10 20.00 
8201 - heparin binding 57 8 1.7e-09 14.04 
5201 - extracellular matrix structural constituent 48 7 6.8e-09 14.58 
IPR000885 - Fibrillar collagen, C-terminal 10 4 2.4e-08 40.00 
IPR008160 - Collagen triple helix repeat 72 6 1.5e-07 8.33 
6817 - phosphate transport 85 7 3.9e-07 8.24 
6935 - chemotaxis 87 7 3.9e-07 8.05 
IPR001811 - Small chemokine, interleukin-8 like 31 5 5.7e-07 16.13 
8009 - chemokine activity 38 5 1.6e-06 13.16 
50766 - positive regulation of phagocytosis 21 3 3.9e-06 14.29 
19864 - IgG binding 5 2 2.2e-05 40.00 
IPR001614 - Myelin proteolipid protein PLP 3 2 3.1e-05 66.67 
IPR007237 - CD20/IgE Fc receptor beta subunit 14 3 3.8e-05 21.43 
IPR001916 - Glycoside hydrolase, family 22 8 2 5.0e-05 25.00 
IPR002086 - Aldehyde dehydrogenase 26 2 5.3e-05 7.69 
45576 - mast cell activation 9 2 7.7e-05 22.22 
3796 - lysozyme activity 10 2 8.1e-05 20.00 
IPR001751 - Calcium-binding protein, S-100/ICaBP type 15 3 9.3e-05 20.00 
5229 - intracellular calcium activated chloride channel 
activity 3 3 9.4e-05 100.00 
IPR002227 - Tyrosinase 3 3 9.8e-05 100.00 
IPR002035 - von Willebrand factor, type A 44 4 1.1e-04 9.09 
 
Changed group breakdown: 
Group P-value  Probe-set ID  Rank Gene ID  Gene Symbol  Title  
30020 - extracellular matrix 
structural constituent 
conferring tensile strength 
1.8e-02 1427883_a_at 10 AW550625 Col3a1 procollagen, type III, alpha 1 
 6.5e-04 1455494_at 21 BI794771 Col1a1 procollagen, type I, alpha 1 
 9.3e-06 1452250_a_at 23 BI455189 Col6a2 procollagen, type VI, alpha 2 
 1.5e-07 1448590_at 27 NM_009933 Col6a1 procollagen, type VI, alpha 1 
 4.3e-09 1449154_at 35 NM_007729 Col11a1 procollagen, type XI, alpha 1 
 5.2e-10 1450857_a_at 54 BF227507 Col1a2 procollagen, type I, alpha 2 
show the whole group 1.9e-10 1434479_at 87 AV246911 Col5a1 Procollagen, type V, alpha 1 (Col5a1), mRNA 
5581 - collagen 2.2e-02 1427883_a_at 10 AW550625 Col3a1 procollagen, type III, alpha 1 
 9.5e-04 1455494_at 21 BI794771 Col1a1 procollagen, type I, alpha 1 
 1.7e-05 1452250_a_at 23 BI455189 Col6a2 procollagen, type VI, alpha 2 
 3.3e-07 1448590_at 27 NM_009933 Col6a1 procollagen, type VI, alpha 1 
 1.2e-08 1449154_at 35 NM_007729 Col11a1 procollagen, type XI, alpha 1 
 1.7e-09 1450857_a_at 54 BF227507 Col1a2 procollagen, type I, alpha 2 
show the whole group 6.9e-10 1434479_at 87 AV246911 Col5a1 Procollagen, type V, alpha 1 (Col5a1), mRNA 
8201 - heparin binding 4.9e-02 1432466_a_at 14 AK019319 Apoe apolipoprotein E 
 6.1e-03 1448259_at 33 BI452727 Fstl1 follistatin-like 1 
 7.9e-04 1448995_at 51 NM_019932 Cxcl4 chemokine (C-X-C motif) ligand 4 
 2.0e-04 1423606_at 81 BI110565 Postn periostin, osteoblast specific factor 
 1.3e-05 1421228_at 85 AF128193 Ccl7 chemokine (C-C motif) ligand 7 
 6.3e-07 1434479_at 87 AV246911 Col5a1 Procollagen, type V, alpha 1 (Col5a1), mRNA 
 4.3e-08 1448303_at 95 NM_053110 Gpnmb glycoprotein (transmembrane) nmb 
show the whole group 1.7e-09 1422571_at 96 NM_011581 Thbs2 thrombospondin 2 
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5201 - extracellular matrix 
structural constituent 3.0e-02 1427883_a_at 10 AW550625 Col3a1 procollagen, type III, alpha 1 
 1.8e-03 1455494_at 21 BI794771 Col1a1 procollagen, type I, alpha 1 
 4.3e-05 1452250_a_at 23 BI455189 Col6a2 procollagen, type VI, alpha 2 
 1.2e-06 1448590_at 27 NM_009933 Col6a1 procollagen, type VI, alpha 1 
 6.0e-08 1449154_at 35 NM_007729 Col11a1 procollagen, type XI, alpha 1 
 1.2e-08 1450857_a_at 54 BF227507 Col1a2 procollagen, type I, alpha 2 
show the whole group 6.8e-09 1434479_at 87 AV246911 Col5a1 Procollagen, type V, alpha 1 (Col5a1), mRNA 
IPR000885 - Fibrillar 
collagen, C-terminal 6.2e-03 1427883_a_at 10 AW550625 Col3a1 procollagen, type III, alpha 1 
 2.1e-04 1449154_at 35 NM_007729 Col11a1 procollagen, type XI, alpha 1 
 2.5e-06 1423110_at 45 BF227507 --- --- 
show the whole group 2.4e-08 1450857_a_at 54 BF227507 Col1a2 procollagen, type I, alpha 2 
IPR008160 - Collagen triple 
helix repeat 4.4e-02 1427883_a_at 10 AW550625 Col3a1 procollagen, type III, alpha 1 
 4.8e-03 1452250_a_at 23 BI455189 Col6a2 procollagen, type VI, alpha 2 
 2.4e-04 1448590_at 27 NM_009933 Col6a1 procollagen, type VI, alpha 1 
 1.8e-05 1449154_at 35 NM_007729 Col11a1 procollagen, type XI, alpha 1 
 1.7e-06 1423110_at 45 BF227507 --- --- 
show the whole group 1.5e-07 1450857_a_at 54 BF227507 Col1a2 procollagen, type I, alpha 2 
6817 - phosphate transport 5.2e-02 1427883_a_at 10 AW550625 Col3a1 procollagen, type III, alpha 1 
 5.5e-03 1455494_at 21 BI794771 Col1a1 procollagen, type I, alpha 1 
 2.4e-04 1452250_a_at 23 BI455189 Col6a2 procollagen, type VI, alpha 2 
 1.2e-05 1448590_at 27 NM_009933 Col6a1 procollagen, type VI, alpha 1 
 1.1e-06 1449154_at 35 NM_007729 Col11a1 procollagen, type XI, alpha 1 
 4.0e-07 1450857_a_at 54 BF227507 Col1a2 procollagen, type I, alpha 2 
show the whole group 3.9e-07 1434479_at 87 AV246911 Col5a1 Procollagen, type V, alpha 1 (Col5a1), mRNA 
6935 - chemotaxis 7.9e-02 1417936_at 15 AF128196 Ccl9 chemokine (C-C motif) ligand 9 
 4.7e-03 1417266_at 19 BC002073 Ccl6 chemokine (C-C motif) ligand 6 
 2.4e-03 1419394_s_at 49 NM_013650 S100a8 S100 calcium binding protein A8 (calgranulin A) 
 1.7e-04 1448995_at 51 NM_019932 Cxcl4 chemokine (C-X-C motif) ligand 4 
 1.3e-05 1449984_at 56 NM_009140 Cxcl2 chemokine (C-X-C motif) ligand 2 
 2.6e-06 1419483_at 72 NM_009779 C3ar1 complement component 3a 
receptor 1 
show the whole group 3.9e-07 1421228_at 85 AF128193 Ccl7 chemokine (C-C motif) ligand 7 
IPR001811 - Small 
chemokine, interleukin-8 
like 
2.9e-02 1417936_at 15 AF128196 Ccl9 chemokine (C-C motif) ligand 9 
 6.1e-04 1417266_at 19 BC002073 Ccl6 chemokine (C-C motif) ligand 6 
 1.3e-04 1448995_at 51 NM_019932 Cxcl4 chemokine (C-X-C motif) ligand 4 
 4.0e-06 1449984_at 56 NM_009140 Cxcl2 chemokine (C-X-C motif) ligand 2 
show the whole group 5.7e-07 1421228_at 85 AF128193 Ccl7 chemokine (C-C motif) ligand 7 
8009 - chemokine activity 3.5e-02 1417936_at 15 AF128196 Ccl9 chemokine (C-C motif) ligand 9 
 9.2e-04 1417266_at 19 BC002073 Ccl6 chemokine (C-C motif) ligand 6 
 2.4e-04 1448995_at 51 NM_019932 Cxcl4 chemokine (C-X-C motif) ligand 4 
 9.1e-06 1449984_at 56 NM_009140 Cxcl2 chemokine (C-X-C motif) ligand 2 
show the whole group 1.6e-06 1421228_at 85 AF128193 Ccl7 chemokine (C-C motif) ligand 7 
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50766 - positive regulation 
of phagocytosis 7.9e-03 1418666_at 6 NM_008987 Ptx3 pentraxin related gene 
 5.9e-05 1448620_at 9 NM_010188 Fcgr3 Fc receptor, IgG, low affinity III 
show the whole group 3.9e-06 1435477_s_at 24 BM224327 Fcgr2b Fc receptor, IgG, low affinity IIb 
19864 - IgG binding 2.8e-03 1448620_at 9 NM_010188 Fcgr3 Fc receptor, IgG, low affinity III 
show the whole group 2.2e-05 1435477_s_at 24 BM224327 Fcgr2b Fc receptor, IgG, low affinity IIb 
IPR001614 - Myelin 
proteolipid protein PLP 3.0e-03 1423091_a_at 16 AK016567 Gpm6b glycoprotein m6b 
show the whole group 3.1e-05 1451718_at 52 BB768495 Plp1 proteolipid protein (myelin) 1 
IPR007237 - CD20/IgE Fc 
receptor beta subunit 2.8e-02 1424754_at 32 BC024402 Ms4a7 
membrane-spanning 4-
domains, subfamily A, 
member 7 
 1.2e-03 1419599_s_at 60 NM_026835 Ms4a11 
membrane-spanning 4-
domains, subfamily A, 
member 11 
show the whole group 3.8e-05 1419598_at 77 NM_026835 Ms4a6d 
membrane-spanning 4-
domains, subfamily A, 
member 6D 
IPR001916 - Glycoside 
hydrolase, family 22 1.0e-03 1436996_x_at 2 AV066625 Lzp-s P lysozyme structural 
show the whole group 5.0e-05 1423547_at 22 AW208566 Lyzs lysozyme 
IPR002086 - Aldehyde 
dehydrogenase 1.6e-03 1418601_at 1 NM_011921 Aldh1a7 
aldehyde dehydrogenase 
family 1, subfamily A7 
show the whole group 5.3e-05 1416468_at 7 NM_013467 Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 
45576 - mast cell activation 5.1e-03 1448620_at 9 NM_010188 Fcgr3 Fc receptor, IgG, low affinity III 
show the whole group 7.7e-05 1435477_s_at 24 BM224327 Fcgr2b Fc receptor, IgG, low affinity IIb 
3796 - lysozyme activity 1.3e-03 1436996_x_at 2 AV066625 Lzp-s P lysozyme structural 
show the whole group 8.1e-05 1423547_at 22 AW208566 Lyzs lysozyme 
IPR001751 - Calcium-
binding protein, S-
100/ICaBP type 
3.5e-02 1448756_at 38 NM_009114 S100a9 S100 calcium binding protein A9 (calgranulin B) 
 9.4e-04 1419394_s_at 49 NM_013650 S100a8 S100 calcium binding protein A8 (calgranulin A) 
show the whole group 9.3e-05 1424542_at 97 D00208 S100a4 S100 calcium binding protein A4 
5229 - intracellular calcium 
activated chloride channel 
activity 
1.3e-02 1419463_at 70 AF108501 Clca2 chloride channel calcium 
activated 2 
 9.6e-05 1460259_s_at 91 AF108501 Clca1 /// Clca2 
chloride channel calcium 
activated 1 /// chloride 
channel calcium activated 2 
 9.4e-05 1417852_x_at 102 AF047838 Clca1 chloride channel calcium 
activated 1 
IPR002227 - Tyrosinase 2.8e-02 1415862_at 150 BB762957 Tyrp1 tyrosinase-related protein 1 
 6.2e-04 1417717_a_at 214 NM_011661 Tyr tyrosinase 
 9.8e-05 1418028_at 257 NM_010024 Dct dopachrome tautomerase 
IPR002035 - von Willebrand 
factor, type A 6.1e-02 1452250_a_at 23 BI455189 Col6a2 procollagen, type VI, alpha 2 
 2.5e-03 1448590_at 27 NM_009933 Col6a1 procollagen, type VI, alpha 1 
 9.4e-04 1419463_at 70 AF108501 Clca2 chloride channel calcium 
activated 2 
show the whole group 1.1e-04 1460259_s_at 91 AF108501 Clca1 /// Clca2 
chloride channel calcium 
activated 1 /// chloride 
channel calcium activated 2 
Iterative Group Analysis (iGA) report on the differentially 
expressed functional gene classes 
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Top Changed Groups  Group Members  
Changed 
Members  
P-Value 
Changed  Percent Changed 
6583 - melanin biosynthesis from tyrosine 6 4 3.4e-11 66.67 
1533 - cornified envelope 14 5 1.2e-08 35.71 
IPR003347 - Transcription factor jumonji, 
jmjC 21 3 3.9e-08 14.29 
42470 - melanosome 7 3 6.8e-08 42.86 
IPR002227 - Tyrosinase 2 2 1.6e-06 100.00 
15171 - amino acid transporter activity 18 2 2.5e-05 11.11 
31424 - keratinization 23 3 4.3e-05 13.04 
 
Changed group breakdown: 
Group P-value  Probe-set ID  Rank Gene ID  Gene Symbol  Title  
6583 - melanin 
biosynthesis 
from tyrosine 
3.8e-03 1415862_at 10 BB762957 Tyrp1 tyrosinase-related protein 1 
 1.2e-05 1422523_at 15 NM_021882 Si silver 
 3.4e-08 1456095_at 20 BB769772 Tyr tyrosinase 
show the whole 
group 3.4e-11 1418028_at 21 NM_010024 Dct dopachrome tautomerase 
1533 - cornified 
envelope 2.6e-02 1450618_a_at 30 NM_011468 Sprr2a small proline-rich protein 2A 
 4.2e-04 1448745_s_at 35 NM_008508 Lor loricrin 
 9.1e-06 1451613_at 48 AY027660 Hrnr hornerin 
 1.8e-07 1420431_at 60 NM_009100 Rptn repetin 
show the whole 
group 1.2e-08 1422837_at 94 NM_022886 Scel sciellin 
IPR003347 - 
Transcription 
factor jumonji, 
jmjC 
2.6e-03 1426438_at 2 AA210261 Ddx3y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked 
 1.6e-05 1426598_at 5 BB742957 
Uty /// 
LOC546404 /// 
LOC546411 
ubiquitously transcribed 
tetratricopeptide repeat gene, Y 
chromosome /// similar to male-
specific histocompatibility antigen H-
YDb /// similar to male-specific 
histocompatibility antigen H-YDb 
show the whole 
group 3.9e-08 1424903_at 6 AF127244 Jarid1d 
jumonji, AT rich interactive domain 
1D (Rbp2 like) 
42470 - 
melanosome 4.4e-03 1415862_at 10 BB762957 Tyrp1 tyrosinase-related protein 1 
 3.1e-05 1456095_at 20 BB769772 Tyr tyrosinase 
show the whole 
group 6.8e-08 1418028_at 21 NM_010024 Dct dopachrome tautomerase 
General Information 
Mode Representative 
Number of genes on chip  23155 
Number of annotated genes  15966 
Number of groups  8086 
Number of singletons  2867 
Significance threshold  1.2e-04 
File name  K14D6 + CCL3 v WT + CCL3 Positive 
377 
 
IPR002227 - 
Tyrosinase 1.3e-03 1415862_at 10 BB762957 Tyrp1 tyrosinase-related protein 1 
 1.6e-06 1418028_at 21 NM_010024 Dct dopachrome tautomerase 
15171 - amino 
acid transporter 
activity 
4.5e-03 1420504_at 4 AF320226 Slc6a14 
solute carrier family 6 
(neurotransmitter transporter), 
member 14 
show the whole 
group 2.5e-05 1417022_at 7 NM_007515 Slc7a3 
solute carrier family 7 (cationic 
amino acid transporter, y+ system), 
member 3 
31424 - 
keratinization 4.2e-02 1450618_a_at 30 NM_011468 Sprr2a small proline-rich protein 2A 
 1.1e-03 1448745_s_at 35 NM_008508 Lor loricrin 
show the whole 
group 4.3e-05 1451613_at 48 AY027660 Hrnr hornerin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Iterative Group Analysis (iGA) report on the differentially 
expressed functional gene classes 
 
 
 
General Information 
Mode Representative 
Number of genes on chip  23155 
Number of annotated genes  15976 
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Number of groups  8057 
Number of singletons  2885 
Significance threshold  1.2e-04 
File name  K14D6 Control v WT Control Negative 
 
Top Changed Groups  Group Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
1533 - cornified envelope 14 7 9.3e-13 50.00 
31424 - keratinization 23 4 4.1e-06 17.39 
IPR001916 - Glycoside hydrolase, family 22 8 2 4.6e-06 25.00 
3796 - lysozyme activity 10 2 7.4e-06 20.00 
16998 - cell wall catabolism 16 2 2.0e-05 12.50 
IPR001811 - Small chemokine, interleukin-8 
like 31 4 2.2e-05 12.90 
19835 - cytolysis 20 2 3.1e-05 10.00 
19864 - IgG binding 5 2 4.1e-05 40.00 
8009 - chemokine activity 38 4 5.0e-05 10.53 
6935 - chemotaxis 87 5 1.1e-04 5.75 
IPR002227 - Tyrosinase     
 
Changed group breakdown: 
Group P-value  Probe-set ID  Rank Gene ID  Gene Symbol  Title  
1533 - cornified 
envelope 2.1e-02 1420431_at 24 NM_009100 Rptn repetin 
 6.0e-04 1427910_at 42 AK003744 Cst6 cystatin E/M 
 1.4e-05 1427268_at 55 J03458 LOC433621 /// LOC545581 
similar to Acidic ribosomal 
phosphoprotein P0 /// similar 
to Acidic ribosomal 
phosphoprotein P0 
 1.6e-07 1451613_at 59 AY027660 Hrnr hornerin 
 2.0e-09 1429540_at 66 AK008979 Cnfn cornifelin 
 9.5e-12 1422837_at 67 NM_022886 Scel sciellin 
show the whole group 9.3e-13 1448745_s_at 77 NM_008508 Lor loricrin 
31424 - 
keratinization 4.2e-02 1422963_at 30 NM_011475 Sprr2i small proline-rich protein 2I 
 9.6e-04 1449833_at 32 NM_011472 Sprr2f small proline-rich protein 2F 
 8.0e-05 1451613_at 59 AY027660 Hrnr hornerin 
show the whole group 4.1e-06 1448745_s_at 77 NM_008508 Lor loricrin 
IPR001916 - 
Glycoside 
hydrolase, family 22 
5.0e-04 1436996_x_at 1 AV066625 Lzp-s P lysozyme structural 
show the whole group 4.6e-06 1423547_at 7 AW208566 Lyzs lysozyme 
3796 - lysozyme 
activity 6.3e-04 1436996_x_at 1 AV066625 Lzp-s P lysozyme structural 
show the whole group 7.4e-06 1423547_at 7 AW208566 Lyzs lysozyme 
16998 - cell wall 
catabolism 1.0e-03 1436996_x_at 1 AV066625 Lzp-s P lysozyme structural 
show the whole group 2.0e-05 1423547_at 7 AW208566 Lyzs lysozyme 
IPR001811 - Small 
chemokine, 
interleukin-8 like 
3.2e-02 1448995_at 17 NM_019932 Cxcl4 chemokine (C-X-C motif) ligand 4 
 8.2e-04 1417936_at 22 AF128196 Ccl9 chemokine (C-C motif) ligand 9 
 1.1e-04 1417266_at 48 BC002073 Ccl6 chemokine (C-C motif) ligand 6 
show the whole group 2.2e-05 1449984_at 86 NM_009140 Cxcl2 chemokine (C-X-C motif) ligand 2 
19835 - cytolysis 1.3e-03 1436996_x_at 1 AV066625 Lzp-s P lysozyme structural 
show the whole group 3.1e-05 1423547_at 7 AW208566 Lyzs lysozyme 
19864 - IgG binding 1.9e-03 1448620_at 6 NM_010188 Fcgr3 Fc receptor, IgG, low affinity III 
show the whole group 4.1e-05 1435477_s_at 33 BM224327 Fcgr2b Fc receptor, IgG, low affinity IIb 
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8009 - chemokine 
activity 4.0e-02 1448995_at 17 NM_019932 Cxcl4 
chemokine (C-X-C motif) 
ligand 4 
 1.2e-03 1417936_at 22 AF128196 Ccl9 chemokine (C-C motif) ligand 9 
 2.0e-04 1417266_at 48 BC002073 Ccl6 chemokine (C-C motif) ligand 6 
show the whole group 5.0e-05 1449984_at 86 NM_009140 Cxcl2 chemokine (C-X-C motif) ligand 2 
6935 - chemotaxis 8.9e-02 1448995_at 17 NM_019932 Cxcl4 chemokine (C-X-C motif) ligand 4 
 6.3e-03 1417936_at 22 AF128196 Ccl9 chemokine (C-C motif) ligand 9 
 2.3e-03 1417266_at 48 BC002073 Ccl6 chemokine (C-C motif) ligand 6 
 8.6e-04 1419483_at 78 NM_009779 C3ar1 complement component 3a 
receptor 1 
show the whole group 1.1e-04 1449984_at 86 NM_009140 Cxcl2 chemokine (C-X-C motif) ligand 2 
IPR002227 - 
Tyrosinase 4.3e-02 1418028_at 233 NM_010024 Dct dopachrome tautomerase 
 2.7e-03 1415861_at 474 BB762957 Tyrp1 tyrosinase-related protein 1 
 1.2e-04 1417717_a_at 477 NM_011661 Tyr tyrosinase 
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General Information 
Mode Representative 
Number of genes on chip  23155 
Number of annotated genes  15960 
Number of groups  8038 
Number of singletons  2867 
Significance threshold  1.2e-04 
File name  WT + CCL3 V WT Control Negative 
 
Top Changed Groups  Group Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
1533 - cornified envelope 14 4 8.0e-11 28.57 
42470 - melanosome 7 4 4.6e-08 57.14 
IPR003347 - Transcription factor jumonji, jmjC 18 3 6.7e-08 16.67 
5882 - intermediate filament 93 8 9.3e-08 8.60 
IPR001664 - Intermediate filament protein 57 6 4.5e-07 10.53 
6583 - melanin biosynthesis from tyrosine 6 3 4.4e-06 50.00 
IPR001751 - Calcium-binding protein, S-
100/ICaBP type 14 2 7.1e-06 14.29 
IPR002227 - Tyrosinase 2 2 2.5e-05 100.00 
16338 - calcium-independent cell-cell adhesion 22 3 2.5e-05 13.64 
42383 - sarcolemma 14 3 4.6e-05 21.43 
42802 - identical protein binding 81 4 6.0e-05 4.94 
IPR004031 - PMP-22/EMP/MP20 and claudin 
family 30 3 6.5e-05 10.00 
31424 - keratinization 23 2 8.9e-05 8.70 
5200 - structural constituent of cytoskeleton 91 5 1.0e-04 5.49 
 
Changed group breakdown: 
Group P-value  Probe-set ID  Rank Gene ID  Gene Symbol  Title  
1533 - cornified 
envelope 1.8e-03 1451613_at 2 AY027660 Hrnr hornerin 
 7.1e-06 1420431_at 5 NM_009100 Rptn repetin 
 4.5e-08 1427268_at 9 J03458 LOC433621 /// LOC545581 
similar to Acidic ribosomal 
phosphoprotein P0 /// similar 
to Acidic ribosomal 
phosphoprotein P0 
show the whole 
group 8.0e-11 1448745_s_at 10 NM_008508 Lor loricrin 
42470 - 
melanosome 2.7e-02 1415861_at 63 BB762957 Tyrp1 tyrosinase-related protein 1 
 5.1e-04 1418028_at 80 NM_010024 Dct dopachrome tautomerase 
 5.0e-06 1449896_at 85 NM_053015 Mlph melanophilin 
show the whole 
group 4.6e-08 1456095_at 98 BB769772 Tyr tyrosinase 
IPR003347 - 
Transcription 
factor jumonji, 
jmjC 
1.1e-03 1426438_at 1 AA210261 Ddx3y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked 
 1.8e-05 1424903_at 6 AF127244 Jarid1d jumonji, AT rich interactive domain 1D (Rbp2 like) 
show the whole 
group 6.7e-08 1426598_at 8 BB742957 
Uty /// 
LOC546404 /// 
ubiquitously transcribed 
tetratricopeptide repeat gene, 
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LOC546411 Y chromosome /// similar to 
male-specific histocompatibility 
antigen H-YDb /// similar to 
male-specific histocompatibility 
antigen H-YDb 
5882 - 
intermediate 
filament 
2.3e-02 1429565_s_at 4 AK004318 Lce5a late cornified envelope 5A 
 6.6e-03 1423952_a_at 21 BC010337 Krt2-7 keratin complex 2, basic, gene 7 
 4.5e-03 1419619_at 57 NM_028770 1200016G03Rik RIKEN cDNA 1200016G03 gene 
 3.8e-04 1420647_a_at 59 NM_031170 Krt2-8 /// LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
 3.0e-05 1448169_at 62 NM_010664 Krt1-18 keratin complex 1, acidic, gene 18 
 6.1e-06 1435989_x_at 78 AW322280 LOC434261 similar to cytokeratin EndoA - 
mouse 
 4.8e-07 1423691_x_at 82 M21836 Krt2-8 keratin complex 2, basic, gene 8 
show the whole 
group 9.3e-08 1438849_at 97 BB144669 2310030B04Rik 
RIKEN cDNA 2310030B04 
gene 
IPR001664 - 
Intermediate 
filament protein 
7.2e-02 1423952_a_at 21 BC010337 Krt2-7 keratin complex 2, basic, gene 7 
 1.8e-02 1419619_at 57 NM_028770 1200016G03Rik RIKEN cDNA 1200016G03 gene 
 1.2e-03 1420647_a_at 59 NM_031170 Krt2-8 /// LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
 7.0e-05 1448169_at 62 NM_010664 Krt1-18 keratin complex 1, acidic, gene 18 
 8.4e-06 1435989_x_at 78 AW322280 LOC434261 similar to cytokeratin EndoA - 
mouse 
show the whole 
group 4.5e-07 1423691_x_at 82 M21836 Krt2-8 
keratin complex 2, basic, gene 
8 
6583 - melanin 
biosynthesis 
from tyrosine 
2.3e-02 1415861_at 63 BB762957 Tyrp1 tyrosinase-related protein 1 
 3.7e-04 1418028_at 80 NM_010024 Dct dopachrome tautomerase 
show the whole 
group 4.4e-06 1456095_at 98 BB769772 Tyr tyrosinase 
IPR001751 - 
Calcium-binding 
protein, S-
100/ICaBP type 
1.8e-03 1451613_at 2 AY027660 Hrnr hornerin 
show the whole 
group 7.1e-06 1420431_at 5 NM_009100 Rptn repetin 
IPR002227 - 
Tyrosinase 7.9e-03 1415861_at 63 BB762957 Tyrp1 tyrosinase-related protein 1 
 2.5e-05 1418028_at 80 NM_010024 Dct dopachrome tautomerase 
16338 - calcium-
independent cell-
cell adhesion 
4.7e-02 1448393_at 35 BC008104 Cldn7 claudin 7 
 1.4e-03 1460569_x_at 40 AW611462 Cldn3 claudin 3 
show the whole 
group 2.5e-05 1418283_at 42 NM_009903 Cldn4 claudin 4 
42383 - 
sarcolemma 5.1e-02 1420647_a_at 59 NM_031170 
Krt2-8 /// 
LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
 2.1e-03 1435989_x_at 78 AW322280 LOC434261 similar to cytokeratin EndoA - 
mouse 
show the whole 
group 4.6e-05 1423691_x_at 82 M21836 Krt2-8 
keratin complex 2, basic, gene 
8 
42802 - identical 
protein binding 5.4e-02 1420350_at 11 NM_028625 Sprrl2 small proline rich-like 2 
 1.4e-02 1448393_at 35 BC008104 Cldn7 claudin 7 
 1.1e-03 1460569_x_at 40 AW611462 Cldn3 claudin 3 
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show the whole 
group 6.0e-05 1418283_at 42 NM_009903 Cldn4 claudin 4 
IPR004031 - 
PMP-
22/EMP/MP20 
and claudin 
family 
6.4e-02 1448393_at 35 BC008104 Cldn7 claudin 7 
 2.5e-03 1460569_x_at 40 AW611462 Cldn3 claudin 3 
show the whole 
group 6.5e-05 1418283_at 42 NM_009903 Cldn4 claudin 4 
31424 - 
keratinization 2.9e-03 1451613_at 2 AY027660 Hrnr hornerin 
show the whole 
group 8.9e-05 1448745_s_at 10 NM_008508 Lor loricrin 
5200 - structural 
constituent of 
cytoskeleton 
5.6e-02 1448745_s_at 10 NM_008508 Lor loricrin 
 6.3e-03 1423952_a_at 21 BC010337 Krt2-7 keratin complex 2, basic, gene 7 
 4.6e-03 1420647_a_at 59 NM_031170 Krt2-8 /// LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
 4.3e-04 1448169_at 62 NM_010664 Krt1-18 keratin complex 1, acidic, gene 18 
show the whole 
group 1.0e-04 1423691_x_at 82 M21836 Krt2-8 
keratin complex 2, basic, gene 
8 
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General Information 
Mode Representative 
Number of genes on chip  23155 
Number of annotated genes  15969 
Number of groups  8045 
Number of singletons  2869 
Significance threshold  1.2e-04 
File name  K14D6 +CCL3 vs K14D6 Control negative 
 
Top Changed Groups  Group Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
IPR001101 - Plectin repeat 8 4 3.8e-08 50.00 
42383 - sarcolemma 14 3 6.1e-07 21.43 
30018 - Z disc 27 3 4.8e-06 11.11 
9613 - response to pest, pathogen or 
parasite 31 3 7.4e-06 9.68 
IPR001664 - Intermediate filament protein 59 4 3.7e-05 6.78 
46716 - muscle maintenance 4 2 5.7e-05 50.00 
IPR002017 - Spectrin repeat 19 3 1.1e-04 15.79 
 
Changed group breakdown: 
Group P-value  Probe-set ID  Rank Gene ID  Gene Symbol Title  
IPR001101 - Plectin 
repeat 5.0e-03 1427610_at 10 BC026631 Dsp desmoplakin 
 1.1e-04 1427537_at 32 BC026387 Eppk1 epiplakin 1 
 3.4e-06 1437554_at 64 BM232239 Plec1 plectin 1 
show the whole group 3.8e-08 1428847_a_at 79 BM248206 Macf1 microtubule-actin crosslinking factor 1 
42383 - sarcolemma 5.2e-03 1435989_x_at 6 AW322280 LOC434261 similar to cytokeratin EndoA - 
mouse 
 7.4e-05 1420647_a_at 15 NM_031170 Krt2-8 /// LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
show the whole group 6.1e-07 1423691_x_at 20 M21836 Krt2-8 keratin complex 2, basic, gene 8 
30018 - Z disc 1.0e-02 1435989_x_at 6 AW322280 LOC434261 similar to cytokeratin EndoA - 
mouse 
 2.9e-04 1420647_a_at 15 NM_031170 Krt2-8 /// keratin complex 2, basic, gene 
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LOC434261 8 /// similar to cytokeratin 
EndoA - mouse 
show the whole group 4.8e-06 1423691_x_at 20 M21836 Krt2-8 keratin complex 2, basic, gene 8 
9613 - response to 
pest, pathogen or 
parasite 
1.2e-02 1435989_x_at 6 AW322280 LOC434261 similar to cytokeratin EndoA - 
mouse 
 3.8e-04 1420647_a_at 15 NM_031170 Krt2-8 /// LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
show the whole group 7.4e-06 1423691_x_at 20 M21836 Krt2-8 keratin complex 2, basic, gene 8 
IPR001664 - 
Intermediate filament 
protein 
2.2e-02 1435989_x_at 6 AW322280 LOC434261 similar to cytokeratin EndoA - 
mouse 
 1.4e-03 1420647_a_at 15 NM_031170 Krt2-8 /// LOC434261 
keratin complex 2, basic, gene 
8 /// similar to cytokeratin 
EndoA - mouse 
 5.2e-05 1423691_x_at 20 M21836 Krt2-8 keratin complex 2, basic, gene 8 
show the whole group 3.7e-05 1448169_at 51 NM_010664 Krt1-18 keratin complex 1, acidic, gene 18 
46716 - muscle 
maintenance 4.8e-03 1454904_at 19 BG976607 Mtm1 
X-linked myotubular myopathy 
gene 1 
show the whole group 5.7e-05 1458663_at 50 AI552833 Large Like-glycosyltransferase (Large), mRNA 
IPR002017 - Spectrin 
repeat 1.2e-02 1427610_at 10 BC026631 Dsp desmoplakin 
 2.6e-03 1437554_at 64 BM232239 Plec1 plectin 1 
show the whole group 1.1e-04 1428847_a_at 79 BM248206 Macf1 microtubule-actin crosslinking factor 1 
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General Information 
Mode Representative 
Number of genes on chip  23155 
Number of annotated genes  15985 
Number of groups  8056 
Number of singletons  2858 
Significance threshold  1.2e-04 
File name  K14D6 + CCL3 v WT + CCL3 negative 
 
Top Changed Groups  Group Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
IPR007237 - CD20/IgE Fc receptor beta 
subunit 15 4 8.0e-08 26.67 
IPR001811 - Small chemokine, interleukin-8 
like 31 4 1.4e-07 12.90 
6935 - chemotaxis 87 5 2.1e-07 5.75 
8009 - chemokine activity 38 4 3.3e-07 10.53 
30595 - immune cell chemotaxis 5 3 3.4e-07 60.00 
19864 - IgG binding 5 2 1.8e-05 40.00 
IPR001916 - Glycoside hydrolase, family 22 8 2 2.6e-05 25.00 
3796 - lysozyme activity 10 2 4.2e-05 20.00 
42383 - sarcolemma 14 3 5.4e-05 21.43 
IPR001304 - C-type lectin 99 3 6.3e-05 3.03 
45576 - mast cell activation 9 2 6.5e-05 22.22 
16998 - cell wall catabolism 16 2 1.1e-04 12.50 
 
Changed group breakdown: 
Group P-value  Probe-set ID  Rank Gene ID  Gene Symbol  Title  
IPR007237 - CD20/IgE 
Fc receptor beta 
subunit 
5.6e-03 1424754_at 6 BC024402 Ms4a7 
membrane-spanning 4-
domains, subfamily A, 
member 7 
 3.7e-05 1419599_s_at 10 NM_026835 Ms4a11 
membrane-spanning 4-
domains, subfamily A, 
member 11 
 3.0e-07 1419598_at 15 NM_026835 Ms4a6d 
membrane-spanning 4-
domains, subfamily A, 
member 6D 
show the whole group 8.0e-08 1418826_at 46 NM_027209 Ms4a6b 
membrane-spanning 4-
domains, subfamily A, 
member 6B 
IPR001811 - Small 
chemokine, 
interleukin-8 like 
1.3e-02 1448995_at 7 NM_019932 Cxcl4 chemokine (C-X-C motif) ligand 4 
 2.4e-04 1417266_at 12 BC002073 Ccl6 chemokine (C-C motif) ligand 6 
 1.1e-05 1419728_at 23 NM_009141 Cxcl5 chemokine (C-X-C motif) ligand 5 
show the whole group 1.4e-07 1417936_at 25 AF128196 Ccl9 chemokine (C-C motif) ligand 9 
6935 - chemotaxis 3.7e-02 1448995_at 7 NM_019932 Cxcl4 chemokine (C-X-C motif) ligand 4 
 1.9e-03 1417266_at 12 BC002073 Ccl6 chemokine (C-C motif) ligand 6 
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 1.7e-04 1442082_at 20 BB333624 C3ar1 complement component 3a 
receptor 1 
 6.7e-06 1419728_at 23 NM_009141 Cxcl5 chemokine (C-X-C motif) ligand 5 
show the whole group 2.1e-07 1417936_at 25 AF128196 Ccl9 chemokine (C-C motif) ligand 9 
8009 - chemokine 
activity 1.7e-02 1448995_at 7 NM_019932 Cxcl4 
chemokine (C-X-C motif) 
ligand 4 
 3.6e-04 1417266_at 12 BC002073 Ccl6 chemokine (C-C motif) ligand 6 
 2.1e-05 1419728_at 23 NM_009141 Cxcl5 chemokine (C-X-C motif) ligand 5 
show the whole group 3.3e-07 1417936_at 25 AF128196 Ccl9 chemokine (C-C motif) ligand 9 
30595 - immune cell 
chemotaxis 2.2e-03 1448995_at 7 NM_019932 Cxcl4 
chemokine (C-X-C motif) 
ligand 4 
 1.2e-05 1449254_at 18 NM_009263 Spp1 secreted phosphoprotein 1 
show the whole group 3.4e-07 1419609_at 53 AV231648 Ccr1 chemokine (C-C motif) 
receptor 1 
19864 - IgG binding 4.4e-03 1435477_s_at 14 BM224327 Fcgr2b Fc receptor, IgG, low affinity IIb 
show the whole group 1.8e-05 1448620_at 22 NM_010188 Fcgr3 Fc receptor, IgG, low affinity III 
IPR001916 - 
Glycoside hydrolase, 
family 22 
1.0e-03 1436996_x_at 2 AV066625 Lzp-s P lysozyme structural 
show the whole group 2.6e-05 1423547_at 16 AW208566 Lyzs lysozyme 
3796 - lysozyme 
activity 1.3e-03 1436996_x_at 2 AV066625 Lzp-s P lysozyme structural 
show the whole group 4.2e-05 1423547_at 16 AW208566 Lyzs lysozyme 
42383 - sarcolemma 5.0e-02 1423691_x_at 58 M21836 Krt2-8 keratin complex 2, basic, gene 8 
 1.4e-03 1435989_x_at 64 AW322280 LOC434261 similar to cytokeratin EndoA 
- mouse 
show the whole group 5.4e-05 1420647_a_at 87 NM_031170 Krt2-8 /// LOC434261 
keratin complex 2, basic, 
gene 8 /// similar to 
cytokeratin EndoA - mouse 
IPR001304 - C-type 
lectin 1.8e-02 1420804_s_at 3 NM_010819 Clec4d 
C-type lectin domain family 
4, member d 
 2.0e-03 1450430_at 11 NM_008625 Mrc1 mannose receptor, C type 1 
show the whole group 6.3e-05 1425951_a_at 13 AF240358 Clec4n C-type lectin domain family 4, member n 
45576 - mast cell 
activation 7.9e-03 1435477_s_at 14 BM224327 Fcgr2b 
Fc receptor, IgG, low affinity 
IIb 
show the whole group 6.5e-05 1448620_at 22 NM_010188 Fcgr3 Fc receptor, IgG, low affinity III 
16998 - cell wall 
catabolism 2.0e-03 1436996_x_at 2 AV066625 Lzp-s P lysozyme structural 
show the whole group 1.1e-04 1423547_at 16 AW208566 Lyzs lysozyme 
 
 
 
 
 
